<SEC-DOCUMENT>0001213900-19-004269.txt : 20190315
<SEC-HEADER>0001213900-19-004269.hdr.sgml : 20190315
<ACCEPTANCE-DATETIME>20190315170212
ACCESSION NUMBER:		0001213900-19-004269
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190315
DATE AS OF CHANGE:		20190315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		19685767

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2018_actiniumpharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual
Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended<B>&nbsp;December 31, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transition
Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
For the transition period from _____ to _____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMISSION
FILE NUMBER: 000-52446</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other jurisdiction of</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;incorporation
        or organization)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>275
Madison Avenue, 7<SUP>th</SUP> Fl.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(646)
677-3870</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section&nbsp;12(b) of the Act:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of exchange on which registered</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock, par value $0.001</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYSE
    American</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section&nbsp;12(g) of the Act: None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuant
to Rule 405 of Regulation S-T (Section 232.405 of the chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the act): Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of voting stock held by nonaffiliates of the registrant as of June&nbsp;29, 2018, the last business day
of the registrant&rsquo;s most recently completed second fiscal quarter, based on the closing price of the common stock on the
NYSE AMERICAN on June 29, 2018 was $70,693,197.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 15, 2019, 119,136,036 shares of common stock, $0.001 par value per share, were outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table&nbsp;of
Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 8%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 83%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 9%; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0; text-indent: 0"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART I</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&rsquo;s Common Equity, Related Stockholders Matters, and Issuer Purchases of Equity Securities</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market&nbsp;Risk</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature Page</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (this &ldquo;Report&rdquo;) contains forward-looking statements that involve risks and uncertainties,
principally in the sections entitled &ldquo;Description of Business,&rdquo; &ldquo;Risk Factors,&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations.&rdquo; All statements other than statements of historical
fact contained in this Report, including statements regarding future events, our future financial performance, business strategy
and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking
statements by terminology including &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo;
&ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;should,&rdquo; or &ldquo;will&rdquo; or the negative of these terms or
other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis
for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties
and other factors, including the risks outlined under &ldquo;Risk Factors&rdquo; or elsewhere in this Report, which may cause
our or our industry&rsquo;s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking
statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and
it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent
to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any
forward-looking statements. All forward-looking statements included in this document are based on information available to us
on the date hereof, and we assume no obligation to update any such forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Report. Before
you invest in our securities, you should be aware that the occurrence of the events described in the section entitled &ldquo;Risk
Factors&rdquo; and elsewhere in this Report could negatively affect our business, operating results, financial condition and stock
price. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements
after the date of this Report to conform our statements to actual results or changed expectations.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1. Business.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals Inc. is a clinical-stage, biopharmaceutical company focused on developing and potentially commercializing therapies
for targeted conditioning prior to cell therapies such as a BMT or Bone Marrow Transplant or CAR-T, <FONT STYLE="background-color: white">a
type of cellular therapy that genetically alters a patient&rsquo;s own T cells to target and kill their cancer cells,</FONT> and for
other adoptive cell therapies. In addition, we are also developing potential therapies for targeting and killing of cancer cells
either as single agents or in combination with other drugs. Our targeted therapies are Antibody Radiation-Conjugates or ARC&rsquo;s, that
combine the targeting ability of a monoclonal antibody (mAb) with the cell-killing ability of a radioisotope to deliver radiation
internally in a precise manner to potentially generate more potent efficacy and with less toxicity than radiation that is delivered
externally. We are developing two clinical stage ARC programs that target the antigens CD45 and CD33, respectively, that are currently
being studied in several hematologic indications. We employ our ARCs at higher doses of radioisotope intensity for targeted conditioning
prior to a BMT and at lower doses for targeted conditioning which is also known as lymphodepletion prior to CAR-T and other adoptive
cell therapies. In addition, we are pursuing development of our ARC&rsquo;s at low doses in combination with other therapeutic
modalities such as chemotherapy, targeted agents or immunotherapy and as a monotherapy. Our ARC based clinical programs are underpinned
by our AWE or Antibody Warhead Enabling technology platform where we have data in both liquid and solid tumors, intellectual property
and know-how that we intend to use to create additional ARCs targeting new antigens with multiple radioisotopes such as actinium-225
or Ac-225 or and iodine-131 or I-131. Our AWE technology platform is currently being utilized in a research collaboration with
Astellas Pharma, Inc. centered around our technology for Ac-225.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Targeted
Conditioning Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead targeted conditioning product candidate is Iomab-B, an ARC that is comprised of the anti-CD45 mAb known as
apamistamab or BC8 and the radioisotope iodine-131. CD45 is expressed on leukemia, lymphoma and nucleated immune cells with
an average of 200,000 copies per cell but with minimal expression outside of the hematopoietic system. Iomab-B is currently
being studied in the pivotal Phase 3 SIERRA or <B>S</B>tudy of <B>I</B>omab-B in <B>E</B>lderly <B>R</B>elapsed or <B>R</B>efractory <B>A</B>ML
clinical trial for targeted conditioning prior to a BMT for patients with active, relapsed or refractory (r/r) Acute Myeloid
Leukemia or AML who are over age 55. The SIERRA trial will compare outcomes of patients randomized to receive Iomab-B and
a BMT (the study arm) to those patients randomized to receive physician&rsquo;s choice of salvage chemotherapy (the control
arm). Salvage chemotherapy is also defined as conventional care, as no standard of care exists for this patient
population. Patients who fail to achieve a CR or Complete Response on the control arm are ineligible to proceed to a BMT but
the trial design permits these patients to cross over to the study arm if they meet the eligibility criteria.
The primary endpoint of the SIERRA trial is dCR (durable Complete Remission) of 6 months and the secondary endpoint is 1-year
Overall Survival (OS). The SIERRA trial is currently active at 18 sites in the U.S and Canada that includes many of the
leading BMT sites based on volume.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
and feasibility data from the first 38 patients enrolled on the SIERRA trial which represents 25% of the total of 150
patients to be enrolled in the trial, was presented in an oral presentation at the American Society of Hematology (ASH)
Annual Meeting in December 2018. It was reported that all patients initially randomized to the study arm that received a
therapeutic dose of Iomab-B (18/18) received a BMT, with a median time to BMT of 28 days, and all patients achieved
engraftment in a median time of 16 days despite a high median blast count of 30%. On the control arm, 4/19 patients received
a BMT after receiving conventional care with a median time to BMT of 67 days and median blast count of 26%. Of the patients
failing to achieve a CR with conventional care (15/19), 10 patients were eligible to cross over to the study arm. All cross over
patients (10/10) received a BMT after receiving Iomab-B, with a median time to BMT of 66 days and all patients achieved
engraftment in a median time of 17 days despite high median blast count of 45% at time of cross over. There was no (0/18)
100-day non-relapse mortality reported in the study arm, while 1 of 4 patients in the control arm and 1 of
10 cross over patients experienced 100-day non-relapse mortality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Actimab-MDS is our second
pivotal program for targeted conditioning. Actimab-MDS is an ARC comprised of the anti-CD33 mAb lintuzumab linked to the radioisotope
Actinium-225. CD33 is expressed in a vast majority of patients with MDS. Actimab-MDS is informed by prior experience with our
CD33 ARC in multiple trials for patients with AML, MDS and for patients that progressed from MDS to AML, which is also known as
secondary AML. Data from these trials showed that our CD33 ARC had single-agent activity capable of producing CRs in certain patients
at varying dose levels with minimal extramedullary toxicities. However, dose dependent myelosuppression was seen in many of these
patients. Given this safety and efficacy profile, it was decided to pursue a trial in targeted conditioning in high-risk MDS patients
with this ARC in combination with RIC or Reduced Intensity Conditioning regimens. RIC regimens are comprised of low doses of highly
toxic chemotherapies such as fludarabine, cytarabine, busulfan and melphalan. Actimab-MDS is intended to enable targeted conditioning
prior to a BMT in patients with MDS or Myelodysplastic Syndrome with poor or very poor cytogenetics, which is defined as having
3 or more chromosomal abnormalities. A bone marrow transplant is the only curative treatment option for these patients. However,
these patients have poor outcomes due to high relapse rates following a BMT. We believe we have developed a pathway to a pivotal
trial with input from the FDA that consists of a Phase 1 dose finding clinical trial that will be followed by a Phase 3 pivotal
trial. We are currently finalizing the protocol and pathway for this trial with the FDA and expect to initiate the trial in 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Iomab-ACT construct is a lower dose of Iomab-B (CD45 &ndash; I-131) that we are developing as a targeted conditioning or lymphodepletion
agent prior to CAR-T and adoptive cell therapies. CD45 is an antigen expressed on many cells that are relevant to the mechanism
of CAR-T therapies including lymphocytes, regulatory T cells and macrophages that have been associated with clinical responses
that limit the safety and efficacy of these CAR-T therapies including CRS or Cytokine Release Syndrome, neurotoxicity and durability
of response. Some of these limitations may be attributable to the chemotherapy based conditioning agents that are being used currently
prior to CAR-T therapies. Actinium&rsquo;s Iomab-ACT program is highly differentiated when compared to Fludarabine and Cyclophosphamide
or Flu/Cy or other chemotherapy-based regimens that are used as the standard of practice today for lymphodepletion prior to CAR-T.
Unlike chemotherapy, Iomab-ACT is targeted in nature and due to this targeted effect, we expect can improve CAR-T cell expansion
more efficiently, potentially resulting in responses that are more durable and also with reduced CAR-T related toxicities. Importantly,
the Iomab-ACT program construct enables lymphodepletion through a single-dose, outpatient administration versus Flu/Cy or other
chemo-based lymphodepletion regimens that can require multiple infusions in an inpatient setting over several days. Because of
this potentially superior profile, the Iomab-ACT construct could result in improved access to CAR-T therapy and also better outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CD33
ARC Therapeutics and Combinations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are applying our CD33 targeting
ARC product candidate lintuzumab-Ac-225 to multiple hematologic indications as CD33 is an antigen that has been found to be expressed
in a vast majority of patients with AML and MDS and 25-35% of patients with Multiple Myeloma. Our CD33 development program is examining
the construct at various dose levels and dosing regimens either alone or in combination in these various disease indications. We
currently have multiple clinical trials ongoing, in startup phase, or in planning, to use our CD33 ARC in combination with other
therapeutic modalities such as chemotherapy, targeted agents or immunotherapy. We believe that radiation can be synergistic when
used in combination with these modalities based on our own clinical data, preclinical research and supporting scientific evidence
in the literature. We are also studying our CD33 ARC as a monotherapy in the case of multiple myeloma. The construct has been designated
as Actimab and we add a suffix to clarify the trial for the disease area and if needed the combination. For example, in AML, our
recently concluded phase 2 trial as a single agent named Actimab-A (A for AML) and our ongoing trial in AML in combination with
venetoclax is called the Actimab-A: Ven trial. Our CD33 ARC development program encompasses the following ongoing and planned trials:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Combination
Trials</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         1 Actimab-A: Ven combination trial with the BCL-2 inhibitor Venetoclax (Abbvie/Genentech)
                                         for patients with relapsed or refractory AML at the UCLA Medical center.</FONT></TD></TR>                                                                                                                                 <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         1 Actimab-A: CLAG-M combination trial with the salvage chemotherapy regimen CLAG-M (cladribine,
                                         cytarabine, filgrastim and mitoxantrone) for patients with relapsed or refractory AML
                                         at the Medical College of Wisconsin.</FONT></TD></TR>                                                                                             <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         1 Actimab-A: Ven+HMA Combination trial with the BCL-2 inhibitor Venetoclax (Abbvie/Genentech)
                                         and a hypomethylating Agent (HMA) for patients with relapsed or refractory AML planned
                                         at the MD Anderson Cancer center.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Therapeutic
Trials</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multi-center
                                         Phase 1 Actimab-M trial for patients with penta-refractory multiple myeloma.</FONT></TD></TR>                                                                                                                                     <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Planned
                                         Phase 1 trial of Actimab-A: MRD for post-remission AML patients with positive MRD or
                                         Minimal Residual Disease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Antibody
Warhead Enabling Technology Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary Antibody Warhead Enabling or AWE Technology Platform is supported by intellectual property, know-how and trade secrets
that cover the generation, development, methods of use and manufacture of ARC or Antibody Radiation-Conjugates and certain of
their components. Our AWE technology patent portfolio includes 27 patent families comprised of 110 issued and pending patent applications,
of which 11 are issued and 18 pending in the United States, and 81 are issued and pending internationally the useful life of which
ranges from 2019 to 2039. Our proprietary technology enables the direct labeling, or conjugation and labeling of a biomolecular
targeting agent to a radionuclide warhead and its development and use as a therapeutic regimen for the treatment of diseases such
as cancer. Our intellectual property covers ARC compositions of matter, formulations, methods of administration, and radionuclide
production. Further, our AWE intellectual property covers various methods of use for ARCs in multiple diseases, including indication,
dose and scheduling, radionuclide warhead, and therapeutic combinations. In addition, due to the renewed focus on research and
technology development in 2017 and 2018, we expect the useful life of new intellectual property filed by the company, if granted,
to extend well beyond the current dates in several key areas including for next-generation ARC&rsquo;s of approved therapeutics, combination treatments and targeted radiation
approaches using the isotopes Ac-225, and I-131.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary technology includes methods of conjugation, labeling and use of the radionuclides Ac-225 and I-131. Our technology
covers the use of the &ldquo;gold standard&rdquo; chelator DOTA, (tetracarboxylic acid), an organic compound used to attach, or
conjugate, the radionuclide Ac-225 to monoclonal antibodies and any conceivable derivative thereof. Additionally, we possess intellectual
property protection, know-how and trade secrets covering efficient methods of chelation and labeling of the targeting agent with
Ac-225 as well as newer next-generation methods of chelation or labeling. We are conducting preclinical research with our AWE
Technology Platform to demonstrate proof of concept in liquid and solid tumors for various indications including targeted conditioning,
lymphodepletion, combinations of ARC&rsquo;s with other modalities and as monotherapies to enable research collaborations, partnerships
and expand our development pipeline. In March 2018, we entered into a collaborative research agreement with Astellas Pharma, Inc.
(Astellas) that is utilizing our AWE technology platform to create ARCs using the Ac-225 isotope and select targeting agents owned
by Astellas. In January 2019, we initiated the second module of our research collaboration with Astellas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research pipeline including ongoing and planned clinical trials are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fred
Hutchinson Cancer Research Center is currently studying the BC8 antibody in clinical trials. Trials at the Medical College of
Wisconsin, UCLA Health and MD Anderson Cancer Center are investigator-initiated trials using our product
candidates. We have entered into a collaborative research partnership with Astellas for the use of our AWE Technology
Platform.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Strategy&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to develop our product candidates for targeted conditioning (Iomab-B and Actimab-MDS) and lymphodepletion (Iomab-ACT)
through registration studies and approval either alone or in partnership. If our efforts are successful, we may elect to
commercialize our targeted conditioning products on our own, or in partnership in the United States and out-license the
rights to develop and commercialize these products to one or more strategic partners outside of the United States. If we
elect to commercialize one or more of our targeted conditioning product candidates independently, we intend to scale up our
existing supply chain capabilities, which currently supplies in excess of 18 BMT Centers and major hospitals across our
pipeline, into a commercial distribution network that can supply the top 50-80 bone marrow transplant centers in the U.S.,
where a majority of patients are conditioned and receive their transplants. In the case of our CD33 program trials excluding
the Actimab-MDS opportunity, we intend to potentially develop these up to proof-of-concept and then seek collaborators both
inside and out of the U.S. We also have the option, assuming successful monetization of one or more targeted conditioning
assets via commercialization or collaboration, of developing and commercializing all or certain parts of the CD33 program ourselves. We believe this is a
viable strategy as it affords operating leverage from our supply chain and presence at the largest BMT centers which also
account for a significant portion of cancer treatments. In parallel, we intend to continue to identify development
opportunities with our AWE Technology Platform and extend our leadership position in the use of the radioisotope Ac-225. Our
efforts at further developing our platform center around arming additional targeting agents for various cancers and rare
diseases, producing next generation ARC&rsquo;s of approved therapies, and exploring novel combination approaches that have the potential of replacing external
beam radiation with ARC&rsquo;s that enable delivery of targeted radiation directly to desired site of action. We will
continue to monetize our AWE platform via collaborations and partnerships as we have done with Astellas Inc. We intend to
retain marketing rights for our products in the United States whenever possible and out-license marketing rights to our
partners for the rest of the world. We may also seek to in license other applicable opportunities should such technology
become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
Opportunity&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that targeted conditioning prior to a BMT could result in improved access and outcomes for patients, as well as provide
a pharmacoeconomic benefit. The Center for International Blood and Marrow Transplant Research (CIBMTR) estimates that more than
23,000 patients received an autologous or allogeneic BMT in the United States in 2018. The American Cancer Society estimates that
approximately 174,250 patients will be diagnosed with leukemia, lymphoma or multiple myeloma and that approximately 1.34 million
patients in the United States are living with or are in remission from these diseases. According to the European Bone Marrow Transplantation,
over 35,000 autologous and allogeneic BMTs were performed in 2016. BMT is a potentially curative or potentially best treatment
option for certain patients with these blood-borne cancers, blood disorders and inherited immune system disorders and we intend
to develop our ARC product candidates with the goal of improving BMT access and outcomes for these patients. We believe that eliminating
or reducing chemotherapy-based conditioning prior to BMT can significantly increase the number of patients receiving BMT and that
targeted conditioning can result in less toxicities that could lead to better outcomes. According to a study published in the
Journal of Medical Economics, real-world economic burden of hematopoietic cell transplantation among a large US commercially insured
population with hematologic malignancies, the healthcare cost for patients receiving an autologous BMT were $390,000 while the
healthcare costs for patients receiving an allogeneic BMT were $745,000. We believe that reduction in toxicities and resulting
hospital stays associated with current chemotherapy-based conditioning regimens could reduce these costs. We intend to collect
pharmacoeconomic data in our current and future clinical trials for Iomab-B and other targeted conditioning product candidates
to determine if our therapies result in a cost benefit. Iomab-B has demonstrated efficacy in targeted conditioning prior to a
BMT for blood cancer indications, including AML, MDS, Acute Lymphoblastic Leukemia (ALL), Hodgkin&rsquo;s Lymphoma, Non-Hodgkin&rsquo;s
Lymphoma (NHL) and Multiple Myeloma. These are indications for which Iomab-B can be developed and it is our intention to explore
these opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing our Iomab-ACT program, which uses a lower dose of Iomab-B, as a targeted conditioning or lymphodepletion agent
prior to CAR-T and adoptive cell therapies. There are currently two approved CAR-T therapies and several dozen CAR-T and adoptive
cell therapies in development for multiple hematologic and solid tumor indications. We intend for Iomab-ACT to be utilized
as a lymphodepletion agent prior to CAR-T and adoptive cell therapy that can replace or displace the chemotherapy based lymphodepletion
regimens that are used in standard practice today.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our CD33 program drug candidates, we would compete in the marketplace for cancer treatments estimated to have reached over
$83 billion in 2016 sales, according to &ldquo;The Global Use of Medicines: Outlook Through 2016 Report by the IMS Institute
for Healthcare Informatics, July 2012&rdquo;. While surgery, radiation and chemotherapy remain staple treatments for cancer,
their use is limited by the fact that they often cause substantial damage to normal cells. On the other hand, targeted
monoclonal antibody therapies exert most or all of their effect directly on cancer cells, but often lack sufficient killing
power to eradicate all cancer cells with just the antibody. A relatively newer approach for treating cancer is to combine the
precision of antibody-based targeting agents with the killing power of radiation, or chemotherapy, by attaching powerful
killing agents to precise molecular carriers called monoclonal antibodies. We use mAbs labeled with radioisotopes to deliver
potent doses of radiation directly to cancer cells while sparing healthy tissues. The radioisotopes we use are the alpha
emitter Ac-225 and the beta emitter I-131. I-131 is among the best known and well characterized radioisotopes. It is used
very successfully in the treatment of papillary and follicular thyroid cancer as well as other thyroid conditions. I -131 is
used in combination with a  monoclonal antibody in treatment of NHL and is used in the approved drug AZEDRA<SUP>&reg; </SUP>(iobenguane
I -131) for the treatment of certain neuroendocrine tumors. It is also used experimentally with different carriers in other
cancers. Ac-225 has many unique properties and we believe we are a leader in developing this alpha particle emitting
radioisotope for clinical applications using our proprietary AWE technology platform.&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Trials</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Targeted
Conditioning </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on applying our ARC product candidates for targeted conditioning prior to cell therapies such as BMT and CAR-T to
improve access and outcomes to these important and potentially curative treatments. A BMT may be the only potentially curative
treatment option or the best treatment option for patients with blood cancers such as leukemias, lymphomas and multiple myeloma,
benign blood or marrow disorders such as inherited immune system disorders, sickle cell disease and severe aplastic anemia.
Conditioning is an integral step prior to BMT or an adoptive cell therapy such as CAR-T where the current standard practice is
chemotherapy and/or total body irradiation via external radiation. In the case of BMT, conditioning is intended to eliminate a
patient&rsquo;s bone marrow and immune system to allow transplanted bone marrow stem cells the ability to engraft and reconstitute
the patient&rsquo;s blood counts and immune function. We are currently conducting two clinical trials for product candidates focused
on targeted conditioning for BMT, a pivotal phase 3 trial for Iomab-B and our pivotal Actimab-MDS program, both of which are first
in their class. In our Iomab-ACT program we are studying a lower dose of apamistamab &ndash; I-131 for targeted conditioning prior
to CAR-T and cell therapy to enable lymphodepletion, which eliminates lymphocytes and other immune cells but spares bone marrow
stem cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Iomab-B
Pivotal Phase 3 Program &ndash; SIERRA Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;We
licensed Iomab-B from the Fred Hutchinson Cancer Research Center, or FHCRC, where it was developed and studied extensively in
numerous clinical trials in a range of hematologic indications and patient populations. Iomab-B consists of the anti-CD45 monoclonal
antibody apamistamab (BC8) and the beta emitting radioisotope Iodine-131 (I-131). Apamistamab has been studied in over 10 Phase
1 and Phase 2 clinical trials in patients with AML, MDS, ALL, multiple myeloma and lymphomas in patients with newly diagnosed,
relapsed or refractory and first remission disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
Iomab-B clinical trials leading to our current pivotal Phase 3 trial included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indications</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
    Findings</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced ALL, AML, MDS</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- 95%
    engraftment rate</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(age 16 &ndash; 55)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced AML/ALL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash; Median overall
    survival 2.8 years</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(age 15 &ndash; 55)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AML 1st remission/1<SUP>st</SUP> relapse </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash; 100% engraftment
    rate</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(age
16-50)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash; 63% 3-year
    overall survival</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relapsed/Refractory AML/High-risk MDS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68 in dose escalation study</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;100% engraftment
    rate</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(age 50+)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31 treated at MTD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;1-year survival
    ~40% for all patients</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relapsed/Refractory AML and High-risk MDS<BR>
    (age 18&ndash;50)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-94%
        engraftment rate</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        Median overall survival 4.4 years</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relapsed/Refractory lymphoma</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash; 100% engraftment rate<BR>
    &ndash; 18-month median overall survival</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relapsed/Refractory AML/Advanced ALL, HR MDS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        100% engraftment rate</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        42% 1-year overall survival</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple Myeloma</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        100% engraftment rate</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        77% 2-year overall survival</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relapsed/Refractory AML and HR MDS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        100% engraftment rate</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        66% 1-year overall survival</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-risk
        lymphoma</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(with
        BEAM chemotherapy)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        100% engraftment rate</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
        63% 1-year progression free survival</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-risk AML, ALL or MDS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing</FONT></TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indication selected for our pivotal phase 3 trial is bone marrow conditioning for patients with active,
relapsed or refractory AML over the age of 55. We selected this indication because of the compelling data from the phase 2 proof
of concept trial that showed improved survival after Iomab-B and a BMT compared to historical clinical outcomes when they received
conventional care or salvage chemotherapy. In addition, the choice of this indication is also attractive due to a combination
of factors including; the lack of available effective treatment options for this population of patients who have a very poor survival
prognosis of 3.3 months and who are currently ineligible for a bone marrow transplant due to their poor condition and advanced
state of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pivotal
Phase 3 SIERRA Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently studying Iomab-B in the SIERRA or Study of Iomab-B in Elderly Relapsed or Refractory AML clinical trial,
a 150-patient pivotal Phase 3 multi-center randomized trial that will compare outcomes of patients who receive Iomab-B and a
BMT (the study arm) to those patients receiving physician&rsquo;s choice of salvage chemotherapy (the control arm). Salvage
chemotherapy is defined as conventional care, as no standard of care exists for this patient population. Patients randomized
to receive the control arm who do not achieve a Complete Remission (CR) are able to cross over to the study arm and
receive Iomab-B and a BMT if they meet certain eligibility criteria. Patients with active, relapsed or refractory AML have
dismal prognoses and are typically not offered potentially curative transplant as an option, largely because salvage
treatments have a limited ability to produce a complete remission, which is necessary prior to conventional BMT if
conventional BMT is to be successful. The SIERRA trial is the only pivotal trial offering BMT as an option to patients with
active, relapsed or refractory Acute Myeloid Leukemia age 55 and above. The primary endpoint of the SIERRA trial is dCR or
durable Complete Remission of 6 months and the secondary endpoint is 1-year Overall Survival (OS). The SIERRA trial is
currently enrolling patients at 18 sites in the U.S and Canada that includes many of the leading BMT sites based on
volume.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
and feasibility data from the first 38 patients (25% of planned enrollment) in the SIERRA trial were presented in an oral presentation
at the 61<SUP>st</SUP> American Society of Hematology (ASH) Annual Meeting &amp; Exposition and in a late breaking oral session
at the 2019 Transplantation &amp; Cellular Therapy Meetings&trade; of ASBMT and CIBMTR (TCT Meetings). It was reported that all
patients receiving a therapeutic dose of Iomab-B engrafted despite active disease with high blast counts with median blast counts
of 30% for patients randomized to the Iomab-B arm and a median of 45% for patients that crossed over to receive Iomab-B. 15 of
19 (79%) patients in the control arm failed to achieve a complete response and 67% (10/15) of these patients were eligible for
crossover with all (10/10) being successfully transplanted after treatment with Iomab-B. Patients receiving Iomab-B received a
BMT more quickly post-randomization (28 days) than patients receiving conventional care (67 days) and in the conventional care
arm, there was no difference in time to BMT for patients that crossed over to Iomab-B (66 days) compared to those achieving complete
remission with conventional care (67 days). No Grade 3 or 4 Iomab-B infusion related reactions with all Iomab-B infusions completed
and there was no 100-Day non-relapse mortality in patients randomized to Iomab-B arm. Approximately 94% of patients initially
randomized to receive Iomab-B and a BMT (17/18) achieved Full Donor Chimerism and 90% of patients who crossed-over to receive
Iomab-B and a BMT (9/10), after salvage chemotherapy in the control arm failed to produce a CR or Complete Response, also achieved
Full Donor Chimerism prior to day 100. Additional safety and feasibility analyses will occur when 76 (50%) and 114 (75%) of patients
have been enrolled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actimab-MDS
Program</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Actimab-MDS pivotal program is studying our CD33 ARC that consists of the anti-CD33 mAb lintuzumab conjugated with the radioisotope
Ac-225, which has been studied in multiple Phase 1 and Phase 2 clinical trials in patients with AML and MDS. In 2018, we completed
the Phase 2 Actimab-A clinical trial of our CD33 ARC in patients newly diagnosed with AML age 60 and above ineligible for standard
induction therapy. Each patient in a dose cohort received fractionated doses a week apart. Single agent activity was reported
with an Overall Response Rate or ORR of 69% for patients receiving 2.0 &micro;Ci/kg/fraction and 22% in patients receiving 1.5
&micro;Ci/kg/fraction. Minimal extramedullary toxicities were observed; however, myelosuppression was a Dose Limiting Toxicity
(DLT) that was observed at both dose cohorts. The Actimab-MDS pivotal program is designed to leverage the observed myelosuppression
capabilities and minimal extramedullary toxicities of our CD33 ARC as a targeted conditioning agent prior to a BMT in MDS patients
with poor or very poor cytogenetics, which is defined as having 3 or more chromosomal mutations. In this patient population,
BMT is the only treatment option with curative potential and a BMT also has the ability to reverse myelosuppression as transplanted
cells can reconstitute the patient&rsquo;s blood and immune function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
met with the FDA to discuss our Actimab-MDS program and based on these discussions we will conduct a Phase 1 dose confirming study
that will be followed by a pivotal, randomized registration trial. The Phase 1 trial will enroll 7-18 patients where patients
will receive 2.0 &ndash; 4.0 &micro;Ci/kg of lintuzumab &ndash; Ac-225 in a single infusion. The pivotal, randomized registration
trial will study our CD33 ARC in combination with RIC or Reduced Intensity Conditioning regimens prior to bone marrow transplant.
RIC regimens are comprised of low doses of highly toxic chemotherapies such as fludarabine, cytarabine, busulfan and melphalan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Iomab-ACT
Program</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Iomab-ACT program uses a lower dose of Iomab-B (CD45 &ndash; I-131) that we are developing as a targeted conditioning agent
for lymphodepletion prior to CAR-T and adoptive cell therapies. Currently, lymphodepletion for CAR-T and adoptive cell
therapies utilizes Fludarabine and Cyclophosphamide or Flu/Cy and other chemotherapies. The dose range for the Iomab-ACT
program is supported by clinical data with Iomab-B, pharmacokinetic modeling and preclinical data supporting its
effectiveness at selective targeting of cells necessary to achieve effective lymphodepletion. In February 2019, we presented
data from our preclinical findings at the 2019 Transplantation &amp; Cellular Therapy Meetings&trade; of ASBMT and CIBMTR
(TCT Meetings) that showed that a single infusion of an anti-CD45 antibody labelled with Iodine-131 can effectively deplete
greater than 90% of lymphocytes, including CD4 and CD8 T cells, CD19 B cells and NK cells, which is necessary for adoptive
cell therapies like CAR-T to expand and persist. Tregs or regulatory T cells, including CD4+, CD25+ and FoxP3+ Tregs, which
can exert negative pressure on cell therapy expansion and persistence, were suppressed for at least 21 days post
lymphodepletion with Iomab-ACT. The multi-modal mechanism of action directed at CD45 expressing cells also depleted
macrophages, which are implicated in the development of CRS or Cytokine Release Syndrome, and splenocytes while red blood
cells, platelets, neutrophils and bone marrow stem cells were preserved. Additionally, MicroSPECT/CT imaging showed that
Iomab-ACT homed to immune privileged sites including lymph nodes, spleen, liver and bone marrow. Finally, an in vivo
animal model showed that adoptively transferred cytotoxic T cells persisted in mice following administration of CD45 targeted
lymphodepletion and were able to control tumor cells compared to untreated mice. We intend to study our Iomab-ACT program in
a human clinical trial in 2019. We are currently speaking with potential investigators and collaborators from academia and
industry and evaluating possible clinical trial protocols.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CD33
ARC Therapeutics and Combinations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our ARC product candidate that consists of the anti-CD33 mAb lintuzumab and the radioisotope Ac-225 for
multiple hematologic malignancies including AML, MDS and Multiple Myeloma. The CD33 development program is examining the
construct at various dose levels and dosing regimens either alone or in combination in these various disease indications. Our
CD33 ARC is a second-generation construct that was developed at the Memorial Sloan Kettering Cancer Center, or MSKCC. The
first-generation product consisted of the same monoclonal antibody lintuzumab but utilized the radioisotope bismuth-213 or
Bi-213. In preclinical and Phase 1 clinical studies lintuzumab-Ac-225 has demonstrated at least 500-1000 times higher potency
than the first-generation predecessor lintuzumab-Bi-21 upon which it is based. This difference is due to intrinsic
physicochemical properties of lintuzumab-Ac-225 that were first established in vitro, in which lintuzumab-Ac-225 killed
multiple cell lines at doses at least 1,000 times lower based on LD50 values than lintuzumab-Bi-213 analogs. Key factors in
lintuzumab-Ac-225&rsquo;s higher potency is the yield of 4 alpha-emitting isotopes per Ac-225 compared to 1 alpha decay for
bismuth 213 and much longer half-life of 10 days for Ac-225 vs 46 minutes for Bi-213.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have multiple clinical trials ongoing, in startup phase, or in planning, to use our CD33 ARC in combination with other
therapeutic modalities such as chemotherapy, targeted agents or immunotherapy. We believe that radiation can be synergistic when
used in combination with these modalities based on our own clinical data, preclinical research and supporting scientific evidence
in the literature. We are also studying our CD33 ARC as a monotherapy in the case of multiple myeloma. The construct has been
designated as Actimab and we add a suffix to clarify the trial for the disease area and if needed the combination. For example,
in AML, our recently concluded phase 2 trial as a single agent named Actimab-A (A for AML) and our ongoing trial in AML in combination
with venetoclax is called the Actimab-A: Ven trial. Our CD33 ARC development program encompasses the following ongoing and planned
trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Combination
Trials</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
1 Actimab-A combination trial with the BCL-2 inhibitor Venetoclax for patients with relapsed or refractory AML</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have initiated a Phase 1 investigator initiated clinical trial at the UCLA Medical Center that will study our CD33 ARC in combination
with Venetoclax (VEN), a BCL-2 inhibitor that is jointly developed and marketed by Abbvie and Genentech. Venetoclax is approved
for patients with CLL or Chronic Lymphocytic Leukemia and SLL or Small Lymphocytic Leukemia as well as patients newly diagnosed
with AML who are 75 and older who are ineligible for standard chemotherapy in combination with a hypomethylating agent or low-dose
cytarabine. BCL-2 is one of several proteins encoded by the BCL2 gene family, which regulates apoptosis or programmed cell death.
MCL-1 is another protein encoded by the BCL2 gene family that is also overexpressed in cancers, including relapsed or refractory
AML, that prevents apoptosis and promotes resistance to venetoclax, which does not bind to MCL-1. It has been demonstrated that
MCL-1 levels can be depleted with radiation but only external radiation was used in these studies. In our preclinical studies,
it was demonstrated that our CD33 ARC combined with venetoclax resulted in increased cancer cell death than either agent alone.
Our Actiamb-A: VEN trial will study our CD33 ARC in combination with Venetoclax alone and will be a 3+3 dose-escalation study
that is intended to determine the MTD or maximum tolerable dose of our CD33 ARC, determine ORR and evaluate OS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
1 Actimab-A combination trial with salvage chemotherapy regimen CLAG-M (cladribine, cytarabine, filgrastim and mitoxantrone) for
patients with relapsed or refractory AML </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting a Phase 1 investigator initiated clinical trial at the Medical College of Wisconsin that is studying our CD33 ARC
in combination with the CLAG-M salvage chemotherapy regimen in patients with relapsed or refractory AML. Our Actimab-A: CLAG-M
trial is a 3+3 design, dose escalation study evaluating safety and tolerability, response rates, rates of BMT, PFS or progression-free
survival and OS. Dosing began at 0.25 uCi/kg and in February 2019, we announced that we successfully completed the first patient
cohort and that no dose limiting toxicities (DLTs) were observed. We have initiated the second patient cohort in which patients
will receive 0.50 uCi/kg of Actimab-A. Assuming no DLTs are observed in the second cohort, the study will progress to the third
and final cohort where patients will receive a dose of 0.75 uCi/kg.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
1 Actimab-A Combination trial with BCL-2 inhibitor Venetoclax and a Hypomethylating Agent for patients with relapsed or refractory
AML </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to initiate a Phase 1 investigator-initiated trial at the University of Texas MD Anderson Cancer Center that will study
our CD33 ARC in combination with Venetoclax and a hypomethylating agent for patients with relapsed or refractory AML. Venetoclax
is approved for patients newly diagnosed with AML who are 75 and older who are ineligible for standard chemotherapy in combination
with a hypomethylating agent or low-dose cytarabine. Similar to our combination trial with Venetoclax alone, this Actimab-A: VEN+HMA
trial will study the potential for our CD33 ARC to reduce MCL-1 levels thereby removing a potential resistance mechanism to Venetoclax
making the AML cells susceptible to apoptosis or programmed cell death. This trial will be a 3+3 design, dose-escalation study
that is intended to determine the MTD or maximum tolerable dose of our CD33 ARC, determine ORR and evaluate OS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Therapeutic
Trials</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Multi-center
Phase 1 Actimab-M trial for patients with penta refractory multiple myeloma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD33
expression has been identified in 25-35% of patients with multiple myeloma. Like other hematologic malignances, multiple myeloma
is sensitive to radiation. Therefore, we are studying our CD33 ARC in patients with penta refractory multiple myeloma in the multi-center
Phase 1 Actimab-M open label, dose escalation trial which is a 3+3 design, dose-escalation study. This trial was initiated as
an investigator sponsored study at one site but the was subsequently brought in house and is now being pursued under company IND
as a multi-center trial. Per the protocol, patients are administered a starting dose level of 0.5 &mu;Ci/Kg&nbsp;via infusion
on day 1 of each cycle for up to 8 cycles with each cycle lasting 42 days. Assuming safety at this dose level, escalation to a
second dose level of 1.0 &mu;Ci/kg for up to 4 cycles, also of 42 days per cycle is planned. The total dose received per patient
is not to exceed 4.0 &mu;Ci/kg. In the event of dose limiting toxicities (DLTs) at the 0.5 &mu;Ci/Kg&nbsp;dose level, a dose level
of 0.25 &mu;Ci/Kg&nbsp;will be explored. The Phase 1 trial will estimate maximum tolerated dose (MTD), assess adverse events,
measure response rates (objective response rate, complete response rate, stringent complete response rate, very good partial response
rate and partial response rate) as well as progression free survival (PFS) and overall survival (OS). To our knowledge, we are
the only company developing a CD33 targeting agent for patients with multiple myeloma and the only company studying an alpha-particle
(Actinium-225) radioisotope in this indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
1 trial of Actimab-A for post-remission AML patients with positive MRD or Minimal Residual Disease </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are planning a Phase 1 clinical trial that will study our CD33 ARC in patients with AML that have achieved remission but have
detectable MRD. Patients with detectable MRD after achieving remission with induction therapy have a higher probability of relapse
and therefore poorer long-term outcomes. Consolidation therapy often follows induction therapy that today consists of chemotherapy,
HMAs, targeted agents, BMT or supportive care. However, following induction therapy patients may be ineligible or unable to tolerate
these therapies. This planned Actimab-A: MRD trial will be a 3+3 design, dose escalation study where patients will receive a single
infusion of a low dose (0.5 &ndash; 1.0 &mu;Ci/Kg) of our CD33 ARC for up to 4 cycles with patients being assessed for MRD status
on day 29 &plusmn; 7 days. This study will evaluate safety and tolerability and establish MTD as well as assess effect on MRD,
PFS and OS. The goal of our efforts in patients with detectable MRD is to use our CD33 ARC to prevent relapse and put the patient&rsquo;s
disease in a manageable chronic state with a chemotherapy free treatment that is well tolerated with minimal extramedullary toxicities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Antibody
Warhead Enabling Technology Platform and Program</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary Antibody Warhead Enabling or AWE Technology Platform is supported by intellectual property, know-how and trade secrets
that cover the generation, development, methods of use and manufacture of ARC or Antibody Radiation-Conjugates and certain of
their components. As of March 2019, we have 27 patent families comprising 110 issued and pending patent applications, of which
11 are issued and 18 are pending in the United States that are related to our AWE Technology Platform in the U.S. having expirations
between 2019 and 2039 and 81 issued or pending patents outside of the U.S. Our proprietary technology enables the direct labeling,
or conjugation and labeling of a biomolecular targeting agent to a radionuclide warhead and its development and use as a therapeutic
regimen for the treatment of diseases such as cancer. Our intellectual property covers ARC compositions of matter, formulations,
methods of administration, and radionuclide production. Further, our AWE intellectual property covers various methods of use for
ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations. In addition,
due to the renewed focus on research and technology development in 2017 and 2018, we expect the useful life of new intellectual
property filed by the company, if granted, to extend well beyond the current dates in several key areas including for next generation ARCs,
combination treatments and targeted radiation approaches using the isotopes Ac-225 and I-131.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2017, we announced the availability of our proprietary AWE Technology Platform for partnerships and collaborations.
In tandem, we demonstrated the utility of the AWE Technology Platform intellectual property, know-how and trade secrets
to generate a next generation ARC of an approved therapeutic molecule by generating preclinical results showing the dramatic enhancement in anti-tumor potency
following the conjugation and labeling of a therapeutic antibody, daratumumab, with Ac-225. Daratumumab is an anti-CD38
antibody which is marketed by Johnson &amp; Johnson (JNJ) under the trade name&nbsp;Darzalex<SUP>&reg;</SUP> for the
treatment of multiple myeloma. We successfully demonstrated the efficient labeling daratumumab with Ac-225 without
compromising CD38 target engagement and antibody effector function. Furthermore, pre-clinical testing of
the&nbsp;Ac-225-daratumumab asset in an <I>in vivo</I> xenograft tumor model was also performed. Specifically,
Ac-225-daratumumab was well tolerated in mice and was shown to increase the <I>in vivo</I> potency over naked daratumumab by
at least 30-fold and led to a survival advantage in this model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
applied our AWE Technology Platform to the development of our Iomab-ACT program. The patent estate related to our Iomab-ACT program
covers composition of matter, formulation and methods of use. Actinium believes this patent estate is important to potential partners
in industry and academia as it may enable the optimization of CAR-Ts through improved lymphodepletion, which may not be possible
with Flu/Cy given patents that exist on its use in conjunction with CAR-T. In addition, the patent estate is broad and is applicable
to indications where CAR-Ts have already been approved and to emerging indications that the growing field of CAR-T developers
are pursuing such as solid tumors. Key filings of the estate cover claims including composition and methods of use in targeted
lymphodepletion prior to adoptive cell therapies such as CAR-T with autologous and allogeneic cell therapy in solid or hematologic
cancer indications. The filings also include methods of use for targeted lymphodepletion in combination with genetically engineered
CAR cells, including those that lack expression of endogenous checkpoint receptors or T cell receptors and targeted conditioning
in preparation for administration of gene edited cell therapy for the treatment of non-malignant inherited genetic disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have led and successfully demonstrated the adaptability and robust labeling that can be achieved with the AWE Technology Platform.
AWE-derived ARCs provide versatility in use as demonstrated by the applicability as anti-cancer therapies as single agents or
in combination, but also as modalities for targeted conditioning prior to cell therapies such as bone marrow transplant or adoptive
cell therapies. Moreover, the AWE Program provides a potential partner with access to the technology, the know-how, and the capabilities
and facilities to execute on ARC generation and development. The studies with daratumumab-Ac-225 provides one example of the enhanced
therapeutic effect that can be achieved from the utilization of our core platform technology to potently radiolabel an asset with&nbsp;a
radionuclide warhead, positioning the generation of ARCs as a viable therapeutic approach. Iomab-ACT demonstrates how our AWE
Technology Platform can be applied to create ARCs for specific indications and applications as we were able to use our apamistamab-I-131
construct and develop a lower dose version when compared to Iomab-B that is intended to be used for lymphodepletion as opposed
to myeloablation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we entered into a collaborative research partnership with Astellas Pharma, Inc. (Astellas) to utilize our AWE Technology
Platform with selected targeting agents owned by Astellas. Under the agreement, we are conducting preclinical validation studies.
In exchange, we received an upfront fee and Astellas provides funding for the ongoing preclinical research. In January 2019, we
announced that we successfully completed the first module of and that we initiated the second module of the collaboration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to utilize our AWE technology platform to enable future additional collaborations and partnerships. In addition to our
CSO, we have 3 PhD level employees that contribute to our efforts related to AWE in addition to an external VP of R&amp;D and
post-doctoral associate. We also utilize a network of external R&amp;D facilities and personnel that perform work on our behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current operations are primarily focused on furthering the development of our clinical drug candidates for targeted conditioning,
our CD33 program combination and monotherapy trials, supporting investigator-initiated clinical trials that use our drug candidates,
actively managing our current supply chain, supporting collaborations and further developing our AWE platform and supporting our
pre-commercial market development and supply chain activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
related to Iomab-B include progressing the ongoing multi-center Phase 3 pivotal trial (a trial that leads to registration trial
marketing approved by the FDA), which includes investigator engagement, site activation and supporting patient enrollment. In
addition, we are focused on commercial-scale manufacturing of apamistamab suitable for an approval trial and preparation of appropriate
regulatory submissions. We are also focused on producing final Iomab-B drug product material that consists of apamistamab labelled
with the isotope I-131. We have secured access to I-131 from multiple commercial global suppliers. We project that these suppliers
have sufficient I-131 production capacity to meet our commercial needs for the Iomab-B program. We are aware of other global manufacturers
and suppliers of I-131with whom we believe we can secure commercial supply agreement if necessary. Operations related to our Actimab-MDS
pivotal program include preparation for appropriate regulatory submissions, protocol development and investigator engagement.
For our Iomab-ACT program we are producing preclinical data supporting its use as a targeted conditioning agent to enable lymphodepletion
prior to CAR-T and other adoptive cell therapies, evaluation potential clinical trials and related protocols and developing a
regulatory strategy for our planned clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of our CD33 program, key ongoing activities include planning, initiating and progressing our Phase 1 trials including
our two combination trials with venetoclax, our combination trial with CLAG-M, Actimab-M trial in for patients with multiple myeloma
and our MRD trial, managing isotope and other materials supply chain and managing the manufacturing of the finished drug candidate
product. We have secured access to Ac-225 through a renewable contractual arrangement with the United States Department of Energy,
or DOE. We project that these quantities are sufficient to support early stages of commercialization of actinium isotope-based
products and that the DOE&rsquo;s accelerator route of production of Ac-225 has the potential to provide commercial quantities
of Ac-225. We have also developed our own proprietary process for industrial-scale Ac-225 production in a cyclotron in quantities
adequate to support full product commercialization. In addition, we are aware of numerous sources from which we may secure additional
quantities of the Ac-225 isotope.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our clinical programs, we are conducting research and development with our AWE Technology Platform to support existing
clinical programs and develop new clinical opportunities. We are also executing on our collaborative research partnership with
Astellas. Related to our supply chain, we are undertaking planning and evaluation activities to support our future needs related
to infrastructure, commercialization or clinical trial site expansion. Activities related to market development are ongoing and
include physician engagement and education, referral pattern analysis, site evaluation and patient advocacy engagement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property Portfolio and Regulatory Protections</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed or in-licensed numerous patents and patent applications and possess substantial know-how and trade
secrets related to the development and manufacture of our products. As of March 2019, our patent portfolio includes: 28
patent families comprised of 111 issued and pending patent applications, of which 12 are issued and 18 are pending in the
United States, and 81 are issued and pending internationally. Several non-provisional patent applications are expected to be
filed in 2019 based on provisional patent applications filed in 2018. This is part of an ongoing strategy to strengthen
our intellectual property position. About one fifth of our patents are in-licensed from third parties and the remainder
are Actinium-owned. These patents cover key areas of our business, including use of actinium-225 and other alpha-
or beta-emitting isotopes attached to cancer specific carriers like monoclonal antibodies, methods for manufacturing
key components of our product candidates including actinium-225, an alpha particle emitting radioisotope and carrier
antibodies, or Iodine-131, a beta particle emitting radioisotope, and methods for manufacturing finished product candidates
for use in cancer treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own five issued patents including one divisional patent in the United States and 47 patents outside of the United States, including
one divisional patent related to the manufacturing of actinium-225 in a cyclotron, that will expire between 2024 &ndash; 2030.
Four related global patents are pending. We own or have licensed the rights to six issued patents in the United States and 14
issued patents outside of the United States related to the generation of radioimmunoconjugates that will expire between 2019 and
2030. Nine related United States or global patents are pending, Further, we own the rights to 20 additional pending patents in
the United States and abroad related to radioimmunoconjugate composition, formulation administration, and methods of use in solid
or liquid cancers. This matter includes composition, administration, and methods of treatment for our products Actimab-A and Iomab-B.
In addition, for Iomab-ACT, we own 4 patents pending and 1 provisional patent application covering methods of use and composition
in cancer and non-malignant disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulatory
Protections</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indications for which we are developing our product candidates for are orphan drug designations, which are disease indications
that affect fewer than 200,000 patients in the United States and less than 5 in 10,000 patients in the European Union (&ldquo;EU&rdquo;).
We have received orphan drug designation for Iomab-B and our lintuzumab-CD33 ARC for patients with AML in both the United States
and the EU. As a result, if our products are to be approved, they may receive 7 years and 10 years of market exclusivity in the
US and EU, respectively. In addition, our product candidates are biologics combined with radioisotopes. The Hatch-Waxman Act requires
that a manufacturer of generic drugs, for which a biologic drug is called a biosimilar, requires that the manufacturer demonstrate
bioequivalence. We believe that due to the nature of radioisotopes having half-lives combined with the complexities of biologic
drugs would make it difficult for a manufacturer to demonstrate bioequivalence of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the field of targeted conditioning, pharmaceuticals currently used for myeloablation prior to a bone marrow transplant or lymphodepletion
prior to CAR-T are largely generic chemotherapeutic agents and/or radiation. In targeted conditioning, we face competition from
Magenta Therapeutics, Inc., who is developing an anti-CD45 and anti-117 Antibody Drug Conjugate (ADC) and Allogene Therapeutics
who is developing an anti-CD52 monoclonal antibody. However, both programs are at the preclinical stage. To our knowledge, we
are the only company with a pivotal Phase 3 trial for a targeting conditioning agent and the only anti-CD45 ARC in clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our CD33 ARC, there are several companies developing drugs for AML, MDS and Multiple Myeloma based on numerous approaches/modalities
including chemotherapy, targeted agents, antibody drug conjugates naked monoclonal antibodies, bispecific antibodies, immunotherapies
and cellular therapies. Specific to CD33, Mylotarg&trade;, an ADC developed and marketed by Pfizer is the only FDA approved CD33
targeted therapy for adult patients and children two years and older with relapsed or refractory CD33-positive AML. Seattle Genetics
was developing SGN-CD33A, a CD33 targeting ADC, but discontinued the development of its clinical trials associated with this product
candidate in June 2017. Immunogen is also developing a CD33 targeting ADC, IMGN779, that is currently in a Phase 1 clinical trial
for r/r AML patients age 18 and above. Amgen is developing a CD3/CD33 bispecific BiTE (AMG330) as is Amphivena (AMV-564), both
of which are in Phase 1 clinical trial for r/r AML patients age 18 and above. Boehringer Ingelheim is developing a CD33 targeting
naked antibody (BI836858) for patients with r/r AML or MDS age 18 and above. These drugs have different safety profiles and mechanisms
of action compared to our drug candidates. AML in older patients remains an area of high medical need that could accommodate many
new products with favorable safety and efficiency profiles. We have begun studying our CD33 ARC in combination with the salvage
chemotherapy regimen CLAG-M for patients with relapsed or refractory AML. Combination therapies are commonly used in hematologic
indications, but we believe we are the only Ac-225 based product candidate that is being explored in combination studies in hematologic
indications. To our knowledge, we are the only company with a CD33 targeting drug and the only AC-225 based ARC product candidate
for patients with multiple myeloma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in the United States and other countries extensively regulate, among other things, the research, development, testing,
manufacture, labeling, promotion, advertising, distribution and marketing of radioimmunotherapy pharmaceutical products such as
those being developed by us. In the United States, the FDA regulates such products under the Federal Food, Drug and Cosmetic Act
(FDCA) and implements regulations. Failure to comply with applicable FDA requirements, both before and after approval, may subject
us to administrative and judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications,
warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or
criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Food and Drug Administration Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation
in the United States and other countries. Most notably, products that may in the future be sold in the United States are subject
to regulation by the FDA. Certain of our product candidates in the United States require FDA pre-marketing approval of a BLA pursuant
to 21 C.F.R. &sect; 314. Foreign countries may require similar or more onerous approvals to manufacture or market these products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA, the Nuclear
Regulatory Commission or other regulatory authorities, which may result in sanctions, including but not limited to, untitled letters,
warning letters, fines, injunctions, consent decrees and civil penalties; customer notifications or repair, replacement, refunds,
recall, detention or seizure of our products; operating restrictions or partial suspension or total shutdown of production; refusing
or delaying our requests for BLA premarket approval of new products or modified products; withdrawing BLA approvals that have
already been granted; and refusal to grant export.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 15, 2019, we have 30 full-time employees. None of these employees are covered by a collective bargaining agreement, and
we believe our relationship with our employees is good. We also engage consultants on an as-needed basis to supplement existing
staff.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>ITEM
1A. RISK FACTORS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
analyzing our company, you should consider carefully the following risk factors, together with all of the other information included
in this Annual Report on Form&nbsp;10-K. Factors that could cause or contribute to differences in our actual results include those
discussed in the following subsection, as well as those discussed above in &ldquo;Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations&rdquo; and elsewhere throughout this Annual Report on Form&nbsp;10-K. Each of the
following risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition,
as well as adversely affect the value of an investment in our company. The risks and uncertainties described below are not the
only ones we face. Additional risks not currently known to us or other factors not perceived by us to present significant risks
to our business at this time also may impair our business operations.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recurring losses and negative cash flows from operations
raise substantial doubt about our ability to continue as a going concern and we may not be able to continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our recurring losses from operations and negative cash flows
from operations raise substantial doubt about our ability to continue as a going concern and as a result, our independent registered
public accounting firm included an explanatory paragraph in its report on our consolidated financial statements for the year ended
December 31, 2018 with respect to this uncertainty. Substantial doubt about our ability to continue as a going concern may create
negative reactions to the price of the common shares of our stock and we may have a more difficult time obtaining financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have prepared our financial statements on a going concern
basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of
business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or amounts of liabilities that might be necessary should we be unable to continue in existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a clinical-stage company and have generated no revenue from commercial sales to date. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a limited operating history. We have no products approved for commercial sale
and have not generated any revenue from product sales to date. We will encounter risks and difficulties frequently experienced
by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not profitable and have incurred losses in each period since our inception. As of December 31, 2018, we had an accumulated
deficit of $186.9 million. For the years ended December 31, 2018 and 2017, we reported a net loss of $23.7 million and $26.6 million,
respectively. We expect to continue to operate at a net loss as we continue our research and development efforts, continue to
conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that
the products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can be no
assurance that if such products are approved they will be successfully commercialized, which would have an adverse effect on our
business prospects, financial condition and results of operation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to obtain additional financing, we will be unable to continue or complete our product development and you will likely
lose your entire investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have sufficient funding for the completion of development nor commercialization of our product candidates and
we will need to continue to seek capital from time to time to continue development of our product candidates and to acquire and
develop other product candidates. Our first product candidate is not expected to be commercialized, if approved, until at least
2020 and any partnering revenues that it may generate may not be sufficient to fund our ongoing operations. Our cash balance as
of December 31, 2018 was $13.7 million. During the year ended December 31, 2018, we raised total net proceeds of approximately
$17.0 million from the sale of our common stock and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Presently, with no further
source of capital either via a financing or a collaboration, we project that we may run out of funds in 2019. We currently do not have any additional source of capital secured.
If we are unable to raise additional funds, we could be required to reduce our spending plans, reduce our workforce, license one
or more of our products or technologies that we would otherwise seek to commercialize ourselves, sell all or some of our assets,
cease operations or even declare bankruptcy. We will require additional cash in order to maximize the commercial opportunity and
continue clinical development of our product candidates. Alternatives available to us to sustain our operations include collaborative
agreements, equity financing, debt and other financing arrangements with potential corporate partners and other sources. However,
there can be no assurance that any such collaborative agreements or other sources of funding will be available to us on favorable
terms, if at all.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business or operations may change in a manner that would consume available funds more rapidly than anticipated and substantial
additional funding may be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary
products, business or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory
environment or a change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it
or on favorable terms or indeed on any terms. In addition, from time to time, we may not be able to secure enough capital in a
timely enough manner which may cause the generation of a going-concern opinion from our auditors which can and may impair our
stock market valuation and also our ability to finance on favorable terms or indeed on any terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into
or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other
offering at a price per share that is equal to or greater than the price per share paid by investors, and investors purchasing
shares or other securities in the future could have rights superior to existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot raise adequate funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research
and development activities, clinical studies or future operations. We may also be required to obtain funds through arrangements
with collaborators, which arrangements may require us to relinquish rights to certain technologies or products that we otherwise
would not consider relinquishing, including rights to future product candidates or certain major geographic markets. We may further
have to license our technology to others. This could result in sharing revenues which we might otherwise have retained for ourselves.
Any of these actions may harm our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of funding we will need depends on many factors, including the progress, timing and scope of our product development programs;
the progress, timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory
approvals; the time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our
ability to enter into and maintain collaborative, licensing and other commercial relationships; and our partners&rsquo; commitment
of time and resources to the development and commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have limited access to the capital markets and even if we can raise additional funding, we may be required to do so on terms that
are dilutive to you.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited access to the capital markets to raise funds. The capital markets have been unpredictable in the recent past for
radioisotope and other oncology companies and unprofitable companies such as ours. In addition, it is generally difficult for
development-stage companies to raise capital under current market conditions. The amount of capital that a company such as ours
is able to raise often depends on variables that are beyond our control. As a result, we may not be able to secure financing on
terms attractive to us, or at all. If we are able to consummate a financing arrangement, the amount raised may not be sufficient
to meet our future needs. If adequate funds are not available on acceptable terms, or at all, our business, including our technology
licenses, results of operations, financial condition and our continued viability will be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are highly dependent on the success of Iomab-B and the SIERRA trial and we many not able to complete the necessary clinical development
or our development efforts may not result in the data necessary to receive regulatory approval</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iomab-B,
which we licensed from the Fred Hutchinson Cancer Research Center, in June 2012 is our lead program to which we allocate a significant
portion of our resources. We are currently enrolling patients in the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly
Relapsed or Refractory AML), a 150-patient multi-center randomized trial that will compare outcomes of patients who receive Iomab-B
and a BMT to those patients receiving physician&rsquo;s choice of salvage chemotherapy, defined as conventional care, as no standard
of care exists for this patient population. The SIERRA trial may be unsuccessful and fail to demonstrate a safety and efficacy
profile that is necessary to receive favorable regulatory approval. The trials DMC or Data Monitoring Committee may recommend
that the trial be stopped early for safety or efficacy concerns, which could prevent us from completing the SIERRA trial. Even
if Iomab-B receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing
successful commercial operations. Any or all of these factors could have a material adverse impact on our business and ability
to continue operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unable to establish sales, marketing and commercial supply capabilities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates become
approved, we would have to build and establish these capabilities in order to commercialize our approved product candidates. The
process of establishing commercial capabilities will be expensive and time consuming. Even if we are successful in building sales
and marketing capabilities, we may not be successful in commercializing any of our product candidates. Any delays in commercialization
or failure to successfully commercialize any product candidate may have material adverse impacts on our business and ability to
continue operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Regulation&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
FDA or comparable foreign regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval
of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are subject to rigorous regulation by the FDA and numerous other federal, state and foreign
governmental authorities. The process of seeking regulatory approval to market an antibody radiation-conjugate product is
expensive and time-consuming, and, notwithstanding the effort and expense incurred, approval is never guaranteed. If we are
not successful in obtaining timely approval of our products from the FDA, we may never be able to generate significant
revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution of a new antibody
radiation-conjugate product only after a Biologics License Application (BLA) for the product has received FDA approval. The
BLA process is costly, lengthy and inherently uncertain. Any BLA filed by us will have to be supported by extensive data,
including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to the
FDA&rsquo;s satisfaction the safety and efficacy of the product for its intended use. The lengthy approval process as well as
the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our
product candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we
were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on
the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not
include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval process in the United States and in other countries could result in unexpected and significant costs for us and consume
management&rsquo;s time and other resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions,
collect non-clinical data, conduct additional clinical trials or engage in other time-consuming actions, or it could simply deny
our applications. In addition, even if we obtain approval to market our products in the United States or in other countries, the
approval could be revoked, or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness.
We cannot predict with certainty how, or when, the FDA or other regulatory authorities will act. If we are unable to obtain the
necessary regulatory approvals, our financial condition and cash flow may be materially adversely affected, and our ability to
grow domestically and internationally may be limited. Additionally, even if we obtain approval, regulatory authorities may approve
any of our product candidates for fewer or more limited indications that we request. The Company&rsquo;s products may not be approved
for the specific indications that are most necessary or desirable for successful commercialization or profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not demonstrated that any of our products are safe and effective for any indication.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two product candidates in clinical development. In December 2015, the FDA cleared our IND filing for Iomab-B, and
we are currently enrolling patients in a randomized, controlled, pivotal, Phase 3 clinical trial. Assuming the trial meets its
endpoints, it will form the basis for a BLA. Additionally, there are physician IND trials at the FHCRC that have been conducted
or are currently ongoing at FHCRC with Iomab-B and the BC8 antibody we licensed. We have multiple clinical trials ongoing for
our drug candidates under our own sponsorship and multiple investigator-initiated trials ongoing. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict whether we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory
authorities to delay, suspend, or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any
of the following could delay or disrupt the clinical development of our product candidates and potentially cause our product candidates
to fail to receive regulatory approval:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed
    on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving,
    or the inability to obtain, required approvals from institutional review boards (IRBs) or other reviewing entities at clinical
    sites selected for participation in our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling
    patients into clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated
    retention rate of patients in clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat
    or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because
    the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply,
    delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other
    materials necessary to conduct our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA
    or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected
    drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed
    in earlier trials or only observed in a limited number of participants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the
    trial participants are being exposed to unacceptable health risks;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by
    the FDA or a foreign regulatory authority of a clinical hold on a trial; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining
    regulatory agency authorization for the conduct of our clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may suspend, or the FDA or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate
at any time if we or they believe the patients participating in such clinical trials, or in independent third-party clinical trials
for drugs based on similar technologies, are being exposed to unacceptable health risks or for other reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
individuals involved with our clinical trials may serve as consultants to us from time to time and receive stock options or cash
compensation in connection with such services. If these relationships and any related compensation to the clinical investigator
carrying out the study result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship
may have affected interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be
questioned and the utility of the clinical trial itself may be jeopardized. The delay, suspension or discontinuation of any of
our clinical trials, or a delay in the analysis of clinical data for our product candidates, for any of the foregoing reasons,
could adversely affect our efforts to obtain regulatory approval for and to commercialize our product candidates, increase our
operating expenses and have a material adverse effect on our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may
be suspended or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring
board, or DSMB (Data Safety Monitoring Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other
regulatory authorities due to a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct
    the clinical trial in accordance with regulatory requirements or our clinical protocols;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the
    clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical
    hold;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation
    of data by the FDA or similar foreign regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve
    primary or secondary endpoints or other failure to demonstrate efficacy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety
    issues; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate
    funding to continue the clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Modifications
to our product candidates may require federal approvals.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BLA application is the vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale
and marketing in the United States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications
of our products may require additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions
and premarket approvals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new
approvals for a particular use or indication, we may be required to conduct additional clinical studies, which would require additional
expenditures and harm our operating results. If the products are already being used for these new indications, we may also be
subject to significant enforcement actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
clinical trials and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely
affect our ability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our
business prospects, financial condition and results of operation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
FDA or comparable foreign regulatory authorities may disagree with our regulatory plans, and we may fail to obtain regulatory
approval of our product candidates. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2012, we acquired rights to BC8 (Iomab), a clinical stage monoclonal antibody with safety and efficacy data in more than
300 patients in need of a BMT. Iomab-B is our product candidate that links I-131 to the BC8 antibody that is being studied in
an ongoing Phase 3 pivotal trial. Product candidates utilizing this antibody would require BLA approval before they can be marketed
in the United States. We are also evaluating a lower dose of the BC8 antibody and I-131 for lymphodepletion prior to CAR-T or
adoptive cell therapy. We are currently evaluating clinical trials that would use our construct for lymphodepletion. Our lintuzumab-Ac-225
product candidate is also being studied in several Phase 1 trials under our sponsorship and investigator-initiated trials in patients
with AML, myelodysplastic syndrome and multiple myeloma. Product candidates utilizing the lintuzumab antibody would require BLA
approval before they can be marketed in the United States. We are in the early stages of evaluating other product candidates consisting
of conjugates of Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer.
The FDA may not approve these products for the indications that are necessary or desirable for successful commercialization. The
FDA may fail to approve any BLA we submit for new product candidates or for new intended uses or indications for approved products
or future product candidates. Failure to obtain FDA approval for our products in the proposed indications would have a material
adverse effect on our business prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials necessary to support approval of our product candidates are time-consuming and expensive. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiating
and completing clinical trials necessary to support FDA approval of a BLA for Iomab-B, CD33 program candidates, and other product
candidates, is a time-consuming and expensive process, and the outcome is inherently uncertain. Moreover, the results of early
clinical trials are not necessarily predictive of future results, and any product candidate we advance into clinical trials may
not have favorable results in later clinical trials. We have worked with the FDA to develop a clinical trial designed to test
the safety and efficacy of Iomab-B in patients with relapsed or refractory AML who are age 55 and above prior to a BMT. This trial
is designed to support a BLA filing for marketing approval by the FDA, pending results from the trial. We have also worked with
the FDA to develop a regulatory pathway for our Actimab-MDS trial that consists of a dose-confirming Phase 1 trial that can be
followed by a randomized, controlled pivotal trial that could support a BLA filing. In addition, there can be no assurance that
the data generated during the trial will meet our chosen safety and effectiveness endpoints or otherwise produce results that
will eventually support the filing or approval of a BLA. Even if the data from this trial are favorable, these data may not be
predictive of the results of any future clinical trials.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay
regulatory approval and commercialization.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims
or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early
clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will
replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product
candidates are safe and effective for the proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, lintzumab-Ac-225,
or any other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness, we would
not receive FDA approval to market that product candidate in the United States for the indications sought. In addition, such an
outcome could cause us to abandon the product candidate and might delay development of others. Any delay or termination of our
clinical trials will delay or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize
our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse
side effects that are not currently part of a product candidate&rsquo;s profile.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
intellectual property related to antibodies we have licensed has expired or likely expired</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key patents related to the humanized antibody, lintuzumab, which we use in our CD33 program product candidates have expired. It
is generally possible that others may be eventually able to use an antibody with the same sequence, and we will then need to rely
on additional patent protection covering alpha particle drug products comprising Ac-225. Our final drug construct consists of
the lintuzumab antibody labeled with the isotope Ac-225. We have licensed issued patents that relate to the linker technology
we use to conjugate the isotope to the antibody and own issued and pending patents related to isotope production methods and drug
preparation methods. In addition, we possess trade secrets and know how related to the manufacturing and use of isotopes. Any
competing product based on the lintuzumab antibody is likely to require several years of development before achieving our product
candidate&rsquo;s current status and may be subject to significant regulatory hurdles but is nevertheless a possibility that could
negatively impact our business in the future. Neither the antibody portion nor the composition of matter as a whole for the conjugated
Iomab-B product candidate is covered by the claims of any issued patent. Accordingly, there are no patents that would prevent
others from using an antibody with the same antibody sequence in any drug product. We have dedicated research and development
activities towards improving the product&rsquo;s stability to enhance commercial usefulness of the product and now have a proprietary
formulation for which IP is pending. We have and may continue to file patents related to Iomab-B that can provide barriers to
entry but there is no certainty that these patents will be granted or such granting thereof will adequately prevent others from
seeking to replicate and use the BC8 antibody or the construct. We have pending patents related to radioimmunoconjugate composition,
formulation administration, and methods of use in solid or liquid cancers. This matter includes composition, administration, and
methods of treatment for our products Actimab-A and Iomab-B. Any competing product based on the antibody used in Iomab-B is likely
to require several years of development before achieving our product candidate&rsquo;s current status and may be subject to significant
regulatory hurdles but is nevertheless a possibility that could negatively impact our business in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indications for which we are developing our product candidates for are orphan drug designations, which are disease indications
that affect fewer than 200,000 patients in the United States and less than 5 in 10,000 patients in the European Union (&ldquo;EU&rdquo;).
We have received orphan drug designation for Iomab-B and our lintuzumab-CD33 ARC for patients with AML in both the United States
and the EU. As a result, if our products are to be approved, they may receive 7 years 10 years of market exclusivity in the US
and EU, respectively. In addition, our product candidates are biologics combined with radioisotopes. The Hatch-Waxman Act requires
that a manufacturer of generic drugs, which for a biologic drug is called a biosimilar, requires that the manufacturer demonstrate
bioequivalence. We believe that due to the nature of radioisotopes having half-lives combined with the complexities of biologic
drugs would make it difficult for a manufacturer to demonstrate bioequivalence of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
CD33 program clinical trials are testing the same drug construct </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CD33 program is comprised of several clinical trials including several investigator-initiated trials including AML, MDS and Multiple
Myeloma that are studying the same drug construct consisting of lintuzumab-Ac-225. Negative results from any of these trials could
negatively impact our ability to enroll or complete our other trials studying lintzumab-Ac-225. Additionally, negative outcomes
including safety concerns, may result in the FDA discontinuing other trials utilizing lintuzumab-Ac-225.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unable to obtain a sufficient supply of isotopes to support clinical development or at commercial scale.&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iodine-131
is a key component of our Iomab-B drug candidate. We source medical grade I-131 from multiple suppliers including two leading
global manufacturers. Currently, there is sufficient supply of I-131 to advance our ongoing SIERRA clinical trial, support additional
trials we may undertake utilizing I-131 and for commercialization of Iomab-B. We continually evaluate I-131 manufacturers and
suppliers and intend to have at a minimum of three qualified suppliers prior to the commercial launch of Iomab-B. While we consider
I-131 to be commoditized and obtainable through several suppliers, there can be no guarantee that we will be able to secure a
third I-131 supplier or obtain on terms that are acceptable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium-225
is a key component of our CD33 ARC program, AWE platform and other drug candidates that we might consider for development with
the Ac-225 payload. There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier,
the Department of Energy, or DOE. The current Ac-225 currently supplied to Actinium&rsquo;s clinical trials from the DOE is derived
from the natural decay of thorium-229 from so-called &lsquo;thorium-cows&rsquo; and is able to produce sufficient quantities that
are several multiples of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase.
The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that
is currently being evaluated by Actinium. Initial preclinical and modelling results have indicated that the linear accelerator
sourced Ac-225 does not impact labelling efficiency and expected distribution. Per representations made by the Department of Energy,
the capacity of Ac-225 from this route is expected to be sufficient to supply all of Actinium&rsquo;s pipeline and commercial
Ac-225 needs and support new program expansion by not just Actinium but also other companies that are developing Ac-225 based
products. Additional routes of Ac-225 production are being pursued by the DOE including the generation of new thorium cows and
production via a cyclotron. The cyclotron production method for Ac-225 production leverages Actinium&rsquo;s proprietary technology
and know-how and presents an additional path towards production of high-quality Ac-225 that would be able to satisfy commercial
needs. In addition, we are aware of at least six other government and non-government entities globally including the U.S., Canada,
Russia, Belgium, France and Japan that have, or expect to have ability to supply Ac-225 or equipment for its production within
the timeframes relevant to first commercial approval of our Ac-225 ARC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract for supply of this isotope from the DOE must be renewed yearly, and the current contract extends through the end of 2019.
While we expect this contract will be renewed at the end of its term as it has since 2009, there can be no assurance that the
DOE will renew the contract or that change its policies that allow for the sale of isotope to us. Failure to acquire sufficient
quantities of medical grade Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225
based drug candidates that we may develop and would materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to conduct clinical trials to advance our ARC drug candidates is dependent on our ability to obtain the radioisotopes
I-131, Ac-225 and other isotopes we may choose to utilize in the future. Currently, we are dependent on third party manufacturers
and suppliers for our isotopes. These suppliers may not perform their contracted services or may breach or terminate their agreements
with us. Our suppliers are subject to regulations and standards that are overseen by regulatory and government agencies and we
have no control over our suppliers&rsquo; compliance to these standards. Failure to comply with regulations and standards may
result in their inability to supply isotope could result in delays in our clinical trials, which could have a negative impact
on our business. We have developed intellectual property, know-how and trade secrets related to the manufacturing process of Ac-225.
While we have manufactured medical Ac-225 of a purity compared to the cyclotron sourced material in the past, this activity was
terminated due to operating cost reasons and we currently do not have experience in manufacturing medical grade Ac-225 and may
not obtain the resources necessary to establish our own manufacturing capabilities in future. Our inability to build out and establish
our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently do. However, based
on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply to support
our current ongoing clinical trials, current AWE program activities and commercialization should our drug candidates receive approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends on our ability to enroll a sufficient number of
patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials
for a variety of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature
    of the patient population;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility
    criteria defined in the protocol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the
    study population required for analysis of the trial&rsquo;s primary endpoints;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of
    patients to trial sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the
    trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit
    clinical trial investigators with the appropriate competencies and expertise;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical
    trials for similar or alternate therapeutic treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&rsquo;s
    and patients&rsquo; perceptions as to the potential advantages and side effects of the product candidate being studied in
    relation to other available therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain
    and maintain patient consents; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients
    enrolled in clinical trials will not complete a clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, refractory patients, which several of our trials are enrolling, participating in clinical trials are seriously and often
terminally ill and therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of
adverse medical events related or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient
number of patients in our clinical trials, delays in patient enrollment will result in increased costs or affect the timing of
our planned trials, which could adversely affect our ability to advance the development of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>FDA
may take actions that would prolong, delay, suspend, or terminate clinical trials of our product candidates, which may delay or
prevent us from commercializing our product candidates on a timely basis.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the data generated in our clinical trials will be acceptable to FDA or that if future modifications during
the trial are necessary, that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol
made during the course of the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical
trial while the modification is evaluated. In addition, depending on the quantity and nature of the changes made, FDA could take
the position that some or all of the data generated by the clinical trial is not usable because the same protocol was not used
throughout the trial. This might require the enrollment of additional subjects, which could result in the extension of the clinical
trial and the FDA delaying approval of a product candidate. If the FDA believes that its prior approval is required for a particular
modification, it can delay or halt a clinical trial while it evaluates additional information regarding the change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or termination of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining
or maintaining required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate
in a clinical trial, and delays or termination of clinical trials as a result of protocol modifications or adverse events during
the trials, may cause an increase in costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization
of our product candidates or result in the failure of the clinical trial, which could adversely affect our business, operating
results and prospects. Lengthy delays in the completion of our Actimab-A clinical trials would adversely affect our business and
prospects and could cause us to cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties
or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have the ability to independently conduct our pre-clinical and clinical trials for our product candidates and we must rely
on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories
to conduct such trials. Our reliance on these third parties for clinical development activities results in reduced control over
these activities. Moreover, the FDA requires us to comply with regulations and standards, commonly referred to as GCPs (good clinical
practices), for conducting, recording and reporting the results of clinical trials to assure that data and reported results are
credible and accurate and that the trial participants are adequately protected. Our reliance on third parties does not relieve
us of these responsibilities and requirements. If we or any of our third-party contractors fail to comply with applicable GCPs,
the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon
inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies
with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our consultants, contract research organizations and other similar entities with which we are working do not successfully carry
out their contractual duties, meet expected deadlines, or comply with applicable regulations, we may be required to replace them.
Although we believe that there are a number of other third-party contractors, we could engage to continue these activities, we
may not be able to enter into arrangements with alternative third-party contractors or to do so on commercially reasonable terms,
which may result in a delay of our planned clinical trials and delayed development of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our third-party contractors are not our employees, and except for remedies available to us under our agreements with
such third-party contractors, we cannot control whether or not they devote sufficient time and resources to our programs. If these
third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or
if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory
requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended
or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our product candidates
on a timely basis, if at all, and our business, operating results and prospects would be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are regulated by the FDA as biologic products and we intend to seek approval for these products pursuant
to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for
the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal
authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as
&ldquo;interchangeable&rdquo; based on its similarity to an existing brand product. Under the BPCIA, an application for a
biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA.
The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact,
implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA
may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects
for our biologic products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may never achieve market acceptance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iomab-B,
CD33 ARC program candidates and future product candidates that we may develop may never gain market acceptance among physicians,
patients and the medical community. The degree of market acceptance of any of our products will depend on a number of factors,
including the actual and perceived effectiveness and reliability of the product; the results of any long-term clinical trials
relating to use of the product; the availability, relative cost and perceived advantages and disadvantages of alternative technologies;
the degree to which treatments using the product are approved for reimbursement by public and private insurers; the strength of
our marketing and distribution infrastructure; and the level of education and awareness among physicians and hospitals concerning
the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that oncologists and other physicians will not widely adopt a product candidate unless they determine, based on experience,
clinical data, and published peer-reviewed journal articles, that the use of that product candidate provides an effective alternative
to other means of treating specific cancers. Patient studies or clinical experience may indicate that treatment with our product
candidates does not provide patients with sufficient benefits in extension of life or quality of life. We believe that recommendations
and support for the use of each product candidate from influential physicians will be essential for widespread market acceptance.
Our product candidates are still in the development stage and it is premature to attempt to gain support from physicians at this
time. We can provide no assurance that such support will ever be obtained. If our product candidates do not receive such support
from these physicians and from long-term data, physicians may not use or continue to use, and hospitals may not purchase or continue
to purchase, them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
of Iomab-B, CD33 ARC program candidates or any of our other product candidates to significantly penetrate current or new markets
would negatively impact our business financial condition and results of operations<B><I>.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued
regulatory review. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of
the product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates,
which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use,
such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable
foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be
subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct
post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information.
Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements,
may result in, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on
    the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory
    product recalls;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters
    or holds on clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA
    to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license
    approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure
    or detention, or refusal to permit the import or export of our product candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the
    imposition of civil or criminal penalties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&rsquo;s and other regulatory authorities&rsquo; policies may change, and additional government regulations may be enacted
that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or
extent of government regulation that may arise from future legislation or administrative action, either in the United States or
abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we
may not achieve or sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and reimbursement may be limited or unavailable in certain market segments for our product candidates which could limit our sales
of our product candidates, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our product candidates in both domestic and international markets will be substantially dependent on whether
third-party coverage and reimbursement is available for patients that use our products. However, the availability of insurance
coverage and reimbursement for newly approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly
difficult to obtain even if our products are approved by the FDA as safe and efficacious. Patients using existing approved therapies
are generally reimbursed all or part of the product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance
organizations and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and
the level of reimbursement of new drugs, and, as a result, they may not cover or provide adequate payment for these products.
Submission of applications for reimbursement approval generally does not occur prior to the filing of a BLA for that product and
may not be granted until many months after BLA approval. In order to obtain coverage and reimbursement for these products, we
or our commercialization partners may have to agree to a net sales price lower than the net sales price we might charge in other
sales channels. The continuing efforts of government and third-party payors to contain or reduce the costs of healthcare may limit
our revenue. Initial dependence on the commercial success of our products may make our revenues particularly susceptible to any
cost containment or reduction efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that our third-party service providers, consultants or current or former employees have wrongfully used
or disclosed confidential information of third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously
employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants
or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or
our employees&rsquo; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in
defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend on third-party manufacturers to produce our pre-clinical and clinical trial drug supplies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently operate manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We
rely on third-party manufacturers to supply, store, and distribute pre-clinical and clinical supply of our product candidates,
and plan to continue to do so for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development or regulatory approval of our product candidates or commercialization of any approved products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Our
product candidates require precise, high-quality manufacturing. Failure by our contract manufacturer to achieve and maintain high
manufacturing standards could result in patient injury or death, product recalls or withdrawals, delays or failures in testing
or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers may encounter difficulties
involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing periodic and unannounced
inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and other applicable
government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&rsquo; compliance
with these regulations and standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
these third-party contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shut downs,
employee strikes, or any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise
and conduct (either ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability
of third-party manufacturers to consistently supply quality product when required would have a material adverse effect on our
ability to commercialize our products. We have faced delays and risks associated with reliance on key third party manufacturers
in the past and may be faced with such delays and risks in the future. Any future manufacturing interruptions or related supply
issues could have an adverse effect on our company, including delays in clinical trials.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are successful in obtaining marketing approval from the FDA and/or other regulatory agencies for any of our product candidates,
we anticipate continued reliance on third-party manufacturers. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, our product candidates have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers.
If the FDA or other regulatory agencies approve any of our product candidates for commercial sale, we expect that we would continue
to rely, at least initially, on third-party specialized manufacturers to produce commercial quantities of approved products. These
manufacturers may not be able to successfully increase the manufacturing capacity for any approved product in a timely or economic
manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA must review
and approve. If third party manufacturers are unable to successfully increase the manufacturing capacity for a product candidate,
or we are unable to establish our own manufacturing capabilities, the commercial launch of any approved products may be delayed
or there may be a shortage in supply, which in turn could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA
pursuant to inspections that will be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of,
and are completely dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers
cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA
or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.
If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates
or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly
impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may have conflicts with our partners that could delay or prevent the development or commercialization of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may have conflicts with our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement
of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership
of intellectual property developed during our collaboration. If any conflicts arise with any of our partners, such partner may
act in a manner that is averse to our best interests. Any such disagreement could result in one or more of the following, each
of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating
revenues: unwillingness on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration;
uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent
us from entering into additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of
the product, including providing us with product data or materials; unwillingness on the part of a partner to keep us informed
regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those
activities; initiating litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts
by either party to terminate the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition from other biotechnology and pharmaceutical companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates face, and will continue to face, intense competition from large pharmaceutical companies, as well as academic
and research institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry
standards, (iii) emerging competition and (iv) new product introductions. Our competitors have existing products and technologies
that will compete with our product candidates and technologies and may develop and commercialize additional products and technologies
that will compete with our product candidates and technologies. Because several competing companies and institutions have greater
financial resources than us, they may be able to (i) provide broader services and product lines, (ii) make greater investments
in research and development, or R&amp;D, and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development
capabilities than we do and have substantially greater experience in undertaking preclinical and clinical testing of product candidates,
obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. They also have greater name recognition
and better access to customers than us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent
their regulatory approval, limit their commercial potential, or result in significant negative consequences </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials
and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign
authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the
trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and
prospects significantly. Even if any of our product candidates receives marketing approval, as greater numbers of patients use
a product following its approval, an increase in the incidence of side effects or the incidence of other post-approval problems
that were not seen or anticipated during pre-approval clinical trials could result in a number of potentially significant negative
consequences, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw their approval
    of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may
    require the addition of labeling statements, such as warnings or contraindications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required
    to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may elect, or we may be required, to recall
    or withdraw product from the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused
    to patients; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could substantially increase the costs and expenses of developing, commercializing and marketing any such product
candidates or could harm or prevent sales of any approved products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend upon securing and protecting critical intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on obtaining and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the
United States and other jurisdictions, as well as successfully enforcing this intellectual property and defending this intellectual
property against third-party challenges. The degree of future protection of our proprietary rights is uncertain for product candidates
that are currently in the early stages of development because we cannot predict which of these product candidates will ultimately
reach the commercial market or whether the commercial versions of these product candidates will incorporate proprietary technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
patent position is highly uncertain and involves complex legal and factual questions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we cannot predict the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example,
we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and
issued patents; we or our licensors might not have been the first to file patent applications for these inventions; others may
independently develop similar or alternative technologies or duplicate any of our technologies; it is possible that none of our
pending patent applications or the pending patent applications of our licensors will result in issued patents; our issued patents
and issued patents of our licensors may not provide a basis for commercially viable technologies, or may not provide us with any
competitive advantages, or may be challenged and invalidated by third parties; and, we may not develop additional proprietary
technologies that are patentable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, our owned and licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain
trade secret protection for the full commercial extent of our technology. The extent to which we are unable to do so could materially
harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors have applied for and will continue to apply for patents for certain products. Such applications may not result
in the issuance of any patents, and any patents now held or that may be issued may not provide us with adequate protection from
competition. Furthermore, it is possible that patents issued or licensed to us may be challenged successfully. In that event,
if we have a preferred competitive position because of such patents, such preferred position would be lost. If we are unable to
secure or to continue to maintain a preferred position, we could become subject to competition from the sale of generic products.
Failure to receive, inability to protect, or expiration of our patents for medical use, manufacture, conjugation and labeling
of Ac-225, the antibodies that we license from third parties, or subsequent related filings, would adversely affect our business
and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
issued or licensed to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against
infringers, if such enforcement is required, could be significant, and we do not currently have the financial resources to fund
such litigation. Further, such litigation can go on for years and the time demands could interfere with our normal operations.
There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical
industry. We may become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved
in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively
than we can because of their substantially greater financial resources. Litigation may also absorb significant management time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unpatented
trade secrets, improvements, confidential know-how and continuing technological innovation are important to our scientific and
commercial success. Although we attempt to and will continue to attempt to protect our proprietary information through reliance
on trade secret laws and the use of confidentiality agreements with our partners, collaborators, employees and consultants and
other appropriate means, these measures may not effectively prevent disclosure of our proprietary information, and, in any event,
others may develop independently, or obtain access to, the same or similar information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our patent rights are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our
rights to those patents may be terminated, and we will be unable to conduct our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are found to be infringing on patents or trade secrets owned by others, we may be forced to cease or alter our product development
efforts, obtain a license to continue the development or sale of our products, and/or pay damages.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing processes and potential products may violate proprietary rights of patents that have been or may be granted to competitors,
universities or others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents
are issued, the risk increases that our processes and potential products may give rise to claims that they infringe the patents
or trade secrets of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical
testing, manufacturing and marketing of the affected product or process. If any of these actions are successful, in addition to
any potential liability for damages, we could be required to obtain a license in order to continue to conduct clinical tests,
manufacture or market the affected product or use the affected process. Required licenses may not be available on acceptable terms,
if at all, and the results of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume
a substantial portion of our financial resources and the efforts of our personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to protect and enforce our patents does not guarantee that we will secure the right to commercialize our patents.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent is a limited monopoly right conferred upon an inventor, and his successors in title, in return for the making and disclosing
of a new and non-obvious invention. This monopoly is of limited duration but, while in force, allows the patent holder to prevent
others from making and/or using its invention. While a patent gives the holder this right to exclude others, it is not a license
to commercialize the invention where other permissions may be required for commercialization to occur. For example, a drug cannot
be marketed without the appropriate authorization from the FDA, regardless of the existence of a patent covering the product.
Further, the invention, even if patented itself, cannot be commercialized if it infringes the valid patent rights of another party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on confidentiality agreements to protect our trade secrets. If these agreements are breached by our employees or other parties,
our trade secrets may become known to our competitors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets that we seek to protect through confidentiality agreements with our employees and other parties. If these
agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may
not have any remedies against our competitors and any remedies that may be available to us may not be adequate to protect our
business or compensate us for the damaging disclosure. In addition, we may have to expend resources to protect our interests from
possible infringement by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain
compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive
and biological materials, such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws
and regulations governing, among other matters, the handling, storage, use and disposal of these materials and some waste products.
We cannot completely eliminate the risk of contamination or injury from these materials and we could be held liable for any damages
that result, which could exceed our financial resources. We currently maintain insurance coverage for injuries resulting from
the hazardous materials we use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage
for pollution cleanup and removal. Currently the costs of complying with such federal, state, local and foreign environmental
regulations are not significant, and consist primarily of waste disposal expenses. However, they could become expensive, and current
or future environmental laws or regulations may impair our research, development, production and commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may undertake international operations, which will subject us to risks inherent with operations outside of the United States.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Although
we do not have any international operations at this time, we intend to seek market clearances in foreign markets that we believe
will generate significant opportunities. However, even with the cooperating of a commercialization partner, conducting drug development
in foreign countries involves inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign
operations; unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties
in protecting, acquiring, enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and
potentially adverse tax consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to experience any of the difficulties listed above, or any other difficulties, any international development activities
and our overall financial condition may suffer and cause us to reduce or discontinue our international development and registration
efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel,
we may not be able to successfully implement our business strategy. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future operations and successes depend in large part upon the continued service of key members of our senior management team whom
we are highly dependent upon to manage our business. If any member of our current senior management terminates his employment
with us and we are unable to find a suitable replacement quickly, the departure could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success also depends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial,
technical, clinical and regulatory personnel. There can be no assurance that such professionals will be available in the market,
or that we will be able to retain existing professionals or meet or continue to meet their compensation requirements. Furthermore,
the cost base in relation to such compensation, which may include equity compensation, may increase significantly, which could
have a material adverse effect on us. Failure to establish and maintain an effective management team and workforce could adversely
affect our ability to operate, grow and manage our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without
limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These
laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to
patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect
our ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback
    Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying
    remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable
    under a federal healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and
    criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from
    knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors
    that are false or fraudulent;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health
    Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal statutes that prohibit executing
    a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended
    by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain
    requirements relating to the privacy, security, and transmission of individually identifiable health information;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal physician
    sunshine requirements under PPACA, which require certain manufacturers of drugs, devices, biologics, and medical supplies
    to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers
    of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by
    physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents
    of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed
    by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the
    industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government,
    or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that
    require drug manufacturers to report information related to payments and other transfers of value to physicians and other
    healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in
    certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some
of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform
legislation has strengthened these laws. For example, the PPACA, among other things, amends the intent requirement of the federal
anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute
or specific intent to violate it to have committed a violation. Moreover, the PPACA provides that the government may assert that
a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply
to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in
government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations,
any of which could adversely affect our ability to operate our business and our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
federal legislation will increase pressure to reduce prices of pharmaceutical products paid for by Medicare, which could materially
adversely affect our revenue, if any, and our results of operations.</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the MMA, changed the
way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the
elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition,
this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. As a result
of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to
reduce costs. These cost reduction initiatives and other provisions of this legislation could decrease the scope of coverage and
the price that we receive for any approved products and could harm our business. While the MMA applies only to drug benefits for
Medicare beneficiaries, private payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement
rates, and any reduction in reimbursement that results from the MMA may cause a similar reduction in payments from private payors.
This legislation may pose an even greater risk to our drug candidates as a significant portion of the target patient population
for our drug candidates would likely be over 65 years of age and, therefore, many such patients will be covered by Medicare.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act, or collectively, the PPACA, became law in the United States. The goal of the PPACA is to reduce the cost of healthcare and
substantially change the way healthcare is financed by both governmental and private insurers. While we cannot predict what impact
on federal reimbursement policies this legislation will have in general or on our business specifically, the PPACA may result
in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of our drug candidates,
if approved, or any of our future products. In 2012, members of the U.S. Congress and some state legislatures sought to overturn
certain provisions of the PPACA including those concerning the mandatory purchase of insurance. However, on June 28, 2012, the
United States Supreme Court upheld the constitutionality of these provisions. Members of the U.S. Congress have since proposed
a number of legislative initiatives, including possible repeal of the PPACA. We cannot predict the outcome or impact of current
proposals or whether new proposals will be made or adopted, when they may be adopted or what impact they may have on us if they
are adopted. These challenges add to the uncertainty of the legislative changes as part of ACA. Changes that may affect our business
include those governing enrollment in federal healthcare programs, reimbursement changes, fraud and abuse and enforcement. These
changes will impact existing government healthcare programs and will result in the development of new programs, including Medicare
payment for performance initiatives and improvements to the physician quality reporting system and feedback program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Managing
our growth as we expand operations may strain our resources.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to need to grow rapidly in order to support additional, larger, and potentially international, pivotal clinical trials
of our product candidates, which will place a significant strain on our financial, managerial and operational resources. In order
to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.
Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase
our expenses and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially
harm our business, financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expand our business through the acquisition of rights to new product candidates that could disrupt our business, harm our
financial condition and may also dilute current stockholders&rsquo; ownership interests in our company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies
or technologies to do so. Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance
of equity securities; incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify
at the time of acquisition; difficulties in assimilating acquired technologies or the operations of the acquired companies; diverting
our management&rsquo;s attention away from other business concerns; risks of entering markets in which we have limited or no direct
experience; and the potential loss of our key employees or key employees of the acquired companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can make no assurances that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the
value or worth of an acquired product, company or business. In addition, our future success would depend in part on our ability
to manage the rapid growth associated with some of these acquisitions. We cannot assure that we will be able to make the combination
of our business with that of acquired products, businesses or companies work or be successful. Furthermore, the development or
expansion of our business or any acquired products, business or companies may require a substantial capital investment by us.
We may not have these necessary funds, or they might not be available to us on acceptable terms or at all. We may also seek to
raise funds by selling shares of our preferred or common stock, which could dilute each current stockholder&rsquo;s ownership
interest in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to Ownership of Our Common Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
sale of securities by us in any equity or debt financing could result in dilution to our existing stockholders and have a material
adverse effect on our earnings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations primarily through sales of stock and warrants. It is likely that during the next twelve months we
will seek to raise additional capital through the sales of stock and warrants in order to expand our level of operations to continue
our research and development efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
sale of common stock by us in a future offering could result in dilution to our existing stockholders as a direct result of our
issuance of additional shares of our capital stock. In addition, our business strategy may include expansion through internal
growth or by establishing strategic relationships with targeted customers and vendors. In order to do so, or to finance the cost
of our other activities, we may issue additional equity securities that could dilute our stockholders&rsquo; stock ownership.
We may also assume additional debt and incur impairment losses related to goodwill and other tangible assets if we acquire another
company and this could negatively impact our earnings and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Common Stock has been considered a Penny Stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2018, 2017 and 2016, the price of our common stock has traded below $5.00 per share, and therefore has been treated as a penny
stock. Penny stocks generally are equity securities with a price of less than $5.00. Penny stock rules require a broker-dealer,
prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document
that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the
customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson
in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&rsquo;s account.
The broker-dealer must also make a special written determination that the penny stock is a suitable investment for the purchaser
and receive the purchaser&rsquo;s written agreement to the transaction. These requirements may have the effect of reducing the
level of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional
burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities,
which could severely limit their market price and liquidity of our securities. These requirements may restrict the ability of
broker-dealers to sell our common stock and may affect your ability to resell our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock is subject to price volatility which could lead to losses by stockholders and potential costly security litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading volume of our common stock has been and may continue to be extremely limited and sporadic. We expect the market price
of our common stock to fluctuate substantially due to a variety of factors, including market perception of our ability to achieve
our planned growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes
in general conditions in the economy and the financial markets or other developments affecting our competitors or us. This volatility
has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating
performance and could have the same effect on our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our Common Stock may be highly volatile and could fluctuate in response to factors such as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our operating
    results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of developments by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of IND and/or BLA approval, the completion
    and/or results of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions regarding our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by
    us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting standards affecting
    our industry;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our Common Stock or other securities
    in the open market; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond
    our control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock market is subject to significant price and volume fluctuations. In the past, following periods of volatility in the market
price of a company&rsquo;s securities, securities class action litigation has often been initiated against such a company. Litigation
initiated against us, whether or not successful, could result in substantial costs and diversion of our management&rsquo;s attention
and our resources, which could harm our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not intend to pay dividends on our common stock, so any returns will be determined by the value of our common stock. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings,
if any, generated from our operations will be used to finance the growth of our business, and that no dividends will be paid to
holders of our common stock. As a result, the success of an investment in our common stock will depend upon any future appreciation
in its value. There is no guarantee that our common stock will appreciate in value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire
us and make a takeover more difficult to complete, even if such a transaction were in our stockholders&rsquo; interest.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in
our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their
shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions
could adversely affect the price of our stock. Among other things, the certificate of incorporation and bylaws:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that the
    authorized number of directors may be changed by resolution of the board of directors; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative
    vote of a majority of directors then in office, even if less than a quorum; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide the board
    of directors into three classes; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as
    directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as
    to the form and content of a stockholder&rsquo;s notice; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are governed by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware
corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of
three years after the date of the transaction in which the person became an interested stockholder, unless the business combination
is approved in a prescribed manner. A &ldquo;business combination&rdquo; includes mergers, asset sales or other transactions resulting
in a financial benefit to the stockholder. An &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and
associates, owns, or within three years, did own, 15% or more of the corporation&rsquo;s outstanding voting stock. These provisions
may have the effect of delaying, deferring or preventing a change in our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compliance
with the reporting requirements of federal securities laws can be expensive.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and reporting requirements of the Exchange Act and other federal securities laws, and the compliance
obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports and other information with
the Securities and Exchange Commission and furnishing audited reports to stockholders are substantial. In addition, we will incur
substantial expenses in connection with the preparation of registration statements and related documents with respect any offerings
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our ability to
utilize our net operating loss carryforwards and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to utilize our federal net operating loss and tax credit carryforwards may be limited under
Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code.&nbsp; The limitations apply if we experience
an &ldquo;ownership change&rdquo;, generally defined as a greater than 50 percentage point change in the ownership of our equity
by certain stockholders over a rolling three-year period.&nbsp;Similar provisions of state tax law may also apply. We have not
assessed whether such an ownership change has previously occurred.&nbsp;If we have experienced an ownership change at any time
since our formation, we may already be subject to limitations on our ability to utilize our existing net operating losses and
other tax attributes to offset taxable income. In addition, future changes in our stock ownership, which may be outside of our
control, may trigger an ownership change and, consequently, the limitations under Sections 382 and 383 of the Code.&nbsp;As a
result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and other tax
attributes to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to establish and maintain adequate finance infrastructure and accounting systems and controls could impair our ability to comply
with the financial reporting and internal controls requirements for publicly traded companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we operate in an increasingly demanding regulatory environment, including with respect to more complex accounting
rules. Company responsibilities required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing
and maintaining corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures.
Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial
fraud.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compliance with Section 404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant
management efforts. We complied with Section 404 at December 31, 2018 and 2017 and while our testing did not reveal any material
weaknesses in our internal controls, subsequent testing by our independent registered public accounting firm may reveal material
weaknesses in our internal controls that we would be required to remediate in a timely manner so as to be able to comply with
the requirements of Section 404 of the Sarbanes-Oxley Act each year. If we are not able to comply with the requirements of Section
404 of the Sarbanes-Oxley Act in a timely manner each year, we could be subject to sanctions or investigations by the SEC, NYSE
American or other regulatory authorities which would require additional financial and management resources and could adversely
affect the market price of our common stock. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our
business and results of operations could be harmed, and investors could lose confidence in our reported financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
1B. UNRESOLVED STAFF COMMENTS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
2. PROPERTIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own any real property. We lease offices at 275 Madison Avenue, New York, NY. The lease is for 5,790 square feet and has
a term of seven years and three months, with an expiration date of September 6, 2022, with a current annual rate of $312,660 until
June 8, 2019 and $341,610 for the remaining life of the lease. We are also responsible for certain other costs, such as insurance,
taxes, utilities and maintenance. We issued a letter of credit of $390,825 in connection with the lease and maintained a $391,131
certified deposit as collateral for the letter of credit.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
3. LEGAL PROCEEDINGS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.
Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that
may harm business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate,
a material adverse effect on our business, financial condition or operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
4. MINE SAFETY DISCLOSURES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>ITEM
5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDERS MATTERS, AND ISSUER PURCHASE OF EQUITY SECURITIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for quotation on the NYSE AMERICAN under the symbol &ldquo;ATNM&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 15, 2019,
there were 119,136,036 shares of common stock issued and outstanding, which were held by approximately 97 holders of record. There
are no shares of preferred stock outstanding. On March 14, 2019, the closing price of our common stock as reported on the NYSE
AMERICAN was $0.57 per share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Authorized for Issuance under Equity Compensation Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two equity compensation plans defined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s 2013 Stock Plan has an expiration date of September 9, 2023 and the total number of shares of our common stock
available for grant to employees, directors and consultants under the plan is currently 22,750,000 shares. At our Annual Meeting
of Stockholders held in December 2018, our stockholders increased the number of shares available to be granted under the 2013
Stock Plan from 17,750,000 shares to 22,750,000 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s 2013 Equity Incentive Plan has an expiration date of September 9, 2023 and the total number of shares of our common
stock available for grant to employees, directors and consultants under the plan is 1,000,000 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table indicates shares of common stock authorized for issuance under our equity compensation plans as of December 31,
2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Plan category</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> securities&nbsp;to<BR> be&nbsp;issued<BR> upon&nbsp;exercise<BR> of&nbsp;outstanding<BR> options,<BR> warrants<BR> and&nbsp;rights</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<BR> average<BR> exercise<BR> price&nbsp;of<BR> outstanding<BR> options,<BR> warrants<BR> and&nbsp;rights</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> securities<BR> remaining<BR> available<BR> for&nbsp;future<BR> issuance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,236,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.74</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">15,912,235</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,236,101</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.74</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,912,235</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
6. SELECTED FINANCIAL DATA.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following selected financial data should be read in conjunction with our consolidated financial statements and related notes and
the&nbsp;&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;&nbsp;and other
financial data included elsewhere in this Form 10-K. The selected statements of operations and the selected balance sheet data
are derived from our consolidated audited financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Statements of Operations Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: justify">Loss from operations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(23,827,322</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(26,910,788</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(26,847,481</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(24,829,764</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(22,480,544</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(23,653,963</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(26,601,235</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(24,321,724</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(21,025,314</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(24,687,509</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net loss per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.22</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.40</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.50</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.55</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.90</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Weighted-average common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,041,809</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,746,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,463,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,158,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,363,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,673,308</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,399,636</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,519,294</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">25,643,273</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,706,802</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,889,394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,337,107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,528,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26,587,581</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,569,086</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,076,597</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,666,004</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,520,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,613,533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,491,616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,812,797</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,671,103</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,008,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21,974,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,922,530</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
information and financial data discussed below is derived from the audited consolidated financial statements of Actinium Pharmaceuticals,
Inc. for its fiscal years ended December 31, 2018, 2017 and 2016.&nbsp;&nbsp;&nbsp;The consolidated financial statements of Actinium
Pharmaceuticals, Inc. were prepared and presented in accordance with generally accepted accounting principles in the United States.
The information and financial data discussed below is only a summary and should be read in conjunction with the historical financial
statements and related notes of Actinium Pharmaceuticals, Inc. contained elsewhere in this&nbsp;Report. The financial statements
contained elsewhere in this Report fully represent Actinium Pharmaceuticals, Inc.&rsquo;s financial condition and operations;
however, they are not indicative of the Company&rsquo;s future performance. See &ldquo;Cautionary Note Regarding Forward-Looking
Statements&rdquo; above for a discussion of forward-looking statements and the significance of such statements in the context
of this Report.&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals Inc. is a clinical-stage, biopharmaceutical company focused on developing and potentially commercializing therapies
for targeted conditioning prior to cell therapies such as a BMT or Bone Marrow Transplant or CAR-T, a type of cellular therapy
that genetically alters a patient&rsquo;s own T cells to target and kill their cancer cells, and for other adoptive cell therapies.
In addition, we are also developing potential therapies for targeting and killing of cancer cells either as single agents or in
combination with other drugs. Our targeted therapies are Antibody Radiation-Conjugates or ARCs, that combine the targeting ability
of a monoclonal antibody (mAb) with the cell-killing ability of a radioisotope to deliver radiation internally in a precise manner
to potentially generate more potent efficacy and with less toxicity than radiation that is delivered externally. We are developing
two clinical stage ARC programs that target the antigens CD45 and CD33, respectively, that are currently being studied in several
hematologic indications. We employ our ARCs at higher doses of radioisotope intensity for targeted conditioning prior to a BMT
and at lower doses for targeted conditioning which is also known as lymphodepletion prior to CAR-T and other adoptive cell therapies.
In addition, we are pursuing development of our ARC&rsquo;s at low doses in combination with other therapeutic modalities such
as chemotherapy, targeted agents or immunotherapy and as a monotherapy. Our ARC based clinical programs are underpinned by our
AWE or Antibody Warhead Enabling technology platform where we have data in both liquid and solid tumors, intellectual property
and know-how that we intend to use to create additional ARCs targeting new antigens with multiple radioisotopes such as actinium-225
or Ac-225 or and iodine-131 or I-131. Our AWE technology platform is currently being utilized in a research collaboration with
Astellas Pharma, Inc. centered around our technology for Ac-225. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never generated
revenue. Currently we do not have a recurring source of revenues to cover our operating costs. We have incurred net losses and
negative operating cash flows since inception. As of December 31, 2018 and 2017, our accumulated deficit was $186.9 million and
$163.2 million, respectively. Our net loss was $23.7 million, $26.6 million, and $24.3 million for the years ended December 31,
2018, 2017 and 2016, respectively. These conditions raise substantial doubt as to our ability to continue as a going concern.
As of December 31, 2018, we had $13.7 million in cash and cash equivalents. Our consolidated financial statements are prepared
using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated
financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts
and classification of liabilities should we be unable to continue as a going concern. As of the date of filing this report, we
expect that our existing resources will be sufficient to fund our planned operations into the fourth quarter of 2019; however,
additional capital resources will be needed to fund operations longer-term. If we are unsuccessful in accomplishing our plans,
we may have to delay or terminate existing and/or planned clinical trials and other related activity, which could have a material
adverse impact on our business. Our plan to continue as a going concern is includes obtaining capital from the sale of our equity
securities, potential exercise of outstanding warrants, fees from licensing one or more of our product candidates, additional
collaborations with our Iomab-ACT program and AWE technology platform, and short-term borrowings from banks, stockholders or other
related parties, if needed. However, we cannot provide any assurance that we will be successful in accomplishing any of our plans.
Our ability to continue as a going concern is dependent upon our ability to successfully accomplish the plans described above
and eventually to secure other sources of financing and attain profitable operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations &ndash; Year Ended December 31, 2018 Compared to the Year Ended December 31, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for the periods indicated, data derived from our statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Increase</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0.125in">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,094,778</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,719,855</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(625,077</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,732,544</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,190,933</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,453,389</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,827,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,910,788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,083,466</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">173,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,929</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Gain on change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">304,123</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(304,123</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">173,359</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">309,553</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(136,194</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(23,653,963</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(26,601,235</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,947,272</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded no commercial revenues for the years ended December 31, 2018 and 2017, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we entered into a research and option agreement with Astellas to develop Actinium-225 Radiation-Conjugates, or ARCs, using
our Actinium Warhead Enabling, or AWE, Platform Technology. Under this collaboration, we will utilize our AWE Platform to conjugate
and label selected Astellas targeting agents with an Actinium-225 payload. We will also be responsible for conducting preclinical
validation studies on any ARCs generated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses declined by $0.7 million to $17.0 million for the year ended December 31, 2018 compared to $17.7 million
for the year ended December 31, 2017. The decrease was primarily attributable to the recognition of payments received from Astellas,
with such payments accounted for as a reduction in research and development expenses, as well as lower expenses related to Actimab-A
and lower non-cash stock-based compensation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses declined by $2.5 million to $6.7 million for the year ended December 31, 2018 compared to $9.2 million
for the year ended December 31, 2017, primarily due to lower compensation expense, resulting from lower non-cash stock-based compensation
expense during 2018 and one-time charges paid to certain former employees in 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income (Expense)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income of $0.2 million for the year ended December 31, 2018 was attributable to interest income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we accounted for certain instruments which do not have fixed settlement provisions as derivative instruments in accordance with
FASB ASC 815-40<I>, Derivative and Hedging &ndash; Contracts in Entity&rsquo;s Own Equity</I>. This was due to an anti-dilution
provision for certain warrants that provide for a reduction to the exercise price if we issued equity or equity-linked instruments
at an effective price per share less than the exercise price then in effect for the warrant, or a &ldquo;down round provision&rdquo;.
As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value
were recorded as non-cash adjustments within other income in our accompanying Consolidated Statements of Operations. We recorded
a gain on the change in the estimated fair value of warrants of $0.3 million for the year ended December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 1, 2018, we early adopted Accounting Standard Update, or ASU, 2017-11, which revised the guidance for instruments with
down-round provisions. As such, we treated outstanding warrants as free-standing equity-linked instruments that are recorded to
equity in the Consolidated Balance Sheet as of January 1, 2018. As a result, there was no gain or loss from the valuation of the
derivative liability recorded for the year ended December 31, 2018.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net loss decreased by $2.9
million to $23.7 million for the year ended December 31, 2018 compared to $26.6 million for the year ended December 31, 2017. The
decrease was primarily due to lower general and administrative expenses and research and development expenses.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations &ndash; Year Ended December 31, 2017 Compared to the Year Ended December 31, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for the periods indicated, data derived from our statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Increase</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0.125in">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,719,855</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,828,287</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(108,432</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,190,933</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,019,194</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">171,739</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,910,788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,847,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">63,307</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Interest income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,007</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,437</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Gain on change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">304,123</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,530,764</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,226,641</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">309,553</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,525,757</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,216,204</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(26,601,235</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(24,321,724</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,279,511</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded no commercial revenues for the years ended December 31, 2017 and 2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses declined $0.1 million to $17.7 million for the year ended December 31, 2017 compared to $17.8 million
for the year ended December 31, 2016. The decrease was primarily attributable to the higher expenses in 2016 resulting from start-up
costs for a Phase 2 trial for Actimab-A and closing costs associated with a Phase 1 trial of Actimab A, mostly offset by higher
expenses related to Iomab-B.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $0.2 million to $9.2 million for the year ended December 31, 2017 compared to $9.0 million
for the year ended December 31, 2016, primarily as a result of one-time charges paid to certain former employees and higher professional
fees.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income (Expense) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense) was $0.3 million and $2.5 million for the years ended December 31, 2017 and 2016, respectively. The decline is
attributable to the fluctuation of our stock price and its impact on the derivative value of certain warrants we issued in connection
with a financing in December 2012.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss increased by $2.3 million to $26.6 million for the year ended December 31, 2017 compared to $24.3 million for the year ended
December 31, 2016. The increase was primarily due to one-time charges paid to certain former employees and the decrease in noncash
other income, resulting from the lower gain on the change in fair value of our derivative warrant liabilities.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations primarily through sales of our stock and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables sets forth selected cash flow information for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(20,571,056</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(21,553,346</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(20,789,237</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(96,092</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,739</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(109,819</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,981,086</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,814,634</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,775,077</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net&nbsp;change in cash, cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,686,062</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,763,451</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,123,979</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the years ended December 31, 2018 and 2017&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $20.6 million for the year ended December 31, 2018, a decline of $1.0 million compared to
$21.6 million used in operations for the year ended December 31, 2017. The decrease reflects our lower research and development
expenses, our receipt of payments from Astellas and lower compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities of $96 thousand and $25 thousand for the years ended December 31, 2018 and December 31, 2017,
respectively, was for the purchase of equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was mainly generated by the sale of shares of common stock and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;On
October 18, 2018, we entered into a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC
or Lincoln Park, whereby we have the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $32.5
million, subject to certain limitations and conditions set forth in the agreements. As consideration for entering into the agreements,
we issued to Lincoln Park 852,537 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the purchase agreement, Lincoln Park initially purchased 3.4 million shares of common stock, at a price of $0.74 per share,
for a total gross purchase price of $2.5 million. We have the right, from time to time, subject to certain daily limitations,
to direct Lincoln Park to purchase up to an additional $30.0 million. We control the timing and amount of any sales of common
stock to Lincoln Park. In all instances, we may not sell shares of common stock to Lincoln Park if it would result in Lincoln
Park beneficially owning more than 9.99% of its common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase agreement does not limit our ability to raise capital from other sources, except that (subject to certain exceptions)
we may not enter into any variable-rate transaction, including the issuance of any floating conversion rate or variable priced
equity-like securities) during the 30 months after the date of the purchase agreement. We have the right to terminate the purchase
agreement at any time, at no cost to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
December 31, 2018, we elected to sell to Lincoln Park an additional 1.0 million shares and received $0.7 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we sold an aggregate of 30.2 million units consisting of an aggregate of 30.2 million shares of common stock, 7.6
million series A warrants and 22.7 million series B warrants, with each series A warrant having an exercise price of $0.60 per
share and each series B warrant having an exercise price of $0.70 per share, resulting in gross proceeds of approximately $15.1
million, (each unit was sold at $0.50 per unit), and net proceeds of approximately $13.8 million after deducting expenses relating
to dealer-manager fees and other offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the years ended December 31, 2017 and 2016&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $21.6 million for the year ended December 31, 2017 compared to $20.8 million used in operations for the year ended
December 31, 2016, the increase was due to increased activity from our clinical trials and one-time charges paid to certain former
employees.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $25 thousand and $110 thousand for the years ended December 31, 2017 and 2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $18.8 million and $15.8 million for the years ended December 31, 2017 and 2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2017, we issued 2.7 million shares of common stock for gross proceeds of approximately $4.0 million as part of an at-the-market
sales agreement with an investment bank. We paid expenses of approximately $0.2 million resulting in net proceeds of $3.8 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2017, we completed an underwritten public offering of 21.5 million shares of common stock and warrants to purchase 18.3
million shares of common stock at an offering price of $0.75 per share and related warrant. The warrants have an exercise price
of $1.05 per share and have a term of five years. The gross proceeds from this offering were approximately $16.1 million, before
deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company resulting in net
proceeds of approximately $15.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2016, we sold 8.0 million shares of common stock at a price of $1.25 per share through an underwritten public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2016, we issued 3.5 million shares of common stock for net proceeds of $6.8 million as part of an at-the-market sales agreement
with an investment bank</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of filing this report, we expect that our existing resources will be sufficient to fund
our planned operations into the fourth quarter of 2019; however, additional capital resources will be needed to fund operations
longer-term. If we are unsuccessful in accomplishing our plans, we may have to delay or terminate existing and/or planned clinical
trials and other related activity, which could have a material adverse impact on our business. Our plan to continue as a going
concern is includes obtaining capital from the sale of our equity securities, potential exercise of outstanding warrants, fees
from licensing one or more of our product candidates, additional collaborations with our Iomab-ACT program and AWE technology platform,
and short-term borrowings from banks, stockholders or other related parties, if needed. However, we cannot provide any assurance
that we will be successful in accomplishing any of our plans. Our ability to continue as a going concern is dependent upon our
ability to successfully accomplish the plans described above and eventually to secure other sources of financing and attain profitable
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&rsquo;s discussion and analysis of financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP.
The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of
assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements
during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material
changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events,
and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates
are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates
under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Financial Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority
to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair
value hierarchy is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 Inputs &ndash;
    Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to
    access at the measurement date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 Inputs &ndash;
    Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
    These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
    assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or
    liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally
    from or corroborated by market data by correlation or other means.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 Inputs &ndash;
    Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&rsquo;s own assumptions
    about the assumptions that market participants would use in pricing the assets or liabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by us as a reduction
of research and development costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-Based
Payments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair
value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. We account for forfeitures of stock options as they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use the asset and liability method to calculate deferred taxes. Deferred taxes are recognized based on the differences between
the financial reporting and income tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect
when the differences are expected to reverse. We review deferred tax assets for a valuation allowance based upon whether it is
more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against
deferred tax assets, based upon our assessment as to their realization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize tax when the positions meet a &ldquo;more-likely-than-not&rdquo; recognition threshold. There were no tax positions
for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly increase
or decrease within the next year. We recognize interest related to unrecognized tax benefits in interest expense and penalties
in operating expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
Standards Recently Adopted</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued an Accounting Standards Update (&ldquo;ASU&rdquo;)
amending the presentation of restricted cash within the consolidated statements of cash flows. The new guidance requires that
restricted cash be added to cash and cash equivalents on the consolidated statements of cash flows. We adopted this ASU on January
1, 2018 on a retrospective basis with the following impact to our consolidated statements of cash flows for the year ended December
31, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Previously Reported</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustment</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Revised</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Net cash used in investing activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(380,946</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">356,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(24,739</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2018 and December 31, 2017, we had a certified deposit of $391,131 and $390,940, respectively, as collateral for
a letter of credit issued in connection with a lease agreement and as of December 31, 2018, we had restricted cash of $40,075
related to credit card accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the FASB issued ASU No. 2014-09, <I>Revenue from Contracts with Customers</I>. Under the new standard, revenue is recognized
at the time a good or service is transferred to a customer for the amount of consideration for which the entity expects to be
entitled for that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as
of the date of adoption. We adopted this ASU on January 1, 2018 and the adoption did not have a significant impact to our financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, the FASB issued ASU No. 2017-11, <I>Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480);
Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features</I>. These
amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies
to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining
liability or equity classification. The guidance was adopted as of April 1, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Standards</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting standards are issued by the FASB or other standard setting bodies. Unless otherwise discussed, we
believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated
financial position or results of operations upon adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, FASB issued ASU No. 2016-02 <I>Leases</I> (Topic 842), which creates new accounting and reporting guidelines for
leasing arrangements. The standard requires that a lessee recognize the assets and liabilities that arise from operating leases.
A lessee should recognize on its balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset
representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is
permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities.
In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented
using a modified retrospective approach. The guidance in ASU 2016-02 is effective for annual and interim reporting periods beginning
after December 15, 2018. Our initial evaluation of our current leases does not indicate that the adoption of this standard will
have a material impact on our consolidated statements of operations. We do expect that the adoption of the standard will have
an impact on our consolidated balance sheets for the recognition of certain operating leases as right-of-use assets and lease
liabilities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the FASB issued ASU 2018-07 to expand the scope of ASC Topic 718, <I>Compensation - Stock Compensation</I>, to include
share-based payment transactions for acquiring goods and services from nonemployees. The standard is effective for fiscal years,
and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. We are currently
evaluating the impact of the new standard on our financial statements and related disclosures, but this is not expected to have
an impact on our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU 2018-13, <I>Fair Value Measurement - Disclosure Framework (Topic 820).</I> The updated guidance
improves the disclosure requirements on fair value measurements and is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures
modified or removed with a delay of adoption of the additional disclosures until their effective date. We are in the process of
evaluating the provisions of the ASU but do not expect it to have a material effect on our consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the FASB issued ASU 2018-18, C<I>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic
808 and Topic 606,</I> which, among other things, provides guidance on how to assess whether certain collaborative arrangement
transactions should be accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods
within those fiscal years, beginning after December 15, 2019, with early adoption permitted. We are in the process of evaluating
the impact the standard will have on our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsequent
Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2019, we sold
924,500 common shares through our at-the-market program and realized net proceeds of $0.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
December 31, 2018, holders of our March 2018 Series A warrants exercised 2.5 million shares, resulting in proceeds to us of $1.5
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since December 31, 2018, we granted
stock options to our employees to purchase a total of 530,000 common shares at a price range from $0.43 to $0.58 per share
related to new hires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 6, 2019, the Company
executed an amendment to the Company&rsquo;s 2013 Amended and Restated Stock Plan, as amended (the &ldquo;<U STYLE="text-decoration: none">Plan Amendment</U>&rdquo;).
The Plan Amendment increases the number of shares of common stock that the Company is authorized to issue under the plan to 22,750,000
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 6, 2019, the
Company filed a Certificate of Amendment to our Certificate of Incorporation, as amended, with the Secretary of State of the State
of Delaware to increase the number of authorized shares of Actinium&rsquo;s common stock from 400,000,000 to 600,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently exposed to significant market risk related to changes in interest rates. As of December 31, 2018, our cash equivalents
consisted of primarily of short-term money market funds. Our primary exposure to market risk is interest rate sensitivity, which
is affected by changes in the general level of U.S. interest rates. Due to the short-term nature of the cash equivalents in our
portfolio and the low risk profile of our cash equivalents, an immediate 10% change in interest rates would not have a material
effect on the fair market value of our financial position or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently exposed to significant market risk related to changes in foreign currency exchange rates. Our operations may
be subject to fluctuations in foreign currency exchange rates in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a
material effect on our business, financial condition or results of operations during the years ended December 31, 2018, 2017
and 2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_013"></A>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPORT OF MANAGEMENT ON INTERNAL CONTROL
OVER FINANCIAL REPORTING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The management of Actinium
Pharmaceuticals, Inc. (&ldquo;Actinium&rdquo;) is responsible for establishing and maintaining adequate internal control over financial
reporting, as defined in Rule 13a-15(f) or 15d-15(f) under the Securities Exchange Act of 1934. Actinium&rsquo;s internal control
system was designed to provide reasonable assurance to the company&rsquo;s management and Board of Directors regarding the preparation
and fair presentation of published financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium management
assessed the effectiveness of the company&rsquo;s internal control over financial reporting as of December 31, 2018. In making
this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&ldquo;COSO&rdquo;)
in Internal Control &ndash; Integrated Framework (2013 framework). Based on its assessment, Actinium management believes that,
as of December 31, 2018, the Company&rsquo;s internal control over financial reporting is effective based on those criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marcum, LLP, the independent
registered public accounting firm that audited the financial statements included in this Annual Report, has issued an attestation
report on the company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</FONT></TD>
    <TD STYLE="width: 60%; text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited Actinium Pharmaceutical,
Inc.&rsquo;s (the &ldquo;Company&rdquo;) internal control over financial reporting as of December 31, 2018, based on criteria established
in <I>Internal Control-Integrated Framework (2013)</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission.
In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December
31, 2018, based on criteria established in <I>Internal Control&mdash;Integrated Framework (2013)</I> issued by the Committee
of Sponsoring Organizations of the Treadway Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States) (&ldquo;PCAOB&rdquo;), the consolidated balance sheet as of December&nbsp;31, 2018 and the related consolidated
statements of operations, changes in shareholders&rsquo; equity, and cash flows for the year then ended of the Company and our
report dated March 15, 2019 expressed an unqualified opinion with an explanatory paragraph related to the substantial doubt about
the Company&rsquo;s ability to continue as a going concern on those financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness
of internal control over financial reporting included in the accompanying Report of Management on Internal Control over Financial
Reporting. Our responsibility is to express an opinion on the Company&rsquo;s internal control over financial reporting based on
our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our
audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was maintained in all material
respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as
we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Definition and Limitations of Internal
Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A company&rsquo;s internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company&rsquo;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could have a material effect on the
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that degree of compliance with the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Marcum LLP</FONT></TD>
    <TD STYLE="width: 60%; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum LLP</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston, Texas</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying consolidated
balance sheet of Actinium Pharmaceutical, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2018, the related consolidated statements
of operations, changes in stockholders&rsquo; equity and cash flows for the year then ended, and the related notes (collectively
referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 2018, and the results of its operations and its cash flows for
the year then ended, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States) (&ldquo;PCAOB&rdquo;), the Company&rsquo;s internal control over financial reporting as of December 31, 2018, based
on the criteria established in Internal Control&mdash;Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO) in 2013 and our report dated March 15, 2019, expressed an unqualified opinion on the effectiveness
of the Company&rsquo;s internal control over financial reporting.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Explanatory Paragraph &ndash; Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements have been prepared assuming that the Company will continue as a
going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, negative
cash flows and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management&rsquo;s
plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial
statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audit
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Marcum LLP</FONT></TD>
    <TD STYLE="width: 60%; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have served as the Company&rsquo;s auditor since 2012.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum LLP</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston, Texas</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the
accompanying consolidated balance sheet of Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2017,
the related consolidated statements of operations, changes in stockholders&rsquo; equity and cash flows for the years ended December
31, 2017 and 2016, including the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017, and
the results of its operations and its cash flows for the years ended December&nbsp;31, 2017 and 2016, in conformity with accounting
principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial
statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ GBH CPAs, PC</FONT></TD>
    <TD STYLE="width: 60%; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have served as the Company&rsquo;s auditor since 2012.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GBH CPAs, PC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.gbhcpas.com</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston, Texas</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 16, 2018</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Current Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,673,308</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,399,636</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted cash &ndash; current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">616,222</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">439,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 20pt">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,329,605</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,838,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Property and equipment, net of accumulated depreciation of $266,381 and $215,660</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,859</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,859</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Restricted cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">391,131</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">390,940</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,889,394</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">18,337,107</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,814,004</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,650,088</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,239</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,916</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,063,243</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,666,004</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Long-term capital lease obligation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,076,597</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,666,004</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.001 par value; 600,000,000 and 400,000,000 shares authorized; 115,703,044 and 80,072,334 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,703</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,072</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,554,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,744,068</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(186,857,238</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(163,153,037</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,812,797</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,671,103</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,889,394</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">18,337,107</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 30pt">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,094,778</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,719,855</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,828,287</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,732,544</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,190,933</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,019,194</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,827,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,910,788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,847,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,827,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,910,788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,847,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Interest income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">173,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,007</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Gain on change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">304,123</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,530,764</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">173,359</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">309,553</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,525,757</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(23,653,963</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(26,601,235</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(24,321,724</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss per common share - basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.40</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.50</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding - basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">106,041,809</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">66,746,389</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">48,463,268</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statement of Changes in
Stockholders&rsquo; Equity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Years Ended December 31, 2018,
2017 and 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Additional Paid-In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; text-indent: -10pt; padding-left: 10pt">Balance, January 1, 2016</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">44,066,541</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">44,067</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">134,160,059</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(112,230,078</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">21,974,048</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,297,696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,297,778</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Sale of common stock and warrants, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,504,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,504</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,011,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,022,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock from exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock from exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,862</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(126</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Transfer of warrant derivatives from liability to equity classification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,455</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,321,724</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,321,724</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Balance, December 31, 2016</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">55,801,742</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">55,802</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">154,504,329</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(136,551,802</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">18,008,329</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,474,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,474,375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Sale of common stock and warrants, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,172,973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,765,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,789,634</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock from exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,601,235</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,601,235</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Balance, December 31, 2017</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">80,072,334</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">80,072</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">176,744,068</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(163,153,037</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">13,671,103</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Modified retroactive adjustment for derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,238</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,916</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,798,498</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,798,655</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Sale of common stock and warrants, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,614,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,941,623</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,976,237</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of commitment shares to Lincoln Park</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">852,537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">853</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(853</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock from exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,849</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,653,963</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,653,963</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance, December 31, 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">115,703,044</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">115,703</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">195,554,332</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(186,857,238</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8,812,797</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash Flows from Operating Activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(23,653,963</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(26,601,235</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(24,321,724</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,798,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,493,731</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,297,778</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,938</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,523</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Gain on change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(304,123</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,530,764</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">(Increase) decrease in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 40pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,397,129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,032,988</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Increase in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 40pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,133,499</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">405,214</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,720,938</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,571,056</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,553,346</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,789,237</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash Flows from Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Payment of security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,859</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(96,092</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,739</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(59,960</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Net Cash Used In Investing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(96,092</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,739</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(109,819</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash Flows from Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Payments on note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(265,695</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from sales of shares of common stock and warrants, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,976,237</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,814,634</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,022,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from the exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Proceeds from the exercise of warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,849</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Net Cash Provided By Financing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,981,086</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,814,634</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,775,077</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Net change in cash, cash equivalents and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,686,062</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,763,451</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,123,979</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash at beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,790,576</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,554,027</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,678,006</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash, cash equivalents and restricted cash at end of year</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,104,514</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17,790,576</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,554,027</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,007</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Cash paid for taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Stock issuance costs included in accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Prepaid expenses financed by accounts payable and notes payable</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,932</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Capital lease of office equipment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">16,078</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Transfer from derivative liability classification to equity classification</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,455</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 1 - Description of Business and
Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Nature of Business
-</B> Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;, &ldquo;Actinium&rdquo;, or &ldquo;We&rdquo;) is a clinical-stage,
biopharmaceutical company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell
therapies such as a BMT or Bone Marrow Transplant or CAR-T, <FONT STYLE="background-color: white">a type of cellular therapy that
genetically alters a patient&rsquo;s own T cells to target and kill their cancer cells,</FONT> and for other adoptive cell therapies.
In addition, the Company is also developing potential therapies for targeting and killing of cancer cells either as single agents
or in combination with other drugs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Going concern</B>
- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has never generated revenue. Currently
it does not have a recurring source of revenue to cover its operating costs. The Company has incurred net losses and negative
operating cash flows since inception. As of December 31, 2018 and 2017, the Company&rsquo;s accumulated deficit was $186.9 million
and $163.2 million, respectively. The Company&rsquo;s net loss was $23.7 million, $26.6 million, and $24.3 million for the years
ended December 31, 2018, 2017 and 2016, respectively. These conditions raise substantial doubt as to our ability to continue as
a going concern. As of December 31, 2018, in the Company had a balance of its cash and cash equivalents of $13.7 million. The
Company&rsquo;s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States
of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to
continue as a going concern. As of the date of filing this report, the Company expects that its existing resources will be sufficient
to fund its planned operations into the fourth quarter of 2019; however, additional capital resources will be needed to fund operations
longer-term. If the Company is unsuccessful in accomplishing its plans, it may have to delay or terminate existing and/or planned
clinical trials and other related activity, which could have a material adverse impact on its business. The Company plans to continue
as a going concern include obtaining capital from the sale of its equity securities, potential exercise of outstanding warrants,
fees from licensing one or more of our product candidates, additional collaborations with our Iomab-ACT program and AWE technology
platform, and short-term borrowings from banks, stockholders or other related parties, if needed. However, the Company cannot
provide any assurance that we will be successful in accomplishing any of our plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s ability
to continue as a going concern is dependent upon its ability to successfully accomplish the plans described above and eventually
to secure other sources of financing and attain profitable operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Principles of Consolidation
-</B> The consolidated financial statements include the Company&rsquo;s accounts and those of the Company&rsquo;s wholly owned
subsidiaries. All significant intercompany accounts and transactions have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Use of Estimates
in Financial Statement Presentation -</B> The preparation of these consolidated financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Cash and Cash Equivalents
-</B> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Property and Equipment
-</B> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three
to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related
gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets
are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated
useful life of the related property or term of the lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Fair Value of Financial
Instruments</B> <B>- </B>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives
the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable
inputs. As required by ASC 820 &ldquo;<I>Fair Value Measurements and Disclosures</I>&rdquo;, financial assets and liabilities
are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&rsquo;s
assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation
of fair value assets and liabilities and their placement within the fair value hierarchy levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1 Inputs - Unadjusted quoted
prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2 Inputs - Inputs other
than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might
include quoted prices for similar assets or liabilities&nbsp;in&nbsp;active markets, quoted prices for identical or similar assets
or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such
as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated
by market data by correlation or other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3 Inputs - Unobservable
inputs for determining the fair values of assets or liabilities that reflect an entity&rsquo;s own assumptions about the assumptions
that market participants would use in pricing the assets or liabilities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>Income Taxes -</B> The Company provides
for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based
on the differences between the financial statement carrying amounts of existing assets and liabilities at each year-end and their
respective tax bases, and are measured using enacted tax rates in effect for the year in which the differences are expected to
affect taxable income. Significant judgment is required by management to determine the Company&rsquo;s provision for income taxes,
deferred tax assets and liabilities, and the valuation allowance to record against net deferred tax assets, which are based on
complex and evolving tax regulations throughout the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax assets
and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. There were
no tax positions for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly
increase or decrease within the next year. The Company recognizes interest related to unrecognized tax benefits in interest expense
and penalties in operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Tax Cuts and Jobs Act,
or the Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the
Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. As of December
31, 2018, upon completing its analysis of the Act, the Company believes that its disclosures in its financial statements as of
December 31, 2017 remain accurate.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Revenue Recognition
</B>- The Company adopted new accounting guidance for revenue recognition, effective January 1, 2018, which did not have a significant
impact on the Company&rsquo;s financial statements. Beginning January 1, 2018, revenues are recognized when control of the promised
goods or services is transferred to customers in an amount that reflects the consideration expected to be entitled to in exchange
for those goods or services<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Research and Development
Costs -</B> Research and development costs are expensed as incurred. Research and development reimbursements are recorded by the
Company as a reduction of research and development costs.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Share-Based Payments
-</B> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Net Loss Per Common
Share</B> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average
number of common shares outstanding during the reporting period. For the years ended December 31, 2018, 2017 and 2016, the Company&rsquo;s
potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation
of diluted net loss per share as the result would have been anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,236,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,174,592</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,906,886</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55,820,876</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,662,340</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,964,752</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">63,056,977</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,836,932</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,871,638</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Subsequent Events
</B>- The Company&rsquo;s management reviewed all material events through the date the consolidated financial statements were issued
for subsequent event disclosure consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Reclassifications
- </B>Certain reclassifications have been made to the prior-year financial statements to conform to the current-year presentation,
including the addition of restricted cash to cash and cash equivalents on the consolidated statements of cash flows as a result
of the adoption of new accounting guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Accounting Standards
Recently Adopted </B>- In November 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued an Accounting Standards
Update (&ldquo;ASU&rdquo;) amending the presentation of restricted cash within the consolidated statements of cash flows. The new
guidance requires that restricted cash be added to cash and cash equivalents on the consolidated statements of cash flows. The
Company adopted this ASU on January 1, 2018 on a retrospective basis with the impact to its consolidated statements of cash flows
for the year ended December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Previously Reported</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Adjustment</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>As Revised</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Net cash used in investing activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(380,946</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">356,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(24,739</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was
no impact to the cash flows from operating, investing and financing activities for the year ended December 31, 2016 as the
amount of restricted cash did not change during 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary
of cash and cash equivalents and restricted cash at December 31, 2018, 2017 and 2016, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,673,308</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,399,636</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,519,294</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Restricted cash &ndash; current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Restricted cash &ndash; long term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">391,131</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">390,940</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Cash and cash equivalent and restricted cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,104,514</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,790,576</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,554,027</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB
issued ASU No. 2014-09, <I>Revenue from Contracts with Customers</I>. Under the new standard, revenue is recognized at the time
a good or service is transferred to a customer for the amount of consideration for which the entity expects to be entitled for
that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of
adoption. The Company adopted this ASU on January 1, 2018 and the adoption did not have a significant impact to the Company&rsquo;s
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2017, the FASB
issued ASU No. 2017-11, <I>Earnings Per Share</I> (Topic 260); <I>Distinguishing Liabilities from Equity</I> (Topic 480); <I>Derivatives
and Hedging</I> (Topic 815): (Part I) <I>Accounting for Certain Financial Instruments with Down Round Features.</I> These amendments
simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard
the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability
or equity classification. The guidance was adopted as of April 1, 2018. See Note 2 for further discussion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B>Recent Accounting Standards &ndash;
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016,
FASB issued ASU No. 2016-02 <I>Leases</I> (Topic 842), which creates new accounting and reporting guidelines for leasing
arrangements. The standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A
lessee should recognize on its balance sheet a liability to make lease payments (the lease liability) and a right-of-use
asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a
lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and
lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the
earliest period presented using a modified retrospective approach. The guidance in ASU 2016-02 is effective for annual and
interim reporting periods beginning after December 15, 2018. The Company&rsquo;s initial evaluation of its current leases
does not indicate that the adoption of this standard will have a material impact on its consolidated statements of
operations. However, the Company does expect that the adoption of the standard will have an impact on its
consolidated balance sheets for the recognition of certain operating leases as right-of-use assets and lease liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2018, the FASB
issued ASU 2018-07 to expand the scope of ASC Topic 718, <I>Compensation - Stock Compensation</I>, to include share-based payment
transactions for acquiring goods and services from nonemployees. The standard is effective for fiscal years, and for interim periods
within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating
the impact of the new standard on its financial statements and related disclosures, but does not expect this ASU to have a material
impact on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the
FASB issued ASU 2018-13, <I>Fair Value Measurement - Disclosure Framework (Topic 820).</I> The updated guidance improves the disclosure
requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay
of adoption of the additional disclosures until their effective date. The Company is in the process of evaluating the provisions
of the ASU but does not expect it to have a material effect on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, the
FASB issued ASU 2018-18, C<I>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,</I>
which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be
accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impact
the standard will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the
SEC adopted the final rule under SEC Release No. 33-10532, <I>Disclosure Update and Simplification</I>, amending certain disclosure
requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure
requirements on the analysis of stockholders&rsquo; equity for interim financial statements. Under the amendments, an analysis
of changes in each caption of stockholders&rsquo; equity presented in the balance sheet must be provided in a note or separate
statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which
a statement of comprehensive income is required to be filed. The Company anticipates its first presentation of changes in stockholders&rsquo;
equity will be included in its Form 10-Q for the three months ended March 31, 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B>Note 2  -
Derivative Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, the Company
accounted for certain instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with
FASB ASC 815-40,&nbsp;<I>Derivative and Hedging &ndash; Contracts in Entity&rsquo;s Own Equity</I>. This was due to an anti-dilution
provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity-linked instruments
in the future at an effective price per share less than the exercise price then in effect for the warrant (&ldquo;down round provision&rdquo;).
As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value
were recorded as non-cash adjustments within other income (expense), net, in the Company&rsquo;s accompanying Consolidated Statements
of Operations. The Company recorded a gain on the change in the estimated fair value of warrants of $0.3 million and $2.5 million
for the years ended December 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 1, 2018,
the Company early adopted ASU 2017-11, which revised the guidance for instruments with down-round provisions. As such, the Company
treats outstanding warrants as free-standing equity-linked instruments that are recorded to equity in the Consolidated Balance
Sheet as of January 1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
the guidance presented in the ASU 2017-11, the fair value of the derivative liability balance for 57,212 warrants as of December
31, 2017 of $16 thousand was reclassified by means of a cumulative-effect adjustment to equity as of January 1, 2018. These warrants
had an original exercise price of $2.34. The exercise price is adjusted based on a formula whenever the Company issues, or is deemed
to have issued, any common shares for no consideration or a consideration per share less than the exercise price of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Company&rsquo;s
adoption of ASU 2017-11, the exercise price of the warrants was reset to $1.25 as a result of various offerings. The difference
of $5 thousand between the fair value of the warrants with the exercise price prior to the price reset and the fair value of the
warrants with the exercise price after the price reset was accounted for as a deemed dividend. The impact of the adoption was as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Amount</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">Derivative liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(15,916</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,154</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,238</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,916</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the
derivative warrants was calculated using a binomial valuation model with the following assumptions at December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Market value of common stock on measurement date (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.66</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Adjusted exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.67</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free interest rate (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.09</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant lives in years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend yield (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Probability of stock offering in any period over 5 years (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Offering price estimated as of December 31, 2017 (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The market value of common stock at the above measurement
dates was based on the Company&rsquo;s closing price quoted on the NYSE American.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The risk-free interest rate was determined by the Company
using the Treasury Bill rate as of the respective measurement date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(3)</TD><TD STYLE="text-align: justify">The volatility was estimated using the historical volatility
of the Company&rsquo;s common stock.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Management does not expect to pay dividends for the foreseeable
future.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Management determines the probability of future stock offering
at each evaluation date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Represents the estimated offering price in future offerings
as determined by management.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt">As a result of an agreement with Lincoln
Park Capital Fund, LLC (See Note 7) the exercise price was further reset to $1.23 per share, with an immaterial change in the fair
value of the warrants before and after the price reset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 3 - Prepaid Expenses and Other
Current Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and
other current assets consisted of the following at December 31, 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>December&nbsp;31,</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>December&nbsp;31,</B></TD><TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Prepaid&nbsp;insurance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">339,336</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">72,371</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid&nbsp;clinical trial expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171,128</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">226,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">105,758</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139,954</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">616,222</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">439,322</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company issued a note payable of $249,239 for its insurance premiums; payments are scheduled during 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 4 - Property and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment
consisted of the following at December 31, 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>December&nbsp;31,</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>December&nbsp;31,</B></TD><TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Lives</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Lab equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">5 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">176,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">116,070</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Office equipment &amp; furniture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3 - 7 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(266,381</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(215,660</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">118,799</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">57,350</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company entered into a five-year capital lease agreement for office equipment and services for $906 per month. At December
31, 2018, the capitalized value associated with the lease agreement was $16,078.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense
consisted of the following for the years ended December 31, 2018, 2017 and 2016, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>December 31,</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>December&nbsp;31,</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>December&nbsp;31,</B></TD><TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2016</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research &amp; development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,170</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,352</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">41,632</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,551</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,586</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,891</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Depreciation expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">50,721</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">55,938</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">77,523</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6 - Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>License and Research Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered
into agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services under
which the Company may incur obligations to make payments including upfront payments as well as milestone and royalty payments.
Notable inclusions in this category are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Oak Ridge National Laboratory (&ldquo;ORNL&rdquo;) &ndash; The Company is contracted to purchase
radioactive material to be used for research and development, with a renewal option at the contract end. During the years ended
December 31, 2018, 2017 and 2016, the Company purchased material from ORNL of approximately $0.3 million, $0.6 million and $1.0
million, respectively. On December 19, 2018, the Company signed a contract with ORNL to purchase $0.2 million of radioactive material
during calendar year 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred
Hutchinson Cancer Research Center (&ldquo;FHCRC&rdquo;) to build upon previous and ongoing clinical trials, with BC8 (licensed
antibody). FHCRC has currently completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive
rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC
upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of
2% of net sales will be due to FHCRC. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">On February 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology
Inc. (&ldquo;Goodwin&rdquo;). Goodwin oversees the current Good Manufacturing Practices (&ldquo;cGMP&rdquo;) production of a monoclonal
antibody used in the Phase 3 clinical trial of Iomab-B. As of December 31, 2018, the remaining cost of the service agreement is
$1.0 million. During the years ended December 31, 2018, 2017 and 2016, the Company paid Goodwin $1.2 million, $1.4 million and
$0.7 million, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">On February 16, 2016, the Company entered into an agreement with Medpace, Inc. (&ldquo;Medpace&rdquo;),
a Contract Research Organization, (&ldquo;CRO&rdquo;). Medpace provides project management services for the Iomab-B study. The
total project is currently estimated to cost approximately $10.2 million. As of December 31, 2018, the remaining cost of the agreement
is approximately $3.3 million. Medpace bills the Company when services are rendered and the Company records the related expense
to research and development costs. During the years ended December 31, 2018, 2017 and 2016, the Company paid Medpace $3.1 million,
$2.8 million and $2.6 million, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">On August 4, 2016, the Company entered into a CRO agreement with George Clinical Services, (&ldquo;George&rdquo;).
George provides project management services for the study of Actimab-A used for a Phase 2 clinical trial. The total project is
estimated to cost approximately $4.6 million. As of December 31, 2018, the remaining cost of the agreement is approximately $0.5
million. George bills the Company when services are rendered and the Company records the related expense to research and development
costs. During the years ended December 31, 2018, 2017 and 2016, the Company paid George $1.9 million, $0.7 million and $0.1 million,
respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lease Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not
own any real property. It currently leases office space located at 275 Madison Avenue, New York, NY. The lease is for 5,790 square
feet and has a term of seven years and three months, with an expiration date of September 6, 2022, with a current annual rate of
$312,660 until June 8, 2019 and $341,610 for the remaining life of the lease. The Company is also responsible for certain other
costs, such as insurance, taxes, utilities, and maintenance. The Company issued a letter of credit of $390,825 in connection with
the lease and maintained a $391,131 certified deposit as collateral for the letter of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2017, the Company
also entered into a license agreement for furniture and fixtures located at its office space. Pursuant to the terms of the agreement,
the Company leases the furniture and fixtures and tenant improvements located in the office space for the same term as the office
space for $7,529 per month. At any time during the term of this amended agreement, the Company has the right to purchase the furniture,
and fixtures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company entered into a five-year lease agreement for office equipment and services for $906 per month and the capitalized value
associated with the lease agreement was $16,078.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future minimum obligations
on all of the Company&rsquo;s operating leases with a term over one year are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">For the year ending December 31:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">419,896</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">431,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">431,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">287,972</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt; text-align: left">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,571,784</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 7 - Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 18, 2018,
the Company and Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;) entered into a purchase agreement and a registration
rights agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&rsquo;s common stock
having an aggregate value of up to $32,500,000, subject to certain limitations and conditions set forth in the agreement. As consideration
for entering into the purchase agreement, the Company issued to Lincoln Park 852,537 shares of common stock, determined to be offering
costs as part of the financing. These shares had a fair value of $0.6 million based on the market price on the issuance date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the purchase
agreement, Lincoln Park initially purchased 3,376,554 shares of common stock, at a price of $0.74 per share, for a total gross
purchase price of $2,500,000. As often as every business day from and after one business day following the date of the initial
purchase and over the 30-month term of the agreement, and up to an aggregate amount of an additional $30,000,000 (subject to certain
limitations) of shares of common stock, the Company has the right, from time to time, at its sole discretion and subject to certain
conditions, to direct Lincoln Park to purchase up to 400,000 shares of common stock, with such amount increasing as the closing
sale price of the common stock increases; provided Lincoln Park&rsquo;s obligation under any single such purchase will not exceed
$1,500,000, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a
&ldquo;Regular Purchase&rdquo;). If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it
then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations
in the agreement, the Company may direct Lincoln Park in an &ldquo;accelerated purchase&rdquo; to purchase an additional amount
of common stock that may not exceed the lesser of (i) 300% the number of shares purchased pursuant to the corresponding Regular
Purchase or (ii) 30% of the total number of shares of the Company&rsquo;s common stock traded during a specified period on the
applicable purchase date as set forth in the agreement. Under certain circumstances and in accordance with the agreement, the Company
may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company controls
the timing and amount of any sales of its common stock to Lincoln Park. There is no upper limit on the price per share that Lincoln
Park must pay for its common stock under the agreement, but in no event will shares be sold to Lincoln Park on a day the closing
price is less than the floor price specified in the agreement. In all instances, the Company may not sell shares of its common
stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement does
not limit the Company&rsquo;s ability to raise capital from other sources at the Company&rsquo;s sole discretion, except that (subject
to certain exceptions) the Company may not enter into any variable rate transaction (as defined in the agreement, including the
issuance of any floating conversion rate or variable priced equity-like securities) during the 30 months after the date of the
Purchase Agreement. The Company has the right to terminate the agreement at any time, at no cost to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through December 31,
2018, the Company elected to sell to Lincoln Park an additional 1.0 million shares and received $0.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, the
Company sold an aggregate of 30,237,894 units consisting of an aggregate of 30,237,894 shares of common stock, 7,559,445 series
A warrants and 22,678,393 series B warrants, with each series A warrant exercisable for one share of common stock at an exercise
price of $0.60 per share and each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per
share, resulting in gross proceeds to Actinium of approximately $15.1 million (each unit was sold at $0.50 per unit), and net proceeds
of approximately $13.8 million after deducting expenses relating to dealer-manager fees and other offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company issued 2,672,973 shares of common stock for gross proceeds of approximately $4.0 million as part
of its At-The-Market sales agreement with an investment bank. The Company paid expenses of approximately $0.2 million resulting
in net proceeds of $3.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2017,
the Company completed an underwritten public offering of 21,500,000 shares of its common stock and warrants to purchase 18,275,000
shares of the Company&rsquo;s common stock at an offering price to the public of $0.75 per share and related warrant. The warrants
have an exercise price of $1.05 per share and have a term of five years. The gross proceeds from this offering were approximately
$16.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company
resulting in net proceeds of approximately $15.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company issued 67,385 common shares for consulting services. The shares have a total value of $99 thousand
based on the Company&rsquo;s stock price on the grant date at $1.47 per share. During the year ended December 31, 2017, the Company
also issued 4,234 common shares for the cashless exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 4, 2016,
the Company sold 8,000,000 shares of its common stock at a price of $1.25 per share to the public through an underwritten public
offering, for net proceeds of $9.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2016, the Company
also issued 3,500,000 shares of common stock for net proceeds of $6.8 million as part of an at-the-market (ATM) sales agreement
with an investment bank.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company issued 125,862 common shares for the cashless exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2013 Amended and Restated Stock Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013,
the Board of Directors of the Company approved the Company&rsquo;s 2013 Stock Plan. The expiration date of the plan is September
9, 2023 and the total number of underlying shares of the Company&rsquo;s common stock available for grant to employees, directors
and consultants of the Company under the plan was 2,750,000 shares. In December 2015, shareholders of the Company approved the
second amendment to the plan and increased the number of shares authorized under the plan to 9,250,000 shares. In December 2016,
shareholders of the Company approved the fifth amendment to the plan and increased the number of shares authorized under the plan
to 12,750,000 shares. In December 2017, shareholders of the Company approved the sixth amendment to the plan and increased the
number of shares authorized under the plan to 17,750,000 shares. In December 2018, shareholders of the Company approved the seventh
amendment to the plan and increased the number of shares authorized under the plan to 22,750,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2013 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013,
the Board approved the Company&rsquo;s 2013 Equity Incentive Plan. The expiration date of the plan is September 9, 2023 and the
total number of shares of the Company&rsquo;s common stock available for grant to employees, directors and consultants of the Company
under the plan was 450,000 shares. In December 2013, the shareholders of the Company approved the plan and increased the number
of shares authorized under the plan to 1,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Restricted Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;During
2018, the Company granted 107,911 restricted common shares for consulting services, which all vested during 2018. The shares
had a total value of $72,825.&nbsp;During the year ended December 31, 2018, the Company issued 156,393 common shares for
restricted shares that became fully vested, of which 81,393 shares were granted prior to 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2018, the Company has yet to issue 254,819 common shares for restricted shares that have vested. As of December 31, 2018, all
restricted shares granted were vested with no unamortized compensation expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company issued 26,000 common shares for restricted shares that became fully vested. The Company also granted
59,393 common shares for consulting services. The shares have a total value of $65,813 based on the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company granted 250,700 shares of restricted common stock to consultants with a fair value of $0.4 million
based on the stock price on the grant dates.&nbsp;The Company issued common shares totaling 21,000 for restricted shares granted
in 2015 and prior years and 60,700 for restricted shares granted in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the years ended December 31, 2018, 2017 and 2016, the Company recorded stock-based compensation expense of $0.1 million, $0.2 million
and $0.6 million, respectively, for the restricted shares granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary
of option activities for the years ended December 31, 2018, 2017 and 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number of Options</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted <BR> Average <BR> Exercise <BR> Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted <BR> Average <BR> Remaining <BR>
    Contractual <BR> Term <BR> (in years)</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Aggregate <BR> Intrinsic <BR> Value</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding, January 1, 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,971,583</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,964,146</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,225,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(266,485</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,212</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.78</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding, December 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,906,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,704</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,597,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,329,794</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">2.85</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding, December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,174,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,648</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,577,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,515,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">2.96</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding, December 31, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,236,101</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">1.74</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">7.97</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">6,400</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Exercisable, December 31, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,021,818</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.88</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">6.55</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2018, the Company granted its employees and members of the Board of Directors 3,577,159 options to purchase Company
common stock with an exercise price ranging from $0.344 to $0.7829 per share, a term of 10 years, and a vesting period from 4 to
4.2 years.&nbsp;The options have an aggregated fair value of $1.7 million that was calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 2.34% to 2.99% (2) expected
life of 6 years, (3) expected volatility range from 78.8% to 80.4%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company granted its employees and members of the Board of Directors 2,597,500 options to purchase Company
common stock with an exercise price ranging from $0.57 to $1.58 per share, a term of 10 years, and a vesting period from 4 to 4.2
years.&nbsp;The options have an aggregated fair value of $2.4 million that was calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 1.84% to 2.28% (2) expected
life of 6 years, (3) expected volatility range from 80.83% to 82.37%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2017, a
director, resigned from the Company and the Company entered into an agreement with the director. Pursuant to the agreement, all
the outstanding vested options, (which originally were to expire 90 days from termination date), as well as 68,200 unvested options
granted prior to December 31, 2016, shall be exercisable until the end of the term of each option grant agreement. As a result
of the modification, the Company recorded an additional expense of approximately $174,000 for the incremental fair value of the
options, calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include:
(1) discount rate range from 0.97% to 1.39% (2) expected life of 3 months to 8.9 years, (3) expected volatility range from 45.72%
to 79.81%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company granted employees, consultants, and its board members 2,225,000 options to purchase the Company&rsquo;s
common stock with exercise prices ranging from $0.95 to $2.25 with a 10-year term vesting over a 4-year period.&nbsp;&nbsp;The
options have an aggregated fair value of $3.1 million that was calculated using the Black-Scholes option-pricing model. Variables
used in the Black-Scholes option-pricing model include: (1) discount rate of 1.28% - 1.97% (2) expected life of 6 years, (3) expected
volatility of 81.45% - 87.95%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended
December 31, 2018, 2017 and 2016, options to purchase 1,515,650, 3,329,794 and 266,485 common shares were cancelled, respectively,
upon the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no exercises
of options during the years ended December 31, 2018 and 2017. During the year ended December 31, 2016, the Company received gross
proceeds of $18,105 for the exercise of stock options for 23,212 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of
all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense
at December 31, 2018 was approximately $2.6 million. During each of the years ended December 31, 2018, 2017 and 2016, the Company
recorded total option expense of approximately $1.7 million, $3.1 million and $3.6 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary
of warrant activities for the years ended December 31, 2018, 2017 and 2016, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Units</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Exercise <BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> Remaining <BR> Contractual <BR> Term <BR> (in&nbsp;years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <BR> Intrinsic <BR> Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding, January 1, 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,018,470</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.73</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.93</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10,199,230</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(183,718</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.90</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding, December 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,964,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,445,786</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,496,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,364</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,789,623</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">2.22</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding, December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,662,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995,373</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,360,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,332</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.66</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(194,598</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">9.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Outstanding, December 31, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">55,820,876</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">1.20</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.04</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">569,038</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Exercisable, December 31, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">55,613,377</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">1.19</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.03</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">566,676</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2018,
the Company amended certain warrants, originally dated December 17, 2012, that had been issued to three entities affiliated with
the family of the Mr. Sandesh Seth, Chairman and CEO, Amrosan LLC, Carnegie Hill Partners, and Bioche Asset Management, LCC, in
the amount of 375,556, 353,023 and 721,068 shares, respectively and extended their date of expiration from December 17, 2019 to
February 21, 2022. The warrants had originally been issued in 2012 as part of investment banking and advisory services provided
by Mr. Seth. The incremental fair value for the warrants due to the amendment was immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, the
Company sold an aggregate of 30,237,894 units consisting of an aggregate of 30,237,894 shares of common stock, 7,559,445 series
A warrants and 22,678,393 series B warrants, with each series A warrant exercisable for one share of common stock at an exercise
price of $0.60 per share and each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2018, the Company granted 122,628 warrants to consultants. The warrants are exercisable for periods ranging from 4
to 5 years at exercise prices ranging from $0.36 to $0.80 per share. The fair value of the warrants was approximately $27 thousand
at the grant date and was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing
model include (1) discount rate range of 2.34% to 2.99%, (2) expected term of 4-5 years, (3) expected volatility range of 77.01%
to 79.00%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2017,
the Company completed an underwritten offering of 21,500,000 shares of its common stock and warrants to purchase an aggregate of
18,275,000 shares of its common stock at a price of $0.75 per share and related warrant. The warrants are exercisable for a period
of 5 years at an exercise price of $1.05 per share. The transaction date relative fair value of the warrants of $4.9 million was
determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing model include (1)
discount rate of 1.83%, (2) expected term of 5 years, (3) expected volatility of 82%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain warrants were
issued to the Company&rsquo;s Executive Chairman (now Chairman and CEO) as part of investment banking and advisory services either
prior to and outside of his role as a Board Member and subsequently Chairman and CEO. On March 14, 2017, the Company canceled a
warrant to purchase 57,212 shares of common stock of the Company, dated December 19, 2012 and issued a new warrant to its Chairman
and CEO to purchase 57,212 common shares with the term of the warrant expiring on February 11, 2022. The new warrant has the same
exercise price in effect as the exercise price as the old warrant, but the expiration date was modified from December 19, 2017
to February 11, 2022. The Company also amended the warrant to purchase common stock of the Company, dated January 31, 2012, issued
to its Chairman and CEO and an entity affiliated with its Chairman and CEO to purchase 64,746 and 99,617 common shares, respectively.
Pursuant to the terms of the warrant amendments, the term of the warrants was extended to February 11, 2022 from January 31, 2019.
As a result of the replacement and modification, the Company recorded an additional non-cash expense of $64 thousand for the incremental
fair value of the new warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company granted 130,000 warrants to consultants. The warrants are exercisable for periods ranging from 5
to 10 years at exercise prices ranging from $0.98 to $1.77 per share. The fair value of the warrants was approximately $116,000
at the grant date and was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing
model include (1) discount rate range of 1.13% to 1.20%, (2) expected term of 5-10 years, (3) expected volatility range of 79.79%
to 84.84%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended
December 31, 2018, 2017 and 2016, the Company recorded stock-based compensation expense related to warrants of $33 thousand, $0.1
million and $0.1 million respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Note 8  - Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Tax Cuts and
Jobs Act, or the &ldquo;Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to
21%. As of December 31, 2017, the Company remeasured its existing deferred tax balance by recording a provisional charge of
$17.9 million, which was fully offset by a change in the valuation allowance. As of December 31, 2018, upon completing its
analysis of the Act, the Company believes that the disclosures in its financial statements as of December 31, 2017 are still
accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income taxes
reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of the Company&rsquo;s deferred tax assets and liabilities
at December 31, 2018 and 2017 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">Net operating losses carry forward</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">34,531,577</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">30,826,534</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,950,963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,731,413</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development/orphan drug credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,896,703</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,324,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Others</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,369</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(46,394,528</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,894,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has recorded
a valuation allowance of $46.4 million and $40.9 million against its deferred tax assets at December 31, 2018 and 2017, respectively,
because management determined that it is not more-likely-than not that those assets will be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For federal income
tax purposes, the Company has approximately $144.5 million of unused net operating losses (&ldquo;NOLs&rdquo;) at December 31,
2018 available for carry forward to future years. Prior NOLs have begun to expire as they are unused.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For state income tax
purposes, the Company has approximately $66.8 million of unused NOLs available for carry forward to future years. These NOLs will
begin to expire in 2035 if unused.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has federal
research and development tax credits of approximately $1.4 million at December 31, 2018 which will begin to expire in 2033 if unused
and orphan drug credits of $7.5 million which will begin to expire in 2037 if unused.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Internal
Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and development tax credits could
be limited by any greater than 50% ownership change during any three-year testing period. As a result of any such ownership change,
portions of the Company&rsquo;s net operating loss carryforwards and research and development tax credits are subject to annual
limitations. Accordingly, the Company&rsquo;s ability to utilize these carryforwards may be limited as a result of an ownership
change which may have already happened or may happen in the future. Such an ownership change could result in a limitation in the
use of the net operating losses in future years and possibly a reduction of the net operating losses available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to
pre-tax losses for the year ended December 31, 2018, 2017 and 2016 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left; text-indent: -10pt; padding-left: 10pt">Federal statutory income taxes</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,967,332</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(21.0</TD><TD STYLE="width: 1%; text-align: left">)%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(9,044,420</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(34.0</TD><TD STYLE="width: 1%; text-align: left">)%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(8,269,386</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(34.0</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">State income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,413,678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,940,945</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7.3</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">973,547</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in federal statutory rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,939,714</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred true-up</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,090,816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,511,380</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43.3</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and Development/Orphan Drug Tax Credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,986,609</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8.4</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,029,074</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11.4</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(141,769</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.6</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Unrealized derivative gain/loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(120,870</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.5</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(956,840</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3.9</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,845</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.1</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,500,214</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,908,066</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,892,196</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">77.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Provision for income tax</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9  - Subsequent Event</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2019, the
Company sold 924,500 common shares through its at-the-market program and realized net proceeds of $0.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since December 31,
2018, holders of the Company&rsquo;s March 2018 Series A warrants exercised approximately 2.5 million shares, resulting in proceeds
to the Company of $1.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since December 31,
2018, the Company granted stock options to its employees to purchase a total of 530,000 common shares at a price range from
$0.43 to $0.58 per share related to new hires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 6, 2019, the Company
executed an amendment to the Company&rsquo;s 2013 Amended and Restated Stock Plan, as amended (the &ldquo;<U>Plan Amendment</U>&rdquo;).
The Plan Amendment increased the number of shares of common stock that the Company is authorized to issue under the plan to 22,750,000
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 6, 2019, the
Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State
of Delaware to increase the number of authorized shares of Actinium&rsquo;s common stock from 400,000,000 to 600,000,000 shares.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_014"></A><B>ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_015"></A><B>ITEM 9A. CONTROLS AND PROCEDURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Disclosure controls
and procedures.</I></B> The Company, under the supervision and with the participation of its management, including the Company&rsquo;s
principal executive officer and principal financial and accounting officer, evaluated the effectiveness of the Company&rsquo;s
&ldquo;disclosure controls and procedures,&rdquo; as such term is defined in Rule 13a-15(e) under the Securities Act of 1934, as
amended (the &ldquo;Exchange Act&rdquo;), as of the end of the period covered by this Annual Report on Form 10-K. Based on that
evaluation, the Company&rsquo;s principal executive officer and principal financial and accounting officer have concluded that
the Company&rsquo;s disclosure controls and procedures are effective as of December 31, 2018 to ensure that information required
to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in Securities and Exchange Commission rules and forms, and includes controls and procedures
designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to
the Company&rsquo;s management, including the Company&rsquo;s principal executive officer and principal financial and accounting
officer, as appropriate, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Management&rsquo;s
Annual Report on Internal Control Over Financial Reporting.</I>&nbsp;</B>The Company&rsquo;s management is responsible for establishing
and maintaining adequate internal control over financial reporting. The Company&rsquo;s internal control over financial reporting
is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
internal control over financial reporting includes policies and procedures that (1)&nbsp;pertain to the maintenance of records
that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; (2)&nbsp;provide reasonable
assurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management
and the directors of the Company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assessed
the effectiveness of the Company&rsquo;s internal control over financial reporting as of December 31, 2018. In making this assessment,
management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal
Control-Integrated Framework (2013). Based on our assessment and those criteria, management concluded that as of December 31, 2018,
the Company&rsquo;s internal control over financial reporting was effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Changes in internal
controls over financial reporting</I>.</B> There were no changes in the Company&rsquo;s internal controls over financial reporting
that occurred during the fourth quarter of the fiscal year covered by this Annual Report on Form 10-K that have materially affected,
or are reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_016"></A><B>ITEM 9B. OTHER INFORMATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>None.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_017"></A><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_018"></A>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The names, positions and ages of our directors
and executive officers as of March 15, 2019, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark S. Berger, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Medical Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anil Kapur</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Commercial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale L. Ludwig, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer (Principal Financial and Accounting Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lead Independent Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the classified
board provisions of our charter, all directors hold office until the next annual meeting of stockholders and the election and qualification
of their successors. Officers are elected annually by the board of directors and serve at the discretion of the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no other&nbsp;arrangements
or understanding between any of our directors and any other persons pursuant to which they were selected as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background of Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal occupations
for the past five years (and, in some instances, for prior years) of each of our directors and executive officers are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B>Sandesh Seth, Chairman and Chief Executive
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Sandesh Seth has
been our Chief Executive Officer since June 2017. Mr. Seth has been a Director since March 2012, our Chairman of the Board since
October 2013, and served as Executive Chairman from August 2014 to June 2017. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Seth has 25+
years of experience in investment banking (Laidlaw&amp; Co (UK) Ltd., Cowen &amp; Co.), equity research (Bear Stearns,
Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business
development and R&amp;D project management). Mr. Seth has an MBA in Finance from New York University; an M.S. in the
Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has
published several scientific articles and was awarded the University Regents Award for Research Excellence at the University
of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified (R.A.C.) by the Regulatory Affairs Professionals Society
which signifies proficiency with U.S. FDA regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That Mr. Seth has served
in various business executive-level positions over the course of his career, has significant investment banking experience, has
developed significant management, operational and leadership skills and is well accustomed to interfacing with investors, analysts, auditors,
C-level executives, and outside advisors, led us to conclude that Mr. Seth should serve as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mark S. Berger, MD., Chief Medical Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Berger has been
our Chief Medical Officer since January 2017. From September 2013 to January 2017 Dr. Berger worked for Kadmon Corporation where
he was Senior Vice President, Clinical Research. In this role he was responsible for all clinical aspects of new drug development
including designing and managing clinical trials in oncology indications (non-small cell lung cancer and glioblastoma) and non-oncology
indications (chronic graft versus host disease and polycystic kidney disease). Dr. Berger joined Kadmon after serving as Chief
Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013. Prior to Deciphera, Dr. Berger was Vice President
for Clinical Development at Gemin X Pharmaceuticals where he led the clinical strategy, design and management of clinical trials
for two novel oncology agents including obatoclax, a pan Bcl-2 inhibitor. Based on the results of a randomized Phase 2 clinical
trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011 for a total consideration of $525 million including $225
million in an upfront cash payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before his work with
biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as
Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of
Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading
a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib
Expanded Access Program (LEAP) that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development
at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody
targeted chemotherapy agent and targeted CD33, similar to Actimab-A. He presented the Mylotarg clinical data at the FDA&rsquo;s
Oncology Drug Advisory Committee meeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Berger has a B.A.
in biology from Wesleyan University and received his M.D. from the University of Virginia School of Medicine. He did his Hematology-Oncology
fellowship at the University of Pennsylvania where he was an Assistant Professor of Medicine, and also was a Research Fellow at
the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in
internal medicine, hematology and medical oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anil Kapur, Chief Commercial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Mr. Kapur joined Actinium in February 2018
from Bristol-Myers Squibb, where he was the Vice President, Head of Early Assets, Biomarkers &amp; External Innovation within the
Worldwide Oncology Commercialization organization and helped advance the company&rsquo;s leading Immuno-Oncology portfolio. Prior
to this position, he was the Vice President &amp; Global Head, Oncology Commercial Portfolio &amp; Product Strategy at Baxalta
and a member of the Oncology Leadership Team. In this role, Mr. Kapur also led the Joint Strategic Committees responsible for advancing
the early Immuno-Oncology partnerships with Symphogen and the allogeneic CAR-T partnership with Precision Bio-Sciences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Mr. Kapur built a distinguished career spanning
15 years at Johnson &amp; Johnson where in his last role, he served as the Vice President, Commercial Leader for the Hematology
Franchise with responsibility for the development and execution of global commercial strategy and launch plans for all Hematology
in-market, late-stage development, and early pipeline assets. He is credited with significantly shaping the clinical development
plans and successful launch and growth of multiple Oncology blockbuster products including IMBRUVICA&reg;, DARZALEX&reg;, and VELCADE&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">At J&amp;J, he led the IMBRUVICA&reg; Joint
Commercial Committee (JCC), established between J&amp;J and Pharmacyclics, and built and led the global team that launched DARZALEX&reg;,
the first biologic for Multiple Myeloma. Anil also held leadership roles of increasing complexity and responsibility in US Marketing,
US Regional Sales, and within the Asia-Pacific Regional Oncology organization covering 14 markets including Japan, China, Australia
and Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Mr. Kapur has an MBA from the Fuqua School
of Business at Duke University, a MS in Industrial Engineering from Louisiana Tech University, and a Bachelor of Engineering from
the Birla Institute of Technology, India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dale L. Ludwig, Ph.D., Chief Scientific Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Ludwig joined Actinium
in January 2018. Dr. Ludwig has worked for 20 years in oncology antibody drug discovery and development at Eli Lilly and Company
and at ImClone Systems, Inc., until its acquisition by Eli Lilly where he supported the development and successful launch of several
biologic oncology drugs including Erbitux&reg;, CyramzaTM, Portrazza&reg;, and LartruvoTM as well as the clinical advancement of
10 additional therapeutic antibodies. Most recently, Dr. Ludwig served Chief Scientific Officer/Vice President of Oncology Discovery
Research - Biologics Technology. In this role he was responsible for directing antibody discovery and development for oncology
biologics and contributed to key strategic and project advancement efforts. Dr. Ludwig was a member of the Oncology Research Senior
Leadership Team and directed the empowered antibody drug discovery programs that included collaborations with Immunogen and Zymeworks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the acquisition
of Imclone by Eli Lilly and Company, Dr. Ludwig served as Head of Molecular &amp; Cellular Engineering at IMClone Systems Incorporated.
In this capacity, Dr. Ludwig served as core team leader for several IND filings and phase 1 advancements for novel antibodies.
In addition, he directed and oversaw the full spectrum of drug development including antibody discovery, screening, selection,
engineering, optimization, cloning and expression. He was also tasked with establishing meaningful preclinical collaborations with
key academic investigators and industry leaders. Post-acquisition he was the research representative to the ImClone-Lilly Transition
Team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before his work in
the biotechnology industry, Dr. Ludwig trained as a postdoctoral associate in the DNA Damage and Repair Group of the Los Alamos
National Laboratory and as a postdoctoral fellow in the Department of Molecular Genetics, Biochemistry and Microbiology at the
University of Cincinnati College of Medicine. Dr. Ludwig has a B.S. in biology with a concentration in microbiology from James
Madison University and received his Ph.D. in Microbiology from East Carolina University.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Steve O&rsquo;Loughlin, Principal Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Steve O&rsquo;Loughlin
has been our Principal Financial Officer since May 2017. Mr. O&rsquo;Loughlin joined Actinium in October 2015 as Vice President,
Finance and Corporate Development, with almost a decade of life sciences industry experience gained from previous positions in
investment banking and publicly traded life sciences companies. Prior to Actinium, from June 2015 to October 2015, Mr. O&rsquo;Loughlin
worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Mr. O&rsquo;Loughlin held the position of Vice
President, Corporate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences
tools company. Previously, From June 2010 to June 2012, Mr. O&rsquo;Loughlin held corporate development positions with Caliber
I.D., a publicly traded diagnostics company. Mr. O&rsquo;Loughlin previously worked in investment banking at Jesup &amp; Lamont
where he focused on the biotechnology and life sciences industries. Mr. O&rsquo;Loughlin has a B.S. in Business Administration
with a concentration in finance from Ramapo College of New Jersey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jeffrey W. Chell, M.D., Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Chell has been
a director of the Company since April 2018. Dr. Chell is also a member of our Audit Committee and Compensation Committee. He has
been the Chief Executive Officer Emeritus of the National Marrow Donor Program (NMDP) since 2017 having served as its CEO since
2000. Dr. Chell has led the NMDP through transformational growth as its Be The Match Registry tripled to more than 12 million donors,
the number of transplants facilitated has grown five fold to over 6,400 annually, and revenue more than tripled to nearly $400
million per year. He is also the co-founder and has served as Executive Director of the Center For International Blood &amp; Marrow
Transplant Research since 2004, a leading research program in the field contributing over 70 research publications per year in
peer-reviewed journals. Dr. Chell also currently serves as chair of CLR Insurance, a captive insurance company domiciled in the
Cayman Islands. From 2014 to 2016, Dr. Chell served as co-chair of Bone Marrow Donors Worldwide (BMDW) during its IT transformation
project, improving revenues and reducing costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to joining the
NMDP, he served as President, Allina Medical Clinics, a 450 physician multi-specialty medical group from 1994 to 1999. Prior to
that he practiced Internal Medicine in Minneapolis and in the U.S. Air Force Medical Corps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Chell received
his M.D. from the University of Minnesota and his training in Internal Medicine at the University of Wisconsin, Madison. Dr. Chell
is a diplomate of the American Board of Internal Medicine, a member of the American Society of Hematology and a member of the American
Society of Blood and Marrow Transplantation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">He has received multiple
honors including the 2018 Public Service award of the American Society For Blood and Marrow Transplantation, 2017 Most Admired
CEO by the Minneapolis/St. Paul Business Journal, 2010 Healthcare Executive of the Year by the Minneapolis/St, Paul Business Journal,
and the 2017 Bone Marrow Foundation Service Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>David Nicholson, Ph.D., Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">David Nicholson has
been a Director of the Company since 2008. Dr. Nicholson is also a member of our Compensation Committee and Corporate Governance
Committee. In August 2014, Dr. Nicholson joined Actavis plc and Forest Laboratories, Inc. as Senior Vice President, Actavis Global
Brands R&amp;D. From March 2012 to August 2014, Dr. Nicholson was on the Executive Committee of Bayer CropScience as Head of Research
&amp; Development responsible for the integration of the company&rsquo;s R&amp;D activities into one global organization. Dr. Nicholson
graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University of Wales
(1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-W&uuml;lfing
in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development
of cardiovascular drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From 1988-2007, Dr.
Nicholson held various positions of increasing seniority in the UK, the Netherlands and the USA with Organon, a Business Unit of
Akzo Nobel. Ultimately, he became Executive Vice President, Research &amp; Development, and member of the Organon Executive Management
Committee. He implemented change programs, leading to maximizing effectiveness in research &amp; development, ensuring customer
focus and the establishment of a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough,
Kenilworth, New Jersey as Senior Vice President, responsible for Global Project Management and Drug Safety. From 2009 to December
2011, he was Vice President Licensing and Knowledge Management at Merck in Rahway, New Jersey, reporting to the President of Merck
R&amp;D. As an integration team member, Dr. Nicholson played a role in the strategic mergers of Organon BioSciences, the human
and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck
in 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That Dr. Nicholson
brings over 25 years of pharmaceutical experience to our Board, having served in various pharmaceutical research and development
executive-level positions over the course of his career, and that Dr. Nicholson has developed significant management and leadership
skills relating to the pharmaceutical industry. and is well accustomed to interfacing with investors, analysts, auditors, outside
advisors and governmental officials, led us to conclude that Dr. Nicholson should serve as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ajit S. Shetty, Ph.D., Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Shetty has been
a Director of the Company since March, 2017. Dr. Shetty is also a member of our, Audit Committee, Compensation Committee, and Chairman
of our Corporate Governance Committee. Dr. Shetty joined Janssen Pharmaceutica, Inc. in 1976 ultimately rising to the position
of President in 1986 where he led the establishment of Janssen&rsquo;s business in the U.S. From 1999 to 2008 he was Managing Director
of Janssen Pharmaceutica, during this time the Janssen Group of companies&rsquo; global sales grew from $1 billion to $8 billion,
and from 2004 until 2012 he was Chairman of the Board of Directors. In Dr. Shetty&rsquo;s most recent role at Johnson &amp; Johnson
he was head of Enterprise Supply Chain, where he reported to the CEO and was responsible for the transformation and optimization
of Johnson &amp; Johnson&rsquo;s supply chain. Dr. Shetty earned a Ph.D. in Metallurgy and B.A. Natural Sciences from Trinity College,
Cambridge University and a Master of Business Administration from Carnegie Mellon University. Dr. Shetty has served as a member
of Agile Therapeutics, Inc.&rsquo;s board of directors since February 2016. In 2007, Dr. Shetty was bestowed the title of Baron
by King Albert II of Belgium for his exceptional merits. He is a member of the Board of Trustees of Carnegie Mellon University,
serves on the Board of Governors for GS1 (Global Standards) in Belgium and formerly served on the Corporate Advisory Board of the
John Hopkins Carey Business School. In 2016, Dr. Shetty was named as Chairperson of the Vlaams Instituut voor Biotechnologie (VIB),
a Belgium based life sciences research institute focused on translating scientific results into pharmaceutical, agricultural and
industrial applications. In addition, he was elected Manager of the Year in 2004 in Flanders and received a Life-Time Achievement
Award in India in 2010. We believe Dr. Shetty&rsquo;s qualifications to sit on our Board include his extensive pharmaceutical experience
leading commercial and supply chain operations and his significant education background.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That Dr. Shetty has
37 years of leadership and executive experience in the pharmaceutical industry, that he has significant supply chain knowledge
and that he has experience conducting business in the U.S. and Europe, led us to conclude that Dr. Shetty should serve as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Richard I. Steinhart, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Steinhart has served
as our Director and Chairman of the Audit Committee since November 2013. Mr. Steinhart is also a member of our Corporate Governance
Committee. Since October 2017 Mr. Steinhart has been the Chief Financial Officer of BioXcel Therapeutics, Inc. Since March 2014,
Mr. Steinhart has been a Member of the Board of Directors of Atossa Genetics, Inc. where he is Chairman of the Audit Committee
and a member of the Compensation Committee. Form October 2015 to April 2017, Mr. Steinhart was Vice President and CFO at Remedy
Pharmaceuticals, a privately-held, clinical stage pharmaceutical company. From January 2014 through September 2015 Mr. Steinhart
had been a financial and strategic consultant to the biotechnology and medical device industries. From April 2006 through December
2013, Mr. Steinhart was employed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer
and Secretary. In April 2012, Mr. Steinhart received a promotion to Sr. Vice President, Finance and Chief Financial Officer. From
May 1992 until joining MELA Sciences, Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment
banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street
Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart&rsquo;s other
experience includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies,
where he was a General Partner and Chief Financial Officer. Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers.
He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant (inactive).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">That Mr. Steinhart
brings nearly 30 years of financial experience to our Board, having served in various financial executive-level positions over
the course of his career, and that Mr. Steinhart is a certified public accountant led us to conclude that Mr. Steinhart should
serve as a director and chair the audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
oversees our business affairs and monitors the performance of management. In accordance with our corporate governance principles,
the Board of Directors does not involve itself in day-to-day operations. The directors keep themselves informed through discussions
with the Chairman and Chief Executive Officer and other key executives and by reading the reports and other materials that we send
them and by participating in Board of Directors and committee meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Term of Office</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
into three classes, designated Class I, Class II and Class III. Class I shall consists of two directors, Class II shall consist
of one director, and Class III consists of one director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of each director
is set forth below or until their successors are duly elected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director</B></FONT></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class</B></FONT></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
    (from 2018 Annual Meeting)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Steinhart </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit Shetty</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class III</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, each director shall serve until his successor is duly elected and qualified, or until his or her retirement, death,
resignation or removal. In order to implement a classified board of directors, Class I shall serve a two-year term from the date
of the 2018 Annual Shareholders Meeting; Class II shall serve a three-year term from the date of the 2018 Annual Shareholders Meeting;
and Class III shall serve a one-year term from the date of the 2018 Annual Shareholders Meeting. Directors elected at each annual
meeting are elected for a three-year term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Director Independence</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use the definition
of &ldquo;independence&rdquo; of the NYSE American stock exchange to make this determination. We are listed on the NYSE American
under the symbol &ldquo;ATNM&rdquo;. NYSE MKT corporate governance rule Sec. 803(A)(2) provides that an &ldquo;independent director&rdquo;
means a person other than an executive officer or employee of the company. No director qualifies as independent unless the issuer&rsquo;s
board of directors affirmatively determines that the director does not have a relationship that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director. Under the NYSE American director independence rules,
Jeffrey W. Chell, David Nicholson, Ajit S. Shetty, and Richard I. Steinhart are independent directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Chief Executive Officer&rsquo;s Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, we
amended and restated Mr. Seth&rsquo;s, our Chairman and Chief Executive Officer, August 6, 2015 Executive Chairman Agreement (the
&ldquo;Prior CEO Agreement&rdquo;), as amended. This new agreement sets forth the terms related to his position as Chief Executive
Officer and Chairman of the Board of the Company while retaining and adapting material provisions of the Prior CEO Agreement to
that of his role of Chief Executive Officer. Mr. Seth is currently paid an annual salary of $545,000. The Board reviews the amount
of his base salary and performance bonus and determines the appropriate adjustments to each component of his compensation each
calendar year, and he may be entitled to a cash bonus in an amount to be determined by the board with a target of 50% of the base
salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chairman and CEO
shall also be awarded stock options and/or restricted stock grants at our Board&rsquo;s discretion. Mr. Seth&rsquo;s agreement
includes severance benefits, including in the event of a change of control of the Company, and to provide for immediate vesting
of options in accordance with our Amended and Restated 2013 Stock Plan. The term of the agreement is until February 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Chief Medical Officer Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In December 2016, the Company and Dr. Mark
S. Berger entered into an agreement (the &ldquo;Berger Employment Agreement&rdquo;), to employ Dr. Berger as our Chief Medical
Officer. Dr. Berger&rsquo;s employment with the Company is on an &ldquo;at will&rdquo; basis, meaning that either Dr. Berger or
the Company may terminate his employment at any time for any reason or no reason, without further obligation or liability, except
as provided in his employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Pursuant to the Berger Employment Agreement, Dr. Berger is entitled
to the following compensation and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dr. Berger&rsquo;s current annual base salary is $400,000
per year. Dr. Berger may be entitled to a cash bonus in an amount to be determined by the Board with a target of 30% of the base
salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dr. Berger is also eligible to participate in the
Company&rsquo;s benefit plans that are generally provided for executive employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Principal Financial Officer Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In August 2018, we amended and restated
Mr. O&rsquo;Loughlin&rsquo;s, our Principal Financial Officer, September 17, 2015 Employment Agreement (the &ldquo;Prior CFO Agreement&rdquo;),
as amended. This new agreement (the &ldquo;CFO Employment Agreement&rdquo;) sets forth the terms related to his position as Principal
Financial Officer of the Company while retaining and adapting material provisions of the Prior CFO Agreement to that of his role
of Principal Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Mr. O&rsquo;Loughlin&rsquo;s employment with the Company is
on an &ldquo;at will&rdquo; basis, meaning that either Mr. O&rsquo;Loughlin or the Company may terminate his employment at any
time for any reason or no reason, without further obligation or liability, except as provided in his employment agreement. Mr.
O&rsquo;Loughlin is entitled to the following compensation and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mr. O&rsquo;Loughlin&rsquo;s
current annual base salary is $285,000 per year, and Mr. O&rsquo;Loughlin may be entitled to a cash bonus in an amount to be determined
by the Board with a target of 30% of the base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">From time to time the Board may grant him options
or restricted stock to purchase common shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mr. O&rsquo;Loughlin is eligible to receive all standard
benefits that Company employees are eligible to receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Chief Scientific Officer&nbsp;Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and Dr.
Dale Ludwig, effective January 2018, entered into an Offer Letter pursuant to which Dr. Ludwig is the Company&rsquo;s Chief Scientific
Officer. Dr. Ludwig&rsquo;s employment with the Company is on an &ldquo;at will&rdquo; basis, meaning that either Dr. Ludwig or
the Company may terminate his employment at any time for any reason or no reason, without further obligation or liability, except
as provided in his employment agreement. Pursuant to the employment agreement. Dr. Ludwig is entitled to the following compensation
and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dr. Ludwig&rsquo;s current annual
base salary is $325,000 per year, and Dr. Ludwig may be entitled to a cash bonus in an amount to be determined by the Board with
a target of 30% of the base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">From time to time the Board may grant him options
or restricted stock to purchase common shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Dr. Ludwig is eligible to receive all standard benefits
that Company employees are eligible to receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Chief Commercial Officer Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018 the
Company and Anil Kapur entered into an Offer Letter pursuant to which Mr. Kapur is the Company&rsquo;s Chief Commercial Officer.
Mr. Kapur&rsquo;s employment with the Company is on an &ldquo;at will&rdquo; basis, meaning that either Dr. Kapur or the Company
may terminate his employment at any time for any reason or no reason, without further obligation or liability, except as provided
in his employment agreement. Pursuant to the employment agreement. Pursuant to the employment agreement, Mr. Kapur is entitled
to the following compensation and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Mr. Kapur&rsquo;s current annual base salary is $325,000
per year, and he may be entitled to a cash bonus in an amount to be determined by the board with a target of 35% of the base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">From time to time the Board may grant him options
or restricted stock to purchase common shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Mr. Kapur is eligible to receive all standard benefits
that Company employees are eligible to receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board of Directors Meetings and Attendance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal
year 2018, our Board held  nine meetings and did not act by unanimous written consent. Each director attended all of the
meetings of our Board and of any committees of which he was a member during the year ended December&nbsp;31, 2018. It is our
policy that directors should make every effort to attend the annual meeting of stockholders, and each of our directors
attended the annual meeting of stockholders in&nbsp;2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Committees of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has formed three standing committees: audit, compensation and corporate governance. Actions taken by our committees are reported
to the full board. Each of our committees has a charter and each charter is posted on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit
    Committee</B></FONT></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation&nbsp;Committee</B></FONT></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
    Governance Committee</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left"><B>*</B></TD><TD STYLE="text-align: justify">Indicates committee chair</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee,
which currently consists of three directors, provides assistance to our board in fulfilling its legal and fiduciary obligations
with respect to matters involving the accounting, financial reporting, internal control and compliance functions of the company.
The board of directors has determined that Mr.&nbsp;Steinhart is an &ldquo;audit committee financial expert&rdquo; as defined in
Item&nbsp;407(d)(5)(ii) of Regulation S-K. Our audit committee employs an independent registered public accounting firm to audit
the financial statements of the company and perform other assigned duties. Further, our audit committee provides general oversight
with respect to the accounting principles employed in financial reporting and the adequacy of our internal controls. In discharging
its responsibilities, our audit committee may rely on the reports, findings and representations of the company&rsquo;s auditors,
legal counsel, and responsible officers. Our board has determined that all members of the audit committee are financially literate
within the meaning of SEC rules and under the current listing standards of the NYSE AMERICAN. Richard I. Steinhart is the chairman
of the audit committee. <FONT STYLE="background-color: white">The Audit Committee met four times during 2018. Each member of the
Audit Committee was present at all of the Audit Committee meetings held during such director&rsquo;s tenure as a member of the
Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee,
which currently consists of three directors, establishes executive compensation policies consistent with the company&rsquo;s objectives
and stockholder interests. The compensation committee met one time during 2018. Our compensation committee also reviews the performance
of our executive officers and establishes, adjusts and awards compensation, including incentive-based compensation, as more fully
discussed below. In addition, our compensation committee generally is responsible for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">establishing and periodically reviewing our compensation philosophy and the adequacy of compensation
plans and programs for our directors, executive officers and other employees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">overseeing our compensation plans, including the establishment of performance goals under the company&rsquo;s
incentive compensation arrangements and the review of performance against those goals in determining incentive award payouts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">overseeing our executive employment contracts, special retirement benefits, severance, change in
control arrangements and/or similar plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">acting as administrator of any company stock option plans; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">overseeing outside compensation consultants when engaged.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
periodically reviews the compensation paid to our non-employee directors and the principles upon which their compensation is determined.
The compensation committee also periodically reports to the board on how our non-employee director compensation practices compare
with those of other similarly situated public corporations and, if the compensation committee deems it appropriate, recommends
changes to our director compensation practices to our board for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside consulting
firms retained by our compensation committee and management also will, if requested, provide assistance to the compensation committee
in making its compensation-related decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Corporate Governance Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Corporate Governance Committee, which currently
consists of three directors, monitors our corporate governance system. The Corporate Governance Committee met one time during 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nomination of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Board of Director nominations
are selected, or recommended for the Board&rsquo;s selection, by a majority of the independent directors. Our independent directors
include Jeffrey W. Chell, David Nicholson, Richard I. Steinhart and Ajit S. Shetty. These directors are charged with the responsibility
of proposing potential director nominees to the board of directors for consideration. All of our independent directors are independent
directors as defined by the rules of the NYSE AMERICAN. Our independent directors use criteria by which it will seek to evaluate
candidates to serve on our board of directors. The evaluation methodology includes items such as experience in the biotechnology
sector, experience with public companies, executive managerial experience, operations and commercial experience, fundraising experience
and contacts in the investment banking industry, personal and skill set compatibility with current board members, industry reputation,
knowledge of our company generally, and independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Lead Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2017, our board of directors created the position of Lead Director. Our board of directors designated David Nicholson,
an existing independent director, as our Lead Director. Pursuant to the charter of the Lead Director, the Lead Director shall be
an independent,&nbsp;non-employee&nbsp;director designated by our board of directors who shall serve in a lead capacity to coordinate
the activities of the other&nbsp;non-employee&nbsp;directors, interface with and advise management, and perform such other duties
as are specified in the charter or as our board of directors may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family
relationships among any of our officers or directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, none
of our current directors or executive officers has, during the past ten years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding
traffic violations and other minor offenses);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">had any bankruptcy petition filed by or against the business or property of the person, or of any
partnership, corporation or business association of which he was a general partner or executive officer, either at the time of
the bankruptcy filing or within two years prior to that time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending
or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings
and loan, or insurance activities, or to be associated with persons engaged in any such activity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity
Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed,
suspended, or vacated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">been the subject of, or a party to, any federal or state judicial or administrative order, judgment,
decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private
litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation
respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order
of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition
order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as
defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that
has disciplinary authority over its members or persons associated with a member.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth
in our discussion below in &ldquo;Certain Relationships and Related Transactions,&rdquo; none of our directors or executive officers
has been involved in any transactions with us or any of our directors, executive officers, affiliates or associates which are required
to be disclosed pursuant to the rules and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has adopted
a code of ethics, a copy of which is attached as Exhibit 14.1 to the Form 8-K filed on January 2, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compliance with Section 16 (a) of the Exchange Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Section 16(a)
of the Exchange Act, our directors and certain of our officers, and persons holding more than 10 percent of our common stock are
required to file forms reporting their beneficial ownership of our common stock and subsequent changes in that ownership with the
United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based solely upon a
review of copies of such forms filed on Forms 3, 4, and 5, and amendments thereto furnished to us, we believe that as of December
31, 2018, our executive officers and directors have complied on a timely basis with all Section 16(a) filing requirements, except
for a Form 4 filing on March 19, 2018 by Dr. Berger for the purchase of warrants and common stock on March 6, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Discussion and Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee
of our Board of Directors has the responsibility to review, determine and approve the compensation for our executive officers.
Further, our Compensation Committee oversees our overall compensation strategy, including compensation policies, plans and programs
that cover all employees. In 2016, our Stockholders voted on an advisory basis with respect to our compensation program for named
executive officers. Of the votes cast (excluding abstentions and broker non-votes), 69.0% were cast in support of the program.
In light of this, in reviewing the executive compensation program for 2016, our Compensation Committee decided to retain the general
overall program design, which ties a significant portion of the executives&rsquo; pay closely with our performance. In the future,
our Compensation Committee will continue to consider the executive compensation program in light of changing circumstances and
stockholder feedback.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently employ
five executive officers, each of whom serves as a &ldquo;Named Executive Officer&rdquo; (or NEO) for purposes of SEC reporting:
(1) Sandesh Seth, our Chairman and Chief Executive Officer (who we refer to in this Compensation Discussion and Analysis as our
CEO); (2) Steve O&rsquo;Loughlin, our Principal Financial Officer, (3) Mark Berger, our Chief Medical Officer; (4) Dale Ludwig,
our Chief Scientific Officer, and (5) Anil Kapur, our Chief Commercial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Compensation Discussion
and Analysis sets forth a discussion of the compensation for our NEOs as well as a discussion of our philosophies underlying the
compensation for our NEOs and our employees generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Objectives of Our Compensation Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee&rsquo;s
philosophy seeks to align the interests of our stockholders, officers and employees by tying compensation to individual and company
performance, both directly in the form of salary or annual cash incentive payments, and indirectly in the form of equity awards.
The objectives of our compensation program enhance our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>attract and retain qualified and talented individuals; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>provide reasonable and appropriate incentives and rewards to our team for building long-term value within our company, in each
case in a manner comparable to companies similar to ours.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we strive
to be competitive with other similarly situated companies in our industry. The process of developing pharmaceutical products and
bringing those products to market is a long-term proposition and outcomes may not be measurable for several years. Therefore, in
order to build long-term value for our company and its stockholders, and in order to achieve our business objectives, we believe
that we must compensate our officers and employees in a competitive and fair manner that reflects current company activities but
also reflects contributions to building long-term value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We utilize the services
of StreeterWyatt Governance LLC to review compensation programs of peer companies in order to assist the Compensation Committee
in determining the compensation levels for our NEOs, as well as for other employees of our company. StreeterWyatt is a recognized
independent consulting company and services clients throughout the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Elements of Our Compensation Program and Why We Chose Each</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Main Compensation
Components</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company-wide compensation
program, including for our NEOs, is broken down into three main components: base salary, performance cash bonuses and potential
long-term compensation in the form of stock options or restricted stock awards. We believe these three components constitute the
minimum essential elements of a competitive compensation package in our industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Salary</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Base salary is used
to recognize the experience, skills, knowledge and responsibilities required of our NEOs as well as recognizing the competitive
nature of the biopharmaceutical industry. This is determined partially by evaluating our peer companies as well as the degree of
responsibility and experience levels of our NEOs and their overall contributions to our company. Base salary is one component of
the compensation package for NEOs; the other components being cash bonuses, annual equity grants, and company benefit programs.
Base salary is determined in advance whereas the other components of compensation are awarded in varying degrees following an assessment
of the performance of a NEO. This approach to compensation reflects the philosophy of our board of directors and its Compensation
Committee to emphasize and reward, on an annual basis, performance levels achieved by our NEOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Performance Bonus
Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a performance
bonus plan under which bonuses are paid to our NEOs based on achievement of company performance goals and objectives established
by the Compensation Committee and/or our board of directors as well as on individual performance. The bonus program is discretionary
and is intended to: (i) strengthen the connection between individual compensation and our company&rsquo;s achievements; (ii) encourage
teamwork among all disciplines within our company; (iii) reinforce our pay-for-performance philosophy by awarding higher bonuses
to higher performing employees; and (iv) help ensure that our cash compensation is competitive. Depending on the cash position
of the company, the Compensation Committee and our board of directors have the discretion to not pay cash bonuses in order that
we may conserve cash and support ongoing development programs and commercialization efforts. Regardless of our cash position, we
consistently grant annual merit-based stock options to continue incentivizing both our senior management and our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on their employment
agreements, each NEO is assigned a target payout under the performance bonus plan, expressed as a percentage of base salary for
the year. Actual payouts under the performance bonus plan are based on the achievement of corporate performance goals and an assessment
of individual performance, each of which is separately weighted as a component of such officer&rsquo;s target payout. For the NEOs,
the corporate goals receive the highest weighting in order to ensure that the bonus system for our management team is closely tied
to our corporate performance. Each employee also has specific individual goals and objectives as well that are tied to the overall
corporate goals. For employees, mid-year and end-of-year progress is reviewed with the employees&rsquo; managers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Equity Incentive
Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We view long-term compensation,
currently in the form of stock options and restricted stock generally vesting in annual increments over four years, as a tool to
align the interests of our NEOs and employees generally with the creation of stockholder value, to motivate our employees to achieve
and exceed corporate and individual objectives and to encourage them to remain employed by the company. While cash compensation
is a significant component of employees&rsquo; overall compensation, the Compensation Committee and our board of directors (as
well as our NEOs) believe that the driving force of any employee working in a small biotechnology company should be strong equity
participation. We believe that this not only creates the potential for substantial longer term corporate value but also serves
to motivate employees and retain their loyalty and commitment with appropriate personal compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
main components of compensation outlined above, we also have provided contractual severance and/or change in control benefits to
several employees including our Executive Chairman and CEO. The change in control benefits for all applicable persons have a &ldquo;double
trigger.&rdquo; A double-trigger means that the executive officers will receive the change in control benefits described in the
agreements only if there is both (1) a Change in Control of our company (as defined in the agreements) and (2) a termination by
us of the applicable person&rsquo;s employment &ldquo;without cause&rdquo; or a resignation by the applicable persons for &ldquo;good
reason&rdquo; (as defined in the agreements) within a specified time period prior to or following the Change in Control. We believe
this double trigger requirement creates the potential to maximize stockholder value because it prevents an unintended windfall
to management as no benefits are triggered solely in the event of a Change in Control while providing appropriate incentives to
act in furtherance of a change in control that may be in the best interests of the stockholders. We believe these severances or
change in control benefits are important elements of our compensation program that assist us in retaining talented individuals
at the executive and senior managerial levels and that these arrangements help to promote stability and continuity of our executives
and senior management team. Further, we believe that the interests of our stockholders will be best served if the interests of
these members of our management are aligned with theirs. We believe that providing change in control benefits lessens or eliminates
any potential reluctance of members of our management to pursue potential change in control transactions that may be in the best
interests of the stockholders. We also believe that it is important to provide severance benefits to members of our management,
to promote stability and focus on the job at hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also provide benefits
to the executive officers that are generally available to all regular full-time employees of our company, including our medical
and dental insurance, and a 401(k) plan. Further, we do not have deferred compensation plans, pension arrangements or post-retirement
health coverage for our executive officers or employees. All of our employees not specifically under contract are &ldquo;at-will&rdquo;
employees, which means that their employment can be terminated at any time for any reason by either us or the employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Determination of
Compensation Amounts</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of factors
impact the determination of compensation amounts for our NEOs, including the individual&rsquo;s role in the company and individual
performance, length of service with the company, competition for talent, individual compensation package, assessments of internal
pay equity and industry data. Stock price performance has generally not been a factor in determining annual compensation because
the price of our common stock is subject to a variety of factors outside of our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Industry Survey
Data</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In collaboration with
StreeterWyatt, we establish and maintain a list of peer companies to best assure ourselves that we are compensating our executives
on a fair and reasonable basis, as set forth above under the heading &ldquo;Objectives of our Compensation Program.&rdquo; We also
utilize StreeterWyatt-prepared data for below-executive level personnel, which data focuses on biotechnology companies that can
be considered peers in terms of numerous variables including phase of development, size, therapeutic and technological focus among
others. The availability of peer data is used by the Compensation Committee strictly as a guide in determining compensation levels
with regard to salaries, cash bonuses and performance related annual equity grants to all employees. However, the availability
of this data does not imply that the Compensation Committee is under any obligation to exactly follow peer companies in compensation
matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Determination of
Base Salaries</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a guideline for
NEO base salary, we perform formal benchmarks against respective comparable positions in our established peer group. We adjust
salaries based on our assessment of our NEOs&rsquo; levels of responsibility, experience, overall compensation structure and individual
performance. The Compensation Committee is not obliged to raise salaries purely on the availability of data. Merit-based increases
to salaries of executive officers are based on our assessment of individual performance and the relationship to applicable salary
ranges. Cost of living adjustments may also be a part of that assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 36; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Performance Bonus
Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the
beginning of each calendar year, preliminary corporate goals that reflect our business priorities for the coming year are prepared
by the CEO with input from the other executive officers. These goals are weighted by relative importance. The draft goals and proposed
weightings are presented to the Compensation Committee and the Board and discussed, revised as necessary, and then approved by
our board of directors. The Compensation Committee then reviews the final goals and their weightings to determine and confirm their
appropriateness for use as performance measurements for purposes of the bonus program. The goals and/or weightings may be re-visited
during the year and potentially restated in the event of significant changes in corporate strategy or the occurrence of significant
corporate events. Following the agreement of our board of directors on the corporate objectives, the goals are then shared with
all employees in a formal meeting(s), and are reviewed periodically throughout the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Determination of
Equity Incentive Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To assist us in assessing
the reasonableness of our equity grant amounts, we have reviewed StreeterWyatt supplied information. Such information included
equity data from a cross-section of similar companies in our industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Equity Grant Practices</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All stock options and/or
restricted stock granted to the NEOs and other executives are approved by the Compensation Committee. Exercise prices for options
are set at the closing price of our common stock on the date of grant. Grants are generally made: (i) on the employee&rsquo;s start
date and (ii) at board of director meetings held each February and following annual performance reviews. However, grants have been
made at other times during the year. The size of year-end grants for each NEO is assessed against our internal equity guidelines.
Current market conditions for grants for comparable positions and internal equity may also be assessed. Also, grants may be made
in connection with promotions or job-related changes in responsibilities. In addition, on occasion, the Compensation Committee
may make additional special awards for extraordinary individual or company performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Compensation Setting
Process</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Annually, at a meeting
of our board of directors and the Compensation Committee, overall corporate performance and relative achievement of the corporate
goals for the prior year are assessed. The relative achievement of each goal is assessed and quantified and the summation of the
individual components results in a corporate goal rating, expressed as percentages. The Compensation Committee then approves the
final disbursement of salary increases, cash bonuses and option or restricted stock grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
looks to the CEO&rsquo;s performance assessments of the other NEOs and his recommendations regarding a performance rating for each,
as well as input from the other members of our board of directors. These recommendations may be adjusted by the Compensation Committee
prior to finalization. For the CEO, the Compensation Committee evaluates his performance, taking into consideration input from
the other members of our board of directors, and considers the achievement of overall corporate objectives by both the CEO specifically
and the company generally. The CEO is not present during the Compensation Committee&rsquo;s deliberations regarding his compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
has the authority to directly engage, at our company&rsquo;s expense, any compensation consultants or other advisors (such as StreeterWyatt)
that it deems necessary to determine the amount and form of employee, executive and director compensation. In determining the amount
and form of employee, executive and director compensation, the Compensation Committee has reviewed and discussed historical salary
information as well as salaries for similar positions at comparable companies. However, the availability of this data does not
imply that the Compensation Committee is under any obligation to exactly follow peer companies&rsquo; compensation practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We paid consultant
fees to StreeterWyatt of $10,000 during the year ended December 31, 2018. NEOs may have indirect input in the compensation results
for other executive officers by virtue of their participation in the performance review and feedback process for the other executive
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_019"></A><B>ITEM 11. EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
provides information regarding the compensation earned during the fiscal years ended December 31, 2018 and 2017 for our named executive
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name/Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus (1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other Compensation</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Sandesh Seth (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">545,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">280,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">549,253</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,374,253</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">306,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">306,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Kaushik J. Dave,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Former CEO (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">577,942</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">244,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">932,708</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mark Berger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">137,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">612,313</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">343,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">234,695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">578,445</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dragan Cicic,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Former COO (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">389,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">73,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">507,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Anil Kapur</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">294,402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">211,261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">505,663</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dale Ludwig</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">323,769</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">424,695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nitya Ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">323,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">399,525</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Former Executive Vice President (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">177,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">198,896</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">376,169</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Steve O&rsquo;Loughlin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">285,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">145,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">505,552</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">235,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">97,907</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">383,059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The bonus disclosed in this column relates to performance
in the prior year, but was contingent upon board approval, and was paid in the year disclosed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Mr. Seth was appointed Chief Executive Officer on June 5, 2017. Prior to this, Mr. Seth was Executive Chairman
and was paid an annual consulting fee and bonus. In March 2017, Mr. Seth was awarded stock options to purchase 750,000 shares for
$1.39, having an option award value of $734,301 and in April 2017, Mr. Seth received a bonus as Executive Chairman of $215,000.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Dr. Dave resigned from the company on May 12, 2017. His
2017 salary includes a severance of $410,000.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Dr. Cicic resigned from the company on May 12, 2017. His
2017 salary includes a severance of $283,000.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Dr. Ray resigned from the company on December 21, 2018.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the compensation
of our non-employee directors for the 2018 fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>Name</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Fees Earned or <BR> Paid in Cash</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Stock<BR> Awards</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Option<BR> Awards <BR>(1)</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>All Other <BR> Compensation</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Total</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Jeffrey W. Chell (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">34,607</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">59,366</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">93,973</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">David Nicholson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">63,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">104,694</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ajit J. Shetty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">58,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">99,694</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Richard Steinhart</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">66,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">107,285</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the end of December 31, 2018, the aggregate number of option awards outstanding for each director was as follows: (i) for Dr.
Chell, 150,000, (ii) for Dr. Nicholson, 349,900, (iii) for Dr. Shetty, 150,000, and (iv) for Mr. Steinhart, 299,950.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chell was appointed a director on April 27, 2018.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
SEC rules, the amounts shown reflect the aggregate grant date fair value of option awards granted to Non-Employee Directors during
2018, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our non-employee directors
are paid an annual fee of $40,000 and receive annual option grants. Dr. Nicholson as Lead Director receives an additional annual
fee of $10,000. Board committee members receive the following compensation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">BOD Committee</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Chairman</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Member</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Audit</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Corporate Governance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year-End Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
- 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth all unexercised options that have been awarded to our named executives by the Company that were outstanding as of December
31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="17" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0">Name<BR> (a)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> Securities <BR> Underlying <BR> Unexercised <BR> Options <BR> (#) <BR> (Exercisable) (b)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> Securities <BR> Underlying <BR> Unexercised <BR> Options <BR> (#) <BR> (Unexercisable) (c)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <BR> Incentive <BR> Plan <BR> Awards: <BR> Number of <BR> Securities <BR> Underlying <BR> Unexercised Unearned <BR> Options <BR> (#) <BR> (d)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <BR> Exercise <BR> Price <BR> ($) <BR> (e)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <BR> Expiration Date<BR> (f)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> Shares or <BR> Units of <BR> Stock That <BR> Have Not <BR> Vested <BR> (#) <BR> (g)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Market <BR> Value of <BR> Shares <BR> or Units <BR> of Stock <BR> That <BR> Have Not <BR> Vested <BR> ($) <BR> (h)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <BR> Incentive <BR> Plan <BR> Awards: <BR> Number <BR> of <BR> Unearned <BR> Shares, <BR> Units or <BR> Other <BR> Rights <BR> That <BR> Have Not <BR> Vested <BR> (#) <BR> (i)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <BR> Incentive <BR> Plan <BR> Awards: <BR> Market or <BR> Payout <BR> Value of <BR> Unearned <BR> Shares, <BR> Units or <BR> Other <BR> Rights <BR> That <BR> Have Not <BR> Vested <BR> ($) <BR> (j)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 8%; white-space: nowrap">Sandesh Seth</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">24,975</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">8/30/2022</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/19/2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/23/2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2/15/2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/15/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">373,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/14/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/13/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: center; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Mark Berger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1/17/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/13/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Anil Kapur</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">475,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.6369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2/06/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Dale&nbsp;Ludwig</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.723</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1/08/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Nitya Ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/21/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/21/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0">Steve O&rsquo;Loughlin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/28/2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/15/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/14/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/13/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 102(b)(7) of
the Delaware General Corporation Law allows a corporation to provide in its certificate of incorporation that a director of the
corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty
as a director, except where the directors breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct
or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate
law or obtained an improper personal benefit. Our certificate of incorporation provides for this limitation of liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the
General Corporation Law of the State of Delaware provides that a Delaware corporation may indemnify any person who was, is or is
threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was
an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director,
officer employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such
action, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed
to the corporation&rsquo;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe
that his conduct was illegal. A Delaware corporation may indemnify any persons who are, or were, a party to any threatened, pending
or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director,
officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo;
fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided
such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&rsquo;s best
interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent
is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense
of any action referred to above, the corporation must indemnify him against the expenses which such officer or directors has actually
and reasonably incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 further
authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of
another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising
out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide
that we will indemnify our directors and officers to the fullest extent authorized by the General Corporation Law of the State
of Delaware.&nbsp;&nbsp;Expenses (including attorneys&rsquo; fees) incurred by an officer or director of the Corporation in defending
any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final
disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay
such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company as authorized
under Delaware law.&nbsp;&nbsp;Such expenses (including attorneys&rsquo; fees) incurred by former directors and officers or other
employees and agents of the Company or by persons serving at the request of the Company as directors, officers, employees or agents
of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if
any, as the Company deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indemnification
rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under
any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&rsquo;s official
capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be
a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a general
liability insurance policy that covers liabilities of directors and officers of our corporation arising out of claims based on
acts or omissions in their capacities as directors or officers. We have also entered in to Indemnification Agreements with our
executive officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the present time,
there is no pending litigation or proceeding involving a director, officer, employee, or other agent of ours in which indemnification
would be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for such
indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_020"></A><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
shows the beneficial ownership of our Common Stock as of March 5, 2019 held by (i) each person known to us to be the beneficial
owner of more than five percent (5%) of any class of our shares; (ii) each director; (iii) each executive officer; and (iv) all
directors and executive officers as a group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules of the SEC, and generally includes voting power and/or investment power with
respect to the securities held.&nbsp;&nbsp;Shares of Common Stock subject to options and warrants currently exercisable or which
may become exercisable within 60 days of March 5, 2019, are deemed outstanding and beneficially owned by the person holding such
options or warrants for purposes of computing the number of shares and percentage beneficially owned by such person, but are not
deemed outstanding for purposes of computing the percentage beneficially owned by any other person.&nbsp;&nbsp;Except as indicated
in the footnotes to this table, the persons or entities named have sole voting and investment power with respect to all shares
of our Common Stock shown as beneficially owned by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The percentages below
are based on fully diluted shares of our Common Stock equivalents as of March 5, 2019. Unless otherwise indicated, the principal
address of each of the persons below is c/o Actinium Pharmaceuticals, Inc., 275 Madison Ave, 7th floor, New York, NY 10016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 41; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
the principal address of each of the persons below is c/o Actinium Pharmaceuticals, Inc., 275 Madison Ave, 7<SUP>th</SUP> floor,
New York, NY 10016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive Officers and Directors</B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Shares of Common Stock and Preferred Stock Beneficially Owned</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage of Ownership<SUP>(a)</SUP></B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,830,147</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">282,500</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Berger, M.D.</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">268,000</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anil Kapur</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201,500</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale Ludwig, Ph.D.</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,000</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell, M.D.</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,000</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(6)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson, Ph.D.</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">241,400</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty, Ph.D.</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,230</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(8)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,196</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(9)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Directors and Officers as a Group (9 persons)</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,219,973</FONT></TD>
    <TD STYLE="white-space: nowrap; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(10)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7</B></FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>%</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All other 5% holders</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">*</TD><TD STYLE="text-align: justify">less than 1%</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Based&nbsp;on 117,337,447 shares of Common Stock outstanding
as of March 5, 2019</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Warrants to purchase an aggregate of 64,747 shares of Common
Stock of the Company at an exercise price of $0.784 per share, exercisable on a cashless basis, warrants to purchase an aggregate
of 99,617 of Common Stock of the Company at an exercise price of $0.784 per share, exercisable on a cashless basis issued to Amrosan,
LLC, a partnership in which the majority member interest is owned by the family of Mr. Seth, and warrants to purchase 57,212 shares
of Common Stock at an exercise price of $1.23 per share. Excludes warrants to purchase an aggregate of 375,556 shares of Common
Stock of the Company at par value per share, exercisable on a cashless basis issued to Amrosan, LLC as the warrants are not exercisable
upon less than 90 days&rsquo; notice. The holder may waive the 90-day exercise notice requirement by giving 65 days prior notice
of such waiver. Excludes 353,023 warrants issued to Carnegie Hill Asset Partners and irrevocable trust linked to Mr. Seth&rsquo;s
family and 721,068 warrants issued to Bioche Asset Management, LLC, a partnership in which the majority member interest is owned
by the family of Mr. Seth whose terms are the same as those issued to Amrosan LLC. On August 30, 2012 and December 12, 2012, Mr.
Seth was granted options to purchase an aggregate of 49,950 shares of Common Stock at an exercise price of $1.50 per share. On
September 13, 2014, Mr. Seth was granted an option to purchase 280,000 shares with an exercise price of $6.13 per share. On February
18, 2015, Mr. Seth was granted an option to purchase 150,000 shares with an exercise price of $3.58 per share. On April 15, 2016,
Mr. Seth was granted an option to purchase 500,000 shares at an exercise price of $1.99 per share. On March 14, 2017, Mr. Seth
was granted options to purchase an aggregate of 750,000 shares of Common Stock at an exercise price of $1.39 per share. On July
13, 2018, Mr. Seth was granted an option to purchase 1,000,000 shares at an exercise price of $0.7829 per share. All options are
subject to vesting. Within 60 days of March 5, 2019, 1,464,950 options will have vested. Includes 161,458 shares of Common Stock
and 39,375 March 2018 Series B Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(2)</TD><TD STYLE="text-align: justify">On October 1, 2015, Mr. O&rsquo;Loughlin was granted 100,000 options with an exercise price of
$1.79&nbsp;per&nbsp;share. On April 14, 2016, Mr. O&rsquo;Loughlin was granted options to purchase of 50,000 shares of&nbsp;Common
Stock at an exercise price of $1.99 per share. On March 14, 2017, Mr. O&rsquo;Loughlin was granted options to purchase 100,000
shares of&nbsp;Common Stock at an exercise price of $1.39 per share. On July 13, 2018, Mr. O&rsquo;Loughlin was granted an option
to purchase 265,000 shares of Common Stock at an exercise price of $0.7829 per share. All options are subject to vesting. Within
60&nbsp;days of March 5, 2019, 239,500 options will have vested. Includes 35,500 shares of Common Stock and 7,500 March 2018 Series
B Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(3)</TD><TD STYLE="text-align: justify">On January 17, 2017, Dr. Berger was granted an option to purchase 325,000 shares with an exercise
price of $1.04 per share. On July 13, 2018, Dr. Berger was granted an option to purchase 250,000 shares at an exercise price of
$0.7829 per share. All options are subject to vesting. Within 60 days of March 5, 2019, 238,500 options will have vested. Includes
19,000 shares of Common Stock and 10,500 March 2018 Series B Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(4)</TD><TD STYLE="text-align: justify">On February 6, 2018, Mr. Kapur was granted an option to purchase 475,000 shares with an exercise
price of $0.64 per share. This option is subject to vesting. Within 60 days of March 5, 2019, 161,500 options will have vested.
Includes 40,000 shares of Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(5)</TD><TD STYLE="text-align: justify">On January 8, 2018, Dr. Ludwig was granted an option to purchase 200,000 shares with an exercise
price of $0.72 per share. This option is subject to vesting. Within 60 days of March 5, 2019, 72,000 options will have vested.
Includes 10,000 shares of Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(6)</TD><TD STYLE="text-align: justify">On April 27, 2018, Dr. Chell was granted an option to purchase 75,000 shares with an exercise price
of $0.347 per share. On July 13, 2018, Dr. Chell was granted an option to purchase 75,000 shares at an exercise price of $0.7829
per share. All options are subject to vesting. Within 60 days of March 5, 2019, 36,000 options will have vested.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(7)</TD><TD STYLE="text-align: justify">On February 12, 2012, Dr. Nicholson was granted an option to purchase 49,950 shares of Common Stock
at an exercise price of $0.784 per share and on August 12, 2012 and December 19, 2012, Dr. Nicholson was granted options to purchase
an aggregate of 49,950 shares at an exercise price of $1.50 per share. On February 18, 2015, Dr. Nicholson was granted an option
to purchase 25,000 shares with an exercise price of $3.58 per share. On April 15, 2016, Dr. Nicholson was granted an option to
purchase 75,000 shares at an exercise price of $1.99 per share. On March 14, 2017, Dr. Nicholson was granted an option to purchase
75,000 shares at an exercise price of $1.39 per share. On July 13, 2018, Dr. Nicholson was granted an option to purchase 75,000
shares at an exercise price of $0.7829 per share. All options are subject to vesting. Within 60 days of March 5, 2019 231,400 options
will have vested. Includes 10,000 shares of Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(8)</TD><TD STYLE="text-align: justify">On March 28, 2017, Dr. Shetty was granted an option to purchase 75,000 shares of Common Stock with
an exercise price of $1.58 per share. On July 13, 2018, Dr. Shetty was granted an option to purchase 75,000 shares at an exercise
price of $0.7829 per share. All options are subject to vesting. Within 60 days of March 5, 2019, 55,500 shares will have vested.
Includes 22,730 shares of Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(9)</TD><TD STYLE="text-align: justify">On December 16, 2013 Mr. Steinhart was granted an option to purchase 49,950 shares of Common Stock
at an exercise price of $6.70 per share. On February 18, 2015, Mr. Steinhart was granted an option to purchase 25,000 shares at
an exercise price of $3.58 per share. On April 15, 2016, Mr. Steinhart was granted an option to purchase 75,000 shares at an exercise
price of $1.99 per share. On March 14, 2017, Mr. Steinhart was granted an option to purchase 75,000 shares at an exercise price
of $1.39 per share. On July 13, 2018, Mr Steinhart was granted an option to purchase 75,000 shares at an exercise price of $0.7829
per share. All options are subject to vesting. Within 60 days of March 5, 2019, 185,446 options will have vested. Includes 9,500
shares of Common Stock and 10,500 March 2018 Series B Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.38in">(10)</TD><TD STYLE="text-align: justify">Includes warrants to purchase 226,989 shares of Common Stock, vested options to purchase 2,684,796
shares of Common Stock and 308,188 shares of Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 43; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_021"></A><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B>Transactions with Related Persons</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Competition Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers
have signed non-competition agreements, which provide that all inventions become the immediate property of us and require invention
assignments. The agreements provide that the executive officers will hold proprietary information in the strictest confidence and
not use the confidential information for any purpose not expressly authorized by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_022"></A><B>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND
SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below shows
the aggregate fees billed for professional services for the audits and audit-related fees of the Company&rsquo;s annual financial
statements included in Form 10-K for the time periods of August 9, 2018 through December 31, 2018 by Marcum LLP, or Marcum, and
for January 1, 2018 through August 8, 2018 by GBH CPAs PC, or GBH, and for the year ended December 31, 2017 by GBH. GBH resigned
as the Company&rsquo;s auditors as a result of combining its practice with Marcum effective July 1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR>
 December&nbsp;31,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR>
 December&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Audit Fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">113,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">116,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit &ndash; Related Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">All Other Fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">141,800</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">177,300</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-Approval Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2015, the Audit
Committee adopted policies and procedures for the pre-approval of audit and non-audit services performed by the independent registered
public accountants pursuant to which the Audit Committee generally is required to pre-approve the audit and permissible non-audit
services performed by the independent registered public accountants in order to ensure that the provision of such services does
not impair the registered accountants&rsquo; independence.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 45; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><A NAME="a_023"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_024"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    </B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 9%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390016017124/f8k092816ex1i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated September 28, 2016, by and between H.C. Wainwright &amp; Co., LLC and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 1.1 to Form 8-K filed on September 29, 2016).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002475/fs32017ex1ii_actiniumpharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At Market Issuance Sales Agreement, dated March 16, 2017, between FBR Capital Markets &amp; Co, and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 1.2 to Form S-3 filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10v_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated At-the-Market Market Issuance Sales Agreement, dated July 3, 2017, among FBR Capital Markets &amp; Co., MLV &amp; Co. LLC, JonesTrading Institutional Services LLC, and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.5 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017007992/f8k072817ex1i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated as of July 28, 2017,&nbsp;by and between Actinium Pharmaceuticals, Inc. and Oppenheimer &amp; Co. Inc. as representative of the several underwriters party thereto (incorporated by reference to Exhibit 1.1 to Form 8-K filed on July 28, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex1-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dealer-Manager Agreement, dated February 15, 2018, between Maxim Group LLC and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 1.1 to Form 8-K filed on February 15, 2018).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000107878212003323/f8k122112_ex2z1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Exchange Agreement, dated December 28, 2012, by and among Cactus Ventures, Inc., Actinium Pharmaceuticals, Inc., Diane S. Button, and the shareholders of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to Form 8-K filed on January&nbsp;2, 2013).</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001029/f8k031113ex10i_cactus.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Exchange Agreement, dated March 11, 2013, by and among Cactus Ventures, Inc., Actinium Pharmaceuticals, Inc, and the shareholders of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on March 11, 2013).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390013004770/fs12013a1ex2iii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Exchange Agreement, dated August 22, 2013, by and among&nbsp;Actinium Pharmaceuticals, Inc, Actinium Corporation, and the shareholders of Actinium Corporation&nbsp;(incorporated by reference to Exhibit 2.3 to Form S-1/A filed on August 22, 2013).</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filed with the SEC on April 17, 2013).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January&nbsp;31, 2014).</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February&nbsp;7, 2014).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Actinium&rsquo;s Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex3-7_actinium.htm">Certificate of Amendment to Actinium&rsquo;s Certificate of Incorporation, as amended, filed on March 6, 2019</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex4viii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Warrant, dated December 27, 2013 and January 10, 2014&nbsp;(incorporated by reference to Exhibit 4.8 to Form S-1 filed on January&nbsp;31, 2014).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390015000762/f8k020615ex4i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 6, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017007992/f8k072817ex10i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 28, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agency Agreement between Action Stock Transfer Corporation and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 15, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed on February 15, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-3_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed on February 15, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-4_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Non-Transferable Subscription Rights Certificate (incorporated by reference to Exhibit 4.4 to Form 8-K filed on February 15, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex4-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revised Form of Non-Transferable Subscription Rights Certificate. (incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 26, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018015315/f10q0918ex4-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Warrant to Purchase Common Stock, dated November 8, 2018, issued to Amrosan LLC (incorporated by reference to Exhibit 4.1 to Form 10-Q filed on November 9, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018015315/f10q0918ex4-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Warrant to Purchase Common Stock, dated November 8, 2018, issued to Carnegie Hill Partners (incorporated by reference to Exhibit 4.2 to Form 10-Q filed on November 9, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018015315/f10q0918ex4-3_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Warrant to Purchase Common Stock, dated November 8, 2018, issued to Bioche Asset Management, LLC (incorporated by reference to Exhibit 4.3 to Form 10-Q filed on November 9, 2018).</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390016011534/f10k2015ex10xxxxxvi_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 22, 2015 (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 11, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390016011534/f10k2015ex10lvii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office Space License Agreement, dated March 19, 2016, by and between Actinium Pharmaceuticals, Inc. and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.57 to Form 10-K filed on March 11, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390016019421/f8k121316ex1i_actiniumpharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 13, 2016 (incorporated by reference to Exhibit 1.1 to Form 8-K filed on December 14, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lix_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.59 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lx_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement, dated March 16, 2017, by and between Actinium Pharmaceuticals, Inc. and Dragan Cicic. (incorporated by reference to Exhibit 10.60 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxi_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Actinium Pharmaceuticals, Inc. Warrant to Purchase Common Stock, dated March 14, 2017 issued to Sandesh Seth (incorporated by reference to Exhibit 10.61 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Actinium Pharmaceuticals, Inc. Warrant to Purchase Common Stock, dated March 14, 2017 issued to Amrosan LLC (incorporated by reference to Exhibit 10.62 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxiii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant to Purchase Common Stock of Actinium Pharmaceuticals, Inc., dated March 14, 2017, issued to Sandesh Seth (incorporated by reference to Exhibit 10.63 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxiv_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter, dated December 27, 2016, by and between Dr. Mark S. Berger and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.64 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxv_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential Information and Invention Assignment Agreement, dated December 27, 2016, by and between Dr. Mark S. Berger and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.65 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxvi_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification Agreement, dated March 16, 2017, by and between Actinium Pharmaceuticals, Inc. and Mark S. Berger (incorporated by reference to Exhibit 10.66 to Form 10-K filed on March 16, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on March 28, 2017). </FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10ii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Form 8-K filed on March 28, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10iii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential Information and Invention Assignment Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to Form 8-K filed on March 28, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017004962/f8k050517ex10i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Amended and Restated Consulting Agreement, dated May 5, 2017, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 11, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10ii_actinium.htm">Offer Letter, dated September 17, 2015, between Steve O&rsquo;Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on May 15, 2017).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10iii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification Agreement, dated May 15, 2017, between Steve O&rsquo;Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Form 10-Q filed on May 15, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment and Consent Agreement, dated June 6, 2017, between&nbsp;275 Madison Avenue RPW 1 LLC and 275 Madison Avenue RPW 2 LLC,&nbsp;Relmada Therapeutics, Inc., and&nbsp;Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10iii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated License Agreement, Dated June 8, 2017, between Relmada Therapeutics, Inc., and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10iv_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter, dated May 26, 2017, between Nitya G. Ray and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.4 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10vi_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement, dated June 6, 2017, between Sergio Traversa and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.6 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10vii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement, dated May 22, 2017, between Dragan Cicic and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.7 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10viii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation and Settlement Agreement, dated May 12, 2017, between Kaushik Dave and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.8 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10ix_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation and Settlement Agreement, dated May 12, 2017, between Dragan Cicic and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.9 to Form 10-Q filed on August 4, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-56_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sixth Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 16, 2018).</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-57_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter, effective January 2, 2018, between Dale L. Ludwig and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.57 to Form 10-K filed on March 16, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-58_actinium.htm">Indemnification Agreement, dated January 5, 2018, between Dale L. Ludwig and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.58 to Form 10-K filed on March 16, 2018).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-59_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter, effective January 31, 2018, between Anil Kapur and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.59 to Form 10-K filed on March 16, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-60_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification Agreement, dated February 8, 2018, between Anil Kapur and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.60 to Form 10-K filed on March 16, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 1, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.2 to Form 8-K filed on May 1, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-3_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential Information and Invention Assignment Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.3 to Form 8-K filed on May 1, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 9, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Steve O&rsquo;Loughlin (incorporated by reference to Exhibit 10.2 to Form 10-Q filed on August 9, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018014103/f8k101918ex10-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement, dated October 18, 2018, by and between Actinium Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 18, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018014103/f8k101918ex10-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated October 18, 2018, by and between Actinium Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to Form 8-K filed on October 18, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2018ex10-37_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement, dated December 21, 2018, between Actinium Pharmaceuticals, Inc. and Nitya Ray.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2018ex10-38_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated At Market Issuance Sales Agreement, dated December 28, 2018, by and among Actinium Pharmaceuticals, Inc. and B. Riley FBR, Inc. and JonesTrading Institutional Services LLC.</FONT></A></TD></TR>

<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">10.39</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2018ex10-39_actinium.htm">Seventh Amendment to the 2013 Amended and Restated Stock Plan, as amended.</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000107878212003323/f8k122112_ex14z1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics (incorporated by reference to Exhibit 14.1 to Form 8-K filed on January&nbsp;2, 2013).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001800/f10k2014ex21i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Form 10-K filed on March 16, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex23-1_actinium.htm">Consent of GBH CPAs, PC.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex23-2_actinium.htm">Consent of Marcum LLP.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex31-1_actinium.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex31-2_actinium.htm">Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex32-1_actinium.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex32-2_actinium.htm">Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS&nbsp;&nbsp;**</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH&nbsp;**</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Schema</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL&nbsp;**</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Calculation Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF&nbsp;**</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Definition Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB
    **</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Label Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE
    **</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Presentation Linkbase</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
herewith. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement
or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_025"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the Registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 15, 2019</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 36%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer (Duly&nbsp;Authorized Officer,<BR>
    Principal Executive Officer) </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Steve O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve
    O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer (Duly&nbsp;Authorized Officer, Principal
    Financial and Accounting Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf
of the Registrant and in the capacities and on the dates indicated.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sandesh Seth</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh
    Seth</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jeffrey Chell</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Chell</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David Nicholson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Nicholson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Richard I. Steinhart</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    I. Steinhart</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Ajit J. Shetty</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 15, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit
    J. Shetty</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">71</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.7
<SEQUENCE>2
<FILENAME>f10k2018ex3-7_actinium.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO ACTINIUM'S CERTIFICATE OF INCORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.7</B></P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="page1.jpg" ALT="" STYLE="height: 1071px; width: 700px"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;<IMG SRC="page2.jpg" ALT="" STYLE="height: 164px; width: 700px"></P>

<P STYLE="margin: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>3
<FILENAME>f10k2018ex10-37_actinium.htm
<DESCRIPTION>CONSULTING AGREEMENT, DATED DECEMBER 21, 2018, BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND NITYA RAY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
10.37<FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CONSULTING
AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective
Date: December 22, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
CONSULTING AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;) is entered into by and between Actinium Pharmaceuticals, Inc., a Delaware
corporation with a business address at Actinium Pharmaceuticals, Inc., having a place of business at 275 Madison Ave, 7<SUP>th
</SUP>Floor, New York, NY. 10016, (&ldquo;API&rdquo;). (the &ldquo;<U>Company</U>&rdquo;), and Nitya G. Ray, Ph.D. with a business
address at 14 Baybury Court, East Hanover, NJ 07936 (&ldquo;<U>Consultant</U>&rdquo;), as of the date set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company wishes to obtain the services of Consultant for certain purposes, and Consultant wishes to provide such services,
all subject to the terms and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants contained herein, the Company and Consultant hereby agree to be legally bound
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Services</U></B>. During the Term, Consultant
shall perform for the Company the consulting services described in <U>Schedule 1</U> (the &ldquo;<U>Services</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Compensation</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Fees for Services</U>. In connection with the Services, the Company shall pay Consultant $250 US dollars per hour for direct
project work and $125 US dollars per hour for travel time authorized by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Benefits</U>. Consultant is not an employee of the Company and will not be entitled to participate in or receive any benefit
or right as a Company employee under any Company employee benefit and welfare plan, including, without limitation, employee insurance,
pension, savings and security plans as a result of his entering into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Expenses</U>. The Company shall reimburse Consultant for all pre-approved, reasonable expenses that are actually incurred and
necessary for the performance of Services by Consultant. Consultant shall invoice the Company for such expenses, which invoice
shall include reasonable supporting documentation (such as receipts) verifying such expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
<U>Taxes and Withholdings</U>. All taxes relating to Consultant&rsquo;s performance under this Agreement shall be the responsibility
of Consultant. In particular, Consultant shall be solely responsible for the payment of all federal, state and local taxes or
contributions imposed or required under unemployment insurance, social security and income tax laws that pertain to the compensation
paid or reimbursements provided to Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Duties of Consultant</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Availability of Consultant</U>. Consultant shall hold himself available to Services (a) during normal business hours, other
reasonable times and such other times as the parties may agree, (b) at the Company&rsquo;s offices, places the Company may request
from time to time or such other places as the parties may agree.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Efforts of Consultant</U>. Consultant shall perform Services conscientiously and in a professional manner, and devote his best
efforts and abilities thereto. Consultant shall observe all policies and procedures of the Company, and such other directives
as may be promulgated from time to time by the Company&rsquo;s officers or board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<U>No Conflicting Agreements</U>. Consultant represents and warrants that Consultant is not a party to any existing agreement
that would prevent Consultant from entering into and performing its obligations under this Agreement in accordance with its terms.
Consultant shall not enter into any agreement that is in conflict with, or that would prohibit or impair the performance of, Consultant&rsquo;s
obligations under this Agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<U>Independent Contractor</U>. Consultant understands and agrees that he is acting solely as an independent contractor of the
Company in performing any of the Services and as such agrees that, at all times, Consultant is not an employee of the Company.
This Agreement shall not be construed as authority for Consultant to act as the Company&rsquo;s agent or in any similar capacity,
nor to make commitments of any kind for the account of or on behalf of the Company, and Consultant shall not take any action suggesting
otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
Intentionally left blank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6
<U>Modification</U>. Consultant agrees that, should a court determine that any provision, term or condition set forth in Sections
7.3 or 7.5 are invalid or unenforceable, the court may alter or modify any such provision, term or condition in a manner so as
to protect the Company&rsquo;s legitimate business interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7
<U>Social Security Number</U>. Consultant certifies that he will supply his correct Social Security Number or Employer Identification
Number (EIN) to the Company. Consultant acknowledges that the Company will rely upon the foregoing certification in filing certain
documents and instruments required by law in connection with this Agreement, including, without limitation, Form 1099 under the
Internal Revenue Code of 1986, as amended (or any successor form).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Confidentiality</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Company Confidential Information</U>. Consultant shall hold in strict confidence, and not use, except for the benefit of the
Company, and not disclose to any person or entity without written authorization of the CEO of the Company, any Confidential Information
(as defined below) of the Company. &ldquo;<U>Confidential Information</U>&rdquo; means any proprietary or confidential information,
technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customer
lists and customers, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering,
marketing, distribution and sales methods and systems, sales and profit figures, finances and other business information disclosed
to Consultant by or on behalf of the Company, either directly or indirectly, whether in writing, orally or by drawings or inspection
of documents or other tangible property; <U>provided</U>, that Confidential Information shall not include any of the foregoing
items to the extent they have become publicly known and made generally available through no act of Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Third Party Information Held by Consultant</U>. Consultant shall not improperly use or disclose to the Company or any of its
directors, officers, employees or agents, any confidential information of any current or former client or other person or entity
with whom Consultant has an agreement or duty to keep such information confidential, and Consultant shall not bring onto the premises
of the Company any such information in any medium unless consented to in writing by such client, person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Third Party Information Held by the Company</U>. Consultant recognizes that the Company has received, and in the future may
receive, from third parties Confidential Information subject to a duty on the Company&rsquo;s part to maintain the confidentiality
of such information and to use it only for certain limited purposes. Consultant shall hold all such information in strict confidence
and not disclose it to any person or entity or use it except as necessary in carrying out Services, consistent with the Company&rsquo;s
agreement with such third party. For purposes of this Agreement, such third party information shall be deemed part of the Confidential
Information of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Required Disclosure of Confidential Information</U>. If Consultant is required by law or court or governmental order to disclose
Confidential Information, Consultant shall give the Company prompt written notice of such requirement such that the Company shall
have the opportunity to apply for a protective order, injunction or for confidential treatment of such Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Ownership of Results</U>. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Assignment of Inventions</U>. Consultant shall promptly make full written disclosure to the Company, shall hold in trust for
the sole right and benefit of the Company, and hereby assigns, transfers and conveys to the Company, or its designee, all of Consultant&rsquo;s
worldwide right, title and interest in and to any and all inventions, original works of authorship, findings, conclusions, data,
discoveries, developments, concepts, improvements, trade secrets, techniques, processes and know-how, whether or not patentable
or registrable under patent, copyright or similar laws, that Consultant may solely or jointly conceive, develop or reduce to practice,
or cause to be conceived, developed or reduced to practice, in the performance of the Services or that result, to any extent,
from use of the Company&rsquo;s premises or property (collectively, the &ldquo;<U>Inventions</U>&rdquo;), including any and all
moral rights and intellectual property rights inherent therein and appurtenant thereto, including, but not limited to, all patent
rights, copyrights, trademarks, know-how and trade secrets and the rights to apply for the same (collectively, &ldquo;<U>Intellectual
Property Rights</U>&rdquo;). Consultant further acknowledges and agrees that all original works of authorship that are made by
Consultant (solely or jointly with others) in the performance of the Services (a &ldquo;<U>Work</U>&rdquo;) and that are protectable
by copyright are &ldquo;works made for hire,&rdquo; as that term is defined in the United States Copyright Act. However, to the
extent that any Work may not, by operation of any applicable law, be a work made for hire, Consultant hereby assigns, transfers
and conveys to the Company all of Consultant&rsquo;s worldwide right, title and interest in and to such Work, including all Intellectual
Property Rights relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Further Assurances</U>. Upon the request and at the expense of the Company, Consultant shall execute and deliver any and all
instruments and documents and take such other acts as may be necessary or desirable to document the assignment and transfer described
in Section 5.1 or to enable the Company to secure its rights in the Inventions, Works and Intellectual Property Rights relating
thereto in any and all jurisdictions, or to apply for, prosecute and enforce Intellectual Property Rights in any and all jurisdictions
with respect to any Inventions or Works, or to obtain any extension, validation, re-issue, continuance or renewal of any such
Intellectual Property Right. Without limiting the foregoing, Consultant shall disclose to the Company all pertinent information
and data with respect thereto and shall execute all applications, specifications, oaths and all other instruments which the Company
deems necessary in order to apply for and obtain such rights and in order to assign and convey to the Company the sole and exclusive
right, title and interest in and to such Inventions, Works and any Intellectual Property Rights relating thereto. If the Company
is unable for any other reason to secure Consultant&rsquo;s signature to apply for or to pursue any application for any United
States or foreign patent, trademark, copyright or other registration covering Inventions or Works assigned to the Company hereunder,
then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant&rsquo;s
agent and attorney in fact, to act for and in Consultant&rsquo;s behalf and stead to execute and file any such applications and
to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or trademark, copyright or other
registrations thereon with the same legal force and effect as if executed by Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Term and Termination</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Term</U>.
The initial term of this Agreement shall begin on the Effective Date, which will be on December 22, 2018 and shall continue until
March 31, 2019 (the &ldquo;<U>Term</U>&rdquo;) unless earlier terminated pursuant to this Section 6. Notwithstanding the foregoing,
the Company and Consultant may agree to extend the Term of the Agreement for an additional three months until June 30, 2019 if
the transition has not been properly completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Termination by the Company</U>. The Company and Consultant shall have the right to terminate this Agreement on 15 days prior
written notice to the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Obligations</U>. Upon termination, the Company shall have no obligation to pay Consultant any fees or expenses that accrued
subsequent to (a) a breach of Consultant&rsquo;s obligations hereunder, (b) the failure of Consultant to perform the Services
as contemplated by this Agreement or (c) the commission of fraud upon the Company by Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Survival</U>. The provisions of Sections 3.4, 3.5, 3.6 and Articles 4, 5, 6 and 7 shall survive the expiration or termination
of this Agreement. The expiration or termination of this Agreement shall not impair any right or obligation of any party accruing
prior to the effective date of such expiration or termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Miscellaneous</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Release of Claims</U>. In consideration for the obligations of the Company set forth in this Agreement, Consultant, on behalf
of himself, and his respective heirs, executors, administrators and assigns (collectively, &ldquo;Employee Releasors&rdquo;),
as may be applicable, hereby fully and forever release the Company and its respective officers, directors, employees, agents,
investors, stockholders (each of such foregoing persons who were or are acting on behalf of or at the Company&rsquo;s direction),
parent, subsidiary and affiliate companies, predecessor and successor companies and assigns, of and from any known or unknown
claim, duty, obligation or cause of action relating to any matters of any kind that any of the Employee Releasors may possess
arising from the employment relationship between Company and Consultant from the beginning of time up until and including the
date of this Agreement including, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
any and all claims relating to or arising from Consultant&rsquo;s employment relationship with the Company and the termination
of those relationships, including, without limitation Consultant&rsquo;s rights to salary and benefits except as provided herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any and all claims for wrongful discharge of employment; breach of contract, both express and implied; breach of a covenant of
good faith and fair dealing, both express and implied, negligent or intentional infliction of emotional distress; negligent or
intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; negligence;
and defamation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any and all claims for violation of any federal, state or municipal statute, including, but not limited to, Title VII of the Civil
Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, and the Americans with Disabilities
Act of 1990, the Older Workers Benefits Protection Act of 1990 (&ldquo;OWBPA&rdquo;), the Americans with Disabilities Act, the
Family and Medical Leave Act, the civil whistleblower protection provisions of the Sarbanes-Oxley Act of 2002 and all other federal,
state and local laws dealing with discrimination on any basis, including but not limited to sex, race, national origin, veteran
status, religion, disability and age. This Agreement also includes any claim of wrongful termination, based on any legal theory
including but not limited to contract and personal injury;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
any and all claims for attorneys&rsquo; fees and costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and Consultant agree that the release set forth in this Section 7.2 shall be and remain in effect in all respects as a
complete general release as to the matters released. This release does not extend to any payments or benefits receivable, or obligations
incurred or specified under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Nonsolicitation</U>. Consultant agrees that for three years he will not either directly or indirectly solicit, induce, recruit
or encourage any of the Company&rsquo;s officers or employees to terminate their relationship with the Company, or attempt to
solicit, induce, recruit or encourage officers, employees or of the Company, either for his own benefit or for the benefit of
any other person or entity. Further, Consultant agrees that he will not use any confidential or proprietary information of the
Company to attempt to negatively influence any of the Company&rsquo;s employees from remaining in the Company or to solicit or
influence or attempt to solicit or influence any employee either directly or indirectly, to join another Company, institution
or other entity in competition with the business of the Company. Consultant agrees that he will be able to earn a livelihood without
violating the restrictions set forth in this Section 7.3. Further, for a period of thirty six (36) months from the date of this
Agreement, he shall not attempt to negatively influence any of the Company&rsquo;s client&rsquo;s or customers from purchasing
Company products or services or to solicit or influence any client, customer or other person either directly or indirectly, to
direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition
with the business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a period of thirty six (36) months from the date of this Agreement, without the prior written consent of the Company, Consultant
will not directly or indirectly (i) acquire or agree, offer, seek or propose to acquire, ownership (including, but not limited
to, beneficial ownership as defined in Rule 13d-3 under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) of
the assets or business or more than fifteen (15%) percent of the outstanding securities issued by the Company or any of its subsidiaries,
(ii) make, or in any way participate in, any &ldquo;solicitation&rdquo; of &ldquo;proxies&rdquo; (as such terms are defined under
Regulation 14A of the Exchange Act) to vote or seek to advise or influence in any matter whatsoever any person or entity with
respect to the voting securities of the Company or any to his subsidiaries; (iii) form, join or in any way participate in a &ldquo;group&rdquo;
(within the meaning of Section 13 (d)(3) of the Exchange Act) with respect to any voting securities of the Company or any of his
subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Non-Competition</U>. During the term of this Agreement and for a period of three (3) years thereafter, Consultant shall not,
either directly or indirectly, engage (as principal, partner, employee, consultant, owner, independent contractor, advisor or
otherwise, with or without compensation) in any business that directly or indirectly is developing, or plans to develop, radioimmuotherapies
for cancer or any other therapy related to bone marrow transplant or other programs that the company is developing (&ldquo;Competing
Business&rdquo;). Notwithstanding the foregoing, this does not prevent Consultant from being engaged or employed with a business
that has a Competing Business as part of its business, so long as you are not engaged or involved in any way in the Competing
Business at such business or enterprise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<U>Notices</U>. All notices and other communications required or permitted hereunder shall be in writing and deemed to have been
given when hand delivered, sent by facsimile or mailed by registered or certified mail or overnight courier with tracking capabilities,
as follows, or as a party may otherwise notify to the other in accordance with this Section 7 (provided that such notice of change
of address or recipient shall be deemed given only when received):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 40%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
    to the Company, to:</I></B></FONT></TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If to Consultant: </I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACTINIUM
    PHARMACEUTICALS, INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nitya G. Ray, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275 Madison
    Ave, 7<SUP>th</SUP> Floor,&#9;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">14 Baybury Court</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York
    City, New York 10016</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">East Hanover, NJ 07936</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Principal Financial Officer&#9;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
<U>Company Property; Return</U>. Consultant shall not remove any Company property from the Company&rsquo;s premises without prior
written authorization from the Company. Promptly upon the expiration or termination of this Agreement, and earlier if requested
by the Company at any time, Consultant shall deliver to the Company (and shall not keep in Consultant&rsquo;s possession or deliver
to anyone else) all Confidential Information of the Company (including all embodiments thereof) and all software, documentation,
devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials,
equipment, other documents or property, or reproductions of any aforementioned items, or any other work product whatsoever, developed
by Consultant as part of or in connection with the Services or otherwise belonging to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
<U>Indemnification</U>. Consultant shall indemnify the Company for all costs, fees (including reasonable attorney&rsquo;s fees),
expenses, losses and other damages arising from (a) any injury to person or damage to property caused by Consultant and (b) any
breach of this Agreement by Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
shall indemnify the Consultant for all costs, fees (including reasonable attorney&rsquo;s fees), expenses, losses and other damages
arising from (a) any injury to person or damage to property caused by Company and (b) any breach of this Agreement by Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
<U>Assignment; No Third Party Beneficiaries</U>. The Company may assign this Agreement without the prior written consent of Consultant.
Consultant hereby acknowledges and agrees that the duties and responsibilities of Consultant hereunder are of a personal nature
and shall not be assignable or delegable in whole or in part by Consultant. All of the terms and provisions of this Agreement
shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal
representatives, successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to
confer on any person or entity other than the parties hereto or their respective successors and permitted assigns, any benefits,
rights or remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
<U>Governing Law, Jurisdiction and Attorney Fees</U>. This Agreement shall be governed by and interpreted in accordance with laws
of the state of New York without giving effect to any conflict of laws provisions. Each party consents to the jurisdiction and
venue of the state and federal courts, as applicable, located in the State of New York, Manhattan County.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9
<U>Equitable Relief</U>. Consultant agrees that the limitations on its ability to solicit the Company&rsquo;s employees and customers
as set forth in Section 3.5 are reasonably necessary to protect the Company&rsquo;s legitimate business interests. Consultant
acknowledges that such limitations will not constitute or cause it or the Principal any undue hardship. Consultant further agrees
that it would be impossible or inadequate to measure and calculate the Company&rsquo;s damages from any breach of the covenants
set forth in Sections 3, 4 and 5 of this Agreement, and that a breach of such covenants could cause serious and irreparable injury
to the Company. Accordingly, the Company shall have available, in addition to any other right or remedy available to it, the right
to obtain an injunction from a court of competent jurisdiction restraining such a breach (or threatened breach) and to specific
performance of any such Section. Consultant further agrees that no bond or other security shall be required in obtaining such
equitable relief and Consultant hereby consents to the issuance of such injunction and to the ordering of specific performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10
<U>Entire Agreement, Amendment and Waiver</U>. This Agreement (including the schedules hereto and any Work Orders) is the sole
agreement between Consultant and the Company with respect to the Services and it supersedes all prior agreements and understandings
with respect thereto, whether oral or written. No amendment, supplement or other modification to any provision of this Agreement
shall be binding unless in writing and signed by both Consultant and the Company. No waiver of any rights under this Agreement
shall be effective unless in writing signed by the party to be charged. A waiver of a breach or violation of any provision of
this Agreement will not constitute or be construed as a waiver of any subsequent breach or violation of that provision or as a
waiver of any breach or violation of any other provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11
<U>Severability</U>. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated
to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or
application of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall
not invalidate or render unenforceable such provision or application in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12
<U>Headings</U>. The headings in this Agreement are intended solely for convenience or reference and shall be given no effect
in the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original
as against any party whose signature appears thereon, but all of which together shall constitute but one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; padding-left: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly executed this Agreement as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 40%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR STYLE="clear: both">
    <FONT STYLE="font-size: 10pt">ACTINIUM PHARMACEUTICALS, INC.</FONT></FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitya
    G. Ray, PhD</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sandesh Seth&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Nitya G. Ray</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
Signature</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized
    Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:
    Sandesh Seth</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chairman and CEO&#9;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is to be executed in duplicate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
return one fully executed copy to the Company at the address above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; padding-left: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>4
<FILENAME>f10k2018ex10-38_actinium.htm
<DESCRIPTION>AMENDED AND RESTATED AT MARKET ISSUANCE SALES AGREEMENT, DATED DECEMBER 28, 2018, BY AND AMONG ACTINIUM PHARMACEUTICALS, INC. AND B. RILEY FBR, INC. AND JONESTRADING INSTITUTIONAL SERVICES LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 10.38</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
PHARMACEUTICALS, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock<BR>
(par value $0.001 per share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amended
and Restated At Market Issuance Sales Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
28, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley FBR, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">299
Park Avenue, 7<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JonesTrading
Institutional Services LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">757
Third Avenue, 23<SUP>rd</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and B. Riley FBR, Inc., as successor by merger
to FBR Capital Markets &amp; Co., (&ldquo;<U>B. Riley FBR</U>&rdquo;) are parties to that certain At Market Issuance Sales Agreement
dated March 16, 2017 (the &ldquo;<U>Original Agreement</U>&rdquo;). Together with JonesTrading Institutional Services LLC (&ldquo;<U>JonesTrading</U>&rdquo;;
each of B. Riley FBR and JonesTrading individually an &ldquo;<U>Agent</U>&rdquo; and collectively, the &ldquo;<U>Agents</U>&rdquo;),
the Company and the Agents desire to amend and restate the Original Sales Agreement with this agreement (the &ldquo;<U>Agreement</U>&rdquo;),
and hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Issuance
and Sale of Shares.</U> The Company agrees that, from time to time during the term of this Agreement, on the terms and
subject to the conditions set forth herein, it may issue and sell through or to the Agents, as agent or principal, shares
(the &ldquo;<U>Placement Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (the
&ldquo;<U>Common Stock</U>&rdquo;), <I>provided however, </I>that in no event shall the Company issue or sell through the
Agents such number of Placement Shares that (a) exceeds the number of shares of Common Stock registered on the effective
Registration Statement (as defined below) pursuant to which the offering is being made, or (b) exceeds the number of
authorized but unissued shares of Common Stock (the lesser of (a) and (b), the &ldquo;<U>Maximum Amount</U>&rdquo;).
Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set
forth in this <U>Section 1</U> on the number of Placement Shares issued and sold under this Agreement shall be the sole
responsibility of the Company and that the Agents shall have no obligation in connection with such compliance. The issuance
and sale of Placement Shares through the Agents will be effected pursuant to the Registration Statement (as defined below),
although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue any
Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations
thereunder (the &ldquo;<U>Securities Act</U>&rdquo;), with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;),
a registration statement on Form S-3 (File No. 333-216748), including a base prospectus relating to certain securities, including
the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company
has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and
regulations thereunder (the &ldquo;<U>Exchange Act</U>&rdquo;). The Company has prepared a prospectus supplement to the base prospectus
included as part of such registration statement, specifically relating to the Placement Shares (the &ldquo;<U>Prospectus Supplement</U>&rdquo;).
The Company will furnish to the Agents, for use by the Agents, copies of the prospectus included as part of such registration
statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares. Except where the context otherwise
requires, such registration statement, and any post-effective amendment thereto, including all documents filed as part thereof
or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently
filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement
pursuant to Rule 430B of the Securities Act, or any subsequent registration statement on Form S-3 filed pursuant to Rule 415(a)(6)
under the Securities Act by the Company to cover any Placement Shares, is herein called the &ldquo;<U>Registration Statement</U>.&rdquo;
The base prospectus, including all documents incorporated or deemed incorporated therein by reference to the extent such information
has not been superseded or modified in accordance with Rule 412 under the Securities Act (as qualified by Rule 430B(g) of the
Securities Act), included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in
which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to
Rule 424(b) under the Securities Act, is herein called the &ldquo;<U>Prospectus</U>.&rdquo; Any reference herein to the Registration
Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated
or deemed incorporated by reference therein, and any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include
the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein (the
&ldquo;<U>Incorporated Documents</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto
shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and
Retrieval System, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively,
&ldquo;<U>EDGAR</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Placements.
</U>Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a &ldquo;<U>Placement</U>&rdquo;), it
will notify an Agent (the &ldquo;<U>Designated Agent</U>&rdquo;) by email notice (or other method mutually agreed to in writing
by the Parties) of the number of Placement Shares, the time period during which sales are requested to be made, any limitation
on the number of Placement Shares that may be sold in any one day and any minimum price below which sales may not be made (a &ldquo;<U>Placement
Notice</U>&rdquo;), the form of which is attached hereto as <U>Schedule 1.</U> The Placement Notice shall originate from any of
the individuals from the Company set forth on <U>Schedule 3</U> (with a copy to each of the other individuals from the Company
listed on such schedule), and shall be addressed to each of the individuals from the Designated Agent set forth on <U>Schedule
3,</U> as such <U>Schedule 3</U> may be amended from time to time. Provided that the Company is otherwise in compliance with the
terms of this Agreement, the Placement Notice shall be effective immediately upon receipt by the Designated Agent unless and until
(i) the Designated Agent declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire
amount of the Placement Shares thereunder has been sold, (iii) the Company suspends or terminates the Placement Notice or (iv)
this Agreement has been terminated under the provisions of <U>Section 13</U>. The amount of any discount, commission or other
compensation to be paid by the Company to the Designated Agent in connection with the sale of the Placement Shares shall be calculated
in accordance with the terms set forth in <U>Schedule 2</U>. It is expressly acknowledged and agreed that neither the Company
nor the Designated Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until
the Company delivers a Placement Notice to the Designated Agent and the Designated Agent does not decline such Placement Notice
pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between
the terms of <U>Sections 2</U> or <U>3</U> of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice
will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <U>Sale
of Placement Shares by the Agents.</U> Subject to the terms and conditions of this Agreement, for the period specified in a Placement
Notice, the Designated Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices
and applicable state and federal laws, rules and regulations and the rules of such national securities exchange that the Company&rsquo;s
Common Stock is listed on (the &ldquo;<U>Exchange</U>&rdquo;), to sell the Placement Shares up to the amount specified in, and
otherwise in accordance with the terms of, such Placement Notice. The Designated Agent will provide written confirmation to the
Company no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has
made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable
by the Company to the Designated Agent pursuant to <U>Section 2</U> with respect to such sales, and the Net Proceeds (as defined
below) payable to the Company, with an itemization of the deductions made by the Designated Agent (as set forth in <U>Section
5(b)</U>) from the gross proceeds that it receives from such sales. Subject to the terms of a Placement Notice, the Designated
Agent may sell Placement Shares by any method permitted by law deemed to be an &ldquo;at the market offering&rdquo; as defined
in Rule 415 of the Securities Act. &ldquo;<U>Trading Day</U>&rdquo; means any day on which Common Stock is purchased and sold
on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <U>Suspension
of Sales.</U> The Company or the Designated Agent may, upon notice to the other party in writing (including by email correspondence
to each of the individuals of the other party set forth on <U>Schedule 3</U>, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
facsimile transmission or email correspondence to each of the individuals of the other party set forth on <U>Schedule </U>3),
suspend any sale of Placement Shares; <I>provided, however</I>, that such suspension shall not affect or impair any party&rsquo;s
obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. While a suspension is in
effect, any obligation under Sections 7(l), 7(m), and 7(n) with respect to the delivery of certificates, opinions, or comfort
letters to the Agents, shall be waived; <I>provided, however</I>, that such waiver shall not apply for the Representation Date
(as defined below) occurring on the date that the Company files its annual report on Form 10-K. Each of the parties agrees that
no such notice under this <U>Section 4</U> shall be effective against any other party unless it is made to one of the individuals
named on <U>Schedule 3</U> hereto, as such Schedule may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <U>Sale
and Delivery to the Designated Agent; Settlement.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <U>Sale
of Placement Shares.</U> On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, upon the Designated Agent&rsquo;s acceptance of the terms of a Placement Notice, and unless the sale of the
Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this
Agreement, the Designated Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts
consistent with its normal trading and sales practices to sell such Placement Shares up to the amount specified in, and otherwise
in accordance with the terms of, such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance
that the Designated Agent will be successful in selling Placement Shares, (ii) the Designated Agent will incur no liability or
obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure
by the Designated Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and
applicable law and regulations to sell such Placement Shares as required under this Agreement and (iii) the Designated Agent shall
be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except as otherwise agreed
by the Designated Agent and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. <U>Settlement
of Placement Shares.</U> Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares
will occur on the second (2<SUP>nd</SUP>) Trading Day (or such earlier day as is industry practice for regular-way trading) following
the date on which such sales are made (each, a &ldquo;<U>Settlement Date</U>&rdquo;). The amount of proceeds to be delivered to
the Company on a Settlement Date against receipt of the Placement Shares sold (the &ldquo;<U>Net Proceeds</U>&rdquo;) will be
equal to the aggregate sales price received by the Designated Agent for the Placement Shares, after deduction for (i) the Designated
Agent&rsquo;s commission, discount or other compensation for such sales payable by the Company pursuant to <U>Section 2</U> hereof,
and (ii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. <U>Delivery
of Placement Shares.</U> On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
transfer the Placement Shares being sold by crediting the Designated Agent&rsquo;s or its designee&rsquo;s account (provided the
Designated Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement
Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery
as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares
in good deliverable form. On each Settlement Date, the Designated Agent will deliver the related Net Proceeds in same day funds
to an account designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer
agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date, through no fault of the Designated
Agent, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in <U>Section 11(a)
</U>hereto, it will (i) hold the Designated Agent harmless against any loss, claim, damage, or reasonable, documented expense
(including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default
by the Company or its transfer agent (if applicable) and (ii) pay to the Designated Agent (without duplication) any commission,
discount, or other compensation to which it would otherwise have been entitled absent such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
<U>Limitations on Offering Size.</U> Under no circumstances shall the Company cause or request the offer or sale of any Placement
Shares if, after giving effect to the sale of such Placement Shares, the aggregate number of Placement Shares sold pursuant to
this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount,
(B) the amount available for offer and sale under the currently effective Registration Statement and (C) the amount authorized
from time to time to be issued and sold under this Agreement by the Company&rsquo;s board of directors, a duly authorized committee
thereof or a duly authorized executive committee, and notified to the Designated Agent in writing. Under no circumstances shall
the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum
price authorized from time to time by the Company&rsquo;s board of directors, a duly authorized committee thereof or a duly authorized
executive committee, and notified to the Designated Agent in writing. Further, under no circumstances shall the Company cause
or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e. <U>Sales
Through Agents</U>. The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of Common Stock
or any other equity security of the Company shall only be effected by or through an Agent, and only a single Agent, on any single
given date, and in no event shall the Company request that more than one Agent sell Securities on the same day; provided however
that (i) the foregoing limitation shall not apply to (A) exercise of any option, warrant, right or any conversion privilege set
forth in the instruction governing such securities, (B) sales solely to employees, directors or security holders of the Company
or its subsidiaries, or to a trustee or other person acquiring such securities for the accounts of such person and (ii) such limitation
shall not apply (A) on any day during which no sales are made pursuant to this Agreement or (B) during a period in which the Company
has notified the Agents that it will not sell Common Stock under this Agreement and (1) no Placement Notice is pending or (2)
after a Placement Notice has been withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Representations
and Warranties of the Company.</U> Except as disclosed in the Registration Statement or Prospectus (including the Incorporated
Documents), the Company represents and warrants to, and agrees with each Agent that as of the date of this Agreement and as of
each Applicable Time (as defined below), unless such representation, warranty or agreement specifies a different date or time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <U>Registration
Statement and Prospectus.</U> The Company and, assuming no act or omission on the part of the Agents that would make such statement
untrue, the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of
Form S-3 under the Securities Act. The Registration Statement has been filed with the Commission and has been declared effective
under the Securities Act. The Prospectus will name B. Riley FBR and JonesTrading as the agents in the section entitled &ldquo;Plan
of Distribution.&rdquo; The Company has not received, and has no notice of, any order of the Commission preventing or suspending
the use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement
and the offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and
comply in all material respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be
described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been so
described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments or supplements and all documents
incorporated by reference therein that were filed with the Commission on or prior to the date of this Agreement have been delivered,
or are available through EDGAR, to the Agents and their counsel. The Company has not distributed and, prior to the later to occur
of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering material
in connection with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus and any
Issuer Free Writing Prospectus (as defined below) to which the Agents have consented, such consent not to be unreasonably withheld,
conditioned or delayed. The Common Stock is currently listed on the Exchange. The Company has not, in the 12 months preceding
the date hereof, received notice from the Exchange to the effect that the Company is not in compliance in all material respects
with the listing or maintenance requirements of the Exchange. The Company has no reason to believe that it will not in the foreseeable
future continue to be in compliance with all such listing and maintenance requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. <U>No
Misstatement or Omission.</U> The Registration Statement, when it became effective, and the Prospectus, and any amendment or supplement
thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects with the
requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date, will
conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes
effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement
thereto, on the date thereof and at each Applicable Time (defined below), did not or will not include an untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading. The documents incorporated by reference in the Prospectus or any Prospectus Supplement did not,
and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue
statement of a material fact or omit to state a material fact required to be stated in such document or necessary to make the
statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall not
apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished
to the Company by an Agent specifically for use in the preparation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. <U>Conformity
with Securities Act and Exchange Act.</U> The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or any
amendment or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission under
the Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or
will conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. <U>Financial
Information.</U> The consolidated financial statements of the Company included or incorporated by reference in the Registration
Statement and the Prospectus, together with the related notes and schedules, present fairly, in all material respects, the consolidated
financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the consolidated statement
of operations, consolidated statement of cash flows and consolidated statement of stockholders&rsquo; equity (deficit) of the
Company for the periods specified and have been prepared in compliance in all material respects with the requirements of the Securities
Act and Exchange Act, as applicable, and in conformity with generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;)
in the United States as in effect as of the time of filing applied on a consistent basis (except for such adjustments to accounting
standards and practices as are noted therein) during the periods involved (subject, in the case of unaudited financial statements,
to normal recurring adjustments and to the extent they may exclude footnotes or may be condensed or summarized statements); the
other financial and statistical data with respect to the Company and the Subsidiaries contained or incorporated by reference in
the Registration Statement and the Prospectus, are accurately and fairly presented and prepared on a basis consistent with the
financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are
required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or
incorporated by reference as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct
or contingent (including any off balance sheet obligations), not described in the Registration Statement, and the Prospectus which
are required to be described in the Registration Statement or Prospectus; and all disclosures contained or incorporated by reference
in the Registration Statement and the Prospectus, if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is
defined by the rules and regulations of the Commission) comply in all material respects with Regulation G of the Exchange Act
and Item 10 of Regulation S-K under the Securities Act, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e. <U>Conformity
with EDGAR Filing.</U> The Prospectus delivered to the Agents for use in connection with the sale of the Placement Shares pursuant
to this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing via
EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f. <U>Organization.
</U>The Company and any subsidiary that is a significant subsidiary (as such term is defined in Rule 1-02 of Regulation S-X promulgated
by the Commission) (each, a &ldquo;<U>Subsidiary</U>&rdquo;, collectively, the &ldquo;<U>Subsidiaries</U>&rdquo;), are, and will
be, duly organized, validly existing as a corporation and in good standing under the laws of their respective jurisdictions of
organization. The Company and the Subsidiaries are, and will be, duly licensed or qualified as a foreign corporation for transaction
of business and in good standing under the laws of each other jurisdiction in which their respective ownership or lease of property
or the conduct of their respective businesses requires such license or qualification, and have all corporate power and authority
necessary to own or hold their respective properties and to conduct their respective businesses as described in the Registration
Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority
would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material
adverse effect on the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&rsquo;
equity or results of operations of the Company and the Subsidiaries taken as a whole, or prevent the consummation of the transactions
contemplated hereby (a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g. <U>Subsidiaries.
</U>As of the date hereof, the Company&rsquo;s only Subsidiaries are set forth on <U>Schedule 6(g)</U>. The Company owns directly
or indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance,
right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully
paid, nonassessable and free of preemptive and similar rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h. <U>No
Violation or Default.</U> Neither the Company nor any Subsidiary is (i) in violation of its charter or by-laws or similar organizational
documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default,
in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan
agreement or other agreement or instrument to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary
is bound or to which any of the property or assets of the Company or any Subsidiary is subject; or (iii) in violation of any law
or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having
jurisdiction over the Company, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default
that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company&rsquo;s
knowledge, no other party under any material contract or other agreement to which it or any Subsidiary is a party is in default
in any respect thereunder where such default would reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>No
Material Adverse Effect.</U> Since the date of the most recent financial statements of the Company included or incorporated by
reference in the Registration Statement and Prospectus, there has not been (other than those noted below in this paragraph) (i)
any Material Adverse Effect, or any development involving a prospective Material Adverse Effect, in or affecting the business,
properties, management, condition (financial or otherwise), results of operations, or prospects of the Company and the Subsidiaries
taken as a whole, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation
or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or the Subsidiaries,
which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock (other than
(A) the grant of additional options or other awards under or outside the Company&rsquo;s existing stock incentive plans, (B) changes
in the number of outstanding shares of Common Stock of the Company due to the issuance of shares upon the exercise or conversion
of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof, (C) as a result of the issuance
of Placement Shares, (D) any repurchases of capital stock of the Company, (E) as described in a proxy statement filed on Schedule
14A or a Registration Statement on Form S-4, or (F) otherwise publicly announced) or outstanding long-term indebtedness of the
Company or the Subsidiaries or (v) any dividend or distribution of any kind declared, paid or made on the capital stock of the
Company or any Subsidiary, other than in each case above (1) in the ordinary course of business. (2) as otherwise disclosed in
the Registration Statement or Prospectus or (3) where such matter, item, change, or development, individually or in the aggregate,
would not make the statements in the Registration Statement or the Prospectus contain an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j. <U>Capitalization.
</U>The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and non-assessable
and, other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights
of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration
Statement and the Prospectus as of the dates referred to therein (other than (i) the grant of additional options or other awards
under the Company&rsquo;s existing stock incentive plans, (ii) changes in the number of outstanding Common Stock of the Company
due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock
outstanding on the date hereof, (iii) as a result of the issuance of Placement Shares, or (iv) any repurchases of capital stock
of the Company) and such authorized capital stock conforms to the description thereof set forth in the Registration Statement
and the Prospectus. The description of the Common Stock in the Registration Statement and the Prospectus is complete and accurate
in all material respects. As of the date referred to therein, the Company did not have material outstanding any options to purchase,
or any rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts
or commitments to issue or sell, any shares of capital stock or other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k. <U>S-3
Eligibility</U>. (i) At the time of filing the Registration Statement and (ii) at the time of the most recent amendment thereto
for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such amendment was by post-effective amendment,
incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus), the Company met the then
applicable requirements for use of Form S-3 under the Securities Act, including compliance with General Instruction I.B.1 of Form
S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l. <U>Authorization;
Enforceability.</U> The Company has full legal right, power and authority to enter into this Agreement and perform the transactions
contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and
binding agreement of the Company enforceable against the Company in accordance with its terms, except to the extent that (i) enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally
and by general equitable principles and (ii) the indemnification and contribution provisions of <U>Section 11</U> hereof may be
limited by federal or state securities laws and public policy considerations in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m. <U>Authorization
of Placement Shares.</U> The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors
of the Company or a duly authorized committee thereof, or a duly authorized executive officer, against payment therefor as provided
herein, will be duly and validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance,
security interest or other claim (other than any pledge, lien, encumbrance, security interest or other claim arising from an act
or omission of an Agent or a purchaser), including any statutory or contractual preemptive rights, resale rights, rights of first
refusal or other similar rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when
issued, will conform in all material respects to the description thereof set forth in or incorporated into the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n. <U>No
Consents Required.</U> No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or any governmental or regulatory authority having jurisdiction over the Company is required for the execution, delivery and performance
by the Company of this Agreement, and the issuance and sale by the Company of the Placement Shares as contemplated hereby, except
for the registration of the Placement Shares under the Securities Act and such consents, approvals, authorizations, orders and
registrations or qualifications as may be required under applicable state securities laws or by the by-laws and rules of the Financial
Industry Regulatory Authority (&ldquo;<U>FINRA</U>&rdquo;) or the Exchange, including any notices that may be required by Exchange,
in connection with the sale of the Placement Shares by the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o. <U>No
Preferential Rights.</U> (i) No person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities
Act (each, a &ldquo;<U>Person</U>&rdquo;), has the right, contractual or otherwise, to cause the Company to issue or sell to such
Person any Common Stock or shares of any other capital stock or other securities of the Company (other than upon the exercise
of options or warrants to purchase Common Stock or upon the exercise of options that may be granted, or issuances of Common Stock
or other equity awards, from time to time under or outside of the Company&rsquo;s stock incentive plans), (ii) no Person has any
preemptive rights, rights of first refusal, or any other rights (whether pursuant to a &ldquo;poison pill&rdquo; provision or
otherwise) to purchase any Common Stock or shares of any other capital stock or other securities of the Company from the Company
which have not been duly waived with respect to the offering contemplated hereby, (iii) no Person has the right to act as an underwriter
or as a financial advisor to the Company in connection with the offer and sale of the Common Stock as contemplated by this Agreement,
and (iv) no Person has the right, contractual or otherwise, to require the Company to register under the Securities Act any Common
Stock or shares of any other capital stock or other securities of the Company, or to include any such shares or other securities
in the Registration Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness of the
Registration Statement or the sale of the Placement Shares as contemplated thereby or otherwise, except for those shares and securities
currently subject to registration statements on file with the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p. <U>Independent
Public Accountant.</U> GBH CPAs, PC (the &ldquo;<U>Accountant</U>&rdquo;), whose report on the consolidated financial statements
of the Company is filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form 10-K filed with the
Commission and incorporated into the Registration Statement, are and, during the periods covered by their report, were independent
public accountants within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States).
To the Company&rsquo;s knowledge the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley
Act of 2002 (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;) with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">q. <U>Enforceability
of Agreements.</U> All agreements between the Company and third parties expressly referenced in the Prospectus, other than such
agreements that have expired by their terms or whose termination is disclosed in documents filed by the Company on EDGAR, are
legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent
that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo;
rights generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited
by federal or state securities laws or public policy considerations in respect thereof, and except for any unenforceability that,
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">r. <U>No
Litigation.</U> There are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company&rsquo;s
knowledge, any legal, governmental or regulatory investigations, to which the Company or a Subsidiary is a party or to which any
property of the Company or any Subsidiary is the subject that, individually or in the aggregate, if determined adversely to the
Company or any Subsidiary, would reasonably be expected to have a Material Adverse Effect or materially and adversely affect the
ability of the Company to perform its obligations under this Agreement; to the Company&rsquo;s knowledge, no such actions, suits
or proceedings are threatened by any governmental or regulatory authority or threatened by others that, individually or in the
aggregate, if determined adversely to the Company or any Subsidiary, would reasonably be expected to have a Material Adverse Effect;
and there are no current or pending legal, governmental or regulatory actions, suits or proceedings or, to the knowledge of the
Company, investigations that are required under the Securities Act to be described in the Prospectus that are not described in
the Prospectus including any Incorporated Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">s. <U>Licenses
and Permits.</U> The Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents, orders, approvals,
permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local
or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties
or the conduct of their respective businesses as described in the Registration Statement and the Prospectus (the &ldquo;<U>Permits</U>&rdquo;),
except where the failure to possess, obtain or make the same would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received written notice of any proceeding relating
to revocation or modification of any such Permit or has any reason to believe that such Permit will not be renewed in the ordinary
course, except where the revocation, modification or failure to obtain the renewal of any such Permit would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t. <U>No
Material Defaults.</U> Neither the Company nor any Subsidiary has defaulted on any installment on indebtedness for borrowed money
or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected
to have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since
the filing of its last Annual Report on Form 10-K, indicating that it (i) has failed to pay any dividend or sinking fund installment
on preferred stock or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more
long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">u. <U>Certain
Market Activities.</U> Neither the Company, nor any Subsidiary, nor to the Company&rsquo;s knowledge any of their respective directors,
officers or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably
be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v. <U>Broker/Dealer
Relationships.</U> Neither the Company nor any Subsidiary or any related entities (i) is required to register as a &ldquo;broker&rdquo;
or &ldquo;dealer&rdquo; in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more
intermediaries, controls or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo;
(within the meaning set forth in the FINRA Manual).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">w. <U>No
Reliance.</U> The Company has not relied upon the Agents or legal counsel for the Agents for any legal, tax or accounting advice
in connection with the offering and sale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">x. <U>Taxes.
</U>The Company and the Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to
be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect.
Except as otherwise disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined
adversely to the Company or any Subsidiary which has had, or would reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or
assessment which has been asserted or threatened against it which could have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">y. <U>Title
to Real and Personal Property.</U> The Company and the Subsidiaries have good and valid title in fee simple to all items of real
property and good and valid title to all personal property (excluding Intellectual Property which is addressed below) described
in the Registration Statement or Prospectus as being owned by them that are material to the businesses of the Company or such
Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those that (i) do not materially interfere
with the use made and proposed to be made of such property by the Company and the Subsidiaries or (ii) would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect. Any real property described in the Registration
Statement or Prospectus as being leased by the Company and the Subsidiaries is held by them under valid, existing and enforceable
leases, except those that (A) do not materially interfere with the use made or proposed to be made of such property by the Company
or the Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">z. <U>Intellectual
Property.</U> To the Company&rsquo;s knowledge, the Company and the Subsidiaries own or possess adequate enforceable rights to
use all patents, patent applications, trademarks (both registered and unregistered), service marks, trade names, trademark registrations,
service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) (collectively, the &ldquo;<U>Intellectual Property</U>&rdquo;)<U>,
</U>necessary for the conduct of their respective businesses as conducted as of the date hereof, except to the extent that the
failure to own or possess adequate rights to use such Intellectual Property would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect; the Company and the Subsidiaries have not received any written notice of any claim
of infringement or conflict which asserted Intellectual Property rights of others, which infringement or conflict, if the subject
of an unfavorable decision, would reasonably be expected to result in a Material Adverse Effect; there are no pending, or to the
Company&rsquo;s knowledge, threatened judicial proceedings or interference proceedings against the Company or its Subsidiaries
challenging the Company&rsquo;s or any of its Subsidiary&rsquo;s rights in or to or the validity of the scope of any of the Company&rsquo;s
or any Subsidiary&rsquo;s patents, patent applications or proprietary information, except for such right or claim that would not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; to the Company&rsquo;s knowledge
no other entity or individual has any right or claim in any of the Company&rsquo;s or any of its Subsidiary&rsquo;s patents, patent
applications or any patent to be issued therefrom by virtue of any contract, license or other agreement entered into between such
entity or individual and the Company or any Subsidiary or by any non-contractual obligation, other than by written licenses granted
by the Company or any Subsidiary, except for such right or claim that would not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect; the Company and the Subsidiaries have not received any written notice of any
claim challenging the rights of the Company or its Subsidiaries in or to any Intellectual Property owned, licensed or optioned
by the Company or any Subsidiary which claim, if the subject of an unfavorable decision would result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">aa. <U>Environmental
Laws.</U> The Company and the Subsidiaries (i) are in compliance in all material respects with any and all applicable federal,
state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety,
the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &ldquo;<U>Environmental
Laws</U>&rdquo;); (ii) have received and are in compliance in all material respects with all permits, licenses or other approvals
required of them under applicable Environmental Laws to conduct their respective businesses as described in the Registration Statement
and the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation
of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any
of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals
or liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bb. <U>Disclosure
Controls.</U> The Company maintains systems of internal accounting controls designed to provide reasonable assurance that (i)
transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)
access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. The Company is not aware of any material weaknesses in its internal control over financial reporting (other
than as set forth in the Registration Statement or the Prospectus). Since the date of the latest audited financial statements
of the Company included in the Prospectus, there has been no change in the Company&rsquo;s internal control over financial reporting
that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial
reporting (other than as set forth in the Registration Statement or the Prospectus). The Company has established disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure controls and
procedures to ensure that material information relating to the Company and the Subsidiaries is made known to the certifying officers
by others within those entities, particularly during the period in which the Company&rsquo;s Annual Report on Form 10-K or Quarterly
Report on Form 10-Q, as the case may be, is being prepared. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the Company&rsquo;s controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K for the fiscal
year most recently ended (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its Form 10-K for the
fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the most recent Evaluation Date. Since the most recent Evaluation Date, there
have been no significant changes in the Company&rsquo;s internal controls (as such term is defined in Item 307(b) of Regulation
S-K under the Securities Act) or, to the Company&rsquo;s knowledge, in other factors that could significantly adversely affect
the Company&rsquo;s internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc. <U>Sarbanes-Oxley
Act.</U> There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&rsquo;s
directors or officers, in their capacities as such, to comply with any applicable provisions of the Sarbanes-Oxley Act and the
rules and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the
Company (or each former principal executive officer of the Company and each former principal financial officer of the Company
as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports,
schedules, forms, statements and other documents required to be filed by it or furnished by it to the Commission during the past
12 months. For purposes of the preceding sentence, &ldquo;principal executive officer&rdquo; and &ldquo;principal financial officer&rdquo;
shall have the meanings given to such terms in the Exchange Act Rules 13a-15 and 15d-15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dd. <U>Finder&rsquo;s
Fees.</U> Neither the Company nor any Subsidiary has incurred any liability for any finder&rsquo;s fees, brokerage commissions
or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to the
Agents pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ee. <U>Labor
Disputes.</U> No labor disturbance by or dispute with employees of the Company or any Subsidiary exists or, to the knowledge of
the Company, is threatened which would reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ff. <U>Investment
Company Act.</U> Neither the Company nor any Subsidiary is or, after giving effect to the offering and sale of the Placement Shares,
will be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company,&rdquo; as such
terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<U>Investment Company Act</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gg. <U>Operations.
</U>The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance in all material
respects with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or the Subsidiaries are subject,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;), except as would not reasonably be expected
to result in a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental agency having
jurisdiction over the Company, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the
Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hh. <U>Off-Balance
Sheet Arrangements.</U> There are no transactions, arrangements and other relationships between and/or among the Company, and/or,
to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structured
finance, special purpose or limited purpose entity (each, an &ldquo;<U>Off Balance Sheet Transaction</U>&rdquo;) that could reasonably
be expected to affect materially the Company&rsquo;s liquidity or the availability of or requirements for its capital resources,
including those Off Balance Sheet Transactions described in the Commission&rsquo;s Statement about Management&rsquo;s Discussion
and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described
in the Registration Statement or the Prospectus which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Underwriter
Agreements.</U> The Company is not a party to any agreement with an agent or underwriter for any other &ldquo;at the market&rdquo;
or continuous equity transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jj. <U>ERISA.
</U>To the knowledge of the Company, (i) each material employee benefit plan, within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;), that is maintained, administered or contributed
to by the Company or any of its affiliates for employees or former employees of the Company and the Subsidiaries has been maintained
in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including
but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;); (ii) no prohibited
transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material
liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative
exemption; (iii) and for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA,
no &ldquo;accumulated funding deficiency&rdquo; as defined in Section 412 of the Code has been incurred, whether or not waived,
and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) equals
or exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions other than,
in the case of (i), (ii) and (iii) above, as would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">kk. <U>Forward-Looking
Statements.</U> No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) (a &ldquo;<U>Forward-Looking Statement</U>&rdquo;) contained in the Registration Statement and the Prospectus has been made
or reaffirmed without a reasonable basis or has been disclosed other than in good faith. The Forward-Looking Statements incorporated
by reference in the Registration Statement and the Prospectus from the Company&rsquo;s Annual Report on Form 10-K for the fiscal
year most recently ended (i) except for any Forward-Looking Statement included in any financial statements and notes thereto,
are within the coverage of the safe harbor for forward looking statements set forth in Section 27A of the Securities Act, Rule
175(b) under the Securities Act or Rule 3b-6 under the Exchange Act, as applicable, (ii) were made by the Company with a reasonable
basis and in good faith and reflect the Company&rsquo;s good faith commercially reasonable best estimate of the matters described
therein as of the respective dates on which such statements were made, and (iii) have been prepared in accordance with Item 10
of Regulation S-K under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ll. <U>Margin
Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the
Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors
of the Federal Reserve System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mm. <U>Insurance.
</U>The Company and the Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company
and the Subsidiaries reasonably believe are adequate for the conduct of their business and as is customary for companies of similar
size engaged in similar businesses in similar industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nn. <U>No
Improper Practices.</U> (i) Neither the Company nor, to the Company&rsquo;s knowledge, the Subsidiaries, nor to the Company&rsquo;s
knowledge, any of their respective executive officers has, in the past five years, made any unlawful contributions to any candidate
for any political office (or failed fully to disclose any contribution in violation of law) or made any contribution or other
payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar
public or quasi-public duty in violation of any law or of the character required to be disclosed in the Prospectus; (ii) to the
Company&rsquo;s knowledge no relationship, direct or indirect, exists between or among the Company or, to the Company&rsquo;s
knowledge, the Subsidiaries or any affiliate of any of them, on the one hand, and the directors, officers and stockholders of
the Company or, the Subsidiaries, on the other hand, that is required by the Securities Act to be described in the Registration
Statement and the Prospectus that is not so described; (iii) to the Company&rsquo;s knowledge no relationship, direct or indirect,
exists between or among the Company or the Subsidiaries or any affiliate of them, on the one hand, and the directors, officers,
stockholders or directors of the Company or, the Subsidiaries, on the other hand, that is required by the rules of FINRA to be
described in the Registration Statement and the Prospectus that is not so described; (iv) there are no material outstanding loans
or advances or material guarantees of indebtedness by the Company or, to the Company&rsquo;s knowledge, the Subsidiaries to or
for the benefit of any of their respective officers or directors or any of the members of the families of any of them; and (v)
to the Company&rsquo;s knowledge the Company has not offered, or caused any placement agent to offer, Common Stock to any person
with the intent to influence unlawfully (A) a customer or supplier of the Company or the Subsidiaries to alter the customer&rsquo;s
or supplier&rsquo;s level or type of business with the Company or the Subsidiaries or (B) a trade journalist or publication to
write or publish favorable information about the Company or the Subsidiaries or any of their respective products or services,
and, (vi) neither the Company nor the Subsidiaries nor, to the Company&rsquo;s knowledge, any employee or agent of the Company
or the Subsidiaries has made any payment of funds of the Company or the Subsidiaries or received or retained any funds in violation
of any law, rule or regulation (including, without limitation, the Foreign Corrupt Practices Act of 1977), which payment, receipt
or retention of funds is of a character required to be disclosed in the Registration Statement or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oo. <U>[Reserved]</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pp. <U>No
Misstatement or Omission in an Issuer Free Writing Prospectus.</U> Each Issuer Free Writing Prospectus, as of its issue date and
as of each Applicable Time (as defined in <U>Section 25</U> below), did not, does not and will not include any information that
conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including
any incorporated document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not
apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information
furnished to the Company by an Agent specifically for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">qq. <U>No
Conflicts.</U> Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation
of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof
and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will
constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company is a
party or to which any of the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as
may have been waived and (ii) such conflicts, breaches and defaults that would not reasonably be expected to have a Material Adverse
Effect; nor will such action result (x) in any violation of the provisions of the organizational or governing documents of the
Company, or (y) in any material violation of the provisions of any statute or any order, rule or regulation applicable to the
Company or of any court or of any federal, state or other regulatory authority or other government body having jurisdiction over
the Company, except where such violation would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rr. <U>Compliance
with Applicable Laws</U>. The Company and the Subsidiaries: (A) are and at all times have been in compliance with all statutes,
rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured
or distributed by the Company or the Subsidiaries (&ldquo;<U>Applicable Laws</U>&rdquo;) except where the failure to be so in
compliance would not reasonably be expected to result in a Material Adverse Effect, (b) have not received any Form 483 from the
FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European Medicines
Agency (the &ldquo;<U>EMA</U>&rdquo;), or any other federal, state, local or foreign governmental or regulatory authority alleging
or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;), which
would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; (C) possess all material
Authorizations for the Company&rsquo;s current state of product development as disclosed in the Registration Statement, and such
Authorizations are valid and in full force and effect and neither the Company nor the Subsidiaries is in material violation of
any term of any such Authorizations; (D) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from the FDA, the EMA, or any other federal, state, local or foreign governmental or
regulatory authority or third party alleging that any Company product, operation or activity is in material violation of any Applicable
Laws or Authorizations and has no knowledge that the FDA, the EMA, or any other federal, state, local or foreign governmental
or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or
proceeding against the Company; (E) have not received notice that the FDA, EMA, or any other federal, state, local or foreign
governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material
Authorizations and has no knowledge that the FDA, EMA, or any other federal, state, local or foreign governmental or regulatory
authority is considering such action; and (F) have filed, obtained, maintained or submitted all reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
for the Company&rsquo;s current state of product development as disclosed in the registration Statement, except where the failure
to file such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments would
not result in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented
by a subsequent submission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ss. <U>Clinical
Studies</U>. All animal and other preclinical studies and clinical trials conducted by the Company or to the Company&rsquo;s knowledge
on behalf of the Company were, and, if still pending are, to the Company&rsquo;s knowledge, being conducted in all material respects
in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by
qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to
those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained
in the Registration Statement and the Prospectus are accurate in all material respects, and, except as set forth in the Registration
Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of
which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration
Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received
any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the
termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described
in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tt. <U>Compliance
Program.</U> The Company has taken such steps as the Company, believes are reasonable and appropriate to comply in all material
respects with applicable regulatory guidelines (including, without limitation, those administered by the FDA, the EMA, and any
other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by
the FDA or EMA); except where such noncompliance would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">uu. <U>OFAC.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The
Company represents that, neither the Company nor any Subsidiary (collectively, the &ldquo;<U>Entity</U>&rdquo;) or to the Company&rsquo;s
knowledge any director, officer, employee, agent, affiliate or representative of the Entity, is a government, individual, or entity
(in this paragraph (ss), &ldquo;<U>Person</U>&rdquo;) that is, or is owned or controlled by a Person that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control
(&ldquo;<U>OFAC</U>&rdquo;), the United Nations Security Council (&ldquo;<U>UNSC</U>&rdquo;), the European Union (&ldquo;<U>EU</U>&rdquo;),
Her Majesty&rsquo;s Treasury (&ldquo;<U>HMT</U>&rdquo;), or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;),
nor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) located,
organized or resident in a country or territory that is the subject of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company represents and covenants that it will not, directly or indirectly, knowingly use the proceeds of the offering, or
knowingly lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering,
whether as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company represents and covenants that, except as detailed in the Prospectus, for the past 5 years, it has not knowingly engaged
in, is not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Person, or in any
country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vv. <U>Stock
Transfer Taxes.</U> On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to
be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully
paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate in the form of Exhibit 7(l) signed by an officer of the Company and delivered to the Agents or to counsel for the
Agents pursuant to or in connection with this Agreement shall be deemed to be a representation and warranty by the Company, as
applicable, to the Agents as to the matters set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <U>Covenants
of the Company</U>. The Company covenants and agrees with the Agents that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <U>Registration
Statement Amendments.</U> After the date of this Agreement and during any period in which a prospectus relating to any Placement
Shares is required to be delivered by the Agents under the Securities Act (including in circumstances where such requirement may
be satisfied pursuant to Rule 172 under the Securities Act) (the <U>&ldquo;Prospectus Delivery Period</U>&rdquo;) (i) the Company
will notify the Agents promptly of the time when any subsequent amendment to the Registration Statement, other than documents
incorporated by reference or amendments not related to any Placement, has been filed with the Commission and/or has become effective
or any subsequent supplement to the Prospectus, other than documents incorporated by reference, has been filed and of any request
by the Commission for any amendment or supplement to the Registration Statement or Prospectus related to the Placement or for
additional information related to the Placement, (ii) the Company will prepare and file with the Commission, promptly upon any
Agent&rsquo;s request, any amendments or supplements to the Registration Statement or Prospectus that, in such Agent&rsquo;s reasonable
opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by the Agents (<I>provided,
however</I>, that the failure of the Agents to make such request shall not relieve the Company of any obligation or liability
hereunder, or affect the Agents&rsquo; right to rely on the representations and warranties made by the Company in this Agreement
and provided, further, that the only remedy the Agents shall have with respect to the failure to make such filing shall be to
cease making sales under this Agreement until such amendment or supplement is filed); and (iii) the Company will cause each amendment
or supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b)
of the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with the Commission
as required pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any amendment
or supplement with the Commission under this <U>Section 7(a)</U>, based on the Company&rsquo;s reasonable opinion or reasonable
objections, shall be made exclusively by the Company). Notwithstanding the foregoing, the Company will not file any amendment
or supplement to the Registration Statement or Prospectus, other than documents incorporated by reference, relating to the Placement
Shares or a security convertible into the Placement Shares unless a copy thereof has been submitted to the Agents within a reasonable
period of time before the filing and the Agents have not reasonably and in good faith objected thereto (<I>provided, however</I>,
that (A) the failure of the Agents to make such objection shall not relieve the Company of any obligation or liability hereunder,
or affect the Agents&rsquo; right to rely on the representations and warranties made by the Company in this Agreement and (B)
the Company has no obligation to provide the Agents any advance copy of such filing or to provide the Agents an opportunity to
object to such filing if the filing does not name the Agents or does not relate to the transaction herein provided; and provided,
further, that the only remedy the Agents shall have with respect to the failure by the Company to obtain such consent shall be
to cease making sales under this Agreement) and the Company will furnish to the Agents at the time of filing thereof a copy of
any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except
for those documents available via EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. <U>Notice
of Commission Stop Orders.</U> The Company will advise the Agents, promptly after it receives notice or obtains knowledge thereof,
of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement,
of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation
or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent
the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the
Agents promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment
or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering of
the Placement Shares or for additional information related to the Registration Statement, the Prospectus or any Issuer Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. <U>Delivery
of Prospectus; Subsequent Changes.</U> During the Prospectus Delivery Period, the Company will use its commercially reasonably
efforts to comply in all material respects with all requirements imposed upon it by the Securities Act, as from time to time in
force, and to file on or before their respective due dates all reports and any definitive proxy or information statements required
to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under
the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant to Rule 430A under the Securities
Act, it will use its commercially reasonable efforts to comply with the provisions of and make all requisite filings with the
Commission pursuant to said Rule 430A and to notify the Agents promptly of all such filings. If during the Prospectus Delivery
Period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
then existing, not misleading, or if during such Prospectus Delivery Period it is necessary to amend or supplement the Registration
Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Designated Agent to suspend the
offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or
Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance; <I>provided,
however</I>, that the Company may delay the filing of any amendment or supplement, if in the judgment of the Company, it is in
the best interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. <U>Listing
of Placement Shares.</U> During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to cause
the Placement Shares to be listed on the Exchange and to qualify the Placement Shares for sale under the securities laws of such
jurisdictions in the United States as the Agents reasonably designates and to continue such qualifications in effect so long as
required for the distribution of the Placement Shares; <I>provided, however</I>, that the Company shall not be required in connection
therewith to qualify as a foreign corporation or dealer in securities or file a general consent to service of process in any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e. <U>Delivery
of Registration Statement and Prospectus.</U> The Company will furnish to the Agents and their counsel (at the reasonable expense
of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein)
and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus
Delivery Period (including all documents filed with the Commission during such period that are deemed to be incorporated by reference
therein), in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably
request and, at the Agents&rsquo; request, will also furnish copies of the Prospectus to each exchange or market on which sales
of the Placement Shares may be made; <I>provided, however</I>, that the Company shall not be required to furnish any document
(other than the Prospectus) to the Agents to the extent such document is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f. <U>Earnings
Statement.</U> The Company will make generally available to its shareholders as soon as practicable, but in any event not later
than 15 months after the end of the Company&rsquo;s current fiscal year-end, an earnings statement covering a 12-month period
that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g. <U>Use
of Proceeds.</U> The Company will use the Net Proceeds as described in the Prospectus in the section entitled &ldquo;Use of Proceeds.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h. <U>Notice
of Other Sales.</U> Without the prior written consent of the Agents, the Company will not, directly or indirectly, offer to sell,
sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase
or acquire, Common Stock during the period beginning on the date on which any Placement Notice is delivered to the Agents hereunder
and ending on the third (3rd) Trading Day immediately following the final Settlement Date with respect to Placement Shares sold
pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement
Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any
other &ldquo;at the market&rdquo; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to
sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities
convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common Stock prior to the termination
of this Agreement; <I>provided, however</I>, that such restrictions will not be required in connection with the Company&rsquo;s
issuance or sale of (i) Common Stock, options to purchase Common Stock or Common Stock issuable upon the exercise of options or
other equity awards, pursuant to any employee or director stock incentive or benefits plan or agreement, stock ownership plan
or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan)
of the Company whether now in effect or hereafter implemented; (ii) Common Stock issuable upon conversion of securities or the
exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR
or otherwise in writing to the Agents, and (iii) Common Stock, or securities convertible into or exercisable for Common Stock,
offered and sold in a privately negotiated transaction to vendors, customers, strategic partners or potential strategic partners
or other investors conducted in a manner so as not to be integrated with the offering of Common Stock hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Change
of Circumstances.</U> The Company will, at any time during the pendency of a Placement Notice advise the Agents promptly after
it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material
respect any opinion, certificate, letter or other document required to be provided to the Agents pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j. <U>Due
Diligence Cooperation.</U> During the term of this Agreement, the Company will cooperate with any reasonable due diligence review
conducted by the Agents or their representatives in connection with the transactions contemplated hereby, including, without limitation,
providing information and making available documents and senior corporate officers, during regular business hours and at the Company&rsquo;s
principal offices, as the Agents may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k. <U>Required
Filings Relating to Placement of Placement Shares.</U> The Company agrees that on such dates as the Securities Act shall require,
the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the
Securities Act (each and every filing under Rule 424(b), a &ldquo;<U>Filing Date</U>&rdquo;), which prospectus supplement will
set forth, within the relevant period, the amount of Placement Shares sold through the Agents, the Net Proceeds to the Company
and the compensation payable by the Company to the Agents with respect to such Placement Shares or, if any such prospectus supplement
is not filed pursuant to Rule 424(b), otherwise include such information in the Company&rsquo;s Exchange Act filings on such date
as shall be required, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on
which such sales were effected as may be required by the rules or regulations of such exchange or market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l. <U>Representation
Dates; Certificate.</U> Each time during the term of this Agreement that the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) amends
or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares)
the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker,
or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating
to the Placement Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) files
an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a
material amendment to the previously filed Form 10-K);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) files
its quarterly reports on Form 10-Q under the Exchange Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) files
a current report on Form 8-K containing amended financial information (other than information &ldquo;furnished&rdquo; pursuant
to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification
of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under
the Exchange Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Each
date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &ldquo;<U>Representation Date.</U>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company shall furnish the Agents (but in the case of clause (iv) above only if any Agent reasonably determines that the information
contained in such Form 8-K is material) with a certificate, in the form attached hereto as <U>Exhibit 7(1)</U>. The requirement
to provide a certificate under this <U>Section 7(1)</U> shall be waived for any Representation Date occurring at a time at which
no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement
Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation
Date on which the Company files its annual report on Form 10-K. Notwithstanding the foregoing, (i) upon the delivery of the first
Placement Notice hereunder and (ii) if the Company subsequently decides to sell Placement Shares following a Representation Date
when the Company relied on such waiver and did not provide the Agents with a certificate under this <U>Section 7(1)</U>, then
before the Agents sell any Placement Shares, the Company shall provide the Agents with a certificate, in the form attached hereto
as <U>Exhibit 7(1)</U>, dated the date of the Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m. <U>Legal
Opinion.</U> On or prior to the date of the first Placement Notice given hereunder the Company shall cause to be furnished to
the Agents written opinions and a negative assurance letter of The Matt Law Firm, PLLC (&ldquo;<U>Company Counsel</U>&rdquo;),
or other counsel reasonably satisfactory to the Agents, in the form attached hereto as Exhibit 7(m)(1) and 7(m)(2), respectively.
Thereafter, within five (5) Trading Days of each Representation Date with respect to which the Company is obligated to deliver
a certificate in the form attached hereto as Exhibit 7(l) for which no waiver is applicable, the Company shall cause to be furnished
to the Agents a written letter of Company Counsel in the form attached hereto as Exhibit 7(m)(2), modified, as necessary, to relate
to the Registration Statement and the Prospectus as then amended or supplemented; <I>provided that, </I>in lieu of such negative
assurance for subsequent periodic filings under the Exchange Act, counsel may furnish the Agents with a letter (a &ldquo;<U>Reliance
Letter</U>&rdquo;) to the effect that the Agents may rely on the negative assurance letter previously delivered under this Section
7(m) to the same extent as if it were dated the date of such letter (except that statements in such prior letter shall be deemed
to relate to the Registration Statement and the Prospectus as amended or supplemented as of the date of the Reliance Letter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n. <U>Comfort
Letter.</U> On or prior to the date of the first Placement Notice given hereunder and within five (5) Trading Days after each
subsequent Representation Date, other than pursuant to <U>Section 7(l)(iii)</U>, the Company shall cause its independent accountants
to furnish the Agents letters (the &ldquo;<U>Comfort Letters</U>&rdquo;), dated the date the Comfort Letter is delivered, which
shall meet the requirements set forth in this <U>Section 7(n)</U>; provided, that if requested by an Agent, the Company shall
cause a Comfort Letter to be furnished to the Agents within ten (10) Trading Days of such request following the date of occurrence
of any restatement of the Company&rsquo;s financial statements. The Comfort Letter from the Company&rsquo;s independent accountants
shall be in a form and substance reasonably satisfactory to the Agents, (i) confirming that they are an independent public accounting
firm within the meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the conclusions and findings of such
firm with respect to the financial information and other matters ordinarily covered by accountants&rsquo; &ldquo;comfort letters&rdquo;
to underwriters in connection with registered public offerings (the first such letter, the &ldquo;<U>Initial Comfort Letter</U>&rdquo;)
and (iii) updating the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter
had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended
and supplemented to the date of such letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o. <U>Market
Activities.</U> The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes
or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of Placement Shares or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M,
or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p. <U>Investment
Company Act.</U> The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor the Subsidiaries
will be or become, at any time prior to the termination of this Agreement, an &ldquo;investment company,&rdquo; as such term is
defined in the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">q. <U>No
Offer to Sell. </U>Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agents in their capacity
as agents hereunder pursuant to <U>Section 23</U>, neither the Agents nor the Company (including its agents and representatives,
other than the Agents in their capacity as such) will make, use, prepare, authorize, approve or refer to any written communication
(as defined in Rule 405), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer
to buy Placement Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">r. <U>Sarbanes-Oxley
Act.</U> The Company will maintain and keep accurate books and records reflecting its assets and maintain internal accounting
controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP and including those policies and procedures that (i) pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the
assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation
of the Company&rsquo;s consolidated financial statements in accordance with GAAP, (iii) that receipts and expenditures of the
Company are being made only in accordance with management&rsquo;s and the Company&rsquo;s directors&rsquo; authorization, and
(iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of
the Company&rsquo;s assets that could have a material effect on its financial statements. The Company will maintain such controls
and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the
applicable regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the
reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission&rsquo;s rules and forms, including, without limitation, controls and procedures designed to ensure
that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated
and communicated to the Company&rsquo;s management, including its principal executive officer and principal financial officer,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and to ensure
that material information relating to the Company or the Subsidiaries is made known to them by others within those entities, particularly
during the period in which such periodic reports are being prepared.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <U>Representations
and Covenants of the Agents.</U> Each of the Agents represents and warrants that it is duly registered as a broker-dealer under
FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered
and sold, except such states in which such Agent is exempt from registration or such registration is not otherwise required. Each
of the Agents shall continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange
Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except such
states in which such Agent is exempt from registration or such registration is not otherwise required, during the term of this
Agreement. Each of the Agents shall comply with all applicable law and regulations in connection with the transactions contemplated
by this Agreement, including the issuance and sale through the Agents of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <U>Payment
of Expenses.</U> The Company will pay all expenses incident to the performance of its obligations under this Agreement, including
(i) the preparation, filing, including any fees required by the Commission, and printing of the Registration Statement (including
financial statements and exhibits) as originally filed and of each amendment and supplement thereto and each Free Writing Prospectus,
in such number as the Agents shall deem reasonably necessary, (ii) the printing and delivery to the Agents of this Agreement and
such other documents as may be reasonably required in connection with the offering, purchase, sale, issuance or delivery of the
Placement Shares, (iii) the preparation, issuance and delivery of the certificates, if any, for the Placement Shares to the Agents,
including any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable upon the sale,
issuance or delivery of the Placement Shares to the Agents, (iv) the fees and disbursements of the counsel, accountants and other
advisors to the Company, (v) the reasonable fees and disbursements of counsel to the Agents up to a maximum of $25,000; (vi) the
fees and expenses of the transfer agent and registrar for the Common Stock, (vii) the filing fees incident to any review by FINRA
of the terms of the sale of the Placement Shares, and (viii) the fees and expenses incurred in connection with the listing of
the Placement Shares on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <U>Conditions
to the Agents&rsquo; Obligations.</U> The obligations of the Agents hereunder with respect to a Placement will be subject to the
continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance
by the Company of its obligations hereunder, to the completion by the Agents of a due diligence review satisfactory to it in its
reasonable judgment, and to the continuing satisfaction (or waiver by the Agents in their sole discretion) of the following additional
conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <U>Registration
Statement Effective.</U> The Registration Statement shall have become effective and shall be available for the sale of all Placement
Shares contemplated to be issued by any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. <U>No
Material Notices.</U> None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request
for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration
Statement or the Prospectus which have not, as of the time of such Placement, been so made; (ii) the issuance by the Commission
or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement
or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension
of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation
or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that requires the making of any changes
in the Registration Statement or the Prospectus so that, in the case of the Registration Statement, it will not contain any materially
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, which changes shall not, as of the time of such
Placement, have so been made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. <U>No
Misstatement or Material Omission.</U> The Agents shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agents&rsquo; reasonable opinion is material,
or omits to state a fact that in the Agents&rsquo; reasonable opinion is material and is required to be stated therein or is necessary
to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. <U>Material
Changes.</U> Except as contemplated in the Prospectus, or disclosed in the Company&rsquo;s reports filed with the Commission,
there shall not have been any Material Adverse Effect, or any development that could reasonably be expected to cause a Material
Adverse Effect in each case is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement
Shares on the terms and in the manner contemplated in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e. <U>Legal
Opinion.</U> The Agents shall have received the opinions and negative assurances of Company Counsel required to be delivered pursuant
<U>Section 7(m)</U> on or before the date on which such delivery of such opinions are required pursuant to <U>Section 7(m)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f. <U>Comfort
Letter.</U> The Agents shall have received the Comfort Letter required to be delivered pursuant <U>Section 7(n)</U> on or before
the date on which such delivery of such letter is required pursuant to <U>Section 7(n)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g. <U>Representation
Certificate.</U> The Agents shall have received the certificate required to be delivered pursuant to <U>Section 7(1)</U> on or
before the date on which delivery of such certificate is required pursuant to <U>Section 7(1)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h. <U>Secretary&rsquo;s
Certificate</U>. On or prior to the first Representation Date, the Agents shall have received a certificate, signed on behalf
of the Company by its corporate Secretary, in form and substance reasonably satisfactory to the Agents and their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>No
Suspension.</U> Trading in the Common Stock shall not have been suspended on the Exchange and the Common Stock shall not have
been delisted from the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j. <U>Other
Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to <U>Section 7(l)</U>, the Company
shall have furnished to the Agents such appropriate further information, certificates and documents as the Agents may reasonably
request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof. The Company
will furnish the Agents with such conformed copies of such opinions, certificates, letters and other documents as the Agents shall
reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k. <U>Securities
Act Filings Made.</U> All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to
the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing
by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l. <U>Approval
for Listing.</U> The Placement Shares shall either have been approved for listing on the Exchange, subject only to notice of issuance,
or the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to, the issuance
of any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m. <U>No
Termination Event.</U> There shall not have occurred any event that would permit the Agents to terminate this Agreement pursuant
to <U>Section 13(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <U>Indemnification
and Contribution.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Company
Indemnification.</U> The Company agrees to indemnify and hold</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">harmless
the Agents, their partners, members, directors, officers, employees and agents and each person, if any, who controls the Agents
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment
thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make
the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included
in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement
or omission; provided that (subject to <U>Section 11(d)</U> below) any such settlement is effected with the written consent of
the Company, which consent shall not unreasonably be delayed or withheld; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) against
any and all expense whatsoever, as incurred (including the reasonable documented fees and disbursements of counsel), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>provided,
however</I>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity
with written information furnished to the Company by an Agent expressly for use in the Registration Statement (or any amendment
thereto), or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Agent
Indemnification.</U> Each Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company
who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against
any and all loss, liability, claim, damage and expense described in the indemnity contained in <U>Section 11(a)</U>, as incurred,
but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement
(or any amendments thereto) or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with information relating to such Agent and furnished to the Company in writing by
such Agent expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Procedure.
</U>Any party that proposes to assert the right to be indemnified under this <U>Section 11</U> will, promptly after receipt of
notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party
or parties under this <U>Section 11</U>, notify each such indemnifying party of the commencement of such action, enclosing a copy
of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any
liability that it might have to any indemnified party otherwise than under this <U>Section 11</U> and (ii) any liability that
it may have to any indemnified party under the foregoing provision of this <U>Section 11</U> unless, and only to the extent that,
such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought
against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled
to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving
notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified,
to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the
indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to
the indemnified party for any legal or other expenses except as provided below and except for the reasonable costs of investigation
subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ
its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified
party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party,
(2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to
it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict
or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying
party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified
party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action within a reasonable
time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other
charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or
parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable
fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time
for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying
party promptly after the indemnifying party receives a written invoice relating to fees, disbursements and other charges in reasonable
detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its
written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise
or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated
by this <U>Section 11</U> (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent
(1) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation,
proceeding or claim and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or
on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Contribution.
</U>In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the
foregoing paragraphs of this <U>Section 11</U> is applicable in accordance with its terms but for any reason is held to be unavailable
from the Company or an Agent, the Company and such Agent will contribute to the total losses, claims, liabilities, expenses and
damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in
settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company
from persons other than the Agents, such as persons who control the Company within the meaning of the Securities Act or the Exchange
Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution)
to which the Company and the Agents may be subject in such proportion as shall be appropriate to reflect the relative benefits
received by the Company on the one hand and the Agents on the other hand. The relative benefits received by the Company on the
one hand and the Agents on the other hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale
of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agents
(before deducting expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided
by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion
as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault
of the Company, on the one hand, and such Agent, on the other hand, with respect to the statements or omission that resulted in
such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations
with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue
or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or such Agent, the intent of the parties and their relative knowledge, access to information and opportunity
to correct or prevent such statement or omission. The Company and each Agent agree that it would not be just and equitable if
contributions pursuant to this <U>Section 11(d)</U> were to be determined by pro rata allocation or by any other method of allocation
that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified
party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this <U>Section
11(d) </U>shall be deemed to include, for the purpose of this <U>Section 11(d)</U>, any legal or other expenses reasonably incurred
by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with
<U>Section 11(c)</U> hereof. Notwithstanding the foregoing provisions of this <U>Section 11(d)</U>, and except in the case of
gross negligence or willful misconduct, an Agent shall not be required to contribute any amount in excess of the commissions received
by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
For purposes of this <U>Section 11(d)</U>, any person who controls a party to this Agreement within the meaning of the Securities
Act or the Exchange Act, and any officers, directors, partners, employees or agents of an Agent, will have the same rights to
contribution as that party, and each officer and director of the Company who signed the Registration Statement will have the same
rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly
after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made
under this <U>Section 11(d)</U>, will notify any such party or parties from whom contribution may be sought, but the omission
to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they
may have under this <U>Section 11(d)</U> except to the extent that the failure to so notify such other party materially prejudiced
the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant
to the last sentence of <U>Section 11(c)</U> hereof, no party will be liable for contribution with respect to any action or claim
settled without its written consent if such consent is required pursuant to <U>Section 11(c)</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <U>Representations
and Agreements to Survive Delivery.</U> The indemnity and contribution agreements contained in Section 11 of this Agreement and
all representations and warranties of the Company and the Agents herein or in certificates delivered pursuant hereto shall survive,
as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agents, any controlling persons,
or the Company (or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement
Shares and payment therefor or (iii) any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <U>Termination.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. An
Agent may terminate this Agreement, written by notice to the Company, as hereinafter specified at any time (1) if there has been,
since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any Material
Adverse Effect, or any development that is reasonably likely to have a Material Adverse Effect or, in the reasonable judgment
of such Agent, is material and adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts
for the sale of the Placement Shares, (2) if there has occurred any material adverse change in the financial markets in the United
States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or
any change or development involving a prospective change in national or international political, financial or economic conditions,
in each case the effect of which is such as to make it, in the reasonable and good faith judgment of such Agent, impracticable
or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in
the Common Stock has been suspended or limited by the Commission or the Exchange, or if trading generally on the Exchange has
been suspended or limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension of trading of
any securities of the Company on any exchange or in the over-the-counter market shall have occurred and be continuing for a period
of at least 10 days, (5) if a major disruption of securities settlements or clearance services in the United States shall have
occurred and be continuing, or (6) if a banking moratorium has been declared by either U.S. Federal or New York authorities. Any
such termination shall be without liability of any party to any other party except that the provisions of <U>Section</U> 9 (Payment
of Expenses), <U>Section 11</U> (Indemnification and Contribution), <U>Section 12</U> (Representations and Agreements to Survive
Delivery), <U>Section 18</U> (Governing Law and Time; Waiver of Jury Trial) and <U>Section 19</U> (Consent to Jurisdiction) hereof
shall remain in full force and effect notwithstanding such termination. If an Agent elects to terminate this Agreement as provided
in this Section 13(a), such Agent shall provide the required notice as specified in Section 14 (Notices).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. The
Company shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole
discretion (for any reason or no reason) at any time after the date of this Agreement. Any such termination shall be without liability
of any party to any other party except that the provisions of <U>Section 9</U> (Payment of Expenses), <U>Section 11</U> (Indemnification
and Contribution), <U>Section 12</U> (Representations and Agreements to Survive Delivery), <U>Section 18</U> (Governing Law and
Time; Waiver of Jury Trial) and <U>Section 19</U> (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding
such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. Each
Agent shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion
(for any reason or no reason) at any time after the date of this Agreement. Any such termination shall be without liability of
any party to any other party except that the provisions of <U>Section 9</U> (Payment of Expenses), <U>Section 11</U> (Indemnification
and Contribution), <U>Section 12</U> (Representations and Agreements to Survive Delivery), <U>Section 18</U> (Governing Law and
Time; Waiver of Jury Trial) and <U>Section 19</U> (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding
such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. Unless
earlier terminated pursuant to this <U>Section 13</U>, this Agreement shall automatically terminate upon the issuance and sale
of all of the Placement Shares through the Agents on the terms and subject to the conditions set forth herein except that the
provisions of <U>Section 9</U> (Payment of Expenses), <U>Section 11</U> (Indemnification and Contribution), <U>Section 12</U>
(Representations and Agreements to Survive Delivery), <U>Section 18</U> (Governing Law and Time; Waiver of Jury Trial) and <U>Section
19</U> (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e. This
Agreement shall remain in full force and effect unless terminated pursuant to <U>Sections 13(a)</U>, <U>(b</U>), <U>(c</U>), or
<U>(d)</U> above or otherwise by mutual agreement of the parties; <I>provided, however</I>, that any such termination by mutual
agreement shall in all cases be deemed to provide that <U>Section 9</U> (Payment of Expenses), <U>Section 11</U> (Indemnification
and Contribution), <U>Section 12</U> (Representations and Agreements to Survive Delivery), <U>Section 18</U> (Governing Law and
Time; Waiver of Jury Trial) and <U>Section 19</U> (Consent to Jurisdiction) shall remain in full force and effect. Upon termination
of this Agreement, the Company shall not have any liability to an Agent for any discount, commission or other compensation with
respect to any Placement Shares not otherwise sold by an Agent under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f. Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided, however</I>,
that such termination shall not be effective until the close of business on the date of receipt of such notice by an Agent or
the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares,
such Placement Shares shall settle in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Notices.</U> All notices or other communications required or permitted to be given by any party to any other party pursuant
to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agents, shall be delivered
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley FBR, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">299
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10171</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: General
Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(212) 457-9947</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:  atmdesk@brileyfbr.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JonesTrading
Institutional Services LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">900
Island Park Drive, Suite 160</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
Island, SC 29492</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Burke
Cook</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:  Burke@jonestrading.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duane
Morris LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1540
Broadway</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10036</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James
T. Seery</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;(973)
424-2088</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:  jtseery@duanemorris.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
if to the Company, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, 7<SUP>th</SUP>&nbsp;Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;(646) 677-3870</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:  sseth@actiniumpharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Matt Law Firm, PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1701
Genesee Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utica,
New York 13501</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thomas Slusarczyk, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&nbsp;&nbsp;&nbsp; (315) 235-2299</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:  tslusarczyk@mattlawfirm.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new
address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally, by email,
or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business
Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) on the next Business Day after timely delivery
to a nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified
or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &ldquo;<U>Business Day</U>&rdquo;
shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
electronic communication (&ldquo;<U>Electronic Notice</U>&rdquo;) shall be deemed written notice for purposes of this <U>Section
14</U> if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be
deemed received at the time the party sending Electronic Notice receives confirmation of receipt by the receiving party. Any party
receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<U>Nonelectronic
Notice</U>&rdquo;) which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic
Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <U>Successors
and Assigns.</U> This Agreement shall inure to the benefit of and be binding upon the Company and each Agent and their respective
successors and the affiliates, controlling persons, officers and directors referred to in <U>Section 11</U> hereof. References
to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except
as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior
written consent of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. <U>Adjustments
for Stock Splits.</U> The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted
to take into account any share consolidation, stock split, stock dividend, corporate domestication or similar event effected with
respect to the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17. <U>Entire
Agreement; Amendment; Severability.</U> This Agreement (including all schedules and exhibits attached hereto and Placement Notices
issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term
hereof may be amended except pursuant to a written instrument executed by the Company and the Agents. In the event that any one
or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable
as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible
extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if
such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to
such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected
in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18. <U>GOVERNING
LAW AND TIME; WAIVER OF JURY TRIAL.</U> THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY
HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19. <U>CONSENT
TO JURISDICTION.</U> EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION
CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT
IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT
FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE
OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR
REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES
THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE
DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20. <U>Use
of Information.</U> The Agents may not use any information gained in connection with this Agreement and the transactions contemplated
by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21. <U>Counterparts.
</U>This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile
transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22. <U>Effect
of Headings.</U> The section and Exhibit headings herein are for convenience only and shall not affect the construction hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23. <U>Permitted
Free Writing Prospectuses.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents, warrants and agrees that, unless it obtains the prior consent of each Agent, which consent shall not be unreasonably
withheld, conditioned or delayed, and each Agent represents, warrants and agrees that, unless it obtains the prior consent of
the Company, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make any offer
relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a
&ldquo;free writing prospectus,&rdquo; as defined in Rule 405, required to be filed with the Commission. Any such free writing
prospectus consented to by the Agents or by the Company, as the case may be, is hereinafter referred to as a &ldquo;Permitted
Free Writing Prospectus.&rdquo; The Company represents and warrants that it has treated and agrees that it will treat each Permitted
Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, and has complied and will
comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the
Commission where required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free writing
prospectuses, if any, listed in <U>Exhibit 23</U> hereto are Permitted Free Writing Prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.
<U>Absence of Fiduciary Relationship.</U> The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Each
Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between
the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party,
on the one hand, and the Agents, on the other hand, has been or will be created in respect of any of the transactions contemplated
by this Agreement, irrespective of whether or not any Agent has advised or is advising the Company on other matters, and the Agents
have no obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly
set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. it
is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. the
Agents have not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this
Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. it
is aware that the Agents and their affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and such Agent has no obligation to disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship or otherwise; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e. it
waives, to the fullest extent permitted by law, any claims it may have against the Agents for breach of fiduciary duty or alleged
breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agents shall
not have any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty
claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors
of Company, other than in respect of the Agents&rsquo; obligations under this Agreement and to keep information provided by the
Company to the Agents and the Agents&rsquo; counsel confidential to the extent not otherwise publicly-available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25. <U>Definitions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.9pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the following terms have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Applicable
Time</U>&rdquo; means (i) each Representation Date and (ii) the time of each sale of any Placement Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, relating to
the Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a &ldquo;road show&rdquo; that
is a &ldquo;written communication&rdquo; within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the
Commission, or (3) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares
or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission
or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g) under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
172</U>,&rdquo; &ldquo;<U>Rule 405</U>,&rdquo; &ldquo;<U>Rule 415</U>,&rdquo; &ldquo;<U>Rule 424</U>,&rdquo; &ldquo;<U>Rule 424(b)</U>,&rdquo;
&ldquo;<U>Rule 430B</U>,&rdquo; and &ldquo;<U>Rule 433</U>&rdquo; refer to such rules under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to financial statements and schedules and other information that is &ldquo;contained,&rdquo; &ldquo;included&rdquo;
or &ldquo;stated&rdquo; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information that is incorporated by reference in the
Registration Statement or the Prospectus, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing
shall be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer
Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed
with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references
in this Agreement to &ldquo;supplements&rdquo; to the Prospectus shall include, without limitation, any supplements, &ldquo;wrappers&rdquo;
or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agents
outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Remainder
of the page intentionally left blank]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Company and each of the Agents, please so indicate in the space
provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and each of the
Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-left: 0">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-indent: 0.3in; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>ACTINIUM PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Sandesh Seth</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%"> Sandesh Seth</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chairman of the Board and CEO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>ACCEPTED as of the date first-above written:</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>B. RILEY FBR, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Patrice McNicoll</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Patrice McNicoll</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Co-Head of Investment Banking</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>JONESTRADING INSTITUTIONAL<BR>
 SERVICES LLC</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Burke Cook</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Burke Cook</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>General Counsel</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM
OF PLACEMENT NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
Market Issuance--Placement Notice</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and subject to the conditions contained in the Amended and Restated At Market Issuance Sales Agreement between Actinium
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and B. Riley FBR, Inc. and JonesTrading Institutional
Services LLC (the &ldquo;<U>Agents</U>&rdquo;), dated December [28], 2018, the Company hereby requests that [<I>Identify Designated
Agent</I>] sell up to [_______] shares of the Company&rsquo;s Common Stock, $0.001 par value per share, at a minimum market price
of $ per share, during the time period beginning [month, day, time] and ending [month, day, time].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay to the Designated Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal
to 3.0% of the gross proceeds from each sale of Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">The Company</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Sandesh Seth</TD>
    <TD>sseth@actiniumpharma.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Steve O&rsquo;Loughlin</TD>
    <TD>soloughlin@actiniumpharma.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>B. Riley FBR</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Matthew Feinberg</TD>
    <TD>mfeinberg@brileyfbr.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ryan Loforte</TD>
    <TD>rloforte@brileyfbr.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Patrice McNicoll</TD>
    <TD>pmcnicoll@brileyfbr.com &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Keith Pompliano</TD>
    <TD>kpompliano@brileyfbr.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>with a copy to atmdesk@brileyfbr.com</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>JonesTrading</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Moe Cohen</TD>
    <TD>moec@jonestrading.com&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Bryan Turley</TD>
    <TD>bturley@jonestrading.com&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>John D&rsquo;Agostini</TD>
    <TD>johnd@jonestrading.com&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ryan Gerety</TD>
    <TD>ryang@jonestrading.com&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With
a copy to JTCM@jonestrading.com</Font></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SCHEDULE 6(g)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MedActinium,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
7(1)</U></B><BR>
<B>Form of Representation Date Certificate </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>____________________,
20___</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Representation Date Certificate (this &ldquo;<U>Certificate</U>&rdquo;) is executed and delivered in connection with <U>Section
7(1)</U> of the Amended and Restated At Market Issuance Sales Agreement (the &ldquo;<U>Agreement</U>&rdquo;), dated December 28,
2018, and entered into between Actinium Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;) and B. Riley FBR, Inc. and JonesTrading
Institutional Services LLC. All capitalized terms used but not defined herein shall have the meanings given to such terms in the
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby certifies as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. As
of the date of this Certificate (i) the Registration Statement does not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and
(ii) neither the Registration Statement nor the Prospectus contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading and (iii) no event has occurred as a result of which it is necessary to amend or supplement
the Prospectus in order to make the statements therein not untrue or misleading for this paragraph 1 to be true.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Each
of the representations and warranties of the Company contained in the Agreement were, when originally made, and are, as of the
date of this Certificate, true and correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Except
as waived by the Agents in writing, each of the covenants required to be performed by the Company in the Agreement on or prior
to the date of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the
Agreement, has been duly, timely and fully performed in all material respects and each condition required to be complied with
by the Company on or prior to the date of the Agreement, this Representation Date, and each such other date prior to the date
hereof as set forth in the Agreement has been duly, timely and fully complied with in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. Subsequent
to the date of the most recent financial statements in the Prospectus, and except as described in the Prospectus, including Incorporated
Documents, there has been no Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. No
stop order suspending the effectiveness of the Registration Statement or of any part thereof has been issued, and no proceedings
for that purpose have been instituted or are pending or threatened by any securities or other governmental authority (including,
without limitation, the Commission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. No
order suspending the effectiveness of the Registration Statement or the qualification or registration of the Placement Shares
under the securities or Blue Sky laws of any</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jurisdiction
are in effect and no proceeding for such purpose is pending before, or threatened, to the Company&rsquo;s knowledge or in writing
by, any securities or other governmental authority (including, without limitation, the Commission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned has executed this Representation Date Certificate as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: Black 1.5pt solid">   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 3.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
23</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permitted
Issuer Free Writing Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>5
<FILENAME>f10k2018ex10-39_actinium.htm
<DESCRIPTION>SEVENTH AMENDMENT TO THE 2013 AMENDED AND RESTATED STOCK PLAN, AS AMENDED
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
10.39&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AMENDMENT
NO. 7</B><BR>
<B>TO</B><BR>
<B>ACTINIUM PHARMACEUTICALS, INC. 2013 AMENDED AND RESTATED STOCK PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to Section 14 of the 2013 Amended and Restated Stock Plan, as amended (the &ldquo;Plan&rdquo;) of Actinium Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), the Board of Directors of the Company has duly adopted a resolution, conditioned upon approval by
the stockholders of the Company, approving this Amendment No. 7 to the Plan to increase the total number of shares of common stock,
par value $.001 per share, of the Company (the &ldquo;Common Stock&rdquo;) reserved and available for issuance under the Plan
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3 of the Plan is hereby amended to read in its entirety as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Subject
to the provisions of Section 14 of the Plan, the maximum aggregate number of Shares reserved for issuance to Participants under
the Plan is 22,750,000, and the maximum aggregate number of Shares that may be granted in the form of Incentive Stock Options
is 22,750,000. The Shares may be authorized, but unissued, or reacquired Common Stock. If an award should expire or become unexercisable
for any reason without having been exercised in full, or is surrendered pursuant to an Option Exchange Program, the unpurchased
Shares that were subject thereto shall, unless the Plan shall have been terminated, become available for future grant under the
Plan. In addition, any Shares of Common Stock which are retained by the Company upon exercise of an award in order to satisfy
the exercise or purchase price for such award or any withholding taxes due with respect to such exercise or purchase shall be
treated as not issued and shall continue to be available under the Plan. Shares issued under the Plan and later repurchased by
the Company pursuant to any repurchase right which the Company may have shall not be available for future grant under the Plan.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
other terms and provisions of the Plan shall remain unchanged and in full force and effect as written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
majority in voting interest of the stockholders present in person or by proxy and entitled to vote at the meeting of stockholders
at which this Amendment No. 5 was considered, has duly approved this Amendment No. 7 to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN WITNESS
WHEREOF</B>, this Amendment No. 7 to the Plan is made effective this 6th day of March, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACTINIUM
    PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    Sandesh Seth &ndash; Chairman and CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>f10k2018ex23-1_actinium.htm
<DESCRIPTION>CONSENT OF GBH CPAS, PC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hereby consent to the incorporation by
reference in Registration Statement No. 333-216748 on Form S-3 and Registration Statements No. 333-216746 and No. 333-197283 on
Form S-8 of Actinium Pharmaceuticals, Inc. of our report dated March 16, 2018 relating to the consolidated financial statements
of Actinium Pharmaceuticals, Inc. as of December 31, 2017 and for the years ended December 31, 2017 and 2016, which report is
included in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">www.gbhcpas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 15, 2019</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>7
<FILENAME>f10k2018ex23-2_actinium.htm
<DESCRIPTION>CONSENT OF MARCUM LLP.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 23.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hereby consent to the incorporation
by reference in Registration Statement No. 333-216748 on Form S-3 and Registration Statements No. 333-216746 and No.
333-197283 on Form S-8 of Actinium Pharmaceuticals, Inc. of our report which includes an explanatory paragraph as to Actinium
Pharmaceuticals, Inc.'s ability to continue as a going concern dated March 15, 2019 relating to the consolidated financial
statements of Actinium Pharmaceuticals, Inc. as of December 31, 2018 and for the year then ended and our report dated March 15, 2019 with respect to our audit of the effectiveness of internal control over financial reporting of Actinium
Pharmaceuticals, Inc. as of December 31, 2018, which reports are included in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Marcum LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Marcum LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 15, 2019</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>f10k2018ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO 18U.S.C SECTION 1350 AS ADOPTED</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXELY
ACT OF 2002</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this report on Form 10-K of Actinium Pharmaceuticals, Inc. for the fiscal year ended December 31, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">4.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the
registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">5.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons
performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">b.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    March 15, 2019</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman
    and Chief Executive Officer (Duly&nbsp;Authorized Officer,<BR>
    Principal Executive Officer) </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>f10k2018ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>Exhibit 31.2</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CERTIFICATION OF PRINCIPAL FINANCIAL
AND ACCOUNTING OFFICER</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PURSUANT TO 18 U.S.C SECTION 1350
AS ADOPTED</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PURSUANT TO SECTION 302 OF THE SARBANES-OXELY
ACT OF 2002</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">I, Steve O&rsquo;Loughlin, certify that:</p>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this report on Form 10-K of Actinium Pharmaceuticals, Inc. for the fiscal year
ended December 31, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant's internal control over financial reporting
that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR></TABLE>



<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">Dated:
    March 15, 2019</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Steve O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve
    O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer (Duly&nbsp;Authorized Officer, Principal
    Financial and Accounting Officer)</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>f10k2018ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>Exhibit 32.1</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER, PURSUANT TO</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>18 U.S.C. SECTION 1350,AS ADOPTED
PURSUANT TO</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">In connection with
the Annual Report of Actinium Pharmaceuticals, Inc. a Delaware corporation (the &ldquo;Company&rdquo;), on Form 10-K for the period
ended December 31, 2018 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section
1350), that to my knowledge:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 63pt">(1) The Report fully complies with the
requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 63pt">(2) The information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 63pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    March 15, 2019</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman
    and Chief Executive Officer (Duly&nbsp;Authorized Officer,<BR>
    Principal Executive Officer) </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR></TABLE>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>f10k2018ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>Exhibit 32.2</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CERTIFICATION OF PRINCIPAL FINANCIAL
AND ACCOUNTING OFFICER, PURSUANT TO</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>18 U.S.C. SECTION 1350,AS ADOPTED
PURSUANT TO</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 45pt; text-align: justify">In connection
with the Annual Report of Actinium Pharmaceuticals, Inc. a Delaware corporation (the &ldquo;Company&rdquo;), on Form 10-K for
the period ended December 31, 2018 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Steve
O&rsquo;Loughlin, Principal Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, 18 U.S.C. Section 1350), that to my knowledge:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 63pt; text-align: justify">(1) The Report fully complies with the
requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 63pt; text-align: justify">(2) The information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">Dated:
    March 15, 2019</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Steve O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve
    O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer (Duly&nbsp;Authorized Officer, Principal
    Financial and Accounting Officer)</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %L E@# 2(  A$! Q$!_\0
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M-Y_ZN'X\5].T <=_PC&M_P#11/&/_@#\/_\ YA:/^$8UO_HHGC'_ , ?A_\
M_,+78T4 <=_PC&M_]%$\8_\ @#\/_P#YA:/^$8UO_HHGC'_P!^'_ /\ ,+78
MT4 <=_PC&M_]%$\8_P#@#\/_ /YA:/\ A&-;_P"BB>,?_ 'X?_\ S"U;B\:>
M$)_&-_\ #R'Q1H$OCW2_#6E>,]2\&1ZM8OXHL/".NZIK.B:+XGN]"6<ZE;Z#
MJNL^'=>TK3]6EMEL;O4-&U.S@G>>RN(X^FH X[_A&-;_ .BB>,?_  !^'_\
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M'_P!^'__ ,PM'_",:W_T43QC_P" /P__ /F%KL:* .._X1C6_P#HHGC'_P
M?A__ /,+1_PC&M_]%$\8_P#@#\/_ /YA:[&B@#CO^$8UO_HHGC'_ , ?A_\
M_,+1_P (SK7_ $43QB?^W'X?_P!/ U=C10!\[^!?&NN^/[GPWI;>)=3TJ<?#
MY/$.JWFD6'AU9=0U/_A)+[P[))/'J^AZQ;PQLVDW$Z0V$5I&CSR;O,C\E(/5
M_P#A&-;_ .BB>,?_  !^'_\ \PM?-?[/'_(RZ7_V23_WJ/C*OL6@#CO^$8UO
M_HHGC'_P!^'_ /\ ,+1_PC&M_P#11/&/_@#\/_\ YA:[&B@#CO\ A&-;_P"B
MB>,?_ 'X?_\ S"T?\(QK?_11/&/_ ( _#_\ ^86NQKB_B-\1O OPB\"^*OB=
M\3?%.C^"/A[X&T6\\1^,?&/B&Z6PT#PQX?TZ/SM2US6]0D'DZ=I&FVX>ZU+4
M;EH[2PLXYKR\FAM8994 '_\ ",:W_P!%$\8_^ /P_P#_ )A:/^$8UO\ Z*)X
MQ_\  'X?_P#S"U>\'^+_  SX_P#"OA[QOX,UJR\1^$O%FCZ?X@\->(--D,VG
M:UHFJVT=YINJZ?,57S[&_M)8KFTN%&R>"6.:,M&ZL> \:?M"_ OX=:]J_A;Q
MW\6_A]X3\3:!X:T#QEKGA[7?%.D:?K>D>$O%7C"R^'WAKQ+J6ESW2WMGH>O^
M.-1LO">D:I<0QV>H:_<+IEM-)=!XU .Q_P"$8UO_ **)XQ_\ ?A__P#,+1_P
MC&M_]%$\8_\ @#\/_P#YA:[&N2\<>//!GPS\,WWC/X@^)]%\'>$],N-)M=0\
M0^(;^#3-)LKG7=9T_P /:-!<WMRZ0Q2:GKFJZ;I5DK,#/?7UM;IF25 0"/\
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M F@:)X.MKC3;'3V\8Z3>_%'3_'VNPR>"?#ES8WP!_5G_ ,(QK?\ T43QC_X
M_#__ .86C_A&-;_Z*)XQ_P# 'X?_ /S"U^#'AC]O?]M+7?VB/$_AS1O'?P3\
M9>&_!O\ P4<^,7[(/CSX,Z=\&-=L/$_P\_9Q\+_">/Q];_M2:_X]C^*=[':C
MX1ZE>Z-'XUBU;3-,\&^/+"_?P]HFH>'/%^I:%!)\IZ?_ ,%3_P#@HM>? P_$
ME_%OP43QGJG_  2YU?\ X*"6?A"7]F3QY9KIGQ@^%WCN#PKJW[+45K-\59=5
MNW^+5G<S2#[65^(_A6[T>:X\.Z/JUI>R0:6 ?U)_\(QK?_11/&/_ ( _#_\
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M3_AZ3T'Q;\ D_AJ,QKC?@=X@\5VWPM\*P6'@&^U.SC36%M[^/Q#X=MDNXO\
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M!G@%O%EWD@=LX&?7 H Z;_A)_&W_ $3/4?\ PJ/"W_R?1_PD_C;_ *)GJ/\
MX5'A;_Y/KT&B@#S[_A)_&W_1,]1_\*CPM_\ )]'_  D_C;_HF>H_^%1X6_\
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MHOQ6O?&=UXW.L^.M9U*S\<ZDFM:GX8L_$WCGQ%XET7P#I.N2>)?%^L:_X/\
MAQHNKV'@'P5X@\4^(+WQ9KOA;PWI6K^(4LM2O9K"V .3^.GP*TC]H74/ &K^
M/_A=XFDU+X:W7B.Z\+^1XK^'^K:%GQ9IMMI>M)KO@7QE:^*_A[XGD:WLK1])
MU'Q#X2U+6?#-S%-/X8U+1GU'5?MW9_!7X?V7[/GPR\,_"'X5_!C4O#W@7PDN
MK'1]*/C/0+UH[C7]=U3Q/KMW)/=:G(XDU3Q#K6JZI+;P"#3[22]:TTNSL--@
MM;*W^E** /#O"WQAU7QEJ'C;2]#^&VO/=_#WQ:W@GQ(+O7O"5O$FO)X>\/\
MB=DT]TUB=KRR&E>)M*_TJ1+9OMGVRU\C_13))V'_  D_C;_HF>H_^%1X6_\
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MI.:]IR*7)"$8_JC_ ,-L:O\ ]%]^+/\ X<;XB?\ Q%'_  VQJ_\ T7WXL_\
MAQOB)_\ $5^5U%?J_P#Q*GX,?]"#,/\ P^YM_P#-)^!?\3^?2@_Z+C+/_$.X
M5_\ G:?JC_PVQJ__ $7WXL_^'&^(G_Q%'_#;&K_]%]^+/_AQOB)_\17Y744?
M\2I^#'_0@S#_ ,/N;?\ S2'_ !/Y]*#_ *+C+/\ Q#N%?_G:?O-\#_BAXO\
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M*,I1PD\+F]#&UTXM0_VS$XE\LKJTK2)S+AW/L9E.3Y=A?$CBG*,=E\+X[/\
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M/_WW9?XT>=H'_/71_P#ONR_QK^?N>?\ U$_^"X>G_/OR^9_:EH=\/_X,E_\
M+#\R=&_X)F> =!$FH:?\>OB'/XIE\1>/_%D^OZW8_#[7XKK7_BY^S[X&_9U^
M*5_?:1JOA^YM]0'B;PSX$L/$=A9W\USI_A_Q-=W,5K9W/A54\,UVGCS_ ()T
M_ _Q!\"+/X#>"/&7C3P!H=NG[/-C/K-UXNU?XC3W&B?LS^(/!?B;X>Z5;>&/
M'VLZQX%T W>I_#_PTGBB_P##'AC1;O6[!-4MI&BEU)[F'] O.T#_ )ZZ/_WW
M9?XT>=H'_/71_P#ONR_QHYZC:?\ M.CNOW<=UMI[.SMT3T06A9J^'U5OC?\
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M6OP\^%MO\'M!O?#<TT0O=<O[CPA:6LFLS>*[C51J6O1'5&6&.::RD^W_ #M
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M@V'6%\,0/;0Z/X<M-!\)WFL^&]4_03[=9?\ /Y:_^!$7_P 75'SM _YZZ/\
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M.T#_ )ZZ/_WW9?XU+AS-MQQ+;=VW!-M^O*4IV22GATEHDIV2_P#)R]]NLO\
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M_P#?=E_C1YV@?\]='_[[LO\ &CV:_DQ'_@M?_(A[1_ST/_ W_P#)E[[=9?\
M/Y:_^!$7_P 71]NLO^?RU_\  B+_ .+JCYV@?\]='_[[LO\ &CSM _YZZ/\
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M72+*TTSQ-:2Z3H?ASQ=X0U7XC^$K/1;33;BX76Y=,U&]MO$+W/C23V;XT?L
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M:[\.0ZPUCI^K)$#5J-OXT[M/[;?++V<6DU;WE[135TU[LH=8SNKU+_PHVO\
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MB#[+;?\ /O!_WYC_ /B:S]6MK<:5J1%O "+"[(/DQ\$028(^7J.U:]9VK_\
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M\1_$C7_VO_AEJGQ C^-=U\+=/\&^'_CK\<O@OX\^"O[06E^%[2]\1Q)8^!O
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MCU^#X;Z1=6'P_N8+GXB6VD^$/%%YJW@/S%\6Z$N@:I'K>CZ?-:21@]I'N_\
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MRV5^EWKT#D=[>[?M[:O?[N:_X';_ &.\_P"@S=?^ ^F__(='V.\_Z#-U_P"
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M ."</_D'LY=E_P"#<1_\D?7'V.\_Z#-U_P" ^F__ "'1]CO/^@S=?^ ^F_\
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M)Z=\+OCEX=\:_$32-0L=2U+6->T+7SK27FD^,[JYLQ]H:M^RA^U=K/P3\,_
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MEW]H7?\ S^_^6OK7_P D4?VA=_\ /[_Y:^M?_)%'U>?>/_D__P @'MX=I?\
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MPW]SIJ2:C;64MQ/8QR74<2-[#_:%W_S^_P#EKZU_\D4?VA=_\_O_ ):^M?\
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MMDN=(U[0UU[2'OH&AUW2W5X+F*TLKV7[;_M"[_Y_?_+7UK_Y(H_M"[_Y_?\
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MQM%L])TAM1N#=Z@VE^!KZP:^NF+%KF\-HT1NK@EW)FGWR$LQ+?,<ZW]H7?\
MS^_^6OK7_P D4VI\UXTZ-NBE&3M\/:G'3W4NNCEO?1*4;6<JE^K4HKOWF^]W
MZ+MK^6MUX-_X*'6/C?Q4_ACQ%\3(/"3_ !9^/^D^$Y_$&O? KQ0UE\$/$/[-
M=C+\'M:.EZCJME+?^+?#?[5,5Y=:9'K5Z-4A\%3-I'B.Y;PU+"ME]H?LB:3^
MT/H?P<M])_:=OM-U;XF6?BOQ<D>M:;=^:-9\)RZQ-<>&-2O--_M/Q&?#=[-8
MS&-O#+^,_',FCV\5M!+XMU20NEM[U_:%W_S^_P#EKZU_\D4?VA=_\_O_ ):^
MM?\ R16<H5)1Y>6DMG>,9J6BMOR=>O?<N-2$7>]1[Z.46M?+GZ=.QTE%<W_:
M%W_S^_\ EKZU_P#)%']H7?\ S^_^6OK7_P D5G]7GWC_ .3_ /R!?MX=I?\
MDG_R9\B?\%(?V9?'7[97[$O[0'[+_P .-?\ "'A3Q;\9O"5KX3T_Q/XYCU>?
MPWH*?V_I&JW6I7MGH5K=:E?R0V^FR):V</V=9;F2,RW<,:,3\S_&7_@G?XQO
M?%'PZ\;?LTV_P?\ A#XGM]-_:\\:_%W4=?\ $OQAUS4_&O[0G[37P-TOX76'
MQ N/&6C7NC?$/78?#6IZ#X?CO=8E\6^%O%"^"-$TSP[X2N/"PT[35L?U3_M"
M[_Y_?_+7UK_Y(H_M"[_Y_?\ RU]:_P#DBCZO/O'_ ,G_ /D ]O#M+_R3_P"3
M/P9U/_@E%^U/?Z%X@\,W'Q\\#ZKI,WA;]OBQ\')<>)/BYH=MX1\1?M<>'OAU
MJ'PJOK'P]H!A\-6T?[-OQ-T'QQK'@;4-(TS2KS3-"\0V)\+6OAC61J,TWIC?
M\$XOVKKWQ=K7C&']H71? _B_Q+\:]?\ '%S\2O#'C7XL:_XV\,> ?%G[  _9
M6UWPSX;M_$D46C32I\?O+_:FT_P^ZZ5X2M_$^GZ?##;6NO0P^([;]FO[0N_^
M?W_RU]:_^2*/[0N_^?W_ ,M?6O\ Y(H^KS[Q_P#)_P#Y /;P[2_\D_\ DS\-
M-6_X)/?'6[^"GPX^'"?&W3-?DLO!GQK\-?&/P#\0?'WQ.\5?"/QQXY^*G[.'
MAGX'Z#\</"5I:Z3H>H^$/$7@'7O"][X[T[P#?:9XBTG4];^)/Q%\47OC$?$>
M_@\<2^\_$O\ X)[?$[QWX;_X):^#KCQ7X U/0?V&7-I\791K7Q$\#:K\2=%N
M_P!EGQC^S#J=GX U/PJEUKOAB:\TWQSJ?BAKFY\0VEV7TVVT(7L<6HW.IV?Z
MI?VA=_\ /[_Y:^M?_)%']H7?_/[_ .6OK7_R11]7GWC_ .3_ /R >WAVE_Y)
M_P#)GX\:W_P2\\7^&OCZWQ$^ .J?"OX1_#GPSX__ ."?C_"SPGX>O?''AK4/
M!'P7_9!T[Q_HOQ!^&5I#X=T]-.CL_B=X;\;#PG!9?:;K3+C1+60^(S>2FVC@
M\=O_ /@E)^V'K_P\^)_A75_VKM%T/6_B3KWPA\?0WO@36/B#9:%X5^(O@/X3
M_$7X5^+)I=$^(-G\2[/X@^ O&XU?P-XP\1>'_'%M>^//$?B2PU?6+_XJV'C;
M2O#/C^+]Z?[0N_\ G]_\M?6O_DBC^T+O_G]_\M?6O_DBCZO/O'_R?_Y /;P[
M2_\ )/\ Y,^ /V</V*OB=\(_VF_B]\?/B;\</%/Q:N?&OB/Q=J/A"Z/C'Q)H
M&GZ5X-\;>'/AE:/\-/$7PJ-AJ/AS5-)^'7B+P%>W/PLUQO&EV?#.A^(-3M+/
MP[8ZUKOBW7?$7JG[,_P!^)GPC^./[</Q*\<:KX&U'P]^TW\>/"?Q9\"6?A>\
M\0W&M^'=%\,? KX6?!$:+XM76=*L;&34;F'X5V?B-)]%N)[2W;7KC1MDD>DP
MZEJ7U7_:%W_S^_\ EKZU_P#)%']H7?\ S^_^6OK7_P D4?5Y]X_^3_\ R >W
MAVE_Y)_\F:5__P ?&D?]A)O_ $VZC6E7,_:P\UG)>7K^7;W:2)C0M3LD:66&
M>S1)9[AI8XT9KH'<VP!E4%@I-,\;V7BO4O"6OV'@;6;#P]XNNM.FBT#6M3LO
M[1L-.U!L>5/<VF'$J!0R!C%.L+LL[6UTL9MY54@XJE%M+22<FI**O4ONXW=D
MTY63MYL7M+1KU(PG4<8\ZI4^1U:CA2;4()SC'GFX\L%*<(N35Y15VORR^*_A
MSX9_%OXE>,?B#?ZCX@\*?:?VD_ /[/::7:VVD3W/C+XI?#&\TL>$M;OO#&HJ
MEND5HNN^+-#L/%%WK%I=GP+JT^IC2KVW?PXL?)#X<?!7X\?#O3?#%IXS^)FA
MZ38_%+X5_LMV^I66@^%=(\2Q^,/@?H?BW5VUB?43XGO9;SPYK)\8:G8>(;NW
M:6XU.2PTB?2+9M'C@GG^W9_@S\=[RS^)&HS>//AVOB[6_'=AJO@&^O/ VCZG
M;Z9X%M5-JGASQE=2Z&EWX@UFTTY[<0ZU'&+F6^T/3&>[6QEEM8,VR^!_QOA\
M50:E>:_\)[WPP^L:KJ&HZ$?!>CQ:B = DM/#3Z+KT7A>.:T72]:DLQJ<>HVF
MH:E<^'-!T[3K#6K?[9?V]=RQ"C%*-;E=-+V=JEU&T8:)2H/FO9).3WBXV44K
M_FU7(*]>M7G7R>5:&92J_P!H*67QC*NJV*Q5IU94<[A[!03E5J4Z$$Y4L12K
M<TZLZL8_*FJ^)_A7XR^&VE:3_P )7XN\+Z5\,_A+XEO$U6YT?P!H4EUX#%KX
MI_9P\10:U-J'B1=&\8^(?B)<Q16FDQKJ$4%MK&B:-J6GW-O/J=CI\_Z:?!CQ
M'#XM^&'@OQ%:_;?L&K>']*O=+74;&VTS4$TFXL+:;2UOK"UOM0CM;LV#V[SQ
M&Y+>8Y956)H\_-:_ CX^PK(MCXR^$UE;/H/AW2DTQ?ASX>DL;+5[;1WE\6:_
M9I#X9LV:Q\2^+(4,_A>5X[1?"NIW*65_I7B'2M/O9?8/@WX%^+/@QK"#QMXE
M\+:AHY\/SK?Z)X<T^'3[33?%HO;2..?06M-"T9;CPS<Z-&T?V35($U/3-2M/
M-M[B[LM4:VTK"O*G.%HSBVIN27.Y.TE)R2_=1U<G>[E;=):W7MY%A\PPF.4L
M1@J\85L)3PU2K'!PP\$Z,Z4:$YR_M3%)4J5"FJ2IPHJJ[1JU)R=-1?T'1117
M$?:A1110 45Y9\<]>\2^%/@M\6O%7@V_M-,\6>%_AOXU\2^&[Z_TY-6L8-;T
M#P[J.KZ:;[3'FMA?6;W=G%%=6PN;=Y8'D6*>&0I(OY-_LY_ML?M7>(/"'P-\
M>_&_24M/AY\>--_8LN/AKXQ\/_!^SM[WXA?%#XV_!CQ1\1/C'\(=$TJ^^*NE
MQZ/X#L-1T[PW!X"^,^LPPP65_JM[X<O-.\8QVY\0VFL*4IQ<HN-D[6;LV^7F
MT771-V3OHWLFR)346HM/57NE=)7MJ^FMNG5=['[;T5^<-E_P4^^ FH^$M \:
MV7A3XK7&B^(/@M\1?V@%2/1_![:EHOPT^"UAX?N_CA=^(M/'C@RZ5XC^#]_X
MJT#PSXT\&[I_$Y\6WTF@Z!IFN7.GZFUE>U3_ (*/_"GPYX(^.7Q.\1>"O'4'
MP[^#'CS6/"$/B71I/"FKKXYTO0/@AX;^/6I^*=%M9_$6E?V7')X+\1VS:-X:
MUJXM?%&O7KV>G:7ID^L3W^DZ2>QJ_P DMTNF[?*DM=7=-6\K[:A[2'\RV;Z[
M)7;VVLS]$**^5_V>OC)XK^*7Q%_:F\/:[)HL_ASX5?%CP+X=^'5QI>D7FD7\
MW@SQK^SU\'/B_;CQ&+O5-2%]K4&I_$34K=KVWCTN%[&*RB;3+>>*9Y?JBLY1
M<79[V3^]*2_!J_G=%)IJZVU7W-I_BCSW4OASI6I_$?PY\2YKW4(]6\-:+J.B
M6EA&;;^SIX-1%TLDUP&MVNO.C%W,$$5S'$2(RZ,4Y*\W\3^(]=M?VE/AKX9M
M]6OX= U/P5XBOK_2([F5-/N[NU35S#//:AA#+*AB@9)9$:2,P1B-D4R"0KW,
MYP^/H8?AZ6-QBQ5/$Y!A\1ET$FOJ67RQ^;4Z>#=X0YG#$4<76YDYIK$)<[::
MC\3P?C\CQV/X_IY-E,LKQ&6\>YAEW$%:4H26=9_2R#A#$XG.8*%:JXPKY?C<
MGP2C4C0J)Y9)NA&,H3J_E;_P6<_X\/ 7_7C:_P#IZO:_G[K^@3_@LY_QX> O
M^O&V_P#3U>U_/UD>H_,5_JQ]&3_DR_"/^#,?_5EC#_G\^F]_RD_XI_\ 8SRK
M_P!9OAX6CKUI,CU'YBC(]1^8K][/Y1'$D[=Q9MJ"-=S%MD:_=C7).V-<G:BX
M5<G &:2DR/4?F*,CU'YB@;;;NVV^[;;[;MM].Y^\_P#P2E^&_P#PF^CV_B+^
MU_[._P"%<:YH.O?9/L7VK^UA?ZAXPA-L)OM,'V(Q'3U_>F.Z#K.P$2LBN/W
M^*'Q(\)?!WX;>/OBSX]U!]*\$_#3P=XD\=^+-1BMY;R>T\/>%-(N];U::ULK
M=6N;Z\%E93"SL+5)+J^NC#:6T<D\T:-^#/\ P3"\:^(_"\/A'1M$OUM-.\:>
M+-)TGQ% ;6TN/MUC:7OBB2"$2W$$LML$-Y<G?:/;RL[H6D98PA_;CXV_"_5_
MB[HOACPG#XD@T'PG#XW\,>)/'EDEKJ_]K>*-"\+:K;:_9>'=(UK1]>T2Y\.2
M3Z]I^EW]WJ)74X[FVT]M)N-/EL=0O ?\G/I04LPCXJ9C/&XBE4P%:,I932II
M*IAL+"I1IXVG6:I1;G6S&-:M3;G6M3G%*4(KV:_Z!?H 8CA^KX"X*CE&!Q.'
MSK"8ZE3XJQ59R=#,LQK8/$XC)Z^#4L56C&EA>'9X3!5U"A@T\32J.5*M-O%3
MZWP-\2_!'Q&\ ^ ?B=X3\0Z?J'@KXG>'O#'BCP/K+W$5O#KVD^,=*M=:\.O9
MB9T,ESJ6GW<,L-FNZY+%H_++HP&98_%SPCK?B+2-!\*37/C:UO\ 5/&N@ZQX
MK\&MIWB'PAX'\0^ UM1K/AWQUK=CJ+KX=UV:YN)=/T_3)H)KJ74-/U&UNDLW
MM6W?FW\*O^"7]Y\.]$^%_@?7OBCX.^)_PH^$EG\>O _@WX3^/_A?K&O>#])^
M$7QI^)7A?XG^'=!MOMGQ+FU*/XA?!/4/"UMX0\ _$R*[@O;KX?7=SX>OM'L[
MI+?58G^._P#@F!>^*H?$VG:7\6?"VC:;XAC_ &_8&G?X3E]8:']NVXGU*\;5
M+C2O'&CV6IW/PDU2ZE;PY,+&U.N6=O8QRC0[N&2\E_GGDH<S7M7:[L^5V2;=
MKZ7NH\K?1N_0_MWFJV7[O6VJYEO9;=+-W7=*W5GZMVNN:)?2Q0V6L:7>37!O
M%@BM=0M+B69M.>.+4!%'%,[R&QEEBCO @8VSRQI/L9U!\H\:_M ?#;P#X]^$
M?P\\0ZE=)JOQIUCQYH'A#5K.V2[\+VFL?#CPAJ7CCQ'I_B;Q DZV7A^Y&A:/
MJ;V$=Z=UY>65Q9@),A%?!5K_ ,$TM0L/' \;:9\3O!6C74?Q;^&OQ2LXM'^%
M%[ITMBO@G]E;5OV8/$'AF.XT_P"(=DTNE>.H-47QYKJ*+>"YU*U31M0M=31H
M]7@Q_"__  2\UKPS%I5W<_&OPEXPU/2_'VJ?$J31O%OP-TZ[^'VJ>(_%_P"R
M'I/[)'CRQU'P=9>.+*T'A+5-+T>V\?Z'X:TV73H-'U:2Y\/7MUK6FW+WP%"A
MUJMJVW*T[M/K9K1V]=5IN#E4Z4[:[W3TOVNGJK^GX'WY^TY^T;X$_9-^"OC#
MX^_$_3?&&H?#WP"FF7?B^?P/H'_"3ZUHNCZCJMGI$FOR:''>6E[>:1I,]];W
M&LR:<MY=V.G"XU$V<EI:74L/ >(OVV?@KHGQ=MO@GI?_  EWCCQG=?LZ:W^U
M-'-X&T*#7/#S?"/1[_3]-BU"'7)-3L;6^UO6[K5M+.B:!I@O;^YLM2L=5NEL
MM*N8[UN"\._L/-X%^$G@?X4>&_C'X[\8Z3X:\-_ [P+KNF_&_4M9^)?@G7O!
M7P@_X1:+5;33_ R:YH.G>']=^(%AX633=9U:.[U"SMK?6=69](U%9$@KQ#X7
M?\$Q;[X(:_\ "F\^'/QK74]"^$_[-/Q\_9JTRT^)'@_5O%'B;6?#/QD\8^%?
M$'A=]4\56'CS1&72O@WX7^'G@#X:^"]#BTDRW'A'1)UN]7M[Z:WFM7&-"SO-
MN2<[.THJ2M'DNK2<6FI=6I*2^'D?,-U;JT4D^6^S:>O-K=)W5NFC77FT]X\(
M_P#!1C]G+Q'X.\ ^/]>N/&WPS\(_%;X%>*?VCOAAK?Q#\,+8V/C[X5^!O"2>
M/?&NH^'[CP[J7B:%O$7A;P3+#XKU3P1J4FG^,G\/M/JVG:'?V6G:K-8?2OP?
M^,GAKXU^'[OQ)X6TSQ%I^F6UQIB6UQKEE8"QURPUKP[HWBG1]>\,:[H6J:[X
M9\3Z#J&D:[9[=2T'6]0CL]3AU+1-36QUG2]0L+?X&^&O_!./Q3X7\!_LF^"?
M%WQSTC67_8D^"?CKX8? C5O#7PH@TFWG\:^,?A)<_!*R^*_Q&\.^*?&7C?2?
M%4WACP'J&L6UEX"A.G>&]7U77=5O]=N+VT.G:7I_T;^R+^Q[X._9*M_B>G@F
M/PWX=T_XJ>)-%\6:G\.OAGX>O_ OP7\):_I>@Q:'JNJ?#OX<WGB+Q/;>#)O&
M<D,>K^*+/2-0@TF:\AL(K:P22RFOM14U049<DI.2?N[N+7/-=5%W<.23;T4N
M:-MF$'5;7,DE;79._+'LVOBYDK:V2=S[&HHHK U"O!OV@_VAO!W[-WAOP=XI
M\;:+XOUK3_'/Q3^'7P=T2'P=INEZG>+XT^*OB6R\'^"H;^/5=;T."TTW4?$F
MI:?ID^I&Y>#3WNX[F^$%DD]S#[S7R7^V-^S3J'[4_P // W@*S\4>'?"]OX1
M^.7P8^,]\_B;P=<^-M,\0)\&O'NC_$&T\(W.DP>)?#*16'BF_P!$MM&U>^GN
M+X6VD7=\T&G3W1@:.H<KG%3=H7]YZ[6?9-[VZ$SYE%\NLK:+SNN]NES@H/\
M@HO^SRT_P>CU"+XA:#;_ !E_:"\<?LKZ5J6N>$DLM+\)?'OP'XAU/PEJ7P_\
M;7RZI-#8SZOXHTJ?0/"^OZ$?$7A3Q!J<]E!8ZZRW<+MO1?MT?"_5?%'Q]\*^
M#_!7Q:\>7/[-'B__ (0KXMZGX7\,:$-%T/58/AWJ/Q*U.XM[[Q!XKT%KW2]'
MT:PBTN[OE@C6[\2:GIVCZ*FK227,MK\R:A_P2X36_A%XU^"6L?%^W7P-X_\
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M6I>)_#=AJGA[0-(^)&M6%]I/@?5-?U/3+#Q/J-G<V>D7%W/$\8]UK\3? /\
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M?$/@.S\1.OAN.R\$WVOZQI,.@>$(]5N8H->U+6-&T8S6_B/4;71Y.@\!?\%
M_@!?^$?!U]XY^)OA@^(_$'A3PIXVU&]\"^$_BU>> K#PI\0?BGJGP@\">)9=
M>\2>!='N-(T76O'EBOA&>X\10Z9-IVOI>-?0VVD0?VE4X7/LZP."KY?AI4(8
M3$^T=:G++<LQ%27MZ2IU.7$XK*\5C*5Z<5&U'&4'2E[U-4JK<WOFO _"V=YQ
M@,_S+#XZMFN6?5E@J]'B'BC+J%+ZEBGB\/[3+<JXHRK)\7R8B3G)X_)\?]8I
MVHXEXK"I8:/T9X\^'OB3QI;V$&G^-_&_@9K)[EY)O"_B7RI+_P"T?9MBW;-;
MP2$6HMW$ 679_I5QYD;MY31YO@3X6^*?!=[=WE_\2/B'XXCN;5[9;'Q/XF\V
MTMG::VE6[A_<W$@N(U@>%-K1IY5U/YBR-Y31>;>,?VYO@#X1F\4Z='J7B[Q3
MX@\'>(?A1X?UGPSX5\"^)KW6R?C/\6KWX'^!=;TV*^T_3;35_#=_\3-)UOPW
M-K.F7EU;I<:1<20"YBN])?4</3?VZ?@CH]AXLNOB'\1?"MO)X?\ %7QX:=?"
M&@_$G4/^$3^&?P(\<V?@CQOXS^)5MJ_A#3[_ ,(V?@#5M6T;1?B-XCNK5?!.
MEZ[>/'I.O:EIUO<7L*AGV<PRV64PE067S4E*B\MRR55JI4565L9+*YYBKS49
M)QS"#BK0A*,&Z;*O _"U;B2GQ95P^.EG]&5*4,7'B+BBGA(RH86I@Z3EDM+B
MBEPW/EP]2I!QJ<.U8U)M5ZT:N)A#%4_6O&_PC\5^,-975K'XI?$KP9"+."U.
MC^&_%!BTXO TK-=[=EN?/G$@$I97)\M?G*A43IO O@7Q%X,TRZTZ_P#%_C'Q
MQ+<Z@U]'J7BCQ)YEY9Q-:6=K_9]L8[61OL@DM9+S]]-*_P!IO+C:4B\M%XGP
M=^UU^S]X]^(</PN\*^.I-1\877BKXC>!;&UG\+>,-*TS4O&OPDL]+U+XB^%M
M*U_6- L-#U/6/#&E:SIVKW$%A?W$=]I4TVH:3-?VME?26WTG4U^(<WK9?2RF
MO4P[P-)4O94?[-RRE52HRE*E?&4LKHYA.TIRNZF/J.I=1JNK&,8QK!<"\,8'
MB#%<4X3#8Z&>8QXIXG%3XAXHQ.%E+&0HPQ/)D^+XHQG#U#GAAZ2@L-P_AEAW
M&4L*L+.K6G6^7]9^!7C/5M6U'4X?C?\ %[28K^_O;V/2[#Q2J6.G17=W-<Q:
M?9K&MNHM+".5+.TS")/LT$1F:2;S)']7T[PMKEAX9B\/2:[XEU"ZCTV?3SXF
MN_$>[7'DF25%U%G-D\1O+<R*\!D\T;HH_-:4[V;TFBC&<2YMCZ.%P^*JX:I1
MP<J<\/&&6Y5AW"5*$*=-RJ83*L)6KI0IP3CB:V)C-IRJ0J3E.<UE' /"^0X[
M,\RRO"9A0QF<4\12S"I7XBXKS*G6IXK$UL775+"9QQ5F^!P+EB,15G&>68'+
M:E&$HT,/4P^&I4<-1^4E_9_\;).9O^%]_&<C<["+_A*P57<&V@"7SHSY9(*B
M6&6,E1OC=<J?8/%WA/7O%.@W>BV>O^)O"=Q=26DB:[X?\1F/5+46MW#<O% S
MVB 1W:1-:W&UXW,$K[7!Z^FT56+XHSG&U\'B<36PM2O@)^TPDX99E%"-.?-"
M5YTL+E&%H8E<U.#Y,70Q<-&N2TIJ>.4^'/"61X#-\LRS!9E0P6>X=87-*5;B
M?C',:E>@J-:@HT,9FW&&:X_+I>RQ%6/MLHQ^48ARE&H\0ZU*C6H_-GA;X*^,
M/#>O:=K5W\8OBKXFM[&66270]:\4[],U!9+:>W6*\4K<$QQO,ERNV/?YL$>U
MT^\.J\>_#KQ+XUBTZ/3_ !UXY\"FP-V97\+>)?*;43<FT,?VTM;P2G[&+61;
M8)+Y>+VY,D;L(6C]IHIU>*,YK8_#YG5K866-PM-TJ%597D].G"#]I=2PE+**
M6!JO][/WZ^!KU%=6J+EAR&%\.>$L'D./X9P^#S*&2YG7CB<;AI\3\8U\35K1
M>&<94\WQ7&&)S[!Q3PF'_=8#/<!0?))2H25?$K$^%> _A?XH\%W=Y<ZA\1OB
M#XY2[M_(2T\4>)C+;6C>;#(+FWQ#<2+.!$T0*M&ACFEWK(WEF.AXU^$7BSQ?
MK)U:Q^*?Q+\&PFWAM_['\.>*#'IP:%2&N%7R[=O-F)W2EE=BV3O*[$C^A**4
M>*,YCF,\UC6PJQ]2E["5;^S,H=-TN6,>58.642R^+Y8Q7M(8"%72_M>9MLGX
M<\)5.'J/"L\%F3R.ABWCZ6%7$_&,,5'%.K4K.I+.8<80XAJ0]I6J/ZM6X@K8
M-)J"PBI0ITZ?DG@;P/XB\&Z5<Z9?^+?&'C>6>_:]34_$_B027UK$UI9VO]GV
M[16CM]C62UDO1YTTTGVF]N<,L(ABC\XU;X$>--3U74=2B^./Q?TR*_U"^OHM
M,LO%2K9:=%>7D]U%IUFL26R"SL(Y4LK3,*R?9H(O.,DN^1_J*BGA^*<YPN,Q
M>/H5L+#%8[E^M5)97D]:%3E:DN3#U\GKX3#ZQ3?U3"86]K2YDVF9AX<\)9ID
M^4Y#CL%F57*\C4EEE"EQ/QC@Z]!2ISI2]MF67\89?G&87IU)K_A6S?-6FU.+
MC4C"I#S6Q\*Z[9^%H_#;Z[XEO+N/2)=+_P"$HN?$>[77FEMY(%U<NUE)"=0A
M:03PF3S5$L<?FM+AF;Q^+X ^-HKH7!^/'QED59&D%NWBL&+DDJF)#+&50D;1
M)%*AV@/&ZY4_55%+!<3YQE[Q<L)6PM-XZK*MBN?+,HQ/M*DO:7<%C,HQ:H)^
MUG^[PJPM)<RM27+#D><>'?">?QRF&:X/,:\<DPT,'EBH<3<7Y8Z&'I_5>2%:
M63\79/+,)KZEAKU\VEFN*ER3Y\3/ZQBOK7F/B_PCKOBK0KG1;/Q!XG\)3W$U
MM*NM^'O$C1ZG;K;SI,T,3O:QXBN54P3!98V,;'YF&Y'\[\*_!;Q?X:U[3]:N
M_C#\5?$]O8R3O+H6M^*1)I>HB6SNK58KQ6CN6\N&6XCO$\I$D^T6L(\Q4WAO
MI*BHPO$>:X+!5\NPU7#0P>)]K[:E/+LKKSE[>FJ57EQ.*RO$XVES022]CC*/
MLW[]+V51N;WS/@/AG.,[P/$68X7'ULWRWZH\'B*7$/%. P]/ZC7GB<-[3*\L
MXHRS),7R5JDY3^O9+COK$6J.+^MT(PH0\4\>_#GQ-XV73%T_QYXZ\"#3A?>;
M_P (KXE$7]IF[:Q,37S-;P2EK$6DJVH2;R]M_=>;&["!HJW@/X8^)_!5Q?3Z
MA\1/B!XY6\@6%+;Q1XF,L%DRR*_GVP$-PXE8 QG#1KL=MXD/EF/W2BDN(\UC
MEKRA5<,LO::='^SLK=5J57VS_P!M>6/,5>K[UUF*:7N)JE^Z"? G#-3B2'%L
M\+CWG\)0E'%KB'BF.%3IX26!@WDD.*(<-RMA9RIM3X<G&<VL1.,\7&.+C\\^
M-/A#XL\6ZR^K6/Q5^)G@^%X881H_AWQ1Y>FQF*-4,L:A+=M\S*992ZNYD=L2
M>7L1.N\$>"?$/@_29=+O_%?B[QK+)?/>)JGB;Q&)+Z"-[6TMQ8Q/':2,;1)+
M:2[4332O]HO+G#+%Y44?K%%%?B/-<3E]+*ZU7#2P-#V7LJ4<NRNE4C[%R=.^
M+HY91Q]3EYY7]KCZKJ7M5=5**B8'@3AG+L_Q?$^#PN/IYWCGBWBL54XAXIQ6
M&F\=['ZUR9/CN*,=D&']I["ER+"9#A%A^67U183VE;VWRWJGP'\::CJ>H:C%
M\<?C!IL5]?WM[%IMGXJ"V=A%=74UQ'86H00*+6SCD6UMQY2'R(H]P+98^L6W
MA37K?PFGAEM?\37%ZFAOH_\ PE<WB,-K[7#V;VHULN]C) =3CD87<;.LB?:$
M0R&3YBWIE%7C.)LWQ]/"T<75PU2G@JE.IAHPRW*<.X3I0ITX.<\)E.$J5TH4
M::<,54Q-.;3E4IU)SJ2J1D_A_P +9#BLTQF583,*&(SFC7H9C.OQ'Q9F4*U+
M$U\3B:T:-#..*\XPN E*MB\1*-3*\-EE:E&<*5"M0H4,-0PWRO;? /QK;WL=
MVWQV^,<\<<WG?9)/%6Z!U#%A$PD,J%!P,212H0!OC=<J?6?&'A'7O%6ASZ/9
M^(?$_A&>::"9=:\/>)&CU*$0OO:&-GM8\13CY90LB,0!DLFZ-_3Z*>*XHSC&
MXC!XO$UL+/$8"7/A9QRS**$:<N:,KSHX;*,-A\0N:,7RXO#XN.EN6SDI8Y7X
M<<)9+EN;Y3EV"S*C@,]HK#YI2K<3\8X^K7I1I5*"C0QN:<89IF6725*I./M<
MHS'*:SDU4E6E5A3JP^;_  G\&/&'AG7]/UN[^,'Q3\46]B]PTN@ZYXH672M1
M6>QN[-8[U7BNFV6\MS'?Q&%8Y?M5G;@RB$RQR=%X^^&WB?QLVEG3OB!X]\"+
MIJ7R31^%?$HB35&O'L6BEOBUM!-YE@+25+4)-Y12_NC+$[B%X_;J*=3BG.:N
M84,TJ5L*\=AZ4J-&JLKR>%.-.2J)J6$IY/3P%5VJU+5*V!K58W7+5BX4W3>'
M\.>$L+D&-X8H8/,HY)F&)CB\7AI<3\8UL34Q$98::G3SC$<88C/\+%2PF'?L
M,%GV"PS4)QEAI1KXF.)\-\!?#+Q/X*FU";4/B%X_\=+?0PQ1P>*?$QEAL#%(
M[M-:@0W#K+*&$;D-&I1<,'.PQY/C+X/^+?%FM3:O9?%?XF^$()8X8UT;P]XH
M\K38/)@AA9XE$=LVZ9XWN)3(LCF::7$GE^7'']$440XHSF&8U,UC6PJQ]6DJ
M-2L\LRB5-TU&$5%8.>42P$'RPBO:4\!3JNS;JMRDY%7PYX2K</X;A:I@LRED
M>$Q;QU#"QXGXQIXF&)E4KU7.6<4N,*7$%>#GB*S^KXGB#$81*48+"*G2H4Z'
ME/@KP7X@\(Z0^E7WBCQ9XSE:\DNUU7Q+XD,E_'');VL/V-'CM9&-LCV\ER@D
MED<37=P RQ>5''YAJ/P&\:7^I7VH1_'+XP:?%>7UU>1Z=:>*R+2RCN;F2=+*
MV"F("VM4D%O"!'&!%&@V+T'U+11AN*,YPF*Q>-P];"PQ./:>*G+*\GK0J-2Y
MER4,1E&(PN'][6V$PN$3V::T#,O#GA+-LJRG),?@LRJY9D<)0RRA2XGXQP5:
MA&5)T9*MF&6\89=FN8MTVX\V;YKFTT_WD9QJI55YG%X3UZ+PBOA<^(/$\EZ/
M#[:(?%S^(HSXB-TU@;+_ (2#<VGM:_VLLI^WH6C:$72KN#)D'R6S^ GC2UOX
M+U_CI\8KJ.&X6<V4WBK-M,JOO\B17,JF)L;"'CD4KPR.N5/U-14X/B;., L6
ML+6PM-8ZK.MBN?+,IQ'M*E15%-P>+RG%O#IJM42IX1X6E'F3A2@X4W3O.?#W
MA7/Y95/-<'F.(EDF'IX7+70XEXNRQ4*%&>$J4X5HY-Q;D\<PDIX+#-ULUCFN
M(FH3C4Q%2&(Q<,5Y1XU\):OXJTF'08O$WBKP9+?7\)CUSPYK[MJ$3VT-S=K"
M<P0.L$OD$LT4J.)4AW;H3*IYSP/\&?$7A#Q'8:[?_&GXF^+K6S^U>;H'B+5C
M=Z3?BXL+NS1;N&62;(MI;F._A:(1R+=V=N?,\KS8Y/:+_P#X^='_ .PD_P#Z
M:M3K\0/^"K?Q&^+_ (?^/O[*7P]^''QN^)'P=TCX@>'OBJFMOX!\7S^%VUC5
MM)M])O/#=K,&N;;3;K4]0U-(?#VDF_8*+C6O)B823*#]#P=#.N(<3'A/ YE@
M,LPF88/-\5B:N+RG!XZ,*6$P57$XJU595B<UC*IA\.X4UA<;1=.:YZ;HOFF?
M.\>Y7PIDTZ7B!FV3YOFV;9/C,@PN!A@>)^(,JA*M5S&-#+^?+Z/%&7<-5XT<
M7C'.L\QR3&+$TY*EBEBX1HTH?KW\2_AOK/C^31WTKXE^-OA^NEQ7\<\7A&_^
MPQZJUX]D\4M^4:.622Q%I)':@2>6J7MSN1F*,K/AK\-=9\ SZM+JGQ,\;^/T
MU*&TBA@\7:@U]%IK6LEP[S66^25HY+D3K'/M90ZP1;@Q52O\P,?B']J)[?1]
M/LOVPOVK_$VNZCH7B0ZWJWAOXR^'CX6\$?$OPG\-YO$=Y\&]:M+K5I-:U3QG
MK7C&SO=(TR6QGLK&WT=K 1'6K\ZE=66C\#?B;^UEX8_:$_88M?&O[6GQ0\=0
M?%7XF:+I7Q8^',WQ8;Q%9^#]8-_8ZG!X!\5:98:_J<CM?^#=<T2^U2VUJWM#
M'K<>NZ1'%-'I8GD_1:GAKGL,BQ>5T^->'JN P^$Q^(C@?]6Z]+%XB&!PV8YS
M4C#'5,JGF-)5?[,KQI5L5C\-&4ZF&HKFHXG#TJ_YI3XYX0J<883BJKP%Q52S
MW$XS+J$LR_UVQ=3+L/4Q]7+>':4JF14^*8<.5G2I9K0=6AA>'L5)*GB<7+EQ
MF%Q.+P_])_CKX.>(?&/B&ZUS3_C-\2_!UM<);+'H7AS56L]*M/(M+>V<V\,4
MD.#<20/=S-())#<7,Q\SR_+CC]!\ ^$K_P %Z#_8VI>+_$7C:X^V370UGQ/<
M_:]26.6*WC%H)B6<V\;0O,@D>1EEN)@K+'LC3\@I_P#@H_\ $SP3\3_#VE^,
M['1?$7@O4_VC?VP?@M%%X;T?1X+K6$^%OQF^&/PD^$AEU*W\8:OJ?A>P\/R^
M/)]6^+'BO5?"\EHUG9B^TW3+*#R+>]WOB-_P53>TO;#0/!OP_M_#OC/2?$'A
M>X\1>%?&OB+P[JMYJ-@E]9Z-X_\ AG++X8U6[@\-_$31-4U[1A#<Z?/XQMK.
MVCEN=2TV-KB"QE_$L3G^:8S+J&58BO0G@<-[%4:4,NRJC5C[!2C2YL9A\KP^
M/J\JD^;VV.JNI>]5U6DU^ZY=P-PUE7$&-XHP.$QU/.LP>,>+Q%7B'BK&X6;Q
M\Z53%>SR?,.*,?D.%YYT:;IK!Y'@UADI1PBPD*E6%3[^U/X >*M0U2^U&+]H
M'XOV$5Y?7%VFGVFN2QV=HD\[S+:6\:7$:);PJXAB1$15C5555  'M0\-7P\#
M?\(A_P )5KYU+_A%SX>_X34RV_\ PDYO?[+_ +._X28S^3]E_MOSO^)GYOV?
MR/MWS>3L^2O@;]ES]N/6OC)\4I_AUXN\/^&4A\7%=3\ Z[X+\0V>L6&DMI7[
M.'[+OQD\7^"]>#.EUJ=WIFM?'C6++2/$MO;Z<;VUT&?3KW0+6?39M5O_ -)J
MTQW$>;YC#!4\77P]2&7U:=;"*GEF3X9PJ4HTH0=26$RC"2Q,5&A33IXN6*I3
M:DZE*I*I4E4RR7@#A7AZMFU?*<%F%"KGF'K87,WB.)>+\SC6H8BKBZU6-"GG
M/%N<4LNG*IC<2XULJI97B*49PIT:]*EA\+3POS/IW[/_ (JL-3LM0D_:"^+]
M]%:7D%V]A=:Y)):720S+*UK/%)/(CP2JIBD1T=61BK*RDJ?8_'OA._\ &>@-
MHNG>+O$/@JX:[AN?[9\,W/V34]D4<R&U\X%76"5I4E<1NC,\$08M'O1^UHIX
MOB7.,=B\%CL3B,//$Y=)RPDX97DU"%-N2FW4H8;)\-AL2N9)VQ>&Q:6R25T\
M\K\.^$LFRK.<DR[ YC2RW/Z<:6:4JW%'&6/KUJ<:3H16'S#,^,,RS3+6J3:<
M\HS/*:CE^\E4E52JKP?P+\&_$7@_Q%9ZY?\ QG^)?C"UM5N5DT+Q'JK7FE7G
MVBSN;5/M,,LDV?L\EPEY"T821;FU@/F>7YD<G0?$KX:ZSX^FTF72_B9XW\ +
MID-Y%-#X1U!K&/4VNI+5TFOMDD3226HMWC@RS*J7$V "Q)]8HHJ<2YS5S.CF
M\\1AWF%"BZ%*JLKR:-*-*2J1<98.&3PR^I*U6:52K@*M57355.,' H>'?"6'
MX<Q?"E' YC'(L=BXX[$X:7%'&57%SQ,9X>HIT\YK<85N(,/3Y\+0;P^%S_"X
M5J,X/"N%;$0K^0_#3X67W@"]UC4-3^('BOQ]=ZK:V-G'<>+98+RYTZ&SENI7
M2SO"KW@2\:XB%S"UP8&^Q6K+$'CW'$\<_!GQ%XO\1WVNV'QI^)GA"UNQ:B+0
M?#NJM9Z38BWL;6T<6L,4D.!<2V\E],THDD:ZN[@^9Y7E1Q^\T44^)<XI9E7S
M>GB,,L?B*2H5JKRO)ITI4TJ:2C@YY//+Z<K4H7J4<!2JNS<JK<YN97\/.$\3
MP[@^%*V!S&61X#%/&X7#1XHXRI8N&(E/$U'.IG-#C"CQ!B8<^+KM8?%Y_B\*
ME*$8X90HX>&'XSP'X4O_  9H":+J/BSQ!XTN$N9KC^VO$US]KU-DE6)5MC,2
MSM#$8V>,.[LK2R!2L>Q$\9U#]G_Q5>ZE=7\?[07Q?LXKF[EN5L+;7)([6W22
M4R"WACCGC1(4!V*B(B*HPB(H"CZ9HHPG$F<8'%XW'8;$8>&)S&7-BYSRO)J\
M*DE)SO3H8G)\3AL,N9MVPF&PD>CBTDD9KX=\)9UE639+F.!S&KEV04I4<KI4
M>*.,L!7HTY48T)+$8_+.,,MS/,I.E&*53-\RS:JI)U(U8U7*K+*T339=(T;1
M]+N=2O=:NM+TNPTZ?6M3:-]3U66SM8;>;4K^2)(XVO;^2(W5VT:)&T\CLJ*N
M "M6BO%J5)U:E2K4:<ZM2=2;48P3G4G.I-J%.,*<$YU)M0ITZ=.":C"G"$80
MA]C1HT\/1HX>DG&E0HTJ%*,IU*LE2H4J5"FI5:U2K6JR5.C34JE:M5K5))U*
MM6K5G4JU/RL_;@_Y.S_8B_[!W[0O_J+>%JZ.N<_;@_Y.S_8B_P"P=^T+_P"H
MMX6KHZ@U/@;]IW]K#XY_L_>.-.T;2/V=OA'KGPV\1-%IOA7XQ_%_]L[X>?LX
M>&=6\40>$=2\7:_H-W9^,O 6NPZ1_8=MI=Q;6T]]KL5SXEE2>31;"2&RO9+?
MZY^$WCAOB=\*OAG\29+&UTN3X@_#_P '^-9=-L+_ /M;3K";Q/X?T_69[/3-
M7\FW&LZ7;S7CQ:9K"V\$>K6"V^HQPQQW*H/CC_@H[9ZWJOPD\!:'%X<\;>*_
M NK_ !+"?$G1O 4W[(]EJS:9I?@_Q+KOA?4+_4_VU+2_^#VGZ)IOBK3+*:Z>
MUM'\93:@VE1Z+/!:KJ(F^I_V>=4O-<^ 7P1UK4;[7M3OM7^$_@#4[K4O%.I>
M%M9\37\M]X8TVY-WX@UCP*S^!]5UFX$BR:CJ7@MV\(WMTTESX;/]C265 'L%
M%%% '(_L.?\ )W'[;'_7K\%?_4:U"OT5^*W@KP9\0/"@\-^/M1NM/\-R:YH&
MJ7"VWB&?PW'J%[H.J6^M:5I]_=P7%M]NTV34K&UGO-%N'DL=6CM_L>H6UW8R
M7%M+^=7[#G_)W'[;'_7K\%?_ %&M0K[@_:F_9X\$_M8?L\_%[]GCX@6\$GAS
MXK>!M?\ "C:A):0WESX<U;4=/GCT#Q=I4<XV)K?A/6OL/B#1Y@5,>H:? 2=A
M=6TTO2NW%<L;R2NXKVE2[2TNTFW:^MK=49J]JEDF^:5D]$WRPLF^E]KGD>D?
ML2_LLI\0/$GQ \+V>KZ=X_UCXK/\?'U3PI\3O%.G77ACXDZYX!A^&>L>*_"V
MEZ/KT6G>%[?QG\,4T_P9XITO3]/@\/\ BW0;+2IM8TZ_U.QLM3B[G5?V/O@G
MJGC#_A.?[/\ %VG>(/\ A;6E?'8RZ5X^\865F_Q<T?X7#X,6WCF6P75WM9M7
MG^&H3PUJ"S1R66I*B:I>VD^M#^T3^;W@;P__ ,%$_"W@/]GWQ='\.?AY\,OC
MO\8]%\0>&?VJO'&G>"M+^()\%>(O@]X+T3P5^S_9W^@^'V74M4^%/Q%U#1O&
MOCWQ8GAX6VH>%;[QAI7A>R\2^$+&277K?KO$?Q=_X*<Z?K_Q)'@/X=WWC&]/
MC7]L[PY\,M!\7?#CP]X3\!R>'_!_PLT;Q'^RMXCO_$L&M0:Q"GBOXDIJO@Z;
M4-6UR*P\16=P[:EIOA@1VNMP[.%1O2O!V3C=U%LI.#UVY;QNKOX;2LN;6%*"
M6M*2UOI!]5S)VO>^MGIOITT^P-*_8 _9NT32]&T73-&\;6^E>'_!GP)^'VD6
M)^)?CF>"T\(_LT_$"Y^*7P3TD+<ZW,9AX)\=WEUKT%W.9;[5Y;B2TU^YU2P*
MVJMTW_@GO^RUI%S=ZCI_@SQ)#K5WK/@[Q*?$$GQ+^(]WKL?BGX=^-?'?Q!\
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M+QG<W'C'0M3^'EWXDL-(T77KFY?0_B?IVL:1J_A)?)6X,GSM^U!_P41_:/\
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M_P!BS>%=7\;^+-,UP_!**WUO0?AYXJFTBWO?VBO%'B3P'\(--N[N\L+%DO\
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MO1I*UTUJGJKIJ]TQ63_Y?RTOJ[?>M=GW6]FG:UC[?_M#5/\ GG+_ .""Z_\
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M^D:M>Z;JMQ#9O]I5,IJ-E+#QBWLFFO+^7N-0<M8UY->5G^IS7]H:I_SSE_\
M!!=?_+FC^T-4_P"><O\ X(+K_P"7-=+12]K#_GS3_K_MT?LY?\_9_A_F<U_:
M&J?\\Y?_  077_RYH_M#5/\ GG+_ .""Z_\ ES72T4>UA_SYI_U_VZ'LY?\
M/V?X?YG-?VAJG_/.7_P077_RYH_M#5/^><O_ ((+K_Y<UTM%'M8?\^:?]?\
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M=?\ RYH_M#5/^><O_@@NO_ES72T4>UA_SYI_U_VZ'LY?\_9_A_F<U_:&J?\
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MKX$^+=K\4)?C5_P65F\)ZAXAM=!/[._PQMO =KJ^D?&[4#<^)1\&O&3^*G^
MUSH&L:3I%AXIE\?S^$H=8F\!6^HZFOC"+09KHK?1&$RJ3G)IU(MJ%.7,GS+W
MI4X*+>EG%23:UTC;3=4YJ,4U!J\IJUK/W5.5[:Z/ET?]Y;[/]^**_GN\*2_'
M;PAXW_8.^,/P$B^+'C77= _9<_9N^#?[2?P;\03?$.STGQ!HGQ]L-?T"Z^,'
MB>P\76YTF/X@_ +XQ:1X"\4?$R\E;_A-K7X<Z_XOMM;EMH6L7;S_ ,&:M^TE
MJ7[!OQ'^ 'P<\=?%^W_:<G_:-_:\\:Z;\7O&TWC?1/$>I^$/@C\9/%?Q!^$_
MB'5O$?CC3,2>%/BO8:/\*_#::)IKV<6O?"'5/%]IX>MG?3;R$5]6VM4C;FC%
MW5N6\ZD9.2YFTH\D97UYE-6V8O;?W'LVK.][1C)*+M9M\S6MK.+ONC^E&N0^
M('AGP-XS\#^+?"OQ.T7PWXB^'>O^'M6TSQMHGC&TT^^\*ZEX8N;*9-:MO$-K
MJJOILND-8^<;[[:/LZ0*\DC*J;AY_P#LV_&6/]H+X%?"WXPGPUK_ ()U'QUX
M,T'6_$/@?Q5HNL>'O$?@CQ3=:=;OXF\'ZSI.NV=AJ5O?^&M;-]I$LDML(;O[
M(MY:2SVD\,\GL6I:;I^LZ=?Z1J]C::GI6JV=UIVIZ;?V\5W8ZAI]["]M>6-[
M:3I)!=6EU;RR07-O,CQ30R/'(C(S \[3C)IW3C*SL]4XNSLT]TUHT^S3V9K=
M-76J:NK[--=5\]5;NK'PY8?#+]@76-2BO+7Q3\-?$GB:VC\'7>C>([KX_:MX
MG\;^&8/AAHGB?4?"$O@OQ9?_ !$U'Q7X*M?#7AKQ+XOO1_PB6J:-!-H6LZ]<
M:H+K3[R^>3T*S_8H_97B@TYM%^%NFZ5I]I%\$I-)MO#/B;QCH6CVT7[/&NZI
MXN^",VGZ?H/B2QTR)? ?B;7=8\3:1+;VZB]UO5K[6-6;4KZZEN&_/CQ+^RS\
M0O%4W_!9B*Y_9[GE3]HO0K>']F:;5;7X;/%XLU>P_8QTK]G@W&AA?$MR_A.6
M3Q9;ZQIMM/XDC\./)X5OO[1=HK6^N+>/<FT;_@ICITJ>!/!>J^(O#?PRL/'?
MA73[?QWK/AOX0>+?B+X=\#7_ .RIH<4-WX?\.QZ]X>TSQ1X<\(_M56NK_P#"
M4:'JUQI_BF?PQ+IUGI-WJ?@I[YH.EQ;7NU[6Y;\]1)6E3C-VY6[N+DX-6W3M
M9W1C=+>DGO;EB]U*45>Z6C23O?9J^EF?=0_8=_96*11S?"'2KN)3JJ7,.H:[
MXNU&'5['6_BA??&O5]#\1PW_ (@N8_$_AG4/BQJ>H>/KKPMXB75/#LGB.\N+
MTZ9^\9*BOOV&?V7-3&N+J'PTGO%\26?QSL-<2X\>?$F1-0M/VF+RPO\ X]02
MH?&&U$^*-YI>GS^)_)$9F>TB^RFU 8-\J^)K/_@H9)J'QYGT77/B5J5SJ7Q?
M\+^!?@[I,&F?L[>$O V@_"Z_^#^BRZK\6TO)K;7_ !M+;:5\<X/$]GJ^AZGJ
MFM>)Y?!TGAV'3=/-I=:CXJLO$?A=\7O^"@?Q$^,?B3X:1>([^W^*WPAN/V%M
M5^)GA'6+#X/)\*?"&E?$7X-G5_VE_#GCZ\\+QW?B*_NM5\0Z=KNM_#V[\$:A
MJFHV6O3:#966H1^$8-;M4%"HTVJ\=%=_O):+W7=]E>25]N;3R#FA=+V3U=E[
MJUW7Y)NW;4_12]_80_9+U*X\1W>I?!G1=2NO%^D>-= \37&H:WXNOIM:T7XB
M>$_!G@CQIIM])=>(97DM->\.?#OP/:W,0*B&]\,:3KEG]FUVV&I&UXE_9/\
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MJ/V96$^:]I3Y[+?F<EK9V3?RU6YK&UKJ/+=O2R3TNM4@HHHJ"@HHHH ****
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MK\1?@C^T[^UI\!H/C9\$?BIX2\9?$?QOIW[1WPP\9:#\6=9T3Q/\0O"/@O\
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MSJ-[8:1XBTB3352U\0Z0B7-U:W%]9RL;2Y^7[:H Y']AS_D[C]MC_KU^"O\
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M[+1:Z]>NEQJQ:]YQ3[:O_P!M-.BLS^U(O^?34_\ P6WG_P :H_M2+_GTU/\
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M_BOP_IYU7]FG0-*NY/C]X1\._P!K:5J?@_Q)+XZ\/:9X/O!XBLI(?1/VR/\
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M7&CQZ1 ^N:EXSU&]\/>'-,L]0N->ENK?2M)T2VO[>WTBSM[N\U6>]OY;2Q]
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MU9?R*RUU=VTK7CK87-3_ ));J_\ $T3O_>WTVT3UL]#]U/[+'_00U3_P-?\
M^)H_LL?]!#5/_ U__B:_)3]LSX<?'GX]_LO_  *TO[7+I7[66@_$G5?BE\*/
MB#\)O!_Q2M?"&A?$7X5^'_B!XL^%,OC$ZQX>TS5?"O@OXC:AI?@+P;\0=.\:
MVVE^'[O4O%-[#IJ7-K8Z5<1?-^CZ[^V#X.^-?[9G[4FE?";QMHGQ3\4?LA?L
M<_&G_A!_''@[QCXK\&:'-X)UCXB:]^T1^RS\-/%+Q:-X-?XEZ7\*+OP78B?P
MWJ;V>K_%IK'4]3T_5H+;5;2S(QG*-_;14O>7*U#5J<(QL^76,E)OFY='&W*[
MW3;@G;V<FM'=.>SC*3TYMU9*U]4[WTL_W[_LL?\ 00U3_P #7_\ B:/[+'_0
M0U3_ ,#7_P#B:_-ZQ^,G[8NJ?&CX=>$9?!NB0?!/Q-\.O WQ/U/QOXM^'?CR
M&[\3:1XY\8^.#\0/A7,G@2R\467@;XH_"+X80_#VZTNT\2W6C:?XT\2:MXAF
M-U+I]F]II'S%^RO\5?VV?AU\*?V??AM9?!?QF-*T#P[^S?H<%A\0_A_X\E\1
M^-8/'/Q>\=>&OVF]8\<>+];NK";X9W7[/'@'3M$\:^';/Q+ UY\0/M=K!IS>
M)$\1:=;Z4N6K9OVL+Z.UZ>S4MWR:.\;6L][MJVI>G>W)+JK^_NK=.?;7>_I?
MI^WW]EC_ *"&J?\ @:__ ,31_98_Z"&J?^!K_P#Q-?B=IO[7G_!1#_A&=)\0
MW_P>O;G69OA/X$^).I^%%_9F^,&DPMXSF_:8F^&7C+X4VUR^J:IJ6FO<?!65
M/B;;"[34/$NAR6D.O3?VAX<GGTL_:7[.OQS_ &B_B#^T%\5?!WQ+^%OB/PO\
M(;+PM?ZI\./%^L?"_P 3>!UN/$WA;XR?$?X?>(-!EOM6U/4H+BQU7P7I?PX\
M<^$YM1%GJ?BS3->U3Q7I-K9Z#-'H>@*4:T4VZD&HIMVE3;T:6BY-7K=6W2;&
MG2DTE"2;M:ZJ+=7U]_0^W_[+'_00U3_P-?\ ^)H_LL?]!#5/_ U__B:U**R]
MK4_F_"'_ ,@:>SA_+^,__DS+_LL?]!#5/_ U_P#XFC^RQ_T$-4_\#7_^)K4H
MH]K4_F_"'_R >SA_+^,__DS+_LL?]!#5/_ U_P#XFC^RQ_T$-4_\#7_^)K4H
MH]K4_F_"'_R >SA_+^,__DS+_LL?]!#5/_ U_P#XFO-/BI\3_AA\$/#MIXM^
M+'Q"3P+X:O\ 7]%\+6FM:W?W<=C/XB\1WB:=X?T998+:?%_K>I2P:9I4#A6O
M]3N;33K7S;V[MH)?7Z^(/^"A/P2^)G[0G[.J?#3X3:;HVH^+6^,_[._CT'7O
M$:^%[&TT;X0?'/P!\6M<EBU%M)UO=JEWIG@FXTG1(#820_VQJ-C<7DD5C;W3
MBH3E*<5*?+%R2D[05EK=W=.VGF3*$5&3C"\DKI7GJ]--)^I[/X!^.7P-^*>I
MZ=H?P[^,OASQAKFJZ3XMURRT+0_%=K>:VVE^ ?%=MX$\<7-QHZL-2L3X0\:W
MEKX4\2V]]:VUSHGB&9-)U&&WOCY(]D_LL?\ 00U3_P #7_\ B:_'OXN?L ?$
M?PQK6MZW^R7%?>"=?U+]GG]K22V\<7GQBU_P_P"-KG]KC]I7XP?"+XJI\0_$
M^MZ;9W4NKZ59:MX"UN]UN)HY_#QCN=&T+3O",VCP&WM>K\8_ ?\ X* >*/B!
M\7==TOXH77@3P9XR\)^.?#'A?3O#OQ<O-<U_P_J:?%/X6>-/AYXXL=&\1>#4
M\#PWT_@FS^)/P\U[PCI,/A"VL-(GBTQ?&6N:AK7_  L#3M79V<:\4FMIQAS)
MW[1@^FO?37=6BUKIT9-W^RYV>G=S7^6NFS/U9_LL?]!#5/\ P-?_ .)KA+#Q
MY\.-5^(>O?"73/B/IFH_$[PMX<TCQ=XF\!V/B:TNO%/A_P ,Z_>7EAHFM:UH
M\$CWFF6&K7>GWL.GS7D4/VLVTC0AXP'/P+\'_P!G?]M[2OBK\*/$7QD^/NKZ
MIX,\)_#CX46MWHWPY\6W=II#^-?"5U\2;;XFZ7\0=%\=V?BF_P#'6A?%#1_$
MG@749-<77+[Q-HWB+P?_ &?I.K:+IME9ZSJ_O&B_!WX@Z=^W]X[^/O\ PC/A
MRS^%?B3]ESP#\(8=;M=?@'B:_P#''A7XE^.?&VH7VI>&8](C_P")9/I/B_3]
M(L]5DUJXO6N-&GCEL(K)K*9H;:<E[92M!R3BHI.2:2C[U-7NKO1)Z??2BG9^
MS:O-)IN5^6S;EI/2SLM=/T^L[NT>S6">*^U!F%_IT166Z,D;QW%_;6\J.C(0
MP:*5QV()#*00#6]6;JO_ ![0_P#82TC_ -.MG6@[I&K/(RHBC+.[!54>K,2
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M7-T:NGZ-:I[6UO:]E:M:_MX6NU\*W3LUMNGI;>^AUW_"0P_\\8?_  ;:/_\
M)U'_  D,/_/&'_P;:/\ _)U8>D>/?"6HZ+X>U75+BS\(7WB'PY8^)1X7\77N
MA:7XHT>VN](36KJRUK3X=3O;>"_T6T,RZR+*]O[&TDM+MX[ZXM8A<MIZIXH\
M,Z781WQN]/OY+S1M1UW1=,TVXT^ZU7Q+8Z9IQU2X/ANS-Q&=9=K/RY8C:.T)
M6:!Y)HXI!)2YJ&WL9]OC_I?C\[:ARUO^?T>_P?\  +/_  D,/_/&'_P;:/\
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MH_X2&'_GC#_X-M'_ /DZMWR(/^>,7_?M/\*/(@_YXQ?]^T_PJ>?#_P#/F?\
MX&O\RN2O_P _8_\ @'_ ,+_A(8?^>,/_ (-M'_\ DZC_ (2&'_GC#_X-M'_^
M3JW?(@_YXQ?]^T_PH\B#_GC%_P!^T_PHY\/_ ,^9_P#@:_S#DK_\_8_^ ?\
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M2I&SO1_Y\5/_  )]K]NVOIKMJ+EK?\_X?^ KO;\]/73?0]#_ .$AA_YXP_\
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M  D,/_/&'_P;:/\ _)U;OD0?\\8O^_:?X4>1!_SQB_[]I_A1SX?_ )\S_P#
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MV?W.S_ ?+7>U:+]()_DC"_X2&'_GC#_X-M'_ /DZC_A(8?\ GC#_ .#;1_\
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MK_\ *Q>UI?\ /VE_X,I__+#M\'T/Y&C!]#^1KB/^&)OAQ_T?U\>/_#P^"/\
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M;FTL-4M[V]M-0:]\BVOQ:V_[/>1?_P#093_P#MO_ (NCR+__ *#*?^ =M_\
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MJVFVG[2.-;\&MJK-XX30A;-I5D^B+>Z?<_JQY%__ -!E/_ .V_\ BZ/(O_\
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MUJVJ/>WWQIU_3K<"ULK6XLOZ-/(O_P#H,I_X!VW_ ,71Y%__ -!E/_ .V_\
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M_/J.]G^[CHM=?@\O)/5IM+7]U?[)TK_H&:?_ . 5M_\ &Z/[)TK_ *!FG_\
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MN;&[CCN(FB=[6^LI8+RSN%5RT%U:3PW-O*%F@ECE1'%?[;<_] G4/^_FE?\
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M =0TSQ3<^'FNO$/@F70-5UC5?!'ACQ/+<6NJ6%FEA^@7VVY_Z!.H?]_-*_\
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M/L8+?Z,^VW/_ $"=0_[^:5_\LZ/MMS_T"=0_[^:5_P#+.J_?:>^]-OWL-/\
MRI_3UT>HKTOY?_*4_P#Y7_7S=_*?#7[/7P9\'>-I_B%X9\!:3H_BF6[UG4(+
MFTEU :9I.I^)-,T/1O$FK>'O#DEZ_AOPWJWB/2?#6@Z=K^IZ!I.FWVL6NF01
M:A/<!Y_.]FK/^VW/_0)U#_OYI7_RSH^VW/\ T"=0_P"_FE?_ "SJ7";W:?36
MI3>G;6H-3@MDUUTIU%_[C-"BL_[;<_\ 0)U#_OYI7_RSH^VW/_0)U#_OYI7_
M ,LZ7LY?W?\ P.G_ /+!^TC_ 'O_  "I_P#(&A16?]MN?^@3J'_?S2O_ )9T
M?;;G_H$ZA_W\TK_Y9T>SE_=_\#I__+ ]I'^]_P" 5/\ Y T**S_MMS_T"=0_
M[^:5_P#+.C[;<_\ 0)U#_OYI7_RSH]G+^[_X'3_^6![2/][_ , J?_(&A16?
M]MN?^@3J'_?S2O\ Y9T?;;G_ *!.H?\ ?S2O_EG1[.7]W_P.G_\ + ]I'^]_
MX!4_^0.+\>_"7X<_%"[\#7WC_P *:=XGN_AIXRT[XA> YM0>[#>%_&^DP7-K
MIGBC2Q;7,"Q:Q8VM[>VMK=NLCPVU]>VZ8AO+E)?1*S_MMS_T"=0_[^:5_P#+
M.C[;<_\ 0)U#_OYI7_RSI\DVDM+*]E[2G97=W;]YI=ZNW47/#5VE=[OV=36V
MU_W>MC0KF/%/@SPQXUM])M/%.D6^M6NAZ_I7BC3+>Z>X6&WUW1)7GTN^:*&:
M)+DVDKM(MM=B>SE8CS[>4*H&O]MN?^@3J'_?S2O_ )9T?;;G_H$ZA_W\TK_Y
M9TN2:U5E_P!Q*?\ \L'SP>_,_P#N'4_^5FA16?\ ;;G_ *!.H?\ ?S2O_EG1
M]MN?^@3J'_?S2O\ Y9T>SE_=_P# Z?\ \L#VD?[W_@%3_P"0-"BL_P"VW/\
MT"=0_P"_FE?_ "SH^VW/_0)U#_OYI7_RSH]G+^[_ .!T_P#Y8'M(_P![_P
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MP%?C9\"/VZOCG\(-)^)W[/\ ^T%#_P )G\>O O[5G@[P@OQ"\6S6UOX.\/?
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MI%KK6G:%XIN?!&O^!OV6_BG:> =:U'3M9EBU":[\6'3_ !%X+OK[04CADO\
M5->?3O#D&H36%Y#;^LZ;^WU^SUK&I^#-%TF?XE:QJ_C6#XGWEO8:%\(_B)XC
M?0+'X,:]I'AGXFZCXHN?#OA_5;'2M-\+:SX@T"UFU!+NZL]337=&N]#FU.SU
M*SGFIK$KK5:[J<W%Z<VCYK/37\[/1I+#O[-+T<()[VU7+?<^OO[#TC_H'VW_
M '[_ /KT?V'I'_0/MO\ OW_]>OC%/^"AG[.ETT=GI$WQ%\0>(9/$7Q:\*?\
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MK4DE9*[U<NPI0HP7,Z<+72TIQ;U=EIR]S]'/[#TC_H'VW_?O_P"O1_8>D?\
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M;M8$FM+:WTRT:YU&T7Q+X4EUONOV5?BSKGQY_9J^ _QJ\3:7I.B>(OBM\)_
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M\&_"WPPTWXE:UHOB/4+X>'-;L-:\,P>+]5@\&^(]-TOQ1Y>FV>JZ2/$-I?\
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M^4/V9_V??$?P*\0?'6^U'7O#=WX<^*OC/P+XP\->$_"NF:GI.D^"I_#OP=\
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MVEE$PD*)(2@<1.VU"Y6,HI7>2/UG_LW5_P#G\/\ X,+O_P"1Z_)WX-?\I?\
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M+H(\4>,]7^(G@#P_^S_\)?V@_$'Q&?P]I'A<ZUH^G>%_"GQ2MIO%;?8;O2-
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MS&S*5#PPNI8$ Y!%=!9?\?FK_P#7Y;_^FVQKSKXL? CX+?'?0+GPO\9_A5X
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M(O#$OQ \(Z/XGDT"/7&T]M8CTE]5M;AK)-3;2M,:]6 H+@V%J90Q@CV^*?\
M#M7_ ()^_P#1FO[.7_AJ/"/_ ,K*^FEC<AQF!RFACUG=+$9;@JF"D\##*:F'
MJQEC\;C8U(O&585HR2Q?LY1:Y;PO%V9\ZL)G>%QN9UL#_8U3#YAC*>,BL9/-
M(5Z<HX'!X.4&L)3G1E&^$YXR3YK3M)71Z%_PVO\ L:?]';?LR?\ A^OA7_\
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M6_#?_@HAK_Q5\1?##P7HWPKT;PCXA\8>%)_&?B%?BMXVO/AC;SZ7I'[06L?
M[QMX=^&MWJ?AC4['QGX]\!:7HT_Q$US2K34)=!OK34O"6C^&?$NO:=XKM/&%
ME^FI\/Z"1$#HFD$00&V@!TVRQ#;%9$-O$/)Q' 4FF0Q)MCVRR+MP[ O_ +#T
M0QVL)T?2S#8_\>47]GVGEV?[G[/_ **GD[;?]Q^X_<A/W/[O[GRT2J8:5W[*
MI=[.].RT:V5D];.VFM]>C%"NOMT[=K5-=;[M-[77H?A[^SQ_P4>\7>'/A9\/
MM#\1:5J7QPU6TD\/7&K>,;_Q1 _C[XLI\6OVT?BQ^SWI>@_"71](T*;3O&OB
M3X)^'_#.B^,_B=9M<Z6MAX.U/PXZBRMM2&MQ^BM_P50\4O:WNGQ?L]R6OBR[
M^.FF_!W0#J?C[0[?X<VT.N>!?B?XT\,>(M?^+-J+SX>)IOC*]^&3>"O#5Q:^
M(XKR+Q+XO\/0>*M&\,736NE:S^O<6@:%#]G\G1=)B^R//):^5IUG']FDN81;
MW#V^R$>2]Q;JL$[1[6EA412%D 6D.@:"8+FU.B:0;6\E>>[MCIMF8+J>1XY)
M)KF$P^7/+))#$[R2JSL\4;,2R*0W4PK;;HU+MMZ2@EJV]E9==DDM+*R!0Q"2
M7M*>BMM/M;=IOYW??5GX]>)OVV_B!\0_VF/V;O!&FP'X*:9X:_; T#X-_%7X
M>WWCW3=0\9^.-,\8?L6^,_C.FLZGHFEZ/=Z)J?P@@\=ZOX7\)>$/&^A^)YK#
MQ-XT\)7TEI=26=_'I:_LK]JMO^?B#_O]'_\ %55&D:2)Q<C2].%R(/LHN!96
MPG%KO:3[,)?*\P0>8[/Y.[R][,VW<Q)D_LW3O^?"R_\  6#_ .-UG.5&7*HQ
MJ044U_R[=[N]V[I]TKW=G;9%Q59<UW3DVT_^7BM96MM;[K?B3?:K;_GX@_[_
M $?_ ,51]JMO^?B#_O\ 1_\ Q50_V;IW_/A9?^ L'_QNC^S=._Y\++_P%@_^
M-U'[KO5^ZG_F5^\_Z=_?4_R)OM5M_P _$'_?Z/\ ^*H^U6W_ #\0?]_H_P#X
MJH?[-T[_ )\++_P%@_\ C=']FZ=_SX67_@+!_P#&Z/W7>K]U/_,/WG_3O[ZG
M^1\G_##]DCX?_".7Q%IWA+QKXM'@76OC7XY_:$TWX?:G>>'[W1/"_P 4/B)K
MFJ^*_$=YH^I+HT'B.;PV?%^NZQXKT[PQJNKZA9V&KW[QI.^D6]EI5M\YZ)_P
M2U^#&B:;\/K"W^+7Q5>?X4^$_A_X?^'NIBY^'4%YH&L?"W]HI?VF_ WBV6"#
MP,FF:MJ&E?$!1I]UHNI:?/X6U+PJ6TZXT0:@L6KQ?IY_9NG?\^%E_P" L'_Q
MNC^S=._Y\++_ ,!8/_C=:*JDVU4K7>[M2UTMK\M'WZW(=-NUXTM+VUJZ7=]/
M*^MNG2Q^=2_\$W?@[(=9CU3XA^-/$VG>(_#/[1?AW7]#\6:9\*=>T+5A^U'\
M;?#O[07Q3N+S3+GX?+!-;3?$;PKI%QH&FS>;;Z'I#7]E:N;R>UU.P[7X4?L+
M?#'X*>(M&\2> ?B!X\AFL_AYX4^&^NZ5XHU'PYX[T?Q'I/P\^(GCOXI?#6^,
M/C/0];U#P_J7P]\5_$CQ5%X7F\.:EIJ67AZ?2]*>.6ZT#0]5T_[@_LW3O^?"
MR_\  6#_ .-T?V;IW_/A9?\ @+!_\;H=:Z:=2M9[JU*STMMZ?IV0*FU9J-*Z
MV=ZFA^;7@G_@F/\  SP9I/AW0?\ A8/Q*U[2-/7]G_\ X2NTU75O"<#>/Y/V
M5_B5XC^*OP%FURXTGPQIT^DMX/\ $_B6==4C\*/H,'B_3--TJR\017(34)-2
MI:3_ ,$KOV9-%@T);"_US?X;^(^M_$C2M)NXO!M_\/1=^+/AIJ?PF\<:!<_"
M:\\-S?#5/#OCOPGJ]W<>*=.TCPUI$=UXE2UUJP&FQ1S:=<_IE_9NG?\ /A9?
M^ L'_P ;H_LW3O\ GPLO_ 6#_P"-T>V>O[ROKO\ PM=^UN[^6FB20O9?W*7_
M )4_KI]^I\,^$?V"?A!X&^+>@_%3POXU\=Z3;^%_C;XU_:%\/> +:]\&#PAI
MGQ*^(WPD/P6\;20F3PE)KZ>%=8\&O.]IX5@UJ"Q\/ZM=32^'I=,TJ'3='T_[
ML^U6W_/Q!_W^C_\ BJA_LW3O^?"R_P# 6#_XW1_9NG?\^%E_X"P?_&ZF4X3M
MS2JRLK*ZI;;]UU[W?F6HSC?E5-7=W9U-_N9-]JMO^?B#_O\ 1_\ Q5'VJV_Y
M^(/^_P!'_P#%5#_9NG?\^%E_X"P?_&Z/[-T[_GPLO_ 6#_XW4_NN]7[J?^8_
MWG_3O[ZG^1-]JMO^?B#_ +_1_P#Q5'VJV_Y^(/\ O]'_ /%5#_9NG?\ /A9?
M^ L'_P ;H_LW3O\ GPLO_ 6#_P"-T?NN]7[J?^8?O/\ IW]]3_(F^U6W_/Q!
M_P!_H_\ XJC[5;?\_$'_ '^C_P#BJA_LW3O^?"R_\!8/_C=']FZ=_P ^%E_X
M"P?_ !NC]UWJ_=3_ ,P_>?\ 3O[ZG^1-]JMO^?B#_O\ 1_\ Q5'VJV_Y^(/^
M_P!'_P#%5#_9NG?\^%E_X"P?_&Z/[-T[_GPLO_ 6#_XW1^Z[U?NI_P"8?O/^
MG?WU/\B;[5;?\_$'_?Z/_P"*KY[UW]FGX-:[\3_%WQ>:TU72/&?Q'\'>'_ '
MQ2D\/>+M:T71_BCX0\)-KA\*Z/X\T*ROX]+UK_A'H?$_B2QTW4DMK76!I.NZ
MCHUUJ%SI$D=E%[]_9NG?\^%E_P" L'_QNC^S=._Y\++_ ,!8/_C=-.G&]I55
M=6=E3U6CL]>Z3]4GHTFDU-[JF[.ZOS[]]O-_)M=3Y'\5?L2_LZ^./$7B?Q%X
MNT[7_$+^,_BC/\7_ !1HNI^-M:G\,ZUXON?@G>_LYSI>:!]L73SX>F^"NHWO
M@*7PU'$FC2:=.UZ]H=95-27FM$_X)]_LS:!?^'-6L$^($FK^%]>^"NOZ9JFH
M_%SQQJEX\W[.VG:UI'P:L-0;4=<N8M1T[P3IGB'6;.VBNXI;G54OYIM?NM5N
M2LZ_;O\ 9NG?\^%E_P" L'_QNC^S=._Y\++_ ,!8/_C=5[16M[2O:UK?N[6M
M;:_9)>B7967(]^2C?_M_O?MWU/C70?V#/V7_  KJNF^)O"WAS4?#/C?2/B!-
M\3=-\?>'O%NJZ+XQ@\67G@F;X<:I=W&JZ;=6R:I#K_@>XFT#Q-#K%KJ#>* 8
M=8\0R:GXBL[+6+:37?V%?V;_ !+XE\8^,=9M/%UUXJ\<>(?%GB'6?$ ^)/BJ
M#5H9/'_PW\,_"'QYI&DW\&JQW.E>'_&7PX\%>#?#>OZ1:2);W)\*:%KL)M_$
MU@FM'[&_LW3O^?"R_P# 6#_XW1_9NG?\^%E_X"P?_&Z/:*]_:5[VM>].]KWM
MOM?IMY!R/;DHV_[?]+[;VZ[GQ/X@_P"">7['/B@ZZNL_##2KB#6?A_I'POM(
M+?5[_3CX6\$^'KGP#?\ AS1/"5]IUW::KHEMX9U7X7^ M7\*I'?RQ^%-2\.P
M7'AM-*^W:LE_K?$+]AC]FWXI7,E]XTTWQ)?7VI>"?#/P[\6WFE_$#Q+X7E\>
M>$/!7C\_%'P7I/C)/"VIZ+;ZH?"/CN;4-?\ #M]!!8ZCIDFLZY8078TK5[^Q
MG^PO[-T[_GPLO_ 6#_XW1_9NG?\ /A9?^ L'_P ;H]JM'[2OIMK#3T][R7S2
M>^HN1Z^Y1UWTGK^']>F@^.>UC1(Q<QL(T5 TER))"% 4%Y'=GD<@99W9G8Y9
MB22:?]JMO^?B#_O]'_\ %5#_ &;IW_/A9?\ @+!_\;H_LW3O^?"R_P# 6#_X
MW4?NN]7[J?\ F7^\_P"G?WU/\B;[5;?\_$'_ '^C_P#BJX'XE_#?X:_&/PG=
M>!OB;X=T3QAX7NK_ $?5_P"S-3=E:SUOP[JEIKGAW7])O[2>VU+1/$/A[6K"
MRUC0-?T>\L=9T75+.VU#3+ZUNX(IE[C^S=._Y\++_P !8/\ XW1_9NG?\^%E
M_P" L'_QNA.FFFG536J:5--/R:D'[QZ-4VNSY_\ (^6]7_8R_9@\1/K-WXB\
M"GQ#K7B*Z\3S^(?%6N^//'>J^,]<M?&OA#1_ 'B_0-5\8WOBN;Q+>>#_ !+X
M*\/Z+X:UCP3+JA\(WFFZ79*^B>?;13+7N_V*/V6[S6KO7I/ L\%[>>)9_%\E
MOIWQ$^(FDZ-!X@G^$+_  WNG>']+\86>A:5##\$I#\+[+3=,TZTTNP\'I%IM
ME96Y@AE3ZL_LW3O^?"R_\!8/_C=']FZ=_P ^%E_X"P?_ !NJ]HO^?E?MO#;_
M ,")Y)?R4?NG_D?(=C^P?^R#I=C'8:3\++#1XX9[BY@NM(\:^/--U6VGO_AA
MH?P7UB:TUFR\6PZM9R^(?A7X;T7P3XEEM;V&7Q'H]A&=:>^O&DNWZ=/V0/V7
MH-3AU6P^%_AS1I;4Z?<V-CH&I:QH&@Z=K.C_  QE^"^B>*]+\-:-J]CX?TSQ
MQH/PGF?X>Z#XYL-,MO%VB^%%@TG3=9M;:TM%@^E?[-T[_GPLO_ 6#_XW1_9N
MG?\ /A9?^ L'_P ;H]HO^?E?[X?_ "7]?F<DOY*/W2_^1/E>']BK]E:*X^&M
MV?AS:W-S\'O#GPP\)?#2>_\ &GCC4)?"'A[X+^*)_&'PMT_2Y+WQ5.Q_X0[6
M[JX.GW=T;B^N]*FD\/:M=:AH#?V;5.']AK]DB&WM+)?A?I[Z=IO@QOA]I&E3
M>,?&T^D:%X0'Q&L/BY9:1H&E3>*7L-".B?$O2=(\9^&-2TFWL]7\*:UH^CS>
M&M0TJ+2K"&W^M/[-T[_GPLO_  %@_P#C=']FZ=_SX67_ ("P?_&Z/:+_ )^5
M_OAU=_YN[;]6^X<C_DH_=/\ R/D_5_V(?V4M=LM:T_5/AW'<6WB;P;\4O /B
MCR_'7CRSG\4^&OC?XKTGQQ\8(O$UU8^++:ZU[5_B3XIT'0]6\7>)M4FNO$VJ
MOH^F6DFKK86<-JOU=9BPL;2ULK>X7R+.V@M8//O'NIO)MXEAC\ZYN9I;BXEV
M(OF3SRR32OF261W9F+O[-T[_ )\++_P%@_\ C=']FZ=_SX67_@+!_P#&Z3E"
M7Q2K.VU_9ORZR[:>F@TIK:-)7[<Z_0@L'22[U=D=77[; -R,&7(TVQR,@D9'
M<5J5%#!#;J4@AB@0L6*0QI&I8XRQ5 HW' R<9.!D\5+43:E)M7M:*5[7M&,8
MZVTUY;Z=RH)QBD[7O)NU[>]*4M+ZZ<UM3\0/VH?V K?]HOXM?$O]K/\ :ZLM
M1^)NB_#K2M3^'_[(7[*.B2W5UX;5&:/3=%\4>/HM-EAN/$_BSXF>.)4U^7PW
M936>DZ3X73P]IWBZ[UI=(GL-'^MOV5?V#/AM\'OAC\.8/&OA/0+GXI>&-=TK
MQS#K&B1IIR>#-8L#;/IWA7PY+I7V2W'AW2+>!;*]T](GTK5KR?4KTP,L]J\/
MZ$X!QD X.1['!&1Z'!(^A([T5P83+\+@I8BI0II5\96E7Q>(F^?$8BK*3:=6
MK*\G"G'EIT:,>2C0IPA"E2C:4I_=<7^(O%W'&$X;RO/LVK5,@X-RC#Y%PAPS
MA'+"<.<,Y90I0A4IY3D]&<<)2QF95U7S#.\WK4\5G.=YGC<9C,SS3$.I1PV#
M_+G1?B?%XK_: ^&?BG0=6\1>$I=8^*7QV^'/CS1+[Q;XVUC7].TGPSX0^(L&
M@KX_\)7VWP!X0AN?$/AW1O$'P^T&VTE[^XL6T>>TU;4YM4UR*;SK6KFZN/@E
M\0?#7CJXM?&S>!/%/[)WB.?X\>%?&/C.^\(?$WP]J/QATA+GQ3XBTR]U.4>"
M_B-I^A+JFJ?$_2K>^U'2+;3M4T;68[NQL8-+LM)_8K YX')!/ Y(Q@GU(P,'
MJ,#T%-6.-5*+&BHQ8E%50I+DER5  )<DELCYB23DDUVGPY^;.L:E=^-OC'\7
M?A_XF^,6L_"5+<_"'5/V=M2LH[]KC4_ ":)HE[=ZY\-M3O-4ATOQ'KNJ>.(_
M$'A[QS:7>F>(]0ETA=*LM2MI-'NK/S.*36=*,<+"^@VG_@I]<ZD#EL'3/.NO
M^)MG;_R"3D,-5_Y!Q#*1=$,I/ZNE5)4E02I)4D E205)4GD$J2"1C()'0FDV
MK_=7[NWH/N_W>GW?;I[4 ?E/X:^)_P#PF/QO^'/BWP]K_BGP/%XNUC]HSP?X
M]TZ]\4>,O$7B'P_%X5\.^(1X;'Q#\+ZFO_""^$M9L]6T6WUWP3X6T_1TOH=.
M$-O:ZAK$%WJCW/T/^R!JVNE?'?A/Q(UAXIU?PII_P^67XR>%?%'B/Q#X(^,%
MKJND:K<67B5+#Q#<W;>%/B((8?/^(WA^QO=2MDN-1T*]BU.>UN[.WL_M+:O/
M Y(8\#E@  3ZD!5 )Y  ]!2(B1J$C18T!)"HH5068LQ"J  68EB<<L23R30
7ZBBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>13
<FILENAME>atnm-20181231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20181231.xfr; Date: 2019%2D03%2D15T19:01:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:atnm="http://actiniumpharmaceuticals.com/20181231">
    <link:schemaRef xlink:href="atnm-20181231.xsd" xlink:type="simple" />
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_srt_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember318918381">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2016-08-04_custom_GeorgeClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GeorgeClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2016-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_16_Feb_2016T00_00_00_TO_16_Feb_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MedpaceIncMember_AgreementAxis_CROAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MedpaceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GoodwinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GoodwinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GeorgeClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GeorgeClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MedpaceIncMember_AgreementAxis_CROAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MedpaceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_MedpaceIncMember_custom_CROAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MedpaceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_GeorgeClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GeorgeClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_GoodwinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GoodwinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OakRidgeNationalLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_AccountingStandardsUpdate201711Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GoodwinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GoodwinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_MedpaceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MedpaceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GeorgeClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GeorgeClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_DerivativeInstrumentRiskAxis_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_DerivativeInstrumentRiskAxis_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_srt_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AccountingStandardsUpdate201711Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AccountingStandardsUpdate201711Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_TotalstockholdersequityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:TotalstockholdersequityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atnm:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atnm:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atnm:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_OakRidgeNationalLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_GeorgeClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GeorgeClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_MedpaceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MedpaceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_GoodwinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:GoodwinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-10-18_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-18_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-10-18_custom_LincolnParkCapitalFundLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-18_custom_LincolnParkCapitalFundLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-25to2017-08-02_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-25</xbrli:startDate>
        <xbrli:endDate>2017-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-25to2017-08-02_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-25</xbrli:startDate>
        <xbrli:endDate>2017-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-02_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-02to2016-10-04_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-02</xbrli:startDate>
        <xbrli:endDate>2016-10-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-10-04_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-10-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-03to2013-09-30_custom_TwoThousandThirteenStockPlanMember_custom_EmployeesDirectorsAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-03</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_TwoThousandThirteenStockPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_TwoThousandThirteenStockPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_TwoThousandThirteenStockPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TwoThousandThirteenStockPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-03to2013-09-30_custom_EmployeesDirectorsAndConsultantsMember_custom_TwoThousandThirteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-03</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_TwoThousandThirteenStockPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RestrictedStockMember_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_RestrictedStockMember_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-05-15to2017-06-06_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-15</xbrli:startDate>
        <xbrli:endDate>2017-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-15</xbrli:startDate>
        <xbrli:endDate>2017-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-15</xbrli:startDate>
        <xbrli:endDate>2017-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_WarrantsMember_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_WarrantsMember_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-08_custom_WarrantsMember_custom_MrSandeshSethMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:MrSandeshSethMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-08_custom_WarrantsMember_us-gaap_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-08_custom_WarrantsMember_us-gaap_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-08-02_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-02_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-01-31_us-gaap_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-01-31_us-gaap_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ResearchMember_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_OrphanDrugCreditsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">atnm:OrphanDrugCreditsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ResearchMember_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OrphanDrugCreditsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">atnm:OrphanDrugCreditsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember173911536">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember173911536">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-02-26to2017-03-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-02-26</xbrli:startDate>
        <xbrli:endDate>2017-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-12-07to2012-12-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-12-07</xbrli:startDate>
        <xbrli:endDate>2012-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atnm:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-06to2018-12-19_custom_OakRidgeNationalLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-06</xbrli:startDate>
        <xbrli:endDate>2018-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_LincolnParkCapitalFundLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-06_us-gaap_SubsequentEventMember_srt_MinimumMember_custom_DelawareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:DelawareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-06_us-gaap_SubsequentEventMember_srt_MaximumMember_custom_DelawareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:DelawareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-06_us-gaap_SubsequentEventMember_custom_ThePlanAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:ThePlanAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD_per_Share">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">0001388320</dei:EntityCentralIndexKey>
    <dei:TradingSymbol contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">ATNM</dei:TradingSymbol>
    <dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2018-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-03-06_us-gaap_SubsequentEventMember_srt_MinimumMember_custom_DelawareMember" unitRef="shares" decimals="INF">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-03-06_us-gaap_SubsequentEventMember_srt_MaximumMember_custom_DelawareMember" unitRef="shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-03-06_us-gaap_SubsequentEventMember_custom_ThePlanAmendmentMember" unitRef="shares" decimals="INF">22750000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">80072334</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">115703044</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">80072334</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">115703044</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-96092</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-24739</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-12-31_srt_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-380946</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-12-31_srt_RestatementAdjustmentMember" unitRef="USD" decimals="0">356207</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-109819</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">63056977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">30836932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="INF">55820876</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionMember" unitRef="shares" decimals="INF">7236101</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_us-gaap_OptionMember" unitRef="shares" decimals="INF">5174592</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember318918381" unitRef="shares" decimals="INF">25662340</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31_us-gaap_OptionMember" unitRef="shares" decimals="INF">5906886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF">8964752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31" unitRef="shares" decimals="INF">14871638</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Three to five years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">Seven years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Straight-line basis</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">Straight-line basis</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">1000000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
    <atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">Royalty payments of 2% of net sales will be due to FHCRC.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
    <atnm:ProjectEstimatedCost contextRef="From2016-08-01to2016-08-04_custom_GeorgeClinicalMember" unitRef="USD" decimals="0">4600000</atnm:ProjectEstimatedCost>
    <us-gaap:DevelopmentInProcess contextRef="Context_As_Of_16_Feb_2016T00_00_00_TO_16_Feb_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MedpaceIncMember_AgreementAxis_CROAgreementMember" unitRef="USD" decimals="0">10200000</us-gaap:DevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2018-01-01to2018-12-31_custom_GoodwinMember" unitRef="USD" decimals="0">1200000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2018-01-01to2018-12-31_custom_GeorgeClinicalMember" unitRef="USD" decimals="0">1900000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MedpaceIncMember_AgreementAxis_CROAgreementMember" unitRef="USD" decimals="0">3100000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2017-01-01to2017-12-31_custom_MedpaceIncMember_custom_CROAgreementMember" unitRef="USD" decimals="0">2800000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2017-01-01to2017-12-31_custom_GeorgeClinicalMember" unitRef="USD" decimals="0">700000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2017-01-01to2017-12-31_custom_GoodwinMember" unitRef="USD" decimals="0">1400000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2016-01-01to2016-12-31_custom_GeorgeClinicalMember" unitRef="USD" decimals="0">100000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2016-01-01to2016-12-31_custom_MedpaceIncMember" unitRef="USD" decimals="0">2600000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="From2016-01-01to2016-12-31_custom_GoodwinMember" unitRef="USD" decimals="0">700000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="From2018-03-01to2018-03-31_custom_SeriesBWarrantsMember">Each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per share.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="From2018-03-01to2018-03-31_custom_SeriesAWarrantsMember">Each series A warrant exercisable for one share of common stock at an exercise price of $0.60 per share.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <atnm:PurchaseOfMaterials contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">300000</atnm:PurchaseOfMaterials>
    <atnm:PurchaseOfMaterials contextRef="From2017-01-01to2017-12-31_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">600000</atnm:PurchaseOfMaterials>
    <atnm:PurchaseOfMaterials contextRef="From2016-01-01to2016-12-31_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">1000000</atnm:PurchaseOfMaterials>
    <atnm:PurchaseOfMaterials contextRef="From2018-12-06to2018-12-19_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">200000</atnm:PurchaseOfMaterials>
    <us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4849</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">30360466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">3577159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">2597500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">2225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF">18496575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104" unitRef="shares" decimals="INF">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-09-03to2013-09-30_custom_TwoThousandThirteenStockPlanMember_custom_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">2750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-09-03to2013-09-30_custom_EmployeesDirectorsAndConsultantsMember_custom_TwoThousandThirteenEquityIncentivePlanMember" unitRef="shares" decimals="INF">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3577159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2597500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_custom_ConsultantsMember" unitRef="shares" decimals="INF">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31_custom_WarrantsMember_custom_ConsultantsMember" unitRef="shares" decimals="INF">122628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P4Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P4Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD" decimals="0">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">3100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockOptionPlanExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD" decimals="0">1300000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">2500000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">1700000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">3100000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">3600000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember" unitRef="USD" decimals="0">174000</us-gaap:StockOptionPlanExpense>
    <atnm:WarrantsExercisablePeriod contextRef="From2018-01-01to2018-12-31_custom_SeriesAWarrantsMember">P1Y</atnm:WarrantsExercisablePeriod>
    <atnm:WarrantsExercisablePeriod contextRef="From2018-01-01to2018-12-31_custom_SeriesBWarrantsMember">P2Y6M</atnm:WarrantsExercisablePeriod>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD" decimals="0">27000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2018-01-01to2018-12-31_custom_SeriesAWarrantsMember" unitRef="USD" decimals="0">500000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2018-01-01to2018-12-31_custom_SeriesBWarrantsMember" unitRef="USD" decimals="0">2500000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2018-01-01to2018-12-31_us-gaap_AccountingStandardsUpdate201711Member" unitRef="USD" decimals="0">5000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2500000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_custom_ConsultantsMember" unitRef="USD" decimals="0">116000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2017-01-01to2017-12-31_custom_WarrantsMember_custom_ConsultantsMember" unitRef="USD" decimals="0">27000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember" unitRef="USD" decimals="0">4900000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">215660</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">266381</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <atnm:ProjectRemainingCost contextRef="AsOf2018-12-31_custom_GoodwinMember" unitRef="USD" decimals="0">1000000</atnm:ProjectRemainingCost>
    <atnm:ProjectRemainingCost contextRef="AsOf2018-12-31_custom_MedpaceIncMember" unitRef="USD" decimals="0">3300000</atnm:ProjectRemainingCost>
    <atnm:ProjectRemainingCost contextRef="AsOf2018-12-31_custom_GeorgeClinicalMember" unitRef="USD" decimals="0">500000</atnm:ProjectRemainingCost>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_custom_SeriesAWarrantsMember">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_custom_SeriesBWarrantsMember">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_DerivativeMember">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MinimumMember">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MaximumMember">P8Y10M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_WarrantsMember_srt_MaximumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_WarrantsMember_srt_MinimumMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_custom_SeriesAWarrantsMember" unitRef="pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_custom_SeriesBWarrantsMember" unitRef="pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_us-gaap_DerivativeMember" unitRef="pure" id="Foot-00-0" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_custom_ConsultantsMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_custom_WarrantsMember_custom_ConsultantsMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember" unitRef="pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_custom_SeriesAWarrantsMember" unitRef="pure" decimals="INF">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_custom_SeriesBWarrantsMember" unitRef="pure" decimals="INF">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_us-gaap_DerivativeMember" unitRef="pure" id="Foot-01-0" decimals="INF">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="INF">0.791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="INF">0.804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.8083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.8237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.4572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.7981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.8795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.8145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.8484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember" unitRef="pure" decimals="INF">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_custom_WarrantsMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.7900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_custom_WarrantsMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.7701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.7979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2018-01-01to2018-12-31_custom_SeriesAWarrantsMember" unitRef="pure" decimals="INF">0.0206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2018-01-01to2018-12-31_custom_SeriesBWarrantsMember" unitRef="pure" decimals="INF">0.0233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MinimumMember_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="INF">0.0234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_RangeAxis_MaximumMember_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="INF">0.0294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2017-01-01to2017-12-31_custom_WarrantsMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2017-01-01to2017-12-31_custom_WarrantsMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember" unitRef="pure" decimals="INF">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <atnm:MarketValueOfCommonStockOnMeasurementDate contextRef="AsOf2017-12-31_us-gaap_DerivativeMember" unitRef="USD_per_Share" id="Foot-02-0" decimals="INF">0.66</atnm:MarketValueOfCommonStockOnMeasurementDate>
    <atnm:FairValueAssumptionOfferingPrice contextRef="AsOf2017-12-31_us-gaap_DerivativeMember" unitRef="USD_per_Share" id="Foot-03-0" decimals="INF">0.50</atnm:FairValueAssumptionOfferingPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2017-12-31_us-gaap_DerivativeMember" unitRef="USD_per_Share" decimals="INF">1.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2017-12-31_srt_RestatementAdjustmentMember" unitRef="USD" decimals="0">16000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2017-12-31_us-gaap_AccountingStandardsUpdate201711Member" unitRef="USD" decimals="0">57212</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">194598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">1515650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">3329794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">266485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF">1789623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockMember_custom_ConsultantsMember" unitRef="shares" decimals="INF">26000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">3329794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1515650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3329794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">266485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2018-03-01to2018-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">30237894</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2018-01-01to2018-12-31_custom_LincolnParkCapitalFundLlcMember" unitRef="shares" decimals="INF">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_srt_RestatementAdjustmentMember" unitRef="USD_per_Share" decimals="INF">1.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_custom_SeriesAWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_custom_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">2.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_us-gaap_WarrantMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">0.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_us-gaap_WarrantMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_us-gaap_AccountingStandardsUpdate201711Member" unitRef="USD_per_Share" decimals="INF">1.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-08-02_us-gaap_IPOMember" unitRef="USD_per_Share" decimals="INF">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">0.344</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">0.7829</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">0.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">0.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_WarrantsMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">1.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_WarrantsMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">0.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_custom_WarrantsMember_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">0.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_custom_WarrantsMember_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-08-02_custom_WarrantsMember" unitRef="USD_per_Share" decimals="INF">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-03-31_custom_SeriesAWarrantsMember" unitRef="shares" decimals="INF">7559445</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-03-31_custom_SeriesBWarrantsMember" unitRef="shares" decimals="INF">22678393</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_us-gaap_DerivativeMember" unitRef="pure" id="Foot-04-0" decimals="INF">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">15916</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-66154</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">50238</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2018-12-31_custom_TotalstockholdersequityMember" unitRef="USD" decimals="0">-15916</us-gaap:DerivativeLiabilities>
    <atnm:ProbabilityOfStockOfferingInAnyPeriodOverYear contextRef="From2017-01-01to2017-12-31_us-gaap_DerivativeMember" unitRef="pure" id="Foot-05-0" decimals="INF">1.00</atnm:ProbabilityOfStockOfferingInAnyPeriodOverYear>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">390940</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">391131</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RestrictedCashCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:RestrictedCashCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">40075</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">34733</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">17838958</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">14329605</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">439322</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">616222</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">40075</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">17399636</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">13673308</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">20519294</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">18337107</us-gaap:Assets>
    <us-gaap:Assets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">14889394</us-gaap:Assets>
    <us-gaap:RestrictedCash contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">390940</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">391131</us-gaap:RestrictedCash>
    <us-gaap:SecurityDeposit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">49859</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">49859</us-gaap:SecurityDeposit>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">57350</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">118799</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">4666004</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6076597</us-gaap:Liabilities>
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">4666004</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6063243</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">15916</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">4650088</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5814004</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">18337107</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">14889394</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">13671103</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">8812797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">195554332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-186857238</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">18008329</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">21974048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">44067</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">55802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">80072</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">115703</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">134160059</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">154504329</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">176744068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-112230078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-136551802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-163153037</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-163153037</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-186857238</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">176744068</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">195554332</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">80072</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">115703</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-23827322</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-26910788</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-26847481</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">23827322</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">26910788</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">26847481</us-gaap:OperatingExpenses>
    <us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">50721</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">55938</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">77523</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">20170</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">20352</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">41632</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">30551</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">35586</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">35891</us-gaap:Depreciation>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6732544</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">9190933</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">9019194</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">17094778</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">17719855</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">17828287</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">106041809</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">66746389</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="shares" decimals="INF">48463268</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="INF">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="INF">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="USD_per_Share" decimals="INF">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-23653963</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-26601235</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-24321724</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-24321724</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-26601235</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-23653963</us-gaap:NetIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">173359</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">309553</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2525757</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">304123</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2530764</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:Revenues contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">304123</atnm:GainOnChangeInFairValueOfDerivatives>
    <atnm:GainOnChangeInFairValueOfDerivatives contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2530764</atnm:GainOnChangeInFairValueOfDerivatives>
    <us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1798655</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3493731</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">4297778</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-100032</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1397129</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1032988</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-20571056</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-21553346</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-20789237</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1133499</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">405214</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2720938</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">96092</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">24739</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">59960</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">17790576</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">14104514</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">20554027</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">25678006</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">16981086</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">18814634</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">15775077</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Previously Reported&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Adjustment&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(380,946&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;356,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(24,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Term &lt;br /&gt; (in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2016&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,018,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,199,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(183,718&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,964,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,445,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,496,575&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,364&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,789,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2.22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,662,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;995,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,360,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,332&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(194,598&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;9.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55,820,876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;569,038&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55,613,377&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.03&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;566,676&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt;&#13;    Contractual &lt;br /&gt; Term &lt;br /&gt; (in years)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2016&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,971,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,964,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,225,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(266,485&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.51&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,906,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,597,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,329,794&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,174,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,577,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,515,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2.96&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,236,101&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.74&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,021,818&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.55&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">25662340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">55820876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">5174592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">7236101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">5906886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">3971583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF">8964752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF">9018470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">7332</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">23212</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF">9364</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104" unitRef="shares" decimals="INF">183718</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">23212</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="shares" decimals="INF">23212</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">55613377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">3021818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">3.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">4.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">0.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="INF">0.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">1.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">1.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">1.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104" unitRef="USD_per_Share" decimals="INF">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">0.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">0.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">0.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104" unitRef="USD_per_Share" decimals="INF">0.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">9.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="INF">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">2.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">2.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">2.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">2.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember">P3Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P7Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember">P7Y10M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember">P8Y0M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P1Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104">P2Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember">P2Y0M15D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P7Y11M19D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember">P7Y11M12D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember">P7Y10M25D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P3Y7M13D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104">P1Y11M12D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember">P2Y0M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD" decimals="0">995373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD" decimals="0">569038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">2648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">6400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">51704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2015-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">2964146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">1445786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">10199230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="USD" decimals="0">566676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <atnm:StockRepurchasedDuringPeriodValueAdditional contextRef="From2018-10-01to2018-10-18_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">32500000</atnm:StockRepurchasedDuringPeriodValueAdditional>
    <atnm:StockRepurchasedDuringPeriodValueAdditional contextRef="From2018-10-01to2018-10-18_custom_LincolnParkCapitalFundLlcMember" unitRef="USD" decimals="0">30000000</atnm:StockRepurchasedDuringPeriodValueAdditional>
    <atnm:StockRepurchasedDuringPeriodSharesAdditional contextRef="From2018-10-01to2018-10-18_custom_PurchaseAgreementMember" unitRef="shares" decimals="INF">852537</atnm:StockRepurchasedDuringPeriodSharesAdditional>
    <atnm:StockRepurchasedDuringPeriodSharesAdditional contextRef="From2018-10-01to2018-10-18_custom_LincolnParkCapitalFundLlcMember" unitRef="shares" decimals="INF">400000</atnm:StockRepurchasedDuringPeriodSharesAdditional>
    <us-gaap:PurchaseObligation contextRef="AsOf2018-10-18_custom_LincolnParkCapitalFundLlcMember" unitRef="USD" decimals="0">1500000</us-gaap:PurchaseObligation>
    <atnm:AcceleratedPurchaseDescription contextRef="From2018-10-01to2018-10-18_custom_LincolnParkCapitalFundLlcMember">(i) 300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the total number of shares of the Company's common stock traded during a specified period on the applicable purchase date as set forth in the agreement.</atnm:AcceleratedPurchaseDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2018-10-18_custom_LincolnParkCapitalFundLlcMember" unitRef="pure" decimals="INF">0.0999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <dei:EntitySmallBusiness contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:EntityExTransitionPeriod>
    <atnm:WarrantsToPurchaseOfCommonStock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">120628</atnm:WarrantsToPurchaseOfCommonStock>
    <atnm:NumberofWarrentIssued contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">120628</atnm:NumberofWarrentIssued>
    <atnm:NumberofWarrentIssued contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">3565159</atnm:NumberofWarrentIssued>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,236,101&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,174,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,906,886&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55,820,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,662,340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,964,752&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;63,056,977&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,836,932&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,871,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,673,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,399,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,519,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Restricted cash &amp;#8211; current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &amp;#8211; long term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;390,940&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash and cash equivalent and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,104,514&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,790,576&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,554,027&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-01-01to2017-12-31_srt_MinimumMember" unitRef="pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-01-01to2017-12-31_srt_MaximumMember" unitRef="pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31" unitRef="pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:PrepaidInsurance contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">72371</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">339336</us-gaap:PrepaidInsurance>
    <atnm:PrepaidClinicalTrialExpenses contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">226997</atnm:PrepaidClinicalTrialExpenses>
    <atnm:PrepaidClinicalTrialExpenses contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">171128</atnm:PrepaidClinicalTrialExpenses>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">139954</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">105758</us-gaap:OtherPrepaidExpenseCurrent>
    <dei:EntityWellKnownSeasonedIssuer contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityShellCompany contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2018-06-29" unitRef="USD" decimals="0">70693197</dei:EntityPublicFloat>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_custom_LabEquipmentMember">P5Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">P3Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">P7Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_custom_LabEquipmentMember" unitRef="USD" decimals="0">176500</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="0">208680</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_custom_LabEquipmentMember" unitRef="USD" decimals="0">116070</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="0">156940</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">419896</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">431958</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">431958</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">287972</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1571784</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <atnm:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Prepaid Expenses and Other&#13;Current Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prepaid expenses and&#13;other current assets consisted of the following at December 31, 2018 and 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Prepaid&amp;#160;insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;339,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Prepaid&amp;#160;clinical trial expenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,758&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;139,954&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,222&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;439,322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2018,&#13;the Company issued a note payable of $249,239 for its insurance premiums; payments are scheduled during 2019.&lt;/p&gt;</atnm:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 4 - Property and Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment&#13;consisted of the following at December 31, 2018 and 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Lives&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center"&gt;5 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Office equipment &amp;#38; furniture&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;3 - 7 years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(266,381&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(215,660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,799&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57,350&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2018,&#13;the Company entered into a five-year capital lease agreement for office equipment and services for $906 per month. At December&#13;31, 2018, the capitalized value associated with the lease agreement was $16,078.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation expense&#13;consisted of the following for the years ended December 31, 2018, 2017 and 2016, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Research &amp;#38; development&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,632&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,586&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50,721&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55,938&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;77,523&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Prepaid&amp;#160;insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;339,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Prepaid&amp;#160;clinical trial expenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,758&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;139,954&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,222&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;439,322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Lives&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center"&gt;5 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Office equipment &amp;#38; furniture&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;3 - 7 years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(266,381&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(215,660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,799&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57,350&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;For the year ending December 31:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;287,972&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 10pt; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,571,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <atnm:ScheduleOfDepreciationExpenseTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Research &amp;#38; development&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,632&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,586&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50,721&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55,938&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;77,523&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</atnm:ScheduleOfDepreciationExpenseTableTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">The lease is for 5,790 square feet and has a term of seven years and three months, with an expiration date of September 6, 2022, with a current annual rate of $312,660 until June 8, 2019 and $341,610 for the remaining life of the lease.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:PaymentsForLeasingCosts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">312660</us-gaap:PaymentsForLeasingCosts>
    <us-gaap:PaymentsForRent contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7529</us-gaap:PaymentsForRent>
    <atnm:CapitalleaseOfOfficeEquipment contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">16078</atnm:CapitalleaseOfOfficeEquipment>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" xsi:nil="true" />
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" xsi:nil="true" />
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember330937104" xsi:nil="true" />
    <atnm:FairValueOfMarketPrice contextRef="AsOf2018-10-18_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">600000</atnm:FairValueOfMarketPrice>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="From2018-10-01to2018-10-18_custom_LincolnParkCapitalFundLlcMember" unitRef="shares" decimals="INF">3376554</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="From2018-10-01to2018-10-18_custom_LincolnParkCapitalFundLlcMember" unitRef="USD" decimals="0">2500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2018-03-01to2018-03-31_custom_SeriesBWarrantsMember" unitRef="USD" decimals="0">13800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">60000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2017-07-25to2017-08-02_us-gaap_IPOMember" unitRef="USD" decimals="0">15000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2016-10-02to2016-10-04_us-gaap_IPOMember" unitRef="USD" decimals="0">9300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <atnm:Underwrittenoffering contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">21500000</atnm:Underwrittenoffering>
    <atnm:Underwrittenoffering contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember" unitRef="shares" decimals="INF">21500000</atnm:Underwrittenoffering>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_WarrantMember" unitRef="shares" decimals="INF">18275000</atnm:WarrantToPurchaseOfCommonStock>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2017-07-25to2017-08-02_us-gaap_WarrantMember" unitRef="shares" decimals="INF">18275000</atnm:WarrantToPurchaseOfCommonStock>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2017-07-25to2017-08-02_us-gaap_IPOMember" unitRef="shares" decimals="INF">18275000</atnm:WarrantToPurchaseOfCommonStock>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember" unitRef="shares" decimals="INF">18275000</atnm:WarrantToPurchaseOfCommonStock>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2012-01-01to2012-01-31_us-gaap_ChiefExecutiveOfficerMember" unitRef="shares" decimals="INF">99617</atnm:WarrantToPurchaseOfCommonStock>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2012-01-01to2012-01-31_us-gaap_BoardOfDirectorsChairmanMember" unitRef="shares" decimals="INF">64746</atnm:WarrantToPurchaseOfCommonStock>
    <atnm:WarrantToPurchaseOfCommonStock contextRef="From2012-12-07to2012-12-19" unitRef="shares" decimals="INF">57212</atnm:WarrantToPurchaseOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-03-01to2018-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">30237894</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-07-25to2017-08-02_us-gaap_IPOMember" unitRef="shares" decimals="INF">21500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">2672973</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">21000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">852537</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2018-10-18_custom_LincolnParkCapitalFundLlcMember" unitRef="USD_per_Share" decimals="INF">0.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2017-08-02_us-gaap_IPOMember" unitRef="USD_per_Share" decimals="INF">0.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2016-10-04_us-gaap_IPOMember" unitRef="USD_per_Share" decimals="INF">1.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-25to2017-08-02_us-gaap_IPOMember" unitRef="USD" decimals="0">16100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-10-02to2016-10-04_us-gaap_IPOMember" unitRef="USD" decimals="0">8000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">853</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-853</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod contextRef="From2017-07-25to2017-08-02_us-gaap_IPOMember">P5Y</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-01-01to2017-12-31_custom_ConsultantsMember" unitRef="shares" decimals="INF">67385</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockMember_custom_ConsultantsMember" unitRef="shares" decimals="INF">59393</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockMember_custom_ConsultantsMember" unitRef="shares" decimals="INF">250700</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-01-01to2017-12-31_custom_ConsultantsMember" unitRef="USD" decimals="0">99000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockMember_custom_ConsultantsMember" unitRef="USD" decimals="0">65813</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharePrice contextRef="AsOf2017-12-31_custom_ConsultantsMember" unitRef="USD_per_Share" decimals="INF">1.47</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2017-08-02_custom_WarrantsMember" unitRef="USD_per_Share" decimals="INF">0.75</us-gaap:SharePrice>
    <atnm:CommonStockForIssuedCashlessExerciseOfWarrants contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">4234</atnm:CommonStockForIssuedCashlessExerciseOfWarrants>
    <atnm:CommonStockForIssuedCashlessExerciseOfWarrants contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">125862</atnm:CommonStockForIssuedCashlessExerciseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2013-09-03to2013-09-30_custom_TwoThousandThirteenStockPlanMember_custom_EmployeesDirectorsAndConsultantsMember">2023-09-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2013-09-03to2013-09-30_custom_EmployeesDirectorsAndConsultantsMember_custom_TwoThousandThirteenEquityIncentivePlanMember">2023-09-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2015-01-01to2015-12-31_custom_TwoThousandThirteenStockPlanMember" unitRef="shares" decimals="INF">9250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2016-01-01to2016-12-31_custom_TwoThousandThirteenStockPlanMember" unitRef="shares" decimals="INF">12750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2017-01-01to2017-12-31_custom_TwoThousandThirteenStockPlanMember" unitRef="shares" decimals="INF">17750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2018-01-01to2018-12-31_custom_TwoThousandThirteenStockPlanMember" unitRef="shares" decimals="INF">22750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2013-01-01to2013-12-31_custom_TwoThousandThirteenStockPlanMember" unitRef="shares" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <atnm:RestrictedCommonSharesGranted contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">107911</atnm:RestrictedCommonSharesGranted>
    <atnm:RestrictedCommonSharesGrantedValue contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">72825</atnm:RestrictedCommonSharesGrantedValue>
    <atnm:RestrictedCommonSharesGrantedFullyVested contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">156393</atnm:RestrictedCommonSharesGrantedFullyVested>
    <atnm:RestrictedCommonSharesGrantedFullyVestedValue contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">81393</atnm:RestrictedCommonSharesGrantedFullyVestedValue>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Subsequent Events&#13;&lt;/b&gt;- The Company's management reviewed all material events through the date the consolidated financial statements were issued&#13;for subsequent event disclosure consideration.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition&#13;&lt;/b&gt;- The Company adopted new accounting guidance for revenue recognition, effective January 1, 2018, which did not have a significant&#13;impact on the Company&amp;#8217;s financial statements. Beginning January 1, 2018, revenues are recognized when control of the promised&#13;goods or services is transferred to customers in an amount that reflects the consideration expected to be entitled to in exchange&#13;for those goods or services&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development&#13;Costs -&lt;/b&gt; Research and development costs are expensed as incurred. Research and development reimbursements are recorded by the&#13;Company as a reduction of research and development costs.&amp;#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments&#13;-&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing&#13;model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee&#13;is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common&#13;Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average&#13;number of common shares outstanding during the reporting period. For the years ended December 31, 2018, 2017 and 2016, the Company&amp;#8217;s&#13;potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation&#13;of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,236,101&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,174,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,906,886&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55,820,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,662,340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,964,752&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;63,056,977&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,836,932&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,871,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value of Financial&#13;Instruments&lt;/b&gt; &lt;b&gt;- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,&#13;in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives&#13;the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable&#13;inputs. As required by ASC 820 &amp;#8220;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;&amp;#8221;, financial assets and liabilities&#13;are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s&#13;assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation&#13;of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 1 Inputs - Unadjusted quoted&#13;prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement&#13;date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 2 Inputs - Inputs other&#13;than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might&#13;include quoted prices for similar assets or liabilities&amp;#160;in&amp;#160;active markets, quoted prices for identical or similar assets&#13;or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such&#13;as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated&#13;by market data by correlation or other means.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 3 Inputs - Unobservable&#13;inputs for determining the fair values of assets or liabilities that reflect an entity&amp;#8217;s own assumptions about the assumptions&#13;that market participants would use in pricing the assets or liabilities.&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash and Cash Equivalents&#13;-&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents.&#13;Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation&#13;-&lt;/b&gt; The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned&#13;subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates&#13;in Financial Statement Presentation -&lt;/b&gt; The preparation of these consolidated financial statements in conformity with accounting&#13;principles generally accepted in the United States of America requires management to make estimates and assumptions that affect&#13;the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of&#13;expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Reclassifications&#13;- &lt;/b&gt;Certain reclassifications have been made to the prior-year financial statements to conform to the current-year presentation,&#13;including the addition of restricted cash to cash and cash equivalents on the consolidated statements of cash flows as a result&#13;of the adoption of new accounting guidance.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <atnm:AccountingPronouncementsRecentlyAdopted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Accounting Standards&#13;Recently Adopted &lt;/b&gt;- In November 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued an Accounting Standards&#13;Update (&amp;#8220;ASU&amp;#8221;) amending the presentation of restricted cash within the consolidated statements of cash flows. The new&#13;guidance requires that restricted cash be added to cash and cash equivalents on the consolidated statements of cash flows. The&#13;Company adopted this ASU on January 1, 2018 on a retrospective basis with the impact to its consolidated statements of cash flows&#13;for the year ended December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Previously Reported&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Adjustment&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(380,946&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;356,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(24,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There was&#13;no impact to the cash flows from operating, investing and financing activities for the year ended December 31, 2016 as the&#13;amount of restricted cash did not change during 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary&#13;of cash and cash equivalents and restricted cash at December 31, 2018, 2017 and 2016, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,673,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,399,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,519,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Restricted cash &amp;#8211; current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &amp;#8211; long term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;390,940&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash and cash equivalent and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,104,514&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,790,576&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,554,027&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2014, the FASB&#13;issued ASU No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under the new standard, revenue is recognized at the time&#13;a good or service is transferred to a customer for the amount of consideration for which the entity expects to be entitled for&#13;that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of&#13;adoption. The Company adopted this ASU on January 1, 2018 and the adoption did not have a significant impact to the Company&amp;#8217;s&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July 2017, the FASB&#13;issued ASU No. 2017-11, &lt;i&gt;Earnings Per Share&lt;/i&gt; (Topic 260); &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (Topic 480); &lt;i&gt;Derivatives&#13;and Hedging&lt;/i&gt; (Topic 815): (Part I) &lt;i&gt;Accounting for Certain Financial Instruments with Down Round Features.&lt;/i&gt; These amendments&#13;simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard&#13;the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability&#13;or equity classification. The guidance was adopted as of April 1, 2018. See Note 2 for further discussion.&lt;/p&gt;</atnm:AccountingPronouncementsRecentlyAdopted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;Recent Accounting Standards &amp;#8211;&#13;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In February 2016,&#13;FASB issued ASU No. 2016-02 &lt;i&gt;Leases&lt;/i&gt; (Topic 842), which creates new accounting and reporting guidelines for leasing&#13;arrangements. The standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A&#13;lessee should recognize on its balance sheet a liability to make lease payments (the lease liability) and a right-of-use&#13;asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a&#13;lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and&#13;lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the&#13;earliest period presented using a modified retrospective approach. The guidance in ASU 2016-02 is effective for annual and&#13;interim reporting periods beginning after December 15, 2018. The Company&amp;#8217;s initial evaluation of its current leases&#13;does not indicate that the adoption of this standard will have a material impact on its consolidated statements of&#13;operations. However, the Company does expect that the adoption of the standard will have an impact on its&#13;consolidated balance sheets for the recognition of certain operating leases as right-of-use assets and lease liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In June 2018, the FASB&#13;issued ASU 2018-07 to expand the scope of ASC Topic 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;, to include share-based payment&#13;transactions for acquiring goods and services from nonemployees. The standard is effective for fiscal years, and for interim periods&#13;within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating&#13;the impact of the new standard on its financial statements and related disclosures, but does not expect this ASU to have a material&#13;impact on its financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, the&#13;FASB issued ASU 2018-13, &lt;i&gt;Fair Value Measurement - Disclosure Framework (Topic 820).&lt;/i&gt; The updated guidance improves the disclosure&#13;requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay&#13;of adoption of the additional disclosures until their effective date. The Company is in the process of evaluating the provisions&#13;of the ASU but does not expect it to have a material effect on its consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2018, the&#13;FASB issued ASU 2018-18, C&lt;i&gt;ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,&lt;/i&gt;&#13;which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be&#13;accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal&#13;years, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impact&#13;the standard will have on its financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, the&#13;SEC adopted the final rule under SEC Release No. 33-10532, &lt;i&gt;Disclosure Update and Simplification&lt;/i&gt;, amending certain disclosure&#13;requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure&#13;requirements on the analysis of stockholders&amp;#8217; equity for interim financial statements. Under the amendments, an analysis&#13;of changes in each caption of stockholders&amp;#8217; equity presented in the balance sheet must be provided in a note or separate&#13;statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which&#13;a statement of comprehensive income is required to be filed. The Company anticipates its first presentation of changes in stockholders&amp;#8217;&#13;equity will be included in its Form 10-Q for the three months ended March 31, 2019.&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="margin: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Nature of Business&lt;/b&gt; - Actinium&#13;Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Actinium&amp;#8221;, or &amp;#8220;We&amp;#8221;) is a clinical-stage, biopharmaceutical&#13;company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell therapies such&#13;as a BMT or Bone Marrow Transplant or CAR-T, &lt;font style="background-color: white"&gt;a type of cellular therapy that genetically&#13;alters a patient&amp;#8217;s own T cells to target and kill their cancer cells,&lt;/font&gt; and for other adoptive cell therapies. In addition,&#13;the Company is also developing potential therapies for targeting and killing of cancer cells either as single agents or in combination&#13;with other drugs.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"&gt;&lt;b&gt;Note 2  -&#13;Derivative Liabilities&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Historically, the Company&#13;accounted for certain instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with&#13;FASB ASC 815-40,&amp;#160;&lt;i&gt;Derivative and Hedging &amp;#8211; Contracts in Entity&amp;#8217;s Own Equity&lt;/i&gt;. This was due to an anti-dilution&#13;provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity-linked instruments&#13;in the future at an effective price per share less than the exercise price then in effect for the warrant (&amp;#8220;down round provision&amp;#8221;).&#13;As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value&#13;were recorded as non-cash adjustments within other income (expense), net, in the Company&amp;#8217;s accompanying Consolidated Statements&#13;of Operations. The Company recorded a gain on the change in the estimated fair value of warrants of $0.3 million and $2.5 million&#13;for the years ended December 31, 2017 and 2016, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of April 1, 2018,&#13;the Company early adopted ASU 2017-11, which revised the guidance for instruments with down-round provisions. As such, the Company&#13;treats outstanding warrants as free-standing equity-linked instruments that are recorded to equity in the Consolidated Balance&#13;Sheet as of January 1, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with&#13;the guidance presented in the ASU 2017-11, the fair value of the derivative liability balance for 57,212 warrants as of December&#13;31, 2017 of $16 thousand was reclassified by means of a cumulative-effect adjustment to equity as of January 1, 2018. These warrants&#13;had an original exercise price of $2.34. The exercise price is adjusted based on a formula whenever the Company issues, or is deemed&#13;to have issued, any common shares for no consideration or a consideration per share less than the exercise price of warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior to the Company&amp;#8217;s&#13;adoption of ASU 2017-11, the exercise price of the warrants was reset to $1.25 as a result of various offerings. The difference&#13;of $5 thousand between the fair value of the warrants with the exercise price prior to the price reset and the fair value of the&#13;warrants with the exercise price after the price reset was accounted for as a deemed dividend. The impact of the adoption was as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: justify"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(15,916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(50,238&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;Total stockholders&amp;#8217; equity&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15,916&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the&#13;derivative warrants was calculated using a binomial valuation model with the following assumptions at December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Adjusted exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.09&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Warrant lives in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.1 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected dividend yield (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Probability of stock offering in any period over 5 years (5)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Offering price estimated as of December 31, 2017 (6)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The market value of common stock at the above measurement&#13;dates was based on the Company&amp;#8217;s closing price quoted on the NYSE American.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The risk-free interest rate was determined by the Company&#13;using the Treasury Bill rate as of the respective measurement date.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The volatility was estimated using the historical volatility&#13;of the Company&amp;#8217;s common stock.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(4)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Management does not expect to pay dividends for the foreseeable&#13;future.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(5)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Management determines the probability of future stock offering&#13;at each evaluation date.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(6)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Represents the estimated offering price in future offerings&#13;as determined by management.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt"&gt;As a result of an agreement with Lincoln&#13;Park Capital Fund, LLC (See Note 7) the exercise price was further reset to $1.23 per share, with an immaterial change in the fair&#13;value of the warrants before and after the price reset.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: justify"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(15,916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(50,238&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;Total stockholders&amp;#8217; equity&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15,916&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 88%; text-align: left"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Adjusted exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.09&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Warrant lives in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.1 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected dividend yield (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Probability of stock offering in any period over 5 years (5)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Offering price estimated as of December 31, 2017 (6)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The market value of common stock at the above measurement&#13;dates was based on the Company's closing price quoted on the NYSE American.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The risk-free interest rate was determined by the Company&#13;using the Treasury Bill rate as of the respective measurement date.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The volatility was estimated using the historical volatility&#13;of the Company's common stock.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(4)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Management does not expect to pay dividends for the foreseeable&#13;future.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(5)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Management determines the probability of future stock offering&#13;at each evaluation date.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.38in; text-align: left"&gt;(6)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Represents the estimated offering price in future offerings&#13;as determined by management.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">254819</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockMember_custom_ConsultantsMember" unitRef="USD" decimals="0">40000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <atnm:StockIssuedDuringPeriodRestrictedStockAwardNotIssued contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">60700</atnm:StockIssuedDuringPeriodRestrictedStockAwardNotIssued>
    <atnm:FairValueAssumptionsExpectedDiscountRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0234</atnm:FairValueAssumptionsExpectedDiscountRate>
    <atnm:FairValueAssumptionsExpectedDiscountRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0184</atnm:FairValueAssumptionsExpectedDiscountRate>
    <atnm:FairValueAssumptionsExpectedDiscountRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0299</atnm:FairValueAssumptionsExpectedDiscountRate>
    <atnm:FairValueAssumptionsExpectedDiscountRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0228</atnm:FairValueAssumptionsExpectedDiscountRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2017-05-15to2017-06-06_us-gaap_DirectorMember">Pursuant to the agreement, all the outstanding vested options, (which originally were to expire 90 days from termination date), as well as 68,200 unvested options granted prior to December 31, 2016, shall be exercisable until the end of the term of each option grant agreement.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">18105</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">18105</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="USD" decimals="0">23</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">18082</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-11-08_custom_WarrantsMember_custom_MrSandeshSethMember" unitRef="shares" decimals="INF">375556</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-11-08_custom_WarrantsMember_us-gaap_BoardOfDirectorsChairmanMember" unitRef="shares" decimals="INF">353023</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-11-08_custom_WarrantsMember_us-gaap_ChiefExecutiveOfficerMember" unitRef="shares" decimals="INF">721068</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:OtherExpenses contextRef="From2017-07-01to2017-08-02_custom_WarrantsMember" unitRef="USD" decimals="0">20400000</us-gaap:OtherExpenses>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">30826534</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">34531577</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">3731413</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2950963</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <atnm:IncomeTaxReconciliationResearchAndDevelopment contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">6324998</atnm:IncomeTaxReconciliationResearchAndDevelopment>
    <atnm:IncomeTaxReconciliationResearchAndDevelopment contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">8896703</atnm:IncomeTaxReconciliationResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">11369</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">15285</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">40894314</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">46394528</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2035-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchMember_us-gaap_DomesticCountryMember">2033-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="From2018-01-01to2018-12-31_custom_OrphanDrugCreditsMember">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">17900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-4967332</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-9044420</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-8269386</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1413678</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1940945</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-973547</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">17939714</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1986609</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3029074</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">141769</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <atnm:IncomeTaxReconciliationDeferredTrueUp contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <atnm:IncomeTaxReconciliationDeferredTrueUp contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3090816</atnm:IncomeTaxReconciliationDeferredTrueUp>
    <atnm:IncomeTaxReconciliationDeferredTrueUp contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-10511380</atnm:IncomeTaxReconciliationDeferredTrueUp>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-120870</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-956840</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">40049</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">12845</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">13632</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5500214</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-6908066</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">18892196</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">-0.073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2016-01-01to2016-12-31" unitRef="pure" decimals="INF">-0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">0.674</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2016-01-01to2016-12-31" unitRef="pure" xsi:nil="true" />
    <atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" xsi:nil="true" />
    <atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">0.118</atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps>
    <atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps contextRef="From2016-01-01to2016-12-31" unitRef="pure" decimals="INF">-0.433</atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">-0.084</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">-0.114</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="From2016-01-01to2016-12-31" unitRef="pure" decimals="INF">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2016-01-01to2016-12-31" unitRef="pure" decimals="INF">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="From2016-01-01to2016-12-31" unitRef="pure" decimals="INF">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="INF">0.232</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="INF">-0.26</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-01-01to2016-12-31" unitRef="pure" decimals="INF">0.777</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2016-01-01to2016-12-31" unitRef="pure" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">144500000</us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesForeign contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">66800000</us-gaap:IncomeTaxReconciliationTaxContingenciesForeign>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-12-31_us-gaap_ResearchMember_us-gaap_DomesticCountryMember" unitRef="USD" decimals="0">1400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-12-31_custom_OrphanDrugCreditsMember" unitRef="USD" decimals="0">7500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2019-01-01to2019-01-31_us-gaap_SubsequentEventMember" unitRef="shares" decimals="INF">924500</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="shares" decimals="INF">11504427</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">24172973</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">34614448</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">16976237</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">18789634</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">16022667</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-01-01to2019-01-31_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">400000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="USD" decimals="0">11504</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">24173</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">34614</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">16011163</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">18765461</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">16941623</us-gaap:StockIssuedDuringPeriodValueOther>
    <atnm:ExercisedSeriesWarrantsIssuedForThePeriod contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">2500000</atnm:ExercisedSeriesWarrantsIssuedForThePeriod>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <atnm:WarrantsToExercisableTerm contextRef="From2016-01-01to2016-12-31_custom_WarrantsMember_srt_MaximumMember">P10Y</atnm:WarrantsToExercisableTerm>
    <us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesPayableCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">249239</us-gaap:NotesPayableCurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">13354</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">173359</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5430</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-5007</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">16976237</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">18814634</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">16022667</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsToAcquireInvestments contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireInvestments contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireInvestments contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">49859</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">265695</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">18105</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:InterestPaidNet contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">5007</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">25000</atnm:StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses>
    <atnm:StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <atnm:PrepaidExpensesFinancedByAccountsPayableAndNotesPayable contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">276932</atnm:PrepaidExpensesFinancedByAccountsPayableAndNotesPayable>
    <atnm:PrepaidExpensesFinancedByAccountsPayableAndNotesPayable contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <atnm:PrepaidExpensesFinancedByAccountsPayableAndNotesPayable contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">16078</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <atnm:TransferFromDerivativeLiabilityClassificationToEquityClassification contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <atnm:TransferFromDerivativeLiabilityClassificationToEquityClassification contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <atnm:TransferFromDerivativeLiabilityClassificationToEquityClassification contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">17455</atnm:TransferFromDerivativeLiabilityClassificationToEquityClassification>
    <us-gaap:SharesOutstanding contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">44066541</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">55801742</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">80072334</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">115703044</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="shares" decimals="INF">81700</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">93385</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">156393</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1798655</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3474375</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">4297778</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="USD" decimals="0">82</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">93</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">157</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4297696</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3474282</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1798498</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <atnm:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="shares" decimals="INF">125862</atnm:StockIssuedDuringPeriodSharesWarrantsExercised>
    <atnm:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">4234</atnm:StockIssuedDuringPeriodSharesWarrantsExercised>
    <atnm:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF">7332</atnm:StockIssuedDuringPeriodSharesWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4849</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="USD" decimals="0">126</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">4</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="0">7</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-126</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-4</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4842</atnm:StockIssuedDuringPeriodValueWarrantsExercised>
    <atnm:TransferOfWarrantDerivativesFromLiabilityToEquityClassification contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">17455</atnm:TransferOfWarrantDerivativesFromLiabilityToEquityClassification>
    <atnm:TransferOfWarrantDerivativesFromLiabilityToEquityClassification contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember173911521" unitRef="USD" xsi:nil="true" />
    <atnm:TransferOfWarrantDerivativesFromLiabilityToEquityClassification contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17455</atnm:TransferOfWarrantDerivativesFromLiabilityToEquityClassification>
    <atnm:ModifiedRetroactiveAdjustmentForDerivativeLiability contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">15916</atnm:ModifiedRetroactiveAdjustmentForDerivativeLiability>
    <atnm:ModifiedRetroactiveAdjustmentForDerivativeLiability contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" xsi:nil="true" />
    <atnm:ModifiedRetroactiveAdjustmentForDerivativeLiability contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">66154</atnm:ModifiedRetroactiveAdjustmentForDerivativeLiability>
    <atnm:ModifiedRetroactiveAdjustmentForDerivativeLiability contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-50238</atnm:ModifiedRetroactiveAdjustmentForDerivativeLiability>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-3686062</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2763451</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-5123979</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <atnm:CapitalLeaseAgreement contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">P5Y</atnm:CapitalLeaseAgreement>
    <atnm:OfficeEquipmentServices contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">906</atnm:OfficeEquipmentServices>
    <us-gaap:LineOfCredit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">390825</us-gaap:LineOfCredit>
    <atnm:GrossProceedsFromWarrantExercises contextRef="From2018-03-01to2018-03-31_custom_SeriesBWarrantsMember" unitRef="USD" decimals="0">15100000</atnm:GrossProceedsFromWarrantExercises>
    <atnm:AdditionalNoncashExpenseIncrementalFairValue contextRef="From2017-02-26to2017-03-14" unitRef="USD" decimals="0">64000</atnm:AdditionalNoncashExpenseIncrementalFairValue>
    <us-gaap:Deposits contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">391131</us-gaap:Deposits>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2018-01-01to2018-12-31_custom_LincolnParkCapitalFundLlcMember" unitRef="USD" decimals="0">700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Property and Equipment&#13;-&lt;/b&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three&#13;to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives&#13;of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any&#13;related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease&#13;assets are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated&#13;useful life of the related property or term of the lease.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt;&lt;b&gt;Income Taxes -&lt;/b&gt; The Company provides&#13;for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based&#13;on the differences between the financial statement carrying amounts of existing assets and liabilities at each year-end and their&#13;respective tax bases, and are measured using enacted tax rates in effect for the year in which the differences are expected to&#13;affect taxable income. Significant judgment is required by management to determine the Company&amp;#8217;s provision for income taxes,&#13;deferred tax assets and liabilities, and the valuation allowance to record against net deferred tax assets, which are based on&#13;complex and evolving tax regulations throughout the world.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred tax assets&#13;and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. There were&#13;no tax positions for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly&#13;increase or decrease within the next year. The Company recognizes interest related to unrecognized tax benefits in interest expense&#13;and penalties in operating expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Tax Cuts and Jobs Act,&#13;or the Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the&#13;Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. As of December&#13;31, 2018, upon completing its analysis of the Act, the Company believes that its disclosures in its financial statements as of&#13;December 31, 2017 remain accurate.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 6 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;License and Research Agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has entered&#13;into agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services under&#13;which the Company may incur obligations to make payments including upfront payments as well as milestone and royalty payments.&#13;Notable inclusions in this category are:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Oak Ridge National Laboratory (&amp;#8220;ORNL&amp;#8221;) &amp;#8211; The Company is contracted to purchase&#13;radioactive material to be used for research and development, with a renewal option at the contract end. During the years ended&#13;December 31, 2018, 2017 and 2016, the Company purchased material from ORNL of approximately $0.3 million, $0.6 million and $1.0&#13;million, respectively. On December 19, 2018, the Company signed a contract with ORNL to purchase $0.2 million of radioactive material&#13;during calendar year 2019.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred&#13;Hutchinson Cancer Research Center (&amp;#8220;FHCRC&amp;#8221;) to build upon previous and ongoing clinical trials, with BC8 (licensed&#13;antibody). FHCRC has currently completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive&#13;rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC&#13;upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of&#13;2% of net sales will be due to FHCRC. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On February 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology&#13;Inc. (&amp;#8220;Goodwin&amp;#8221;). Goodwin oversees the current Good Manufacturing Practices (&amp;#8220;cGMP&amp;#8221;) production of a monoclonal&#13;antibody used in the Phase 3 clinical trial of Iomab-B. As of December 31, 2018, the remaining cost of the service agreement is&#13;$1.0 million. During the years ended December 31, 2018, 2017 and 2016, the Company paid Goodwin $1.2 million, $1.4 million and&#13;$0.7 million, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On February 16, 2016, the Company entered into an agreement with Medpace, Inc. (&amp;#8220;Medpace&amp;#8221;),&#13;a Contract Research Organization, (&amp;#8220;CRO&amp;#8221;). Medpace provides project management services for the Iomab-B study. The&#13;total project is currently estimated to cost approximately $10.2 million. As of December 31, 2018, the remaining cost of the agreement&#13;is approximately $3.3 million. Medpace bills the Company when services are rendered and the Company records the related expense&#13;to research and development costs. During the years ended December 31, 2018, 2017 and 2016, the Company paid Medpace $3.1 million,&#13;$2.8 million and $2.6 million, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On August 4, 2016, the Company entered into a CRO agreement with George Clinical Services, (&amp;#8220;George&amp;#8221;).&#13;George provides project management services for the study of Actimab-A used for a Phase 2 clinical trial. The total project is&#13;estimated to cost approximately $4.6 million. As of December 31, 2018, the remaining cost of the agreement is approximately $0.5&#13;million. George bills the Company when services are rendered and the Company records the related expense to research and development&#13;costs. During the years ended December 31, 2018, 2017 and 2016, the Company paid George $1.9 million, $0.7 million and $0.1 million,&#13;respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Lease Agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company does not&#13;own any real property. It currently leases office space located at 275 Madison Avenue, New York, NY. The lease is for 5,790 square&#13;feet and has a term of seven years and three months, with an expiration date of September 6, 2022, with a current annual rate of&#13;$312,660 until June 8, 2019 and $341,610 for the remaining life of the lease. The Company is also responsible for certain other&#13;costs, such as insurance, taxes, utilities, and maintenance. The Company issued a letter of credit of $390,825 in connection with&#13;the lease and maintained a $391,131 certified deposit as collateral for the letter of credit.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In 2017, the Company&#13;also entered into a license agreement for furniture and fixtures located at its office space. Pursuant to the terms of the agreement,&#13;the Company leases the furniture and fixtures and tenant improvements located in the office space for the same term as the office&#13;space for $7,529 per month. At any time during the term of this amended agreement, the Company has the right to purchase the furniture,&#13;and fixtures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2018,&#13;the Company entered into a five-year lease agreement for office equipment and services for $906 per month and the capitalized value&#13;associated with the lease agreement was $16,078.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Future minimum obligations&#13;on all of the Company&amp;#8217;s operating leases with a term over one year are:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;For the year ending December 31:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;287,972&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 10pt; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,571,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 7 - Equity&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 18, 2018,&#13;the Company and Lincoln Park Capital Fund, LLC (&amp;#8220;Lincoln Park&amp;#8221;) entered into a purchase agreement and a registration&#13;rights agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&amp;#8217;s common stock&#13;having an aggregate value of up to $32,500,000, subject to certain limitations and conditions set forth in the agreement. As consideration&#13;for entering into the purchase agreement, the Company issued to Lincoln Park 852,537 shares of common stock, determined to be offering&#13;costs as part of the financing. These shares had a fair value of $0.6 million based on the market price on the issuance date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the purchase&#13;agreement, Lincoln Park initially purchased 3,376,554 shares of common stock, at a price of $0.74 per share, for a total gross&#13;purchase price of $2,500,000. As often as every business day from and after one business day following the date of the initial&#13;purchase and over the 30-month term of the agreement, and up to an aggregate amount of an additional $30,000,000 (subject to certain&#13;limitations) of shares of common stock, the Company has the right, from time to time, at its sole discretion and subject to certain&#13;conditions, to direct Lincoln Park to purchase up to 400,000 shares of common stock, with such amount increasing as the closing&#13;sale price of the common stock increases; provided Lincoln Park&amp;#8217;s obligation under any single such purchase will not exceed&#13;$1,500,000, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a&#13;&amp;#8220;Regular Purchase&amp;#8221;). If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it&#13;then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations&#13;in the agreement, the Company may direct Lincoln Park in an &amp;#8220;accelerated purchase&amp;#8221; to purchase an additional amount&#13;of common stock that may not exceed the lesser of (i) 300% the number of shares purchased pursuant to the corresponding Regular&#13;Purchase or (ii) 30% of the total number of shares of the Company&amp;#8217;s common stock traded during a specified period on the&#13;applicable purchase date as set forth in the agreement. Under certain circumstances and in accordance with the agreement, the Company&#13;may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company controls&#13;the timing and amount of any sales of its common stock to Lincoln Park. There is no upper limit on the price per share that Lincoln&#13;Park must pay for its common stock under the agreement, but in no event will shares be sold to Lincoln Park on a day the closing&#13;price is less than the floor price specified in the agreement. In all instances, the Company may not sell shares of its common&#13;stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its&#13;common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The agreement does&#13;not limit the Company&amp;#8217;s ability to raise capital from other sources at the Company&amp;#8217;s sole discretion, except that (subject&#13;to certain exceptions) the Company may not enter into any variable rate transaction (as defined in the agreement, including the&#13;issuance of any floating conversion rate or variable priced equity-like securities) during the 30 months after the date of the&#13;Purchase Agreement. The Company has the right to terminate the agreement at any time, at no cost to the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Through December 31,&#13;2018, the Company elected to sell to Lincoln Park an additional 1.0 million shares and received $0.7 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2018, the&#13;Company sold an aggregate of 30,237,894 units consisting of an aggregate of 30,237,894 shares of common stock, 7,559,445 series&#13;A warrants and 22,678,393 series B warrants, with each series A warrant exercisable for one share of common stock at an exercise&#13;price of $0.60 per share and each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per&#13;share, resulting in gross proceeds to Actinium of approximately $15.1 million (each unit was sold at $0.50 per unit), and net proceeds&#13;of approximately $13.8 million after deducting expenses relating to dealer-manager fees and other offering expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2017, the Company issued 2,672,973 shares of common stock for gross proceeds of approximately $4.0 million as part&#13;of its At-The-Market sales agreement with an investment bank. The Company paid expenses of approximately $0.2 million resulting&#13;in net proceeds of $3.8 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 2, 2017,&#13;the Company completed an underwritten public offering of 21,500,000 shares of its common stock and warrants to purchase 18,275,000&#13;shares of the Company&amp;#8217;s common stock at an offering price to the public of $0.75 per share and related warrant. The warrants&#13;have an exercise price of $1.05 per share and have a term of five years. The gross proceeds from this offering were approximately&#13;$16.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company&#13;resulting in net proceeds of approximately $15.0 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2017, the Company issued 67,385 common shares for consulting services. The shares have a total value of $99 thousand&#13;based on the Company&amp;#8217;s stock price on the grant date at $1.47 per share. During the year ended December 31, 2017, the Company&#13;also issued 4,234 common shares for the cashless exercise of warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 4, 2016,&#13;the Company sold 8,000,000 shares of its common stock at a price of $1.25 per share to the public through an underwritten public&#13;offering, for net proceeds of $9.3 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During 2016, the Company&#13;also issued 3,500,000 shares of common stock for net proceeds of $6.8 million as part of an at-the-market (ATM) sales agreement&#13;with an investment bank.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2016, the Company issued 125,862 common shares for the cashless exercise of warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2013 Amended and Restated Stock Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2013,&#13;the Board of Directors of the Company approved the Company&amp;#8217;s 2013 Stock Plan. The expiration date of the plan is September&#13;9, 2023 and the total number of underlying shares of the Company&amp;#8217;s common stock available for grant to employees, directors&#13;and consultants of the Company under the plan was 2,750,000 shares. In December 2015, shareholders of the Company approved the&#13;second amendment to the plan and increased the number of shares authorized under the plan to 9,250,000 shares. In December 2016,&#13;shareholders of the Company approved the fifth amendment to the plan and increased the number of shares authorized under the plan&#13;to 12,750,000 shares. In December 2017, shareholders of the Company approved the sixth amendment to the plan and increased the&#13;number of shares authorized under the plan to 17,750,000 shares. In December 2018, shareholders of the Company approved the seventh&#13;amendment to the plan and increased the number of shares authorized under the plan to 22,750,000 shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2013 Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2013,&#13;the Board approved the Company&amp;#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September 9, 2023 and the&#13;total number of shares of the Company&amp;#8217;s common stock available for grant to employees, directors and consultants of the Company&#13;under the plan was 450,000 shares. In December 2013, the shareholders of the Company approved the plan and increased the number&#13;of shares authorized under the plan to 1,000,000 shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Restricted Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;During&#13;2018, the Company granted 107,911 restricted common shares for consulting services, which all vested during 2018. The shares&#13;had a total value of $72,825.&amp;#160;During the year ended December 31, 2018, the Company issued 156,393 common shares for&#13;restricted shares that became fully vested, of which 81,393 shares were granted prior to 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31,&#13;2018, the Company has yet to issue 254,819 common shares for restricted shares that have vested. As of December 31, 2018, all&#13;restricted shares granted were vested with no unamortized compensation expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2017, the Company issued 26,000 common shares for restricted shares that became fully vested. The Company also granted&#13;59,393 common shares for consulting services. The shares have a total value of $65,813 based on the services provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2016, the Company granted 250,700 shares of restricted common stock to consultants with a fair value of $0.4 million&#13;based on the stock price on the grant dates.&amp;#160;The Company issued common shares totaling 21,000 for restricted shares granted&#13;in 2015 and prior years and 60,700 for restricted shares granted in 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During&#13;the years ended December 31, 2018, 2017 and 2016, the Company recorded stock-based compensation expense of $0.1 million, $0.2 million&#13;and $0.6 million, respectively, for the restricted shares granted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary&#13;of option activities for the years ended December 31, 2018, 2017 and 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt;&#13;    Contractual &lt;br /&gt; Term &lt;br /&gt; (in years)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2016&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,971,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,964,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,225,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(266,485&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.51&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,906,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,597,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,329,794&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,174,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,577,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,515,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2.96&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,236,101&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.74&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,021,818&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.55&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2018, the Company granted its employees and members of the Board of Directors 3,577,159 options to purchase Company&#13;common stock with an exercise price ranging from $0.344 to $0.7829 per share, a term of 10 years, and a vesting period from 4 to&#13;4.2 years.&amp;#160;The options have an aggregated fair value of $1.7 million that was calculated using the Black-Scholes option-pricing&#13;model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 2.34% to 2.99% (2) expected&#13;life of 6 years, (3) expected volatility range from 78.8% to 80.4%, and (4) zero expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2017, the Company granted its employees and members of the Board of Directors 2,597,500 options to purchase Company&#13;common stock with an exercise price ranging from $0.57 to $1.58 per share, a term of 10 years, and a vesting period from 4 to 4.2&#13;years.&amp;#160;The options have an aggregated fair value of $2.4 million that was calculated using the Black-Scholes option-pricing&#13;model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 1.84% to 2.28% (2) expected&#13;life of 6 years, (3) expected volatility range from 80.83% to 82.37%, and (4) zero expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 6, 2017, a&#13;director, resigned from the Company and the Company entered into an agreement with the director. Pursuant to the agreement, all&#13;the outstanding vested options, (which originally were to expire 90 days from termination date), as well as 68,200 unvested options&#13;granted prior to December 31, 2016, shall be exercisable until the end of the term of each option grant agreement. As a result&#13;of the modification, the Company recorded an additional expense of approximately $174,000 for the incremental fair value of the&#13;options, calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include:&#13;(1) discount rate range from 0.97% to 1.39% (2) expected life of 3 months to 8.9 years, (3) expected volatility range from 45.72%&#13;to 79.81%, and (4) zero expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2016, the Company granted employees, consultants, and its board members 2,225,000 options to purchase the Company&amp;#8217;s&#13;common stock with exercise prices ranging from $0.95 to $2.25 with a 10-year term vesting over a 4-year period.&amp;#160;&amp;#160;The&#13;options have an aggregated fair value of $3.1 million that was calculated using the Black-Scholes option-pricing model. Variables&#13;used in the Black-Scholes option-pricing model include: (1) discount rate of 1.28% - 1.97% (2) expected life of 6 years, (3) expected&#13;volatility of 81.45% - 87.95%, and (4) zero expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended&#13;December 31, 2018, 2017 and 2016, options to purchase 1,515,650, 3,329,794 and 266,485 common shares were cancelled, respectively,&#13;upon the termination of employment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There were no exercises&#13;of options during the years ended December 31, 2018 and 2017. During the year ended December 31, 2016, the Company received gross&#13;proceeds of $18,105 for the exercise of stock options for 23,212 shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of&#13;all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense&#13;at December 31, 2018 was approximately $2.6 million. During each of the years ended December 31, 2018, 2017 and 2016, the Company&#13;recorded total option expense of approximately $1.7 million, $3.1 million and $3.6 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary&#13;of warrant activities for the years ended December 31, 2018, 2017 and 2016, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Term &lt;br /&gt; (in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br /&gt; Intrinsic &lt;br /&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2016&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,018,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,199,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(183,718&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,964,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,445,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,496,575&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,364&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,789,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2.22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding, December 31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,662,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;995,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,360,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,332&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(194,598&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;9.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55,820,876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;569,038&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55,613,377&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.03&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;566,676&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On November 8, 2018,&#13;the Company amended certain warrants, originally dated December 17, 2012, that had been issued to three entities affiliated with&#13;the family of the Mr. Sandesh Seth, Chairman and CEO, Amrosan LLC, Carnegie Hill Partners, and Bioche Asset Management, LCC, in&#13;the amount of 375,556, 353,023 and 721,068 shares, respectively and extended their date of expiration from December 17, 2019 to&#13;February 21, 2022. The warrants had originally been issued in 2012 as part of investment banking and advisory services provided&#13;by Mr. Seth. The incremental fair value for the warrants due to the amendment was immaterial.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2018, the&#13;Company sold an aggregate of 30,237,894 units consisting of an aggregate of 30,237,894 shares of common stock, 7,559,445 series&#13;A warrants and 22,678,393 series B warrants, with each series A warrant exercisable for one share of common stock at an exercise&#13;price of $0.60 per share and each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2018, the Company granted 122,628 warrants to consultants. The warrants are exercisable for periods ranging from 4&#13;to 5 years at exercise prices ranging from $0.36 to $0.80 per share. The fair value of the warrants was approximately $27 thousand&#13;at the grant date and was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing&#13;model include (1) discount rate range of 2.34% to 2.99%, (2) expected term of 4-5 years, (3) expected volatility range of 77.01%&#13;to 79.00%, and (4) zero expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 2, 2017,&#13;the Company completed an underwritten offering of 21,500,000 shares of its common stock and warrants to purchase an aggregate of&#13;18,275,000 shares of its common stock at a price of $0.75 per share and related warrant. The warrants are exercisable for a period&#13;of 5 years at an exercise price of $1.05 per share. The transaction date relative fair value of the warrants of $4.9 million was&#13;determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing model include (1)&#13;discount rate of 1.83%, (2) expected term of 5 years, (3) expected volatility of 82%, and (4) zero expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Certain warrants were&#13;issued to the Company&amp;#8217;s Executive Chairman (now Chairman and CEO) as part of investment banking and advisory services either&#13;prior to and outside of his role as a Board Member and subsequently Chairman and CEO. On March 14, 2017, the Company canceled a&#13;warrant to purchase 57,212 shares of common stock of the Company, dated December 19, 2012 and issued a new warrant to its Chairman&#13;and CEO to purchase 57,212 common shares with the term of the warrant expiring on February 11, 2022. The new warrant has the same&#13;exercise price in effect as the exercise price as the old warrant, but the expiration date was modified from December 19, 2017&#13;to February 11, 2022. The Company also amended the warrant to purchase common stock of the Company, dated January 31, 2012, issued&#13;to its Chairman and CEO and an entity affiliated with its Chairman and CEO to purchase 64,746 and 99,617 common shares, respectively.&#13;Pursuant to the terms of the warrant amendments, the term of the warrants was extended to February 11, 2022 from January 31, 2019.&#13;As a result of the replacement and modification, the Company recorded an additional non-cash expense of $64 thousand for the incremental&#13;fair value of the new warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended&#13;December 31, 2016, the Company granted 130,000 warrants to consultants. The warrants are exercisable for periods ranging from 5&#13;to 10 years at exercise prices ranging from $0.98 to $1.77 per share. The fair value of the warrants was approximately $116,000&#13;at the grant date and was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing&#13;model include (1) discount rate range of 1.13% to 1.20%, (2) expected term of 5-10 years, (3) expected volatility range of 79.79%&#13;to 84.84%, and (4) zero expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended&#13;December 31, 2018, 2017 and 2016, the Company recorded stock-based compensation expense related to warrants of $33 thousand, $0.1&#13;million and $0.1 million respectively.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <atnm:EmployeeOptionToPurchaseShare contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">530000</atnm:EmployeeOptionToPurchaseShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_srt_MinimumMember" unitRef="USD_per_Share" decimals="INF">0.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_srt_MaximumMember" unitRef="USD_per_Share" decimals="INF">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <atnm:EmployeeOptionToPurchaseShares contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">530000</atnm:EmployeeOptionToPurchaseShares>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and&#13;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&#13;-&lt;/b&gt; Actinium Pharmaceuticals, Inc. (the "Company", "Actinium", or "We") is a clinical-stage,&#13;biopharmaceutical company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell&#13;therapies such as a BMT or Bone Marrow Transplant or CAR-T, &lt;font style="background-color: white"&gt;a type of cellular therapy that&#13;genetically alters a patient's own T cells to target and kill their cancer cells,&lt;/font&gt; and for other adoptive cell therapies.&#13;In addition, the Company is also developing potential therapies for targeting and killing of cancer cells either as single agents&#13;or in combination with other drugs. &lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Going concern&lt;/b&gt;&#13;- &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has never generated revenue. Currently&#13;it does not have a recurring source of revenue to cover its operating costs. The Company has incurred net losses and negative&#13;operating cash flows since inception. As of December 31, 2018 and 2017, the Company's accumulated deficit was $186.9 million&#13;and $163.2 million, respectively. The Company's net loss was $23.7 million, $26.6 million, and $24.3 million for the years&#13;ended December 31, 2018, 2017 and 2016, respectively. These conditions raise substantial doubt as to our ability to continue as&#13;a going concern. As of December 31, 2018, in the Company had a balance of its cash and cash equivalents of $13.7 million. The&#13;Company's consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States&#13;of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in&#13;the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the&#13;recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to&#13;continue as a going concern. As of the date of filing this report, the Company expects that its existing resources will be sufficient&#13;to fund its planned operations into the fourth quarter of 2019; however, additional capital resources will be needed to fund operations&#13;longer-term. If the Company is unsuccessful in accomplishing its plans, it may have to delay or terminate existing and/or planned&#13;clinical trials and other related activity, which could have a material adverse impact on its business. The Company plans to continue&#13;as a going concern include obtaining capital from the sale of its equity securities, potential exercise of outstanding warrants,&#13;fees from licensing one or more of our product candidates, additional collaborations with our Iomab-ACT program and AWE technology&#13;platform, and short-term borrowings from banks, stockholders or other related parties, if needed. However, the Company cannot&#13;provide any assurance that we will be successful in accomplishing any of our plans.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;The Company's ability&#13;to continue as a going concern is dependent upon its ability to successfully accomplish the plans described above and eventually&#13;to secure other sources of financing and attain profitable operations.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation&#13;-&lt;/b&gt; The consolidated financial statements include the Company's accounts and those of the Company's wholly owned&#13;subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates&#13;in Financial Statement Presentation -&lt;/b&gt; The preparation of these consolidated financial statements in conformity with accounting&#13;principles generally accepted in the United States of America requires management to make estimates and assumptions that affect&#13;the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of&#13;expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash and Cash Equivalents&#13;-&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents.&#13;Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Property and Equipment&#13;-&lt;/b&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three&#13;to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives&#13;of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related&#13;gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets&#13;are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated&#13;useful life of the related property or term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value of Financial&#13;Instruments&lt;/b&gt; &lt;b&gt;- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,&#13;in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives&#13;the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable&#13;inputs. As required by ASC 820 "&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;", financial assets and liabilities&#13;are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's&#13;assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation&#13;of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 1 Inputs - Unadjusted quoted&#13;prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement&#13;date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 2 Inputs - Inputs other&#13;than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might&#13;include quoted prices for similar assets or liabilities&amp;#160;in&amp;#160;active markets, quoted prices for identical or similar assets&#13;or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such&#13;as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated&#13;by market data by correlation or other means.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 3 Inputs - Unobservable&#13;inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions&#13;that market participants would use in pricing the assets or liabilities.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt;&lt;b&gt;Income Taxes -&lt;/b&gt; The Company provides&#13;for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based&#13;on the differences between the financial statement carrying amounts of existing assets and liabilities at each year-end and their&#13;respective tax bases, and are measured using enacted tax rates in effect for the year in which the differences are expected to&#13;affect taxable income. Significant judgment is required by management to determine the Company's provision for income taxes,&#13;deferred tax assets and liabilities, and the valuation allowance to record against net deferred tax assets, which are based on&#13;complex and evolving tax regulations throughout the world.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred tax assets&#13;and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. There were&#13;no tax positions for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly&#13;increase or decrease within the next year. The Company recognizes interest related to unrecognized tax benefits in interest expense&#13;and penalties in operating expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Tax Cuts and Jobs Act,&#13;or the Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the&#13;Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. As of December&#13;31, 2018, upon completing its analysis of the Act, the Company believes that its disclosures in its financial statements as of&#13;December 31, 2017 remain accurate.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition&#13;&lt;/b&gt;- The Company adopted new accounting guidance for revenue recognition, effective January 1, 2018, which did not have a significant&#13;impact on the Company's financial statements. Beginning January 1, 2018, revenues are recognized when control of the promised&#13;goods or services is transferred to customers in an amount that reflects the consideration expected to be entitled to in exchange&#13;for those goods or services&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development&#13;Costs -&lt;/b&gt; Research and development costs are expensed as incurred. Research and development reimbursements are recorded by the&#13;Company as a reduction of research and development costs.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments&#13;-&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing&#13;model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee&#13;is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common&#13;Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average&#13;number of common shares outstanding during the reporting period. For the years ended December 31, 2018, 2017 and 2016, the Company's&#13;potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation&#13;of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,236,101&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,174,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,906,886&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55,820,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,662,340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,964,752&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;63,056,977&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,836,932&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,871,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Subsequent Events&#13;&lt;/b&gt;- The Company's management reviewed all material events through the date the consolidated financial statements were issued&#13;for subsequent event disclosure consideration.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Reclassifications&#13;- &lt;/b&gt;Certain reclassifications have been made to the prior-year financial statements to conform to the current-year presentation,&#13;including the addition of restricted cash to cash and cash equivalents on the consolidated statements of cash flows as a result&#13;of the adoption of new accounting guidance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Accounting Standards&#13;Recently Adopted &lt;/b&gt;- In November 2016, the Financial Accounting Standards Board ("FASB") issued an Accounting Standards&#13;Update ("ASU") amending the presentation of restricted cash within the consolidated statements of cash flows. The new&#13;guidance requires that restricted cash be added to cash and cash equivalents on the consolidated statements of cash flows. The&#13;Company adopted this ASU on January 1, 2018 on a retrospective basis with the impact to its consolidated statements of cash flows&#13;for the year ended December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Previously Reported&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Adjustment&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(380,946&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;356,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(24,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There was&#13;no impact to the cash flows from operating, investing and financing activities for the year ended December 31, 2016 as the&#13;amount of restricted cash did not change during 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary&#13;of cash and cash equivalents and restricted cash at December 31, 2018, 2017 and 2016, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&amp;#160;31,&lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,673,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,399,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,519,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify"&gt;Restricted cash &amp;#8211; current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &amp;#8211; long term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;391,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;390,940&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash and cash equivalent and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,104,514&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,790,576&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,554,027&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2014, the FASB&#13;issued ASU No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under the new standard, revenue is recognized at the time&#13;a good or service is transferred to a customer for the amount of consideration for which the entity expects to be entitled for&#13;that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of&#13;adoption. The Company adopted this ASU on January 1, 2018 and the adoption did not have a significant impact to the Company's&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July 2017, the FASB&#13;issued ASU No. 2017-11, &lt;i&gt;Earnings Per Share&lt;/i&gt; (Topic 260); &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (Topic 480); &lt;i&gt;Derivatives&#13;and Hedging&lt;/i&gt; (Topic 815): (Part I) &lt;i&gt;Accounting for Certain Financial Instruments with Down Round Features.&lt;/i&gt; These amendments&#13;simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard&#13;the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability&#13;or equity classification. The guidance was adopted as of April 1, 2018. See Note 2 for further discussion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"&gt;&lt;b&gt;Recent Accounting Standards &amp;#8211;&#13;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In February 2016,&#13;FASB issued ASU No. 2016-02 &lt;i&gt;Leases&lt;/i&gt; (Topic 842), which creates new accounting and reporting guidelines for leasing&#13;arrangements. The standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A&#13;lessee should recognize on its balance sheet a liability to make lease payments (the lease liability) and a right-of-use&#13;asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a&#13;lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and&#13;lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the&#13;earliest period presented using a modified retrospective approach. The guidance in ASU 2016-02 is effective for annual and&#13;interim reporting periods beginning after December 15, 2018. The Company's initial evaluation of its current leases&#13;does not indicate that the adoption of this standard will have a material impact on its consolidated statements of&#13;operations. However, the Company does expect that the adoption of the standard will have an impact on its&#13;consolidated balance sheets for the recognition of certain operating leases as right-of-use assets and lease liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In June 2018, the FASB&#13;issued ASU 2018-07 to expand the scope of ASC Topic 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;, to include share-based payment&#13;transactions for acquiring goods and services from nonemployees. The standard is effective for fiscal years, and for interim periods&#13;within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating&#13;the impact of the new standard on its financial statements and related disclosures, but does not expect this ASU to have a material&#13;impact on its financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, the&#13;FASB issued ASU 2018-13, &lt;i&gt;Fair Value Measurement - Disclosure Framework (Topic 820).&lt;/i&gt; The updated guidance improves the disclosure&#13;requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay&#13;of adoption of the additional disclosures until their effective date. The Company is in the process of evaluating the provisions&#13;of the ASU but does not expect it to have a material effect on its consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2018, the&#13;FASB issued ASU 2018-18, C&lt;i&gt;ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,&lt;/i&gt;&#13;which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be&#13;accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal&#13;years, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impact&#13;the standard will have on its financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, the&#13;SEC adopted the final rule under SEC Release No. 33-10532, &lt;i&gt;Disclosure Update and Simplification&lt;/i&gt;, amending certain disclosure&#13;requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure&#13;requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis&#13;of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate&#13;statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which&#13;a statement of comprehensive income is required to be filed. The Company anticipates its first presentation of changes in stockholders'&#13;equity will be included in its Form 10-Q for the three months ended March 31, 2019.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <atnm:GoingConcernPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Going concern&lt;/b&gt;&#13;- &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has never generated revenue. Currently&#13;it does not have a recurring source of revenue to cover its operating costs. The Company has incurred net losses and negative&#13;operating cash flows since inception. As of December 31, 2018 and 2017, the Company's accumulated deficit was $186.9 million&#13;and $163.2 million, respectively. The Company's net loss was $23.7 million, $26.6 million, and $24.3 million for the years&#13;ended December 31, 2018, 2017 and 2016, respectively. These conditions raise substantial doubt as to our ability to continue as&#13;a going concern. As of December 31, 2018, in the Company had a balance of its cash and cash equivalents of $13.7 million. The&#13;Company's consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States&#13;of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in&#13;the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the&#13;recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to&#13;continue as a going concern. As of the date of filing this report, the Company expects that its existing resources will be sufficient&#13;to fund its planned operations into the fourth quarter of 2019; however, additional capital resources will be needed to fund operations&#13;longer-term. If the Company is unsuccessful in accomplishing its plans, it may have to delay or terminate existing and/or planned&#13;clinical trials and other related activity, which could have a material adverse impact on its business. The Company plans to continue&#13;as a going concern include obtaining capital from the sale of its equity securities, potential exercise of outstanding warrants,&#13;fees from licensing one or more of our product candidates, additional collaborations with our Iomab-ACT program and AWE technology&#13;platform, and short-term borrowings from banks, stockholders or other related parties, if needed. However, the Company cannot&#13;provide any assurance that we will be successful in accomplishing any of our plans.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;The Company's ability&#13;to continue as a going concern is dependent upon its ability to successfully accomplish the plans described above and eventually&#13;to secure other sources of financing and attain profitable operations.&lt;/p&gt;</atnm:GoingConcernPolicyTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Note 8  - Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Tax Cuts and&#13;Jobs Act, or the "Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to&#13;21%. As of December 31, 2017, the Company remeasured its existing deferred tax balance by recording a provisional charge of&#13;$17.9 million, which was fully offset by a change in the valuation allowance. As of December 31, 2018, upon completing its&#13;analysis of the Act, the Company believes that the disclosures in its financial statements as of December 31, 2017 are still&#13;accurate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred income taxes&#13;reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting&#13;purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities&#13;at December 31, 2018 and 2017 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-left: 10pt"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,531,577&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,826,534&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,950,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,731,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research and development/orphan drug credits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,896,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,324,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Others&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,369&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(46,394,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40,894,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has recorded&#13;a valuation allowance of $46.4 million and $40.9 million against its deferred tax assets at December 31, 2018 and 2017, respectively,&#13;because management determined that it is not more-likely-than not that those assets will be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For federal income&#13;tax purposes, the Company has approximately $144.5 million of unused net operating losses ("NOLs") at December 31,&#13;2018 available for carry forward to future years. Prior NOLs have begun to expire as they are unused.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For state income tax&#13;purposes, the Company has approximately $66.8 million of unused NOLs available for carry forward to future years. These NOLs will&#13;begin to expire in 2035 if unused.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has federal&#13;research and development tax credits of approximately $1.4 million at December 31, 2018 which will begin to expire in 2033 if unused&#13;and orphan drug credits of $7.5 million which will begin to expire in 2037 if unused.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to Internal&#13;Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and development tax credits could&#13;be limited by any greater than 50% ownership change during any three-year testing period. As a result of any such ownership change,&#13;portions of the Company's net operating loss carryforwards and research and development tax credits are subject to annual&#13;limitations. Accordingly, the Company's ability to utilize these carryforwards may be limited as a result of an ownership&#13;change which may have already happened or may happen in the future. Such an ownership change could result in a limitation in the&#13;use of the net operating losses in future years and possibly a reduction of the net operating losses available.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The&#13;difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to&#13;pre-tax losses for the year ended December 31, 2018, 2017 and 2016 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 28%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Federal statutory income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,967,332&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(9,044,420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,269,386&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413,678&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,940,945&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;973,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Change in federal statutory rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,939,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,090,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,511,380&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Research and Development/Orphan Drug Tax Credit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,986,609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,029,074&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(141,769&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Unrealized derivative gain/loss&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(120,870&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(956,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,845&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,500,214&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,908,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,892,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&lt;b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-left: 10pt"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,531,577&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,826,534&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,950,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,731,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research and development/orphan drug credits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,896,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,324,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Others&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,369&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(46,394,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40,894,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br /&gt; 2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 28%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Federal statutory income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,967,332&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(9,044,420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,269,386&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413,678&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,940,945&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;973,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Change in federal statutory rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,939,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,090,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,511,380&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Research and Development/Orphan Drug Tax Credit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,986,609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,029,074&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(141,769&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Unrealized derivative gain/loss&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(120,870&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(956,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,845&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,500,214&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,908,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,892,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2019-03-15" unitRef="shares" decimals="INF">119136036</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 9  - Subsequent Event&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In January 2019, the&#13;Company sold 924,500 common shares through its at-the-market program and realized net proceeds of $0.4 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Since December 31,&#13;2018, holders of the Company&amp;#8217;s March 2018 Series A warrants exercised approximately 2.5 million shares, resulting in proceeds&#13;to the Company of $1.5 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Since December 31,&#13;2018, the Company granted stock options to its employees to purchase a total of 530,000 common shares at a price range from&#13;$0.43 to $0.58 per share related to new hires.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On March 6, 2019, the Company&#13;executed an amendment to the Company&amp;#8217;s 2013 Amended and Restated Stock Plan, as amended (the &amp;#8220;&lt;u&gt;Plan Amendment&lt;/u&gt;&amp;#8221;).&#13;The Plan Amendment increased the number of shares of common stock that the Company is authorized to issue under the plan to 22,750,000&#13;shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On March 6, 2019, the&#13;Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State&#13;of Delaware to increase the number of authorized shares of Actinium&amp;#8217;s common stock from 400,000,000 to 600,000,000 shares.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-03" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-0" xlink:label="Foot-02_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-02_loc" xlink:to="Footnote-01" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-0" xlink:label="Foot-03_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-03_loc" xlink:to="Footnote-05" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-0" xlink:label="Foot-04_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-04_loc" xlink:to="Footnote-06" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-0" xlink:label="Foot-05_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-05_loc" xlink:to="Footnote-04" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">The market value of common stock at the above measurement dates was based on the Company's closing price quoted on the NYSE AMERICAN.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">The volatility was estimated using the historical volatility of the Company's common stock.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">Management does not expect to pay dividends for the foreseeable future.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">Management determines the probability of future stock offering at each evaluation date.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-05" xml:lang="en-US">Represents the estimated offering price in future offerings as determined by management.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-06" xml:lang="en-US">The risk-free interest rate was determined by the Company using the Treasury Bill rate as of the respective measurement date.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>atnm-20181231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20181231.xfr; Date: 2019%2D03%2D15T19:01:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +qpZs7xRiXgen8uAaHxMWaONGcOdx5ZzWYlBvWpzfTmKny0hqeSOvi3YS+vWgdsO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:atnm="http://actiniumpharmaceuticals.com/20181231" elementFormDefault="qualified" targetNamespace="http://actiniumpharmaceuticals.com/20181231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilities" id="DerivativeLiabilities">
	  <link:definition>00000008 - Disclosure - Derivative Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000009 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000010 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="Equity">
	  <link:definition>00000012 - Disclosure - Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000013 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent" id="SubsequentEvent">
	  <link:definition>00000014 - Disclosure - Subsequent Event</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables" id="DerivativeLiabilitiesTables">
	  <link:definition>00000017 - Disclosure - Derivative Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000019 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="EquityTables">
	  <link:definition>00000021 - Disclosure - Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000022 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1">
	  <link:definition>00000024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2">
	  <link:definition>00000025 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
	  <link:definition>00000026 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails" id="DerivativeLiabilitiesDetails">
	  <link:definition>00000027 - Disclosure - Derivative Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1" id="DerivativeLiabilitiesDetails1">
	  <link:definition>00000028 - Disclosure - Derivative Liabilities (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual" id="DerivativeLiabilitiesDetailsTextual">
	  <link:definition>00000029 - Disclosure - Derivative Liabilities (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000030 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" id="PrepaidExpensesAndOtherCurrentAssetsDetailsTextual">
	  <link:definition>00000031 - Disclosure - Prepaid Expenses and Other Current Assets (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
	  <link:definition>00000032 - Disclosure - Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1" id="PropertyAndEquipmentDetails1">
	  <link:definition>00000033 - Disclosure - Property and Equipment (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
	  <link:definition>00000034 - Disclosure - Property and Equipment (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000035 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
	  <link:definition>00000036 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="EquityDetails">
	  <link:definition>00000037 - Disclosure - Equity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails1" id="EquityDetails1">
	  <link:definition>00000038 - Disclosure - Equity (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" id="EquityDetailsTextual">
	  <link:definition>00000039 - Disclosure - Equity (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000040 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000041 - Disclosure - Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
	  <link:definition>00000042 - Disclosure - Income Taxes (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" id="SubsequentEventDetails">
	  <link:definition>00000043 - Disclosure - Subsequent Event (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
    <element id="atnm_LongTermPurchaseCommitmentMilestonesPayment" name="LongTermPurchaseCommitmentMilestonesPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" name="DescriptionOfRoyaltyPaymentToRelatedParty" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProjectEstimatedCost" name="ProjectEstimatedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PurchaseOfMaterials" name="PurchaseOfMaterials" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantsExercisablePeriod" name="WarrantsExercisablePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProjectRemainingCost" name="ProjectRemainingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MarketValueOfCommonStockOnMeasurementDate" name="MarketValueOfCommonStockOnMeasurementDate" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FairValueAssumptionOfferingPrice" name="FairValueAssumptionOfferingPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear" name="ProbabilityOfStockOfferingInAnyPeriodOverYear" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GainOnChangeInFairValueOfDerivatives" name="GainOnChangeInFairValueOfDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_StockRepurchasedDuringPeriodValueAdditional" name="StockRepurchasedDuringPeriodValueAdditional" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_StockRepurchasedDuringPeriodSharesAdditional" name="StockRepurchasedDuringPeriodSharesAdditional" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AcceleratedPurchaseDescription" name="AcceleratedPurchaseDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantsToPurchaseOfCommonStock" name="WarrantsToPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_NumberofWarrentIssued" name="NumberofWarrentIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PrepaidClinicalTrialExpenses" name="PrepaidClinicalTrialExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ScheduleOfDepreciationExpenseTableTextBlock" name="ScheduleOfDepreciationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CapitalleaseOfOfficeEquipment" name="CapitalleaseOfOfficeEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FairValueOfMarketPrice" name="FairValueOfMarketPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_Underwrittenoffering" name="Underwrittenoffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantToPurchaseOfCommonStock" name="WarrantToPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CommonStockForIssuedCashlessExerciseOfWarrants" name="CommonStockForIssuedCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_RestrictedCommonSharesGranted" name="RestrictedCommonSharesGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_RestrictedCommonSharesGrantedValue" name="RestrictedCommonSharesGrantedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_RestrictedCommonSharesGrantedFullyVested" name="RestrictedCommonSharesGrantedFullyVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_RestrictedCommonSharesGrantedFullyVestedValue" name="RestrictedCommonSharesGrantedFullyVestedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AccountingPronouncementsRecentlyAdopted" name="AccountingPronouncementsRecentlyAdopted" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" name="FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued" name="StockIssuedDuringPeriodRestrictedStockAwardNotIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FairValueAssumptionsExpectedDiscountRate" name="FairValueAssumptionsExpectedDiscountRate" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_IncomeTaxReconciliationResearchAndDevelopment" name="IncomeTaxReconciliationResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_IncomeTaxReconciliationDeferredTrueUp" name="IncomeTaxReconciliationDeferredTrueUp" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" name="EffectiveIncomeTaxReconciliationDeferredTrueUps" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ExercisedSeriesWarrantsIssuedForThePeriod" name="ExercisedSeriesWarrantsIssuedForThePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantsToExercisableTerm" name="WarrantsToExercisableTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" name="StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable" name="PrepaidExpensesFinancedByAccountsPayableAndNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification" name="TransferFromDerivativeLiabilityClassificationToEquityClassification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification" name="TransferOfWarrantDerivativesFromLiabilityToEquityClassification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability" name="ModifiedRetroactiveAdjustmentForDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CapitalLeaseAgreement" name="CapitalLeaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OfficeEquipmentServices" name="OfficeEquipmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GrossProceedsFromWarrantExercises" name="GrossProceedsFromWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AdditionalNoncashExpenseIncrementalFairValue" name="AdditionalNoncashExpenseIncrementalFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EmployeeOptionToPurchaseShare" name="EmployeeOptionToPurchaseShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EmployeeOptionToPurchaseShares" name="EmployeeOptionToPurchaseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FredHutchinsonCancerResearchCenterMember" name="FredHutchinsonCancerResearchCenterMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LicenseAndSponsoredResearchAgreementMember" name="LicenseAndSponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GeorgeClinicalMember" name="GeorgeClinicalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MedpaceIncMember" name="MedpaceIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_GoodwinMember" name="GoodwinMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OakRidgeNationalLaboratoryMember" name="OakRidgeNationalLaboratoryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TotalstockholdersequityMember" name="TotalstockholdersequityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LabEquipmentMember" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LincolnParkCapitalFundLlcMember" name="LincolnParkCapitalFundLlcMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TwoThousandThirteenStockPlanMember" name="TwoThousandThirteenStockPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EmployeesDirectorsAndConsultantsMember" name="EmployeesDirectorsAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TwoThousandThirteenEquityIncentivePlanMember" name="TwoThousandThirteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_MrSandeshSethMember" name="MrSandeshSethMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_OrphanDrugCreditsMember" name="OrphanDrugCreditsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DelawareMember" name="DelawareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ThePlanAmendmentMember" name="ThePlanAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SubsequentEventAbstract" name="SubsequentEventAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" name="SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_DerivativeLiabilitiesTextualAbstract" name="DerivativeLiabilitiesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ProbabilityOfStockOfferingInPeriod" name="ProbabilityOfStockOfferingInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_NumberOfWarrants" name="NumberOfWarrants" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract" name="PrepaidExpensesAndOtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract" name="PrepaidExpensesAndOtherCurrentAssetsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PropertyAndEquipmentDetailsAbstract" name="PropertyAndEquipmentDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PropertyAndEquipmentDetails1Abstract" name="PropertyAndEquipmentDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_PropertyAndEquipmentDetailsTextualAbstract" name="PropertyAndEquipmentDetailsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CommitmentsAndContingenciesDetailsAbstract" name="CommitmentsAndContingenciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AgreementAxis" name="AgreementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="atnm_AgreementDomain" name="AgreementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_FirstCommercialSalePeriod" name="FirstCommercialSalePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_ServicesFees" name="ServicesFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_LeaseTerm" name="LeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" name="CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EquityTextualsAbstract" name="EquityTextualsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_TerminationOfEmployees" name="TerminationOfEmployees" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_WarrantsExercisedByWarrantHolders" name="WarrantsExercisedByWarrantHolders" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_EmployeeOptionsToPurchaseaveragePrice" name="EmployeeOptionsToPurchaseaveragePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_IncomeTaxTextualAbstract" name="IncomeTaxTextualAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SubsequentEventsDetailsAbstract" name="SubsequentEventsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="atnm_SubsequentEventsTextualAbstract" name="SubsequentEventsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>atnm-20181231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20181231.xfr; Date: 2019%2D03%2D15T19:01:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="atnm-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:href="atnm-20181231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="atnm-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:href="atnm-20181231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="atnm-20181231.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="atnm-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilities" xlink:href="atnm-20181231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" xlink:href="atnm-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="atnm-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Equity" xlink:href="atnm-20181231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxes" xlink:href="atnm-20181231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent" xlink:href="atnm-20181231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:href="atnm-20181231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" xlink:href="atnm-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:href="atnm-20181231.xsd#EquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails1" xlink:href="atnm-20181231.xsd#EquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:href="atnm-20181231.xsd#EquityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" xlink:href="atnm-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1" xlink:href="atnm-20181231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual" xlink:href="atnm-20181231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" xlink:href="atnm-20181231.xsd#SubsequentEventDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnmGainOnChangeInFairValueOfDerivatives" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atnmGainOnChangeInFairValueOfDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilities" xlink:title="00000008 - Disclosure - Derivative Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000009 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity" xlink:title="00000012 - Disclosure - Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent" xlink:title="00000014 - Disclosure - Subsequent Event" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables" xlink:title="00000017 - Disclosure - Derivative Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables" xlink:title="00000019 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:title="00000021 - Disclosure - Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000025 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000026 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails" xlink:title="00000027 - Disclosure - Derivative Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1" xlink:title="00000028 - Disclosure - Derivative Liabilities (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual" xlink:title="00000029 - Disclosure - Derivative Liabilities (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000030 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:title="00000031 - Disclosure - Prepaid Expenses and Other Current Assets (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Property and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1" xlink:title="00000033 - Disclosure - Property and Equipment (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" xlink:title="00000034 - Disclosure - Property and Equipment (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000035 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000036 - Disclosure - Commitments and Contingencies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:title="00000037 - Disclosure - Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails1" xlink:title="00000038 - Disclosure - Equity (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:title="00000039 - Disclosure - Equity (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" xlink:title="00000040 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1" xlink:title="00000041 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual" xlink:title="00000042 - Disclosure - Income Taxes (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" xlink:title="00000043 - Disclosure - Subsequent Event (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>atnm-20181231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20181231.xfr; Date: 2019%2D03%2D15T19:01:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="atnm-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:href="atnm-20181231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="atnm-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:href="atnm-20181231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="atnm-20181231.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="atnm-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilities" xlink:href="atnm-20181231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" xlink:href="atnm-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="atnm-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Equity" xlink:href="atnm-20181231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxes" xlink:href="atnm-20181231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent" xlink:href="atnm-20181231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:href="atnm-20181231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" xlink:href="atnm-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:href="atnm-20181231.xsd#EquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails1" xlink:href="atnm-20181231.xsd#EquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:href="atnm-20181231.xsd#EquityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" xlink:href="atnm-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1" xlink:href="atnm-20181231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual" xlink:href="atnm-20181231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" xlink:href="atnm-20181231.xsd#SubsequentEventDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability" xlink:label="loc_atnmModifiedRetroactiveAdjustmentForDerivativeLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmModifiedRetroactiveAdjustmentForDerivativeLiability_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification" xlink:label="loc_atnmTransferOfWarrantDerivativesFromLiabilityToEquityClassification_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmTransferOfWarrantDerivativesFromLiabilityToEquityClassification_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilities" xlink:title="00000008 - Disclosure - Derivative Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000009 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity" xlink:title="00000012 - Disclosure - Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent" xlink:title="00000014 - Disclosure - Subsequent Event" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables" xlink:title="00000017 - Disclosure - Derivative Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables" xlink:title="00000019 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:title="00000021 - Disclosure - Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000025 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000026 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethods_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethods_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_80" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails" xlink:title="00000027 - Disclosure - Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TotalstockholdersequityMember" xlink:label="loc_atnmTotalstockholdersequityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_atnmTotalstockholdersequityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1" xlink:title="00000028 - Disclosure - Derivative Liabilities (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaapDefinedBenefitPlanByPlanAssetCategoriesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaapPlanAssetCategoriesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="loc_us-gaapPlanAssetCategoriesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaapPlanAssetCategoriesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="loc_us-gaapPlanAssetCategoriesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnmMarketValueOfCommonStockOnMeasurementDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_atnmMarketValueOfCommonStockOnMeasurementDate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear" xlink:label="loc_atnmProbabilityOfStockOfferingInAnyPeriodOverYear_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_atnmProbabilityOfStockOfferingInAnyPeriodOverYear_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnmFairValueAssumptionOfferingPrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_30" xlink:to="loc_atnmFairValueAssumptionOfferingPrice_30" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual" xlink:title="00000029 - Disclosure - Derivative Liabilities (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201711Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201711Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DerivativeLiabilitiesTextualAbstract" xlink:label="loc_atnmDerivativeLiabilitiesTextualAbstract_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmDerivativeLiabilitiesTextualAbstract_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract_80" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract_80" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProbabilityOfStockOfferingInPeriod" xlink:label="loc_atnmProbabilityOfStockOfferingInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract_80" xlink:to="loc_atnmProbabilityOfStockOfferingInPeriod_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NumberOfWarrants" xlink:label="loc_atnmNumberOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract_80" xlink:to="loc_atnmNumberOfWarrants_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract_80" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000030 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:title="00000031 - Disclosure - Prepaid Expenses and Other Current Assets (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LabEquipmentMember" xlink:label="loc_atnmLabEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_atnmLabEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract_100" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract_100" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract_100" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract_100" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_100" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1" xlink:title="00000033 - Disclosure - Property and Equipment (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" xlink:title="00000034 - Disclosure - Property and Equipment (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000035 - Disclosure - Commitments and Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000036 - Disclosure - Commitments and Contingencies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_atnmAgreementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GeorgeClinicalMember" xlink:label="loc_atnmGeorgeClinicalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmGeorgeClinicalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnmLicenseAndSponsoredResearchAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmLicenseAndSponsoredResearchAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GoodwinMember" xlink:label="loc_atnmGoodwinMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmGoodwinMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnmOakRidgeNationalLaboratoryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmOakRidgeNationalLaboratoryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnmFredHutchinsonCancerResearchCenterMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmFredHutchinsonCancerResearchCenterMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MedpaceIncMember" xlink:label="loc_atnmMedpaceIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmMedpaceIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnmLongTermPurchaseCommitmentMilestonesPayment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmLongTermPurchaseCommitmentMilestonesPayment_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnmFirstCommercialSalePeriod_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmFirstCommercialSalePeriod_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnmProjectEstimatedCost_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmProjectEstimatedCost_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaapDevelopmentInProcess_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapDevelopmentInProcess_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapPaymentsForLeasingCosts_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ServicesFees" xlink:label="loc_atnmServicesFees_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmServicesFees_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LeaseTerm" xlink:label="loc_atnmLeaseTerm_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmLeaseTerm_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PurchaseOfMaterials" xlink:label="loc_atnmPurchaseOfMaterials_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmPurchaseOfMaterials_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProjectRemainingCost" xlink:label="loc_atnmProjectRemainingCost_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmProjectRemainingCost_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapLineOfCredit_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapDeposits_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_us-gaapPaymentsForRent_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:label="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalleaseOfOfficeEquipment" xlink:label="loc_atnmCapitalleaseOfOfficeEquipment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmCapitalleaseOfOfficeEquipment_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalLeaseAgreement" xlink:label="loc_atnmCapitalLeaseAgreement_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmCapitalLeaseAgreement_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OfficeEquipmentServices" xlink:label="loc_atnmOfficeEquipmentServices_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract_220" xlink:to="loc_atnmOfficeEquipmentServices_220" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:title="00000037 - Disclosure - Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="loc_atnmAggregateIntrinsicValueAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails1" xlink:title="00000038 - Disclosure - Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="loc_atnmAggregateIntrinsicValueAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAggregateIntrinsicValueAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:title="00000039 - Disclosure - Equity (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SeriesAWarrantsMember" xlink:label="loc_atnmSeriesAWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmSeriesAWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SeriesBWarrantsMember" xlink:label="loc_atnmSeriesBWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmSeriesBWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsMember" xlink:label="loc_atnmWarrantsMember_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmWarrantsMember_640" xlink:type="arc" order="641" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LincolnParkCapitalFundLlcMember" xlink:label="loc_atnmLincolnParkCapitalFundLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmLincolnParkCapitalFundLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ConsultantsMember" xlink:label="loc_atnmConsultantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmConsultantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_atnmAgreementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PurchaseAgreementMember" xlink:label="loc_atnmPurchaseAgreementMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmPurchaseAgreementMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TwoThousandThirteenStockPlanMember" xlink:label="loc_atnmTwoThousandThirteenStockPlanMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_atnmTwoThousandThirteenStockPlanMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_atnmTwoThousandThirteenEquityIncentivePlanMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_atnmTwoThousandThirteenEquityIncentivePlanMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnmEmployeesDirectorsAndConsultantsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmEmployeesDirectorsAndConsultantsMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapDirectorMember_610" xlink:type="arc" order="611" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MrSandeshSethMember" xlink:label="loc_atnmMrSandeshSethMember_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmMrSandeshSethMember_730" xlink:type="arc" order="732" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaapBoardOfDirectorsChairmanMember_740" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapBoardOfDirectorsChairmanMember_740" xlink:type="arc" order="742" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember_750" xlink:type="arc" order="752" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnmEquityTextualsAbstract_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_atnmEquityTextualsAbstract_860" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockRepurchasedDuringPeriodSharesAdditional" xlink:label="loc_atnmStockRepurchasedDuringPeriodSharesAdditional_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmStockRepurchasedDuringPeriodSharesAdditional_860" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockRepurchasedDuringPeriodValueAdditional" xlink:label="loc_atnmStockRepurchasedDuringPeriodValueAdditional_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmStockRepurchasedDuringPeriodValueAdditional_860" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueOfMarketPrice" xlink:label="loc_atnmFairValueOfMarketPrice_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmFairValueOfMarketPrice_860" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_860" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_860" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapPurchaseObligation_860" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AcceleratedPurchaseDescription" xlink:label="loc_atnmAcceleratedPurchaseDescription_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmAcceleratedPurchaseDescription_860" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_860" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_860" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_860" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_860" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_860" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts_860" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommonStockForIssuedCashlessExerciseOfWarrants" xlink:label="loc_atnmCommonStockForIssuedCashlessExerciseOfWarrants_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmCommonStockForIssuedCashlessExerciseOfWarrants_860" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_860" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_860" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_860" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_Underwrittenoffering" xlink:label="loc_atnmUnderwrittenoffering_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmUnderwrittenoffering_860" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantToPurchaseOfCommonStock" xlink:label="loc_atnmWarrantToPurchaseOfCommonStock_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmWarrantToPurchaseOfCommonStock_860" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsExercisablePeriod" xlink:label="loc_atnmWarrantsExercisablePeriod_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmWarrantsExercisablePeriod_860" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_860" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NumberofWarrentIssued" xlink:label="loc_atnmNumberofWarrentIssued_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmNumberofWarrentIssued_860" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TerminationOfEmployees" xlink:label="loc_atnmTerminationOfEmployees_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmTerminationOfEmployees_860" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_860" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_860" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_860" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_860" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_860" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_860" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockOptionPlanExpense_860" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_investInvestmentWarrantsExpirationDate_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_investInvestmentWarrantsExpirationDate_860" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnmWarrantsExercisedByWarrantHolders_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmWarrantsExercisedByWarrantHolders_860" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_860" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_860" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_860" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_860" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_860" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_860" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GrossProceedsFromWarrantExercises" xlink:label="loc_atnmGrossProceedsFromWarrantExercises_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmGrossProceedsFromWarrantExercises_860" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapProceedsFromWarrantExercises_860" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapOtherExpenses_860" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionToPurchaseShare" xlink:label="loc_atnmEmployeeOptionToPurchaseShare_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmEmployeeOptionToPurchaseShare_860" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionsToPurchaseaveragePrice" xlink:label="loc_atnmEmployeeOptionsToPurchaseaveragePrice_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmEmployeeOptionsToPurchaseaveragePrice_860" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_860" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_860" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSaleOfStockPricePerShare_860" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsToPurchaseOfCommonStock" xlink:label="loc_atnmWarrantsToPurchaseOfCommonStock_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmWarrantsToPurchaseOfCommonStock_860" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_860" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_860" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_860" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_860" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_860" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_860" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_860" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapSharePrice_860" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_860" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_860" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_860" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGranted" xlink:label="loc_atnmRestrictedCommonSharesGranted_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmRestrictedCommonSharesGranted_860" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedValue" xlink:label="loc_atnmRestrictedCommonSharesGrantedValue_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmRestrictedCommonSharesGrantedValue_860" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedFullyVested" xlink:label="loc_atnmRestrictedCommonSharesGrantedFullyVested_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmRestrictedCommonSharesGrantedFullyVested_860" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedFullyVestedValue" xlink:label="loc_atnmRestrictedCommonSharesGrantedFullyVestedValue_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmRestrictedCommonSharesGrantedFullyVestedValue_860" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued" xlink:label="loc_atnmStockIssuedDuringPeriodRestrictedStockAwardNotIssued_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmStockIssuedDuringPeriodRestrictedStockAwardNotIssued_860" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnmFairValueAssumptionsExpectedDiscountRate_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmFairValueAssumptionsExpectedDiscountRate_860" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_860" xlink:type="arc" order="65" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_860" xlink:type="arc" order="66" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsToExercisableTerm" xlink:label="loc_atnmWarrantsToExercisableTerm_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmWarrantsToExercisableTerm_860" xlink:type="arc" order="67" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_860" xlink:type="arc" order="68" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AdditionalNoncashExpenseIncrementalFairValue" xlink:label="loc_atnmAdditionalNoncashExpenseIncrementalFairValue_860" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnmEquityTextualsAbstract_860" xlink:to="loc_atnmAdditionalNoncashExpenseIncrementalFairValue_860" xlink:type="arc" order="69" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" xlink:title="00000040 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1" xlink:title="00000041 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual" xlink:title="00000042 - Disclosure - Income Taxes (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OrphanDrugCreditsMember" xlink:label="loc_atnmOrphanDrugCreditsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_atnmOrphanDrugCreditsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_IncomeTaxTextualAbstract" xlink:label="loc_atnmIncomeTaxTextualAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmIncomeTaxTextualAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaapOperatingLossCarryforwardsExpirationDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsExpirationDate_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsOther_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsOther_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesForeign_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesForeign_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_90" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" xlink:title="00000043 - Disclosure - Subsequent Event (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DelawareMember" xlink:label="loc_atnmDelawareMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmDelawareMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ThePlanAmendmentMember" xlink:label="loc_atnmThePlanAmendmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmThePlanAmendmentMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnmSubsequentEventsTextualAbstract_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSubsequentEventsTextualAbstract_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ExercisedSeriesWarrantsIssuedForThePeriod" xlink:label="loc_atnmExercisedSeriesWarrantsIssuedForThePeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmExercisedSeriesWarrantsIssuedForThePeriod_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionToPurchaseShares" xlink:label="loc_atnmEmployeeOptionToPurchaseShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmEmployeeOptionToPurchaseShares_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_80" xlink:type="arc" order="7" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>atnm-20181231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20181231.xfr; Date: 2019%2D03%2D15T19:01:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Restatement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="atnm_FredHutchinsonCancerResearchCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FredHutchinsonCancerResearchCenterMember" xlink:to="atnm_FredHutchinsonCancerResearchCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FredHutchinsonCancerResearchCenterMember_lbl" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementAxis" xlink:label="atnm_AgreementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="atnm_LicenseAndSponsoredResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseAndSponsoredResearchAgreementMember" xlink:to="atnm_LicenseAndSponsoredResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseAndSponsoredResearchAgreementMember_lbl" xml:lang="en-US">License and Sponsored Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GeorgeClinicalMember" xlink:label="atnm_GeorgeClinicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GeorgeClinicalMember" xlink:to="atnm_GeorgeClinicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GeorgeClinicalMember_lbl" xml:lang="en-US">George Clinical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MedpaceIncMember" xlink:label="atnm_MedpaceIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MedpaceIncMember" xlink:to="atnm_MedpaceIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MedpaceIncMember_lbl" xml:lang="en-US">Medpace Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GoodwinMember" xlink:label="atnm_GoodwinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GoodwinMember" xlink:to="atnm_GoodwinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GoodwinMember_lbl" xml:lang="en-US">Goodwin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SeriesBWarrantsMember" xlink:label="atnm_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SeriesBWarrantsMember" xlink:to="atnm_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SeriesAWarrantsMember" xlink:label="atnm_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SeriesAWarrantsMember" xlink:to="atnm_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="atnm_OakRidgeNationalLaboratoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OakRidgeNationalLaboratoryMember" xlink:to="atnm_OakRidgeNationalLaboratoryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OakRidgeNationalLaboratoryMember_lbl" xml:lang="en-US">Oak Ridge National Laboratory [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="us-gaap_AccountingStandardsUpdate201711Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201711Member" xlink:to="us-gaap_AccountingStandardsUpdate201711Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201711Member_lbl" xml:lang="en-US">Adoption of ASU 2017-11 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeMember" xlink:to="us-gaap_DerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeMember_lbl" xml:lang="en-US">Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TotalstockholdersequityMember" xlink:label="atnm_TotalstockholdersequityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TotalstockholdersequityMember" xlink:to="atnm_TotalstockholdersequityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TotalstockholdersequityMember_lbl" xml:lang="en-US">Total stockholders' equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LabEquipmentMember" xlink:label="atnm_LabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LabEquipmentMember" xlink:to="atnm_LabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PurchaseAgreementMember" xlink:label="atnm_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseAgreementMember" xlink:to="atnm_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LincolnParkCapitalFundLlcMember" xlink:label="atnm_LincolnParkCapitalFundLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LincolnParkCapitalFundLlcMember" xlink:to="atnm_LincolnParkCapitalFundLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Public offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ConsultantsMember" xlink:label="atnm_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ConsultantsMember" xlink:to="atnm_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TwoThousandThirteenStockPlanMember" xlink:label="atnm_TwoThousandThirteenStockPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TwoThousandThirteenStockPlanMember" xlink:to="atnm_TwoThousandThirteenStockPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TwoThousandThirteenStockPlanMember_lbl" xml:lang="en-US">2013 Stock Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="atnm_EmployeesDirectorsAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeesDirectorsAndConsultantsMember" xlink:to="atnm_EmployeesDirectorsAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EmployeesDirectorsAndConsultantsMember_lbl" xml:lang="en-US">Employees, directors and consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="atnm_TwoThousandThirteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TwoThousandThirteenEquityIncentivePlanMember" xlink:to="atnm_TwoThousandThirteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_TwoThousandThirteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Employees, directors and consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsMember" xlink:label="atnm_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsMember" xlink:to="atnm_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MrSandeshSethMember" xlink:label="atnm_MrSandeshSethMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MrSandeshSethMember" xlink:to="atnm_MrSandeshSethMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MrSandeshSethMember_lbl" xml:lang="en-US">Mr. Sandesh Seth [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BoardOfDirectorsChairmanMember" xlink:to="us-gaap_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OrphanDrugCreditsMember" xlink:label="atnm_OrphanDrugCreditsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OrphanDrugCreditsMember" xlink:to="atnm_OrphanDrugCreditsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OrphanDrugCreditsMember_lbl" xml:lang="en-US">Orphan Drug Credits [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DelawareMember" xlink:label="atnm_DelawareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DelawareMember" xlink:to="atnm_DelawareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DelawareMember_lbl" xml:lang="en-US">Delaware [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ThePlanAmendmentMember" xlink:label="atnm_ThePlanAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ThePlanAmendmentMember" xlink:to="atnm_ThePlanAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ThePlanAmendmentMember_lbl" xml:lang="en-US">The Plan Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="atnm_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DocumentAndEntityInformationAbstract" xlink:to="atnm_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash - current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $266,381 and $215,660</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term capital lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 600,000,000 and 400,000,000 shares authorized; 115,703,044 and 80,072,334 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Gain on change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_2_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability" xlink:label="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability" xlink:to="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability_lbl" xml:lang="en-US">Modified retroactive adjustment for derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock and warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock and warrants, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of commitment shares to Lincoln Park</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of commitment shares to Lincoln Park, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="atnm_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification" xlink:label="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification" xlink:to="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification_lbl" xml:lang="en-US">Transfer of warrant derivatives from liability to equity classification</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="atnm_GainOnChangeInFairValueOfDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GainOnChangeInFairValueOfDerivatives" xlink:to="atnm_GainOnChangeInFairValueOfDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atnm_GainOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US">Gain on change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase) decrease in:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase in:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Payment of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments on note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sales of shares of common stock and warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Stock issuance costs included in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable" xlink:label="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable" xlink:to="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable_lbl" xml:lang="en-US">Prepaid expenses financed by accounts payable and notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Capital lease of office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification" xlink:label="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification" xlink:to="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification_lbl" xml:lang="en-US">Transfer from derivative liability classification to equity classification</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NotesToFinancialStatementsAbstract" xlink:label="atnm_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NotesToFinancialStatementsAbstract" xlink:to="atnm_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SubsequentEventAbstract" xlink:label="atnm_SubsequentEventAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SubsequentEventAbstract" xlink:to="atnm_SubsequentEventAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SubsequentEventAbstract_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GoingConcernPolicyTextBlock" xlink:label="atnm_GoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GoingConcernPolicyTextBlock" xlink:to="atnm_GoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-Based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AccountingPronouncementsRecentlyAdopted" xlink:label="atnm_AccountingPronouncementsRecentlyAdopted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AccountingPronouncementsRecentlyAdopted" xlink:to="atnm_AccountingPronouncementsRecentlyAdopted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AccountingPronouncementsRecentlyAdopted_lbl" xml:lang="en-US">Accounting Standards Recently Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US">Schedule of impacts to consolidated statements of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Summary of cash and cash equivalent and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of derivative warrant instruments activity</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:to="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_lbl" xml:lang="en-US">Schedule of fair values of derivative warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Summary of prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:label="atnm_ScheduleOfDepreciationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:to="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum obligations on the lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of option and warrant activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of difference between income tax provision and U.S federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OptionMember_2_lbl" xml:lang="en-US">Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash and cash equivalent and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Estimated useful lives, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xml:lang="en-US">Property and equipment depreciation method</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal corporate tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_3_lbl" xml:lang="en-US">Additional paid-in capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_lbl" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_lbl" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="atnm_MarketValueOfCommonStockOnMeasurementDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:to="atnm_MarketValueOfCommonStockOnMeasurementDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MarketValueOfCommonStockOnMeasurementDate_lbl" xml:lang="en-US">Market value of common stock on measurement date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Adjusted exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Warrant lives in years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear" xlink:label="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear" xlink:to="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear_lbl" xml:lang="en-US">Probability of stock offering in any period over 5 years</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="atnm_FairValueAssumptionOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueAssumptionOfferingPrice" xlink:to="atnm_FairValueAssumptionOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FairValueAssumptionOfferingPrice_lbl" xml:lang="en-US">Offering price estimated as of December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DerivativeLiabilitiesTextualAbstract" xlink:label="atnm_DerivativeLiabilitiesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DerivativeLiabilitiesTextualAbstract" xlink:to="atnm_DerivativeLiabilitiesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DerivativeLiabilitiesTextualAbstract_lbl" xml:lang="en-US">Derivative Liabilities (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Fair value of the derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProbabilityOfStockOfferingInPeriod" xlink:label="atnm_ProbabilityOfStockOfferingInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProbabilityOfStockOfferingInPeriod" xlink:to="atnm_ProbabilityOfStockOfferingInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProbabilityOfStockOfferingInPeriod_lbl" xml:lang="en-US">Probability of stock offering in period</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NumberOfWarrants" xlink:label="atnm_NumberOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrants" xlink:to="atnm_NumberOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfWarrants_lbl" xml:lang="en-US">Number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Original exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidClinicalTrialExpenses" xlink:label="atnm_PrepaidClinicalTrialExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidClinicalTrialExpenses" xlink:to="atnm_PrepaidClinicalTrialExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PrepaidClinicalTrialExpenses_lbl" xml:lang="en-US">Prepaid clinical trial expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract" xlink:label="atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract" xlink:to="atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_2_lbl" xml:lang="en-US">Prepaid insurance financed by issuance of note payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LabEquipmentMember" xlink:to="atnm_LabEquipmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_LabEquipmentMember_2_lbl" xml:lang="en-US">Lab equipment Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_2_lbl" xml:lang="en-US">Office equipment &amp; furniture Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US">Summary of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful Lives</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_2_lbl" xml:lang="en-US">Research &amp; development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_2_lbl" xml:lang="en-US">General administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PropertyAndEquipmentDetailsTextualAbstract" xlink:label="atnm_PropertyAndEquipmentDetailsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PropertyAndEquipmentDetailsTextualAbstract" xlink:to="atnm_PropertyAndEquipmentDetailsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PropertyAndEquipmentDetailsTextualAbstract_lbl" xml:lang="en-US">Property And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalLeaseAgreement" xlink:label="atnm_CapitalLeaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalLeaseAgreement" xlink:to="atnm_CapitalLeaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalLeaseAgreement_lbl" xml:lang="en-US">Capital lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OfficeEquipmentServices" xlink:label="atnm_OfficeEquipmentServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OfficeEquipmentServices" xlink:to="atnm_OfficeEquipmentServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OfficeEquipmentServices_lbl" xml:lang="en-US">Office equipment and services</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalleaseOfOfficeEquipment" xlink:label="atnm_CapitalleaseOfOfficeEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalleaseOfOfficeEquipment" xlink:to="atnm_CapitalleaseOfOfficeEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalleaseOfOfficeEquipment_lbl" xml:lang="en-US">Capitalized value of lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommitmentsAndContingenciesDetailsAbstract" xlink:label="atnm_CommitmentsAndContingenciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CommitmentsAndContingenciesDetailsAbstract" xlink:to="atnm_CommitmentsAndContingenciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CommitmentsAndContingenciesDetailsAbstract_lbl" xml:lang="en-US">Commitments And Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">For the year ending December 31:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_AgreementAxis_2_lbl" xml:lang="en-US">Agreements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="atnm_CommitmentsAndContingenciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CommitmentsAndContingenciesTextualAbstract" xlink:to="atnm_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CommitmentsAndContingenciesTextualAbstract_lbl" xml:lang="en-US">Commitments and Contingencies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">License fee payment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="atnm_LongTermPurchaseCommitmentMilestonesPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:to="atnm_LongTermPurchaseCommitmentMilestonesPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongTermPurchaseCommitmentMilestonesPayment_lbl" xml:lang="en-US">Milestones Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl" xml:lang="en-US">Description of royalty payment</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FirstCommercialSalePeriod" xlink:label="atnm_FirstCommercialSalePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FirstCommercialSalePeriod" xlink:to="atnm_FirstCommercialSalePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FirstCommercialSalePeriod_lbl" xml:lang="en-US">First commercial sale period</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProjectEstimatedCost" xlink:label="atnm_ProjectEstimatedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProjectEstimatedCost" xlink:to="atnm_ProjectEstimatedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProjectEstimatedCost_lbl" xml:lang="en-US">Project estimated cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentInProcess" xlink:to="us-gaap_DevelopmentInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentInProcess_lbl" xml:lang="en-US">Total project estimated to cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="us-gaap_PaymentsForLeasingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLeasingCosts" xlink:to="us-gaap_PaymentsForLeasingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLeasingCosts_lbl" xml:lang="en-US">Cost of lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ServicesFees" xlink:label="atnm_ServicesFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ServicesFees" xlink:to="atnm_ServicesFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ServicesFees_lbl" xml:lang="en-US">Services fees</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LeaseTerm" xlink:label="atnm_LeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseTerm" xlink:to="atnm_LeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease agreements, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PurchaseOfMaterials" xlink:label="atnm_PurchaseOfMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseOfMaterials" xlink:to="atnm_PurchaseOfMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PurchaseOfMaterials_lbl" xml:lang="en-US">Purchase of materials</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProjectRemainingCost" xlink:label="atnm_ProjectRemainingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProjectRemainingCost" xlink:to="atnm_ProjectRemainingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ProjectRemainingCost_lbl" xml:lang="en-US">Project remaining cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Certified deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent for office</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:label="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:to="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Capitalized lease financial by accounts payable and accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalleaseOfOfficeEquipment" xlink:to="atnm_CapitalleaseOfOfficeEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_CapitalleaseOfOfficeEquipment_2_lbl" xml:lang="en-US">Capital lease of office equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OfficeEquipmentServices" xlink:to="atnm_OfficeEquipmentServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_OfficeEquipmentServices_2_lbl" xml:lang="en-US">Office equipment services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="atnm_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateIntrinsicValueAbstract" xlink:to="atnm_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EquityTextualsAbstract" xlink:label="atnm_EquityTextualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityTextualsAbstract" xlink:to="atnm_EquityTextualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityTextualsAbstract_lbl" xml:lang="en-US">Equity (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockRepurchasedDuringPeriodSharesAdditional" xlink:label="atnm_StockRepurchasedDuringPeriodSharesAdditional" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockRepurchasedDuringPeriodSharesAdditional" xlink:to="atnm_StockRepurchasedDuringPeriodSharesAdditional_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockRepurchasedDuringPeriodSharesAdditional_lbl" xml:lang="en-US">Additional shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockRepurchasedDuringPeriodValueAdditional" xlink:label="atnm_StockRepurchasedDuringPeriodValueAdditional" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockRepurchasedDuringPeriodValueAdditional" xlink:to="atnm_StockRepurchasedDuringPeriodValueAdditional_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockRepurchasedDuringPeriodValueAdditional_lbl" xml:lang="en-US">Additional shares of common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueOfMarketPrice" xlink:label="atnm_FairValueOfMarketPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueOfMarketPrice" xlink:to="atnm_FairValueOfMarketPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FairValueOfMarketPrice_lbl" xml:lang="en-US">Fair value of market price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchased shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Purchased value of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Purchase of shares (will not exceed)</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AcceleratedPurchaseDescription" xlink:label="atnm_AcceleratedPurchaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AcceleratedPurchaseDescription" xlink:to="atnm_AcceleratedPurchaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AcceleratedPurchaseDescription_lbl" xml:lang="en-US">Accelerated purchase, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Maximum beneficially owning, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Received amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sales of aggregate of commonstock units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds from issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance of commitment shares to Lincoln Park</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommonStockForIssuedCashlessExerciseOfWarrants" xlink:label="atnm_CommonStockForIssuedCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CommonStockForIssuedCashlessExerciseOfWarrants" xlink:to="atnm_CommonStockForIssuedCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CommonStockForIssuedCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Common shares issued for cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of shares of restricted stock, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of shares yet to issue of restricted stock, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_Underwrittenoffering" xlink:label="atnm_Underwrittenoffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Underwrittenoffering" xlink:to="atnm_Underwrittenoffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_Underwrittenoffering_lbl" xml:lang="en-US">Underwritten offering common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantToPurchaseOfCommonStock" xlink:label="atnm_WarrantToPurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantToPurchaseOfCommonStock" xlink:to="atnm_WarrantToPurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantToPurchaseOfCommonStock_lbl" xml:lang="en-US">Warrant to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsExercisablePeriod" xlink:label="atnm_WarrantsExercisablePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsExercisablePeriod" xlink:to="atnm_WarrantsExercisablePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantsExercisablePeriod_lbl" xml:lang="en-US">Warrants exercisable period</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NumberofWarrentIssued" xlink:label="atnm_NumberofWarrentIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberofWarrentIssued" xlink:to="atnm_NumberofWarrentIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberofWarrentIssued_lbl" xml:lang="en-US">Number of warrant granted</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TerminationOfEmployees" xlink:label="atnm_TerminationOfEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TerminationOfEmployees" xlink:to="atnm_TerminationOfEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TerminationOfEmployees_lbl" xml:lang="en-US">Termination of employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Description of warrant exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Fair value assumptions, expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Fair value assumptions, expected discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Fair value assumptions, expected volatility rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Fair value assumptions, expected dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Options to purchase common shares, cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Total option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="invest_InvestmentWarrantsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentWarrantsExpirationDate" xlink:to="invest_InvestmentWarrantsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentWarrantsExpirationDate_lbl" xml:lang="en-US">Warrants expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="atnm_WarrantsExercisedByWarrantHolders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsExercisedByWarrantHolders" xlink:to="atnm_WarrantsExercisedByWarrantHolders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantsExercisedByWarrantHolders_lbl" xml:lang="en-US">Warrants exercised by warrant holders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common shares for consulting services, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common shares for consulting services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Restricted stock granted value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Director left - option extension</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GrossProceedsFromWarrantExercises" xlink:label="atnm_GrossProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrossProceedsFromWarrantExercises" xlink:to="atnm_GrossProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrossProceedsFromWarrantExercises_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Net proceeds on exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Gross proceeds from warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionToPurchaseShare" xlink:label="atnm_EmployeeOptionToPurchaseShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeOptionToPurchaseShare" xlink:to="atnm_EmployeeOptionToPurchaseShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EmployeeOptionToPurchaseShare_lbl" xml:lang="en-US">Employees options to purchase granted</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionsToPurchaseaveragePrice" xlink:label="atnm_EmployeeOptionsToPurchaseaveragePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeOptionsToPurchaseaveragePrice" xlink:to="atnm_EmployeeOptionsToPurchaseaveragePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EmployeeOptionsToPurchaseaveragePrice_lbl" xml:lang="en-US">Options to purchase average price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Employees options vesting description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Aggregate series warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsToPurchaseOfCommonStock" xlink:label="atnm_WarrantsToPurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsToPurchaseOfCommonStock" xlink:to="atnm_WarrantsToPurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantsToPurchaseOfCommonStock_lbl" xml:lang="en-US">Number of warrants issued to consultants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Proceeds from common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US">Warrants, vesting period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Number of stock option/restricted shares canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of stock option/warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock options, term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock options, vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Plan expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Number of additional shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGranted" xlink:label="atnm_RestrictedCommonSharesGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGranted" xlink:to="atnm_RestrictedCommonSharesGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RestrictedCommonSharesGranted_lbl" xml:lang="en-US">Restricted common shares granted vested</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedValue" xlink:label="atnm_RestrictedCommonSharesGrantedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGrantedValue" xlink:to="atnm_RestrictedCommonSharesGrantedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RestrictedCommonSharesGrantedValue_lbl" xml:lang="en-US">Restricted common shares granted, value</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedFullyVested" xlink:label="atnm_RestrictedCommonSharesGrantedFullyVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGrantedFullyVested" xlink:to="atnm_RestrictedCommonSharesGrantedFullyVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RestrictedCommonSharesGrantedFullyVested_lbl" xml:lang="en-US">Restricted common shares granted fully vested</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedFullyVestedValue" xlink:label="atnm_RestrictedCommonSharesGrantedFullyVestedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGrantedFullyVestedValue" xlink:to="atnm_RestrictedCommonSharesGrantedFullyVestedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RestrictedCommonSharesGrantedFullyVestedValue_lbl" xml:lang="en-US">Restricted common shares granted fully vested, value</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued" xlink:label="atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued" xlink:to="atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued_lbl" xml:lang="en-US">Restricted stock granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="atnm_FairValueAssumptionsExpectedDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueAssumptionsExpectedDiscountRate" xlink:to="atnm_FairValueAssumptionsExpectedDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_FairValueAssumptionsExpectedDiscountRate_lbl" xml:lang="en-US">Fair value assumptions, expected discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Warrants exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsToExercisableTerm" xlink:label="atnm_WarrantsToExercisableTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsToExercisableTerm" xlink:to="atnm_WarrantsToExercisableTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantsToExercisableTerm_lbl" xml:lang="en-US">Warrants exercisable term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AdditionalNoncashExpenseIncrementalFairValue" xlink:label="atnm_AdditionalNoncashExpenseIncrementalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AdditionalNoncashExpenseIncrementalFairValue" xlink:to="atnm_AdditionalNoncashExpenseIncrementalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AdditionalNoncashExpenseIncrementalFairValue_lbl" xml:lang="en-US">Additional non-cash expense incremental fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_IncomeTaxReconciliationResearchAndDevelopment" xlink:label="atnm_IncomeTaxReconciliationResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncomeTaxReconciliationResearchAndDevelopment" xlink:to="atnm_IncomeTaxReconciliationResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncomeTaxReconciliationResearchAndDevelopment_lbl" xml:lang="en-US">Research and development/orphan drug credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Others</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Federal statutory income taxes, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Change in Federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Change in Federal statutory rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_IncomeTaxReconciliationDeferredTrueUp" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueUp" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncomeTaxReconciliationDeferredTrueUp" xlink:to="atnm_IncomeTaxReconciliationDeferredTrueUp_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueUp_lbl" xml:lang="en-US">Deferred true-up</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl" xml:lang="en-US">Deferred true-up, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and Development/Orphan Drug Tax Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and Development/Orphan Drug Tax Credit, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Unrealized derivative gain/loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Unrealized derivative gain/loss, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision for income tax, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_IncomeTaxTextualAbstract" xlink:label="atnm_IncomeTaxTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncomeTaxTextualAbstract" xlink:to="atnm_IncomeTaxTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncomeTaxTextualAbstract_lbl" xml:lang="en-US">Income Taxes (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US">Net operating loss expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3_lbl" xml:lang="en-US">U.S. Federal statutory rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Decrease related to tax cuts and jobs act</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_lbl" xml:lang="en-US">U.S. Federal statutory rate to pre-tax loss for the years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl" xml:lang="en-US">State income tax purposes, net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign_lbl" xml:lang="en-US">Federal income tax purposes, net operating losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Percentage of ownership</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ThePlanAmendmentMember" xlink:to="atnm_ThePlanAmendmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_ThePlanAmendmentMember_2_lbl" xml:lang="en-US">Plan Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="atnm_SubsequentEventsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SubsequentEventsTextualAbstract" xlink:to="atnm_SubsequentEventsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SubsequentEventsTextualAbstract_lbl" xml:lang="en-US">Subsequent Event (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Realized net proceeds, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Realized net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ExercisedSeriesWarrantsIssuedForThePeriod" xlink:label="atnm_ExercisedSeriesWarrantsIssuedForThePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExercisedSeriesWarrantsIssuedForThePeriod" xlink:to="atnm_ExercisedSeriesWarrantsIssuedForThePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ExercisedSeriesWarrantsIssuedForThePeriod_lbl" xml:lang="en-US">Series A warrants exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds series A warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionToPurchaseShares" xlink:label="atnm_EmployeeOptionToPurchaseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeOptionToPurchaseShares" xlink:to="atnm_EmployeeOptionToPurchaseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_EmployeeOptionToPurchaseShares_lbl" xml:lang="en-US">Employees options to purchase granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Common shares price range</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock authorized shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AcceleratedPurchaseDescription" xlink:to="atnm_AcceleratedPurchaseDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AcceleratedPurchaseDescription_doc" xml:lang="en-US">Description accelerated purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AccountingPronouncementsRecentlyAdopted" xlink:to="atnm_AccountingPronouncementsRecentlyAdopted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AccountingPronouncementsRecentlyAdopted_doc" xml:lang="en-US">Disclosure of accounting policy for accounting pronouncements recently adopted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementAxis_doc" xml:lang="en-US">Agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementDomain" xlink:label="atnm_AgreementDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementDomain" xlink:to="atnm_AgreementDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementDomain_doc" xml:lang="en-US">Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CommonStockForIssuedCashlessExerciseOfWarrants" xlink:to="atnm_CommonStockForIssuedCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CommonStockForIssuedCashlessExerciseOfWarrants_doc" xml:lang="en-US">Number of common shares issued for cashless exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_doc" xml:lang="en-US">Description of royalty payment to related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DocumentAndEntityInformationAbstract" xlink:to="atnm_DocumentAndEntityInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DocumentAndEntityInformationAbstract_doc" xml:lang="en-US">Document and Entity Information.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeOptionsToPurchaseaveragePrice" xlink:to="atnm_EmployeeOptionsToPurchaseaveragePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_EmployeeOptionsToPurchaseaveragePrice_doc" xml:lang="en-US">Options to purchase average price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeOptionToPurchaseShare" xlink:to="atnm_EmployeeOptionToPurchaseShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_EmployeeOptionToPurchaseShare_doc" xml:lang="en-US">It represent employees options to purchase granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityTextualsAbstract" xlink:to="atnm_EquityTextualsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_EquityTextualsAbstract_doc" xml:lang="en-US">Equity textual abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueAssumptionOfferingPrice" xlink:to="atnm_FairValueAssumptionOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FairValueAssumptionOfferingPrice_doc" xml:lang="en-US">Fair value assumption offering price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:to="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_doc" xml:lang="en-US">Fair value of derivative warrants on basis of valuation model.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FirstCommercialSalePeriod" xlink:to="atnm_FirstCommercialSalePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FirstCommercialSalePeriod_doc" xml:lang="en-US">First commercial sale period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FredHutchinsonCancerResearchCenterMember" xlink:to="atnm_FredHutchinsonCancerResearchCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FredHutchinsonCancerResearchCenterMember_doc" xml:lang="en-US">Fred hutchinson cancer research center.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GainOnChangeInFairValueOfDerivatives" xlink:to="atnm_GainOnChangeInFairValueOfDerivatives_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GainOnChangeInFairValueOfDerivatives_doc" xml:lang="en-US">Amount of gain on change in fair value of the derivatives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrossProceedsFromWarrantExercises" xlink:to="atnm_GrossProceedsFromWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GrossProceedsFromWarrantExercises_doc" xml:lang="en-US">Gross proceeds from warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseTerm" xlink:to="atnm_LeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LeaseTerm_doc" xml:lang="en-US">Lease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseAndSponsoredResearchAgreementMember" xlink:to="atnm_LicenseAndSponsoredResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LicenseAndSponsoredResearchAgreementMember_doc" xml:lang="en-US">License and sponsored research agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:to="atnm_LongTermPurchaseCommitmentMilestonesPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongTermPurchaseCommitmentMilestonesPayment_doc" xml:lang="en-US">Long term purchase commitment milestones payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:to="atnm_MarketValueOfCommonStockOnMeasurementDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MarketValueOfCommonStockOnMeasurementDate_doc" xml:lang="en-US">Market value of common stock on measurement date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrants" xlink:to="atnm_NumberOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfWarrants_doc" xml:lang="en-US">Number of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OakRidgeNationalLaboratoryMember" xlink:to="atnm_OakRidgeNationalLaboratoryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OakRidgeNationalLaboratoryMember_doc" xml:lang="en-US">Oak ridge national laboratory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear" xlink:to="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear_doc" xml:lang="en-US">It represent probability of stock offering in any period over five years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProbabilityOfStockOfferingInPeriod" xlink:to="atnm_ProbabilityOfStockOfferingInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ProbabilityOfStockOfferingInPeriod_doc" xml:lang="en-US">Probability of stock offering period .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProjectEstimatedCost" xlink:to="atnm_ProjectEstimatedCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ProjectEstimatedCost_doc" xml:lang="en-US">Project estimated cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ProjectRemainingCost" xlink:to="atnm_ProjectRemainingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ProjectRemainingCost_doc" xml:lang="en-US">Project remaining cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseOfMaterials" xlink:to="atnm_PurchaseOfMaterials_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PurchaseOfMaterials_doc" xml:lang="en-US">Purchase of materials.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ServicesFees" xlink:to="atnm_ServicesFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ServicesFees_doc" xml:lang="en-US">Amount paid for services fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockRepurchasedDuringPeriodSharesAdditional" xlink:to="atnm_StockRepurchasedDuringPeriodSharesAdditional_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockRepurchasedDuringPeriodSharesAdditional_doc" xml:lang="en-US">Stock repurchased during period shares additional.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockRepurchasedDuringPeriodValueAdditional" xlink:to="atnm_StockRepurchasedDuringPeriodValueAdditional_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockRepurchasedDuringPeriodValueAdditional_doc" xml:lang="en-US">Stock repurchased during period value additional.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TerminationOfEmployees" xlink:to="atnm_TerminationOfEmployees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_TerminationOfEmployees_doc" xml:lang="en-US">Termination of employee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsExercisablePeriod" xlink:to="atnm_WarrantsExercisablePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantsExercisablePeriod_doc" xml:lang="en-US">Warrants exercisable period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsExercisedByWarrantHolders" xlink:to="atnm_WarrantsExercisedByWarrantHolders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantsExercisedByWarrantHolders_doc" xml:lang="en-US">Warrants exercised by warrant holders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsToPurchaseOfCommonStock" xlink:to="atnm_WarrantsToPurchaseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantsToPurchaseOfCommonStock_doc" xml:lang="en-US">Number of warrants issued to purchase of common stock to consultants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalleaseOfOfficeEquipment" xlink:to="atnm_CapitalleaseOfOfficeEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CapitalleaseOfOfficeEquipment_doc" xml:lang="en-US">Capitallease of office equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueOfMarketPrice" xlink:to="atnm_FairValueOfMarketPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_FairValueOfMarketPrice_doc" xml:lang="en-US">Fair value of market price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Underwrittenoffering" xlink:to="atnm_Underwrittenoffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_Underwrittenoffering_doc" xml:lang="en-US">Underwritten offering common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantToPurchaseOfCommonStock" xlink:to="atnm_WarrantToPurchaseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantToPurchaseOfCommonStock_doc" xml:lang="en-US">Warrant to purchase of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_doc" xml:lang="en-US">Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGranted" xlink:to="atnm_RestrictedCommonSharesGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RestrictedCommonSharesGranted_doc" xml:lang="en-US">Restricted common shares granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGrantedValue" xlink:to="atnm_RestrictedCommonSharesGrantedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RestrictedCommonSharesGrantedValue_doc" xml:lang="en-US">Amount of restricted common shares granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGrantedFullyVested" xlink:to="atnm_RestrictedCommonSharesGrantedFullyVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RestrictedCommonSharesGrantedFullyVested_doc" xml:lang="en-US">Restricted common shares granted fully vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RestrictedCommonSharesGrantedFullyVestedValue" xlink:to="atnm_RestrictedCommonSharesGrantedFullyVestedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RestrictedCommonSharesGrantedFullyVestedValue_doc" xml:lang="en-US">Amount of restricted common shares granted fully vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantsToExercisableTerm" xlink:to="atnm_WarrantsToExercisableTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantsToExercisableTerm_doc" xml:lang="en-US">Warrants exercisable term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AdditionalNoncashExpenseIncrementalFairValue" xlink:to="atnm_AdditionalNoncashExpenseIncrementalFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AdditionalNoncashExpenseIncrementalFairValue_doc" xml:lang="en-US">Additional non cash expense incremental fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExercisedSeriesWarrantsIssuedForThePeriod" xlink:to="atnm_ExercisedSeriesWarrantsIssuedForThePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ExercisedSeriesWarrantsIssuedForThePeriod_doc" xml:lang="en-US">Warrants exercised shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_doc" xml:lang="en-US">Amount of stock issuance costs included in accounts payable and accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable" xlink:to="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable_doc" xml:lang="en-US">Amount of prepaid expenses financed by accounts payable and notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification" xlink:to="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification_doc" xml:lang="en-US">Transfer from derivative liability classification to equity classification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification" xlink:to="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification_doc" xml:lang="en-US">Amount of transfer of warrant derivatives from liability to equity classification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability" xlink:to="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability_doc" xml:lang="en-US">Amount of modified retroactive adjustment for derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalLeaseAgreement" xlink:to="atnm_CapitalLeaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CapitalLeaseAgreement_doc" xml:lang="en-US">Capital lease agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OfficeEquipmentServices" xlink:to="atnm_OfficeEquipmentServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OfficeEquipmentServices_doc" xml:lang="en-US">Office equipment and services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GoingConcernPolicyTextBlock" xlink:to="atnm_GoingConcernPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GoingConcernPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for going concern.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:to="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses_doc" xml:lang="en-US">Capitalized lease financial by accounts payable and accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TwoThousandThirteenEquityIncentivePlanMember" xlink:to="atnm_TwoThousandThirteenEquityIncentivePlanMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TwoThousandThirteenEquityIncentivePlanMember_2_lbl" xml:lang="en-US">TwoThousandThirteenEquityIncentivePlanMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GainOnChangeInFairValueOfDerivatives" xlink:to="atnm_GainOnChangeInFairValueOfDerivatives_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GainOnChangeInFairValueOfDerivatives_3_lbl" xml:lang="en-US">Gain On Change In Fair Value Of Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_2_lbl" xml:lang="en-US">Restricted Cash, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_3_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FairValueAssumptionsExpectedDiscountRate" xlink:to="atnm_FairValueAssumptionsExpectedDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FairValueAssumptionsExpectedDiscountRate_2_lbl" xml:lang="en-US">FairValueAssumptionsExpectedDiscountRate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EmployeeOptionToPurchaseShares" xlink:to="atnm_EmployeeOptionToPurchaseShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EmployeeOptionToPurchaseShares_2_lbl" xml:lang="en-US">EmployeeOptionToPurchaseShares</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>atnm-20181231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: atnm%2D20181231.xfr; Date: 2019%2D03%2D15T19:01:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="atnm-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:href="atnm-20181231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="atnm-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:href="atnm-20181231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="atnm-20181231.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="atnm-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilities" xlink:href="atnm-20181231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" xlink:href="atnm-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="atnm-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Equity" xlink:href="atnm-20181231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxes" xlink:href="atnm-20181231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent" xlink:href="atnm-20181231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:href="atnm-20181231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" xlink:href="atnm-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="atnm-20181231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual" xlink:href="atnm-20181231.xsd#DerivativeLiabilitiesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:href="atnm-20181231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" xlink:href="atnm-20181231.xsd#PropertyAndEquipmentDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="atnm-20181231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:href="atnm-20181231.xsd#EquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails1" xlink:href="atnm-20181231.xsd#EquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:href="atnm-20181231.xsd#EquityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" xlink:href="atnm-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1" xlink:href="atnm-20181231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual" xlink:href="atnm-20181231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" xlink:href="atnm-20181231.xsd#SubsequentEventDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_atnmDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability" xlink:label="loc_atnmModifiedRetroactiveAdjustmentForDerivativeLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmModifiedRetroactiveAdjustmentForDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification" xlink:label="loc_atnmTransferOfWarrantDerivativesFromLiabilityToEquityClassification" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmTransferOfWarrantDerivativesFromLiabilityToEquityClassification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnmGainOnChangeInFairValueOfDerivatives" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_atnmGainOnChangeInFairValueOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="loc_atnmStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_atnmStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable" xlink:label="loc_atnmPrepaidExpensesFinancedByAccountsPayableAndNotesPayable" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_atnmPrepaidExpensesFinancedByAccountsPayableAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification" xlink:label="loc_atnmTransferFromDerivativeLiabilityClassificationToEquityClassification" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_atnmTransferFromDerivativeLiabilityClassificationToEquityClassification" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilities" xlink:title="00000008 - Disclosure - Derivative Liabilities">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000009 - Disclosure - Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NotesToFinancialStatementsAbstract" xlink:label="loc_atnmNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="loc_atnmPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmNotesToFinancialStatementsAbstract" xlink:to="loc_atnmPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity" xlink:title="00000012 - Disclosure - Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent" xlink:title="00000014 - Disclosure - Subsequent Event">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SubsequentEventAbstract" xlink:label="loc_atnmSubsequentEventAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSubsequentEventAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GoingConcernPolicyTextBlock" xlink:label="loc_atnmGoingConcernPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_atnmGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AccountingPronouncementsRecentlyAdopted" xlink:label="loc_atnmAccountingPronouncementsRecentlyAdopted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_atnmAccountingPronouncementsRecentlyAdopted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables" xlink:title="00000017 - Disclosure - Derivative Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_atnmFairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_atnmFairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NotesToFinancialStatementsAbstract" xlink:label="loc_atnmNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables" xlink:title="00000019 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:label="loc_atnmScheduleOfDepreciationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_atnmScheduleOfDepreciationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:title="00000021 - Disclosure - Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000025 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherRestrictedAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000026 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails" xlink:title="00000027 - Disclosure - Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TotalstockholdersequityMember" xlink:label="loc_atnmTotalstockholdersequityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_atnmTotalstockholdersequityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1" xlink:title="00000028 - Disclosure - Derivative Liabilities (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaapDefinedBenefitPlanByPlanAssetCategoriesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDefinedBenefitPlanByPlanAssetCategoriesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaapPlanAssetCategoriesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="loc_us-gaapPlanAssetCategoriesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnmMarketValueOfCommonStockOnMeasurementDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_atnmMarketValueOfCommonStockOnMeasurementDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear" xlink:label="loc_atnmProbabilityOfStockOfferingInAnyPeriodOverYear" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_atnmProbabilityOfStockOfferingInAnyPeriodOverYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnmFairValueAssumptionOfferingPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="loc_atnmFairValueAssumptionOfferingPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual" xlink:title="00000029 - Disclosure - Derivative Liabilities (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201711Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201711Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DerivativeLiabilitiesTextualAbstract" xlink:label="loc_atnmDerivativeLiabilitiesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmDerivativeLiabilitiesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProbabilityOfStockOfferingInPeriod" xlink:label="loc_atnmProbabilityOfStockOfferingInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract" xlink:to="loc_atnmProbabilityOfStockOfferingInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NumberOfWarrants" xlink:label="loc_atnmNumberOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract" xlink:to="loc_atnmNumberOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmDerivativeLiabilitiesTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000030 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_atnmPrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidClinicalTrialExpenses" xlink:label="loc_atnmPrepaidClinicalTrialExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_atnmPrepaidClinicalTrialExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual" xlink:title="00000031 - Disclosure - Prepaid Expenses and Other Current Assets (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_atnmPrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract" xlink:label="loc_atnmPrepaidExpensesAndOtherCurrentAssetsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_atnmPrepaidExpensesAndOtherCurrentAssetsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPrepaidExpensesAndOtherCurrentAssetsTextualAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PropertyAndEquipmentDetailsAbstract" xlink:label="loc_atnmPropertyAndEquipmentDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPropertyAndEquipmentDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LabEquipmentMember" xlink:label="loc_atnmLabEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_atnmLabEquipmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1" xlink:title="00000033 - Disclosure - Property and Equipment (Details 1)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PropertyAndEquipmentDetails1Abstract" xlink:label="loc_atnmPropertyAndEquipmentDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPropertyAndEquipmentDetails1Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" xlink:title="00000034 - Disclosure - Property and Equipment (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PropertyAndEquipmentDetailsTextualAbstract" xlink:label="loc_atnmPropertyAndEquipmentDetailsTextualAbstract" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalLeaseAgreement" xlink:label="loc_atnmCapitalLeaseAgreement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPropertyAndEquipmentDetailsTextualAbstract" xlink:to="loc_atnmCapitalLeaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OfficeEquipmentServices" xlink:label="loc_atnmOfficeEquipmentServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPropertyAndEquipmentDetailsTextualAbstract" xlink:to="loc_atnmOfficeEquipmentServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalleaseOfOfficeEquipment" xlink:label="loc_atnmCapitalleaseOfOfficeEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmPropertyAndEquipmentDetailsTextualAbstract" xlink:to="loc_atnmCapitalleaseOfOfficeEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000035 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_atnmCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000036 - Disclosure - Commitments and Contingencies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_atnmCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_atnmAgreementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GeorgeClinicalMember" xlink:label="loc_atnmGeorgeClinicalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmGeorgeClinicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnmLicenseAndSponsoredResearchAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmLicenseAndSponsoredResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GoodwinMember" xlink:label="loc_atnmGoodwinMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmGoodwinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnmOakRidgeNationalLaboratoryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmOakRidgeNationalLaboratoryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnmFredHutchinsonCancerResearchCenterMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmFredHutchinsonCancerResearchCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MedpaceIncMember" xlink:label="loc_atnmMedpaceIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmMedpaceIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnmCommitmentsAndContingenciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnmLongTermPurchaseCommitmentMilestonesPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmLongTermPurchaseCommitmentMilestonesPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmDescriptionOfRoyaltyPaymentToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnmFirstCommercialSalePeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmFirstCommercialSalePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnmProjectEstimatedCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmProjectEstimatedCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaapDevelopmentInProcess" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapDevelopmentInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapPaymentsForLeasingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ServicesFees" xlink:label="loc_atnmServicesFees" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmServicesFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LeaseTerm" xlink:label="loc_atnmLeaseTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PurchaseOfMaterials" xlink:label="loc_atnmPurchaseOfMaterials" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmPurchaseOfMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ProjectRemainingCost" xlink:label="loc_atnmProjectRemainingCost" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmProjectRemainingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:label="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmCapitalizedLeaseFinancialByAccountsPayableAndAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalleaseOfOfficeEquipment" xlink:label="loc_atnmCapitalleaseOfOfficeEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmCapitalleaseOfOfficeEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CapitalLeaseAgreement" xlink:label="loc_atnmCapitalLeaseAgreement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmCapitalLeaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OfficeEquipmentServices" xlink:label="loc_atnmOfficeEquipmentServices" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_atnmOfficeEquipmentServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:title="00000037 - Disclosure - Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="loc_atnmAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_atnmAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails1" xlink:title="00000038 - Disclosure - Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_atnmSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AggregateIntrinsicValueAbstract" xlink:label="loc_atnmAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_atnmAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:title="00000039 - Disclosure - Equity (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SeriesAWarrantsMember" xlink:label="loc_atnmSeriesAWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SeriesBWarrantsMember" xlink:label="loc_atnmSeriesBWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsMember" xlink:label="loc_atnmWarrantsMember" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_atnmWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_LincolnParkCapitalFundLlcMember" xlink:label="loc_atnmLincolnParkCapitalFundLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmLincolnParkCapitalFundLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ConsultantsMember" xlink:label="loc_atnmConsultantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementAxis" xlink:label="loc_atnmAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_atnmAgreementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AgreementDomain" xlink:label="loc_atnmAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementAxis" xlink:to="loc_atnmAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_PurchaseAgreementMember" xlink:label="loc_atnmPurchaseAgreementMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmAgreementDomain" xlink:to="loc_atnmPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TwoThousandThirteenStockPlanMember" xlink:label="loc_atnmTwoThousandThirteenStockPlanMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_atnmTwoThousandThirteenStockPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_atnmTwoThousandThirteenEquityIncentivePlanMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_atnmTwoThousandThirteenEquityIncentivePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnmEmployeesDirectorsAndConsultantsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmEmployeesDirectorsAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_MrSandeshSethMember" xlink:label="loc_atnmMrSandeshSethMember" />
      <link:presentationArc order="740" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_atnmMrSandeshSethMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaapBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="750" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnmEquityTextualsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_atnmEquityTextualsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockRepurchasedDuringPeriodSharesAdditional" xlink:label="loc_atnmStockRepurchasedDuringPeriodSharesAdditional" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmStockRepurchasedDuringPeriodSharesAdditional" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockRepurchasedDuringPeriodValueAdditional" xlink:label="loc_atnmStockRepurchasedDuringPeriodValueAdditional" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmStockRepurchasedDuringPeriodValueAdditional" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueOfMarketPrice" xlink:label="loc_atnmFairValueOfMarketPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmFairValueOfMarketPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AcceleratedPurchaseDescription" xlink:label="loc_atnmAcceleratedPurchaseDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmAcceleratedPurchaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_CommonStockForIssuedCashlessExerciseOfWarrants" xlink:label="loc_atnmCommonStockForIssuedCashlessExerciseOfWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmCommonStockForIssuedCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_Underwrittenoffering" xlink:label="loc_atnmUnderwrittenoffering" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmUnderwrittenoffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantToPurchaseOfCommonStock" xlink:label="loc_atnmWarrantToPurchaseOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmWarrantToPurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsExercisablePeriod" xlink:label="loc_atnmWarrantsExercisablePeriod" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmWarrantsExercisablePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_NumberofWarrentIssued" xlink:label="loc_atnmNumberofWarrentIssued" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmNumberofWarrentIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_TerminationOfEmployees" xlink:label="loc_atnmTerminationOfEmployees" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmTerminationOfEmployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_investInvestmentWarrantsExpirationDate" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_investInvestmentWarrantsExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnmWarrantsExercisedByWarrantHolders" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmWarrantsExercisedByWarrantHolders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_GrossProceedsFromWarrantExercises" xlink:label="loc_atnmGrossProceedsFromWarrantExercises" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmGrossProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionToPurchaseShare" xlink:label="loc_atnmEmployeeOptionToPurchaseShare" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmEmployeeOptionToPurchaseShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionsToPurchaseaveragePrice" xlink:label="loc_atnmEmployeeOptionsToPurchaseaveragePrice" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmEmployeeOptionsToPurchaseaveragePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsToPurchaseOfCommonStock" xlink:label="loc_atnmWarrantsToPurchaseOfCommonStock" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmWarrantsToPurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGranted" xlink:label="loc_atnmRestrictedCommonSharesGranted" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmRestrictedCommonSharesGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedValue" xlink:label="loc_atnmRestrictedCommonSharesGrantedValue" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmRestrictedCommonSharesGrantedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedFullyVested" xlink:label="loc_atnmRestrictedCommonSharesGrantedFullyVested" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmRestrictedCommonSharesGrantedFullyVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_RestrictedCommonSharesGrantedFullyVestedValue" xlink:label="loc_atnmRestrictedCommonSharesGrantedFullyVestedValue" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmRestrictedCommonSharesGrantedFullyVestedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued" xlink:label="loc_atnmStockIssuedDuringPeriodRestrictedStockAwardNotIssued" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmStockIssuedDuringPeriodRestrictedStockAwardNotIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnmFairValueAssumptionsExpectedDiscountRate" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmFairValueAssumptionsExpectedDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_WarrantsToExercisableTerm" xlink:label="loc_atnmWarrantsToExercisableTerm" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmWarrantsToExercisableTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_AdditionalNoncashExpenseIncrementalFairValue" xlink:label="loc_atnmAdditionalNoncashExpenseIncrementalFairValue" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmEquityTextualsAbstract" xlink:to="loc_atnmAdditionalNoncashExpenseIncrementalFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" xlink:title="00000040 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_IncomeTaxReconciliationResearchAndDevelopment" xlink:label="loc_atnmIncomeTaxReconciliationResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:to="loc_atnmIncomeTaxReconciliationResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1" xlink:title="00000041 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_IncomeTaxReconciliationDeferredTrueUp" xlink:label="loc_atnmIncomeTaxReconciliationDeferredTrueUp" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_atnmIncomeTaxReconciliationDeferredTrueUp" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:label="loc_atnmEffectiveIncomeTaxReconciliationDeferredTrueUps" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_atnmEffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual" xlink:title="00000042 - Disclosure - Income Taxes (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_OrphanDrugCreditsMember" xlink:label="loc_atnmOrphanDrugCreditsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_atnmOrphanDrugCreditsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_IncomeTaxTextualAbstract" xlink:label="loc_atnmIncomeTaxTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmIncomeTaxTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaapOperatingLossCarryforwardsExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesForeign" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" xlink:title="00000043 - Disclosure - Subsequent Event (Details)">
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SubsequentEventsDetailsAbstract" xlink:label="loc_atnmSubsequentEventsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnmSubsequentEventsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_DelawareMember" xlink:label="loc_atnmDelawareMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmDelawareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ThePlanAmendmentMember" xlink:label="loc_atnmThePlanAmendmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_atnmThePlanAmendmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnmSubsequentEventsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmSubsequentEventsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_ExercisedSeriesWarrantsIssuedForThePeriod" xlink:label="loc_atnmExercisedSeriesWarrantsIssuedForThePeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmExercisedSeriesWarrantsIssuedForThePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnm-20181231.xsd#atnm_EmployeeOptionToPurchaseShares" xlink:label="loc_atnmEmployeeOptionToPurchaseShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_atnmEmployeeOptionToPurchaseShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>page1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 page1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2\ Q@# 2(  A$! Q$!_\0
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M7AV_CT^ZO'GOW;;]ELXS-(.#U5>G3IUJO9_%'PU<:M'IES+=Z;=2C,:ZC;-
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M>B_#B ZK-KGC*XMQ'-K5UBV/.?LD0"1=>F<,>.O!]* .[DD6-2[L%4 DDG
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MAF&0L@C.5QC.YFZYP!ZUT_A'1YO#_A+2](N9(Y9K.W6)WCSM8CN,T ;=%%%
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M+!G9%*Q,9)XR4S@D9."1QGBJ^C^!_#_A^_>\TFR:S=SEHX9G6(G&,^7G;^E
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M:7 8;2$DJI8L<DY))/7F@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.?2Y_P#:=>XV5O/;VZQW%W)=R#K-(B*6_!0!^E<'XV^%DOCG48[C4?$5Q'!
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MQ-X4\?-I6G>*-46SF2*5%>7<8]QP1D]>02/J!VH ^DJ,5YK\2[+4]"^'QO\
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M0;[#1SD #+JQ4GCZ5R/Q?U_Q)X-@L]9TC6F2*XN!;FSDMT9%^1CN!(SGY>E
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MO;_"K1X9%V21O<JRYS@BXDR*YKX7>!/%O@"]O!<VVFW-M?&%9&CO65H@I.6
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M+&, LP8N>-J_..>>YH B^&NDW'Q#^(UWXQU&]@B:SNUN&M8B!(6Q^[ &/N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHI,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]O=NP@)B+C#9ZGJ<<9SVK)M-,GT:U^&7B&SO=3>XU._MX;V66Z>1"'(&S!.
M"N\?04 >R65YXG?QMJ5M>6%HGAR.!6L[I&_?22$+N##>< '?_".@Y-=#Y@]1
M7E=IHD<_Q-\:Z.+R[AMKW3XI7;SV8QO(Q+E,GY?PZ5S_ (>\,Z;XR\?37&D/
M=6OAC1F$$C+>2,;Z<'/.6.%]<=1CUX /=-XX]^E)(24^7&3TR<5X%H-CJOQ0
M@\1:JFI6]O(]\Z12S74OFV,:X,81$8*!C(W'J0?2MS1EC\7^.8M$UG6/[5M=
M-T>-T>TN6CCN9&/,N%;+$ @9S_.@#M/A]XKOO%MCJUQ?V<%I+9:E+9"*&0N
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M<DMT Z XXKJ/$VOW=S%\/8]4U"2RTG5HUEU*XC<P*TGEHRH9!C8"2W&1T]J
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MA$UW;QSF,-N"%U#;<X&<9QG J_7@][<^*O!>G>#==C\13WEGJ!MK>?3O) 0
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M (Z#.<T >P45R/P]N?%-QX7C_P"$NM!!J<4ACSD;I4&,.P7@'J./3-=:>10
M9JEJVJ6VC:3=ZG>LRVUK$TLA5=QV@9X'K7":?>:UXXUKQ,;+6[G2;73)6L+2
M&!%.9@N?-D)!R,G[HQQ7(W'B;4?&GP7\3+JMPT6H:0[1326Q"I<@'C<,=.N<
M8Z ^U 'H.C>.[C4_$]KH]SX;U*Q6\M3>6T\K(X,7K(%)\L]L$GD@=Q7:YP,U
MSG@BVGB\)Z?+/?W5VUQ!'+FX*G9E!\JX X^N:Z(^@H QM:\2V6D:;JEV4ENF
MTV'SKBWM\&14QG/) Z9/7H#3/!OB:/Q?X5L]<BMGMDN=_P"Z=@Q4J[*>1UY6
MO(]/TV]9_BE<G6[UH+5;M)+>3:PN,V[A2[$9^7/ &!P*R=$U3Q-X:^&/A77[
M#6UCL6OOLO\ 9H@&QE\Z3<S,>2Q(/3'&* /I"DS7D_BKQ%XGOO&&KZ+H46J"
M/3[:,HVG)#GSG!(,AD/W>, #WKL/ 5WXCNO"UN?%=I]FU5'9&Y7]XH/RN0O"
MDCC'MGO0!U!.!FN7UCQWIFEZU_8D%MJ&JZL$622STV#S7B0XP7)(5.H/)'!!
M[C/3,2%.!D]AZUY/\"KA]3TCQ!JMZQ?4[K5G^T.WWB!&I4?0%GP.WM0!UVC^
M/[#5O$I\/2:;JNG:H(C,8;V!5^08Y!5F!!SV/8UU@K@M2\16:_%>RTIM&EDO
M;6QDF6^690$A898%<9/*KQ[UQ%MXN^(/B&WB\1:%8ZG)&]RQALPD'V1H5=EV
M%BV\M@<MQR.* /=,TN:\=N]8\9:O\5KSPM::^FFV_P!A6<;;57:+@$@9/+;C
MC)[=JSK+XGZY+X$T6U9GN->U/4)-.6>!%WF.,KND4-A?,PZ@9XR<GIB@#W/-
M)FO)-/U#XA6NB>)FOC=6UM;VAGL+W48XC.K@9966,[2, X/8XZU7TG4?B-'X
M*G\47>MZ6\-SID36T=P%C6%RZ#S78\?<+D\\G'':@#V)FVJ3@GV'>N=\)^+[
M;Q;_ &FUK:75L+"[:U=;E0K,P ). >.O0UP_A'X@:CJ7Q-70/[1.IZ5/9F>*
MYDL_L[%ASN4?Q*<<'W]JU?A0T6_Q<%4B0:]/O/KPN* /1Z*!10 4444 %%%%
M !2'I2T4 <OI/@'0=#UR76=/ANDU"?/G2O?32>;GKO#,0WKSW JU)X2TN3Q-
M'XC:.?\ M6-/+6474@4)C&W8#MQWQCKS6[2T <U%X%\/1:3JFE_8/,M-4E::
M[2:9Y#)(?XLL20<@$$8P0"*I^$_AOH7@^Y%Q8/>7$RH8XFO)_,\E3C<$& %S
M@9P.U=C10 5@>+/!^D^,]+&GZO$S1HX>.2-MKQMZJ?IQ6_10!S'AWP%H'A?3
M+FPL+,2)=+MN7NF\UYQ@C:Y/5<$_* !R>.:IZ3\-=#T>[AECFU&Y@MI#+:65
MW>-);VK<X,<9XR,D G./KS79T8H YVU\'Z99>*9O$=LUVFH7",EQFY=HY@<8
MRK$@;<< 8 R:\W\/>%UUOXF^-IKFXUW3?,GV0O;;X$N(LE9/F*D$9"XP0><B
MO:L4F* .8U'P!X<U/PS'X?FTV*.QA'[CR1M>%NN]&ZAB>I[\YSFDTSP/I^F:
MC<:G]MU&[U.:V%J+V[N?,ECB  "IP .1G.,DY))R<]31B@#D=&^'VDZ+X?U'
M0TGOKO3]0W^?'>3[SEAABI &">N?7FL=?@QX9\BQCEN-7F:RE#P227S%D7 '
MEC  "9 / !]\<5Z-28% ')Q_#W18O%T_B:)[Q-0F^8JL_P"Z#[=N\+CE@">N
M1STJ'3?AMH>G^'+_ $!Y+R^TV\?S7BO)0YC<]61@H(.<'KU&1C)SV>*,4 <M
MI'@BPTG4(;^2^U'4[NWA\FWEU&<2F!>^SY0 3W/6LZS^%NCV.@:MH<.H:K]A
MU5@]PC3H3NR"67Y."P !]0*[G I: *.CZ7'HNCVNF13SS16L8BC>=@S[1T!(
M Z#CIVJZPR,4M% '"S_"S1I;O4&BO=2M=.U%P]YIEM.([>9N^<#< >X5AFKT
MO@/39/&-KXG%Y?QWUK&L,,:2KY2Q@$;-I4_*<G//4GI7644 >(^++"VN_B9J
MDFJQ^+M*3[/%%!>Z,CR17" $G>55B#D@  8^4D]:T=&\#2>,O#UW;^(+OQ"+
M)+T3Z/<:BX2^B4* Q;KA2V< @' R .#7KM)B@#SZ#X0^'[6:ZFM[W5XY+RU^
MS7+K>'=-G[\CD@Y=L\]AV J[)\-=)EM?#]LU]J7E:#(LMD/-3AE8,"WR?-C
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M[75;O3-.T:V0S?9=@DGFD/!RRG"J >/6N+D\:>)X_#GC;23K;KJ'ARX)BO\
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MF?4+TV[,@^8L$CCWC:HR0"23Z]@/1\48% '$2>#-3DU'PG/_ &K9[/#Z$?\
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MZ>C%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK?'*TGF _*0&&!,RD$8R :YSXL>#_%7C/7=/;2]*@-GI_*S27:JTQ)!.%_A
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MZ@C]""!UU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5P/_ &J:BV?$S^&Y\(D^]K<C_P!GH ?J'PK\(ZKK%[JE[IK37-X#YH,S!-Q
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M%<M%/XZ#$RZ;X<=<<"/4)U.?J834OVGQD.NCZ$?^XK-_\C4 =)17-_:O&/\
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MUK_H3M4_\"K3_P".T ='17.?V_K/_0G:G_X%6G_QVD_X2#6/^A.U/_P*M/\
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M],U>!?+6]LG"NR?W6!!##ZBGV7@C3;#PO>:%#/>K%?.\MW<B8^?,[XWL6]2
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MSAX+1T3SXMS!C\R,1@\;E(//7FO1=6^'VB:I9Z1;Q?:-.;1W#V$UBZH\.,9
MW!@0<#.0<X^M 'GFHVDOAO6/%_A6QN9HM%?1SJEK#',P:TDS@A6SD D$XZ<_
M7--=%2Q^%UMXGF\5:U;ZEJ]G#;2%#YSSDD;(T7@[L# (.<;O4UZ7'\/[,V6J
MK<ZG?3ZCJRB.\U,K$)F0 #8HV%$7 Z!?QSC$&H_#+2-3\#6GA2YO+][:R8-:
MW!9!+&0"%^ZH4@ D<CH>N>: .#\*Z:R>-_%'AZ[T@:7I5SHHN&TE;II40Y4
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MP#(?>NPT[X?W\%KI6EZEXA:^T72YEFAM%LA$\I0YB$KASO"G!P%&2.:TM/\
M! L?'=]XK;59Y[F]B,,D+Q*$$>1M"XY&W:O)SGGUH \[TW2=?\3>-O%^A?\
M"8ZO;0Z=Y2PE7!W.5(!;V!'08SFJOA3QEK>O^&O"&@7&I202:E>W$%Q?!]LS
M00A6V!O[S;MNX<\>IK3\/6FH:C\4?'RZ)X@@T^X=TCD$EC]HXQ@2(WF+AE.X
M8((YY!XKJ[CX5Z-%X:TS3=)EET^\TJ7[19:@%$DB3'!9W!P'W;1D<#@8P *
M,?3EUC1/B3<>#8=;O)=,O=/-U;37#^;/;.#@[68<C/8YKGO <?B35?"[^,KS
MQE*GV2.\1(;K A60AL/(>X#-NZ<8 '%>B6'@^^@UN^\07^LQWFN2VWV:TG%G
MY<-HF/X8MY+$MR<MST&*HZ%\-O[)^'6H^#[G5WNXKMI-MPEL(C$' XV[CG!!
M.<]\<8H X;PUJ6K'QQX=M[+6-9NM.U6VE6\N[QR([F15.YX >5 )&#@=*O\
MPVTFZTSPAXQFCUB^6ZL]2O8@ROE&=$3]X58'+$CJ36S8_"[6[36-$U*3QQ<3
MRZ4HB1&T] GDC V*N["DJ,%CD]#VK1TOX?:EI=_KOE>*)CI6K2W,YT\62 )+
M,",ER2S #L-N2!SU! .*\*^*M:NO GABP;4YA=ZYJDL$U_))F2.-?F(4GH3T
M![9K>-WJG@7XEZ1H2WU]J.AZ[&RQK<N9IK:9<Y92>=O*DYSP2?X>;=E\)A9^
M"K/1!K3"_P!/O#=V&I1VNUH'R#S&7(8<<\C/\]RR\'7K^+QXEUS6(M0N[>V-
MO90PV7DPVV[[[@%W)8^N1P2.F, 'F>JKXQ/P]U+7[GQC=EM&OIHK9(HPAF"3
M%"92.O3@=![U[AI-R]WI-G<R8$DT"2,!ZE037!I\-M4/@/5/"]UXG2Z%].9_
MM3:=ADW/O?@2?,2W.>W/7C#+:SU^T^)NBV=MK=S=Z;9Z>$U*UC@:."+$3*C$
MEB-S/M(4$L ">@H ],K@O&6N7K^,_#?A"PO9K%M3\V:YNH5!D6.-"P5"> 6*
MD$XX%=X*XGQYX#;Q5=:;JFG:F^E:UIK%K>[6/>".NUAD=^G;E@0<T >>V-]=
M>#/'GQ'OC<RZE<V.GPR++=$;I"53;NP!TR!^%7?#\_Q,N;[P[J*"]DLIW1M1
M-W<PM#)&[#)C50&7Y2<9R>E;^G?"^^_MG6M0U[Q"FHC6K;R+Z".Q$6?E 78V
M\XVX&..<<U%X?^%^L:?)8V6J^+)]0T'3KE+FSL/LX0[T.4WN23M7CY1P?;%
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MIUKU$C(KS;4/ OB1/B#JNN:+K5C:VNKVRPW)GMS+-!M4*/+7[I^Z#R0.3P:
M.?OO'7B6Z\#>"]7T^_MH;O4KZ.RN@8 ZNY8C)P>!P<J/7M5V%?'G_":W_A1O
M%D1_XEZ7\=X;-=ZCS"NT+T&3G/7@"H[+X5:_;^%-%TE]:T^233=4_M)28'VY
M!R(\@@L"222<'G Z9KKAX>UH?$6?Q,+G3A;267V!;<QR;Q&&+ABV<;MQY&,8
MXZC=0!QMC\0=?7X6K<R[;O6[G5#H\$Z( 0[$A7V\ D8X'&3C/>K6EZA\0X=:
MOXIHK_\ LE[*1H;S4K> -;S*I*DK&WS#(QCW]J/^%37]QX N_#EUJULMQ]O_
M +0L[FWB8!).<AP6Y') (Y'7G&#L:'X5\77-Q]L\9:W:WD]O%+%9162%8U:1
M-K22?*FYL9 &,#)(Z\ '&?\ "1^/E\%>'O%$^MVRPW5Y#"]O';@EXW<C<Y/?
MC&!VKL;K6M4\0_$;5/"NFZC)I4.DVBRR31Q+(\TL@4K][@(H8<=SFJ3_  \\
M0R?#[3?"[:MIA:PN4E28VLF&1#N52-W7=G)]/?FI=<\$>*$\;'Q/X5U>QL;R
M_ME@U,7*,Z_*$ :-<')PO0XQC_:- 'GNG:]KOA/X8:G?Z=?QK>IXB>&>1H0P
MER>3@].1^1KMI;KQW:>/;;P^?$-C+_:5BUR96L\+:%6Y\M<Y;C@;CWSVJFOP
MDUV?P+=:#>ZU8&YN=3^WM,D#D \^XSG.< #'(YZUV-SX;U:X\?Z5XE6:QCBM
M+/[)+ 1(S.&.796X P<8!!S@YZ_* <G:>-]?T#PGXK?59X]3U'1[];.WE$>T
M2%\8+ 8Z9S^E/TV_^(L/BNP06>IW&D3(L=Y)J,<">2Q/,B;&Y QG!]2/0UH/
M\,[K4+/Q78ZMJ<+V^MW'VF.2VA*R02#[N<G#* !QQGGD9&(O#_@_QXALAXF\
M16M[;Z4PFLK>W=T:XE52$\^78&VC/3#;L\YQR <G!XH^($_P\U/Q4/$%J%TV
M]=##]E&9@&4$$]@,\ >_-;'B :G>_'SPY%:ZHUNQT@SIOC$B1[O,#A5.!E@H
MYZ].PQ4MM\._%L/PPU?PJTFA_:;^[,PF$\VQ48AF'^KR""HQUX)J[K7@;Q=?
M^*_#_B73M5TNRU"UT];*]S"\B)R=SQ @[_OL &V_='// !ZBO05Y5\<6U&/0
M=)6UOS#;7.J06\L'E AS\SJQ/4@%!\OTKU5!A "23ZFN.^)/A&]\8>';:UTZ
MXMX;VTOHKR'[3N\MRH(*L5!(&&)X!Y '?- %"\U+Q%<>)[3P;#J,<-R+(WMY
MJT<"AL;R%6.,Y Z $G-3>!M?U>?Q#KWAC7)XKN[TDQE+V--GG1N"1N7LPQVJ
MI=^$O%9\0Z)XH@U#3I-;@B:#4H,O#;W$18L$0[7(VYQDKDXSP>*V_#'AR[L=
M>UGQ!JGV5=2U1D4PV;,T4,48P@W,H+L>K-@>P% '5CI2T@I: "BBB@ HHHH
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M+DJ&7@#>3)%C(()J_P"*KSQ9X5\&>&99O$%P^I3WT,>H%X8F#;\$H#MX"D$
MCKDYZ\ 'K>['4BEW#U%>2^+_ !/>VWCS4-&NO$MUX>@^Q*VES"&-;>28JQ/F
MR.K8&[ XP, C(.,W?%>LZG;7>BQ_\),-/LY=/:1S8!)[B[N"H">6FQV=.Y(4
M#'?I0!TOC?QO:>!](BU&[M+FY2640H(0,!C_ 'F/ XR??%=/NR#TS7@NI:WK
M/BGX/>'[N]D@N]4?Q!% C7$86.1E=U7>H&,=,X[9KHCJOC#P9\0M"L-;UV+6
M=+UUFA -L(C!*"/N[0>,L,9)R,Y P#0!VGAGQE!XFU+6;2&QN+;^R[CR',^
M7/<X'05TN1GJ*\0M_$TGA)OB9JT,2R7"ZFD4(8_*'?Y0QSV&<XXSC&1G-;FE
MW'C^V\6Z45M]9O-)E_=ZC_:ZV<8C)/\ K(O)8X'7Y>?3)SP >J4FX>HI,_+D
MUY-\1O$FLZ;KE_%;^(&TR"VTWSK.&RCCN)KB?.3YB'+)&%4_,0JC.<GD$ ]:
MW#U'YT!@>XKQ>Z\<>+&\/_#_ %"VO[19]8F,-RDEKE9')*AFVD' SG:N,D=<
M<5HZ-XKUKPWXG\7Z-XEU)M732]/_ +3MYEMEA:2,*"Z@#Y0 2 ,]P30!V?C'
MQG9^#+"WN[VVNITGF6!/(3(#'^\>@_K71HV]%;U&:\!\:R:YKWPVTKQ/?:X[
M6][?0R?V9';HL,2ECM ;&\D8/))SGH,5[Y#_ *F/_='\J 'Y%(2#QD5POC;Q
M'J-IXH\.>&=+NOL,VKRL9+T1+(T<:#)"JV1N/3)! ]#6?=77Q!T3PGXF\QK6
M^N[:1?[+O;AX8R\!^\[C*J"HY^8#)S]X<$ ]'E<11O)AGV*6VJ,DXYX'>N/T
MOXE:7JWA;6/$,-E?BSTN9XID\K]Z0H4EMN>  V3GH :Y[P?XOU&]^)#Z(/$#
MZUI?]G^<L\MDD.Z0-M8H550R9!P1D'/!.,UD>%8$M_AC\3HHW=T2ZU$!GC*,
M?]''53R* .[F^(NGV^@>']8EL;Y8-9D1(T\KYHMPR"P]/<=00:[ 'CG%>,Z3
MK6LZ9\._AU+97X2&YN8[2YC>%9#(A+  ,V=H 7' STY&,5L37GCK6/'?B30]
M,US3].MK%(98'DLED<;U)"@9/!YW,<G@8 R10!Z?D49%>/6_Q#UF]^'O@V>2
MZBM-0UR\^R3WZ1IB)4E92X1@5W,%'L"3@=!6_P"$-4\0S^.M>T#4M;MM1M-+
M6-UE6V597\S.%=DPH*XY 7DGM0!Z%29 ZD8I<8 KQOQWXT\2Z!>ZQ<QZU:V3
M6,L;66EI:+.;N'*[WF8$M&I+!025Z8')!H ]DX-&:IZ3>G4=(L;TH(S<VZ3%
M <[=R@XSWZURWQ*U_6_#NB65YHQM-SW\,$J3H265FP #T&2,$X/!XY% ':9'
MJ*,CID9KR!]:^(=E\2H?"K:UI%S)?V7VM7>R*1VBEF#! IW.5V$#<3GC.*;I
MWQ*UO2_!7B>XU8VVH:IHM[]BAF">6MRQ.%+*,=.3@?\ UZ /8LBC('6O*=$\
M2^,K?QA9VUS#?:OI%ZF9YY=$EL!8.-QPI9?F7&/O$]N0<YQ3\1O%>I6,?B?1
M(KF[MS,0=$BT65T\D$@EKK;@O@9^7@$]#@T >W[U#!=PW$$@9YP.O\Q^=8FA
M>*]+\17^K6FGR2/)I<_V>X+)M&_GIGKR"/PKSS3I=?O?CYJD9O88!#I,9B$M
MF6'V<R1N47YQ\V68%SGD'Y1P!9M_'/B!=)\=SR1Z5]IT&<)#L@<1N.<EANR2
M0!WZYZT >K9'K1D5X]8>._&ITWPEK=_'HC:=K>I1630P0R"15?A7+%B,G#G
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M,-Y%&=T1).59#D\$"M:#Q7=6&F^#_#&BQVTFM:E9I(&N@WE00JF6=@""Q(!
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M*D\DK][T R3SZ59T_P"+EKJGA+3M3LM-,VJW]X+"+3O/"?O^O,A'"[2K9QW
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M%% "!0JX'2N#\0^"-7N_'D'BC1-8@L9S:?8I_.@\PJF2=R<XW<]^.!7>YHH
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M\)%V.) -B >IVCZ9YKTUY$C7<[JHR!ECCKTIW% '@D'A'Q$GA#PCJ,&BW/\
M:?AJX87%C-A6G0ON)C.3GK75'2[SQ-\2[3Q?-H^HV5GHVG%8X;A LMQ.2YVJ
MN3D!6ZY'.*]2HQ0!X!=Z+X@NO@A/H0\/:DFHOJ32+"8Q]TN7W=>G./K7NFFR
M&;2[20Q21%H4)CE7:Z\#@CL:MTG% '"?%N+4KWP-<:;I6FW%]<W<B)M@7.Q0
M0Q).?;\ZQM:L]9@\:>&?&^G:3=7=LEH-/O;(Q[9X4+,=X7/.-QXSV'KD>J9%
M&: /'M>T35O$.L:]XJ;1+R%$TI]-T^U*CS[AFSF0K_"OS$#)]Z[?X<K=0>!-
M)L;RRN;2YLX%MY8[A-IW*!R.>1[UU.0>XIU !1110 4444 %%%%  >E<KXIU
M_4['4M*T71+6&74-1=CYMP<101)@NYQR3R, 5U1Z5Y_\1/#_ (EOK_1==\*F
MVDU#27=A;7#;1,&&",Y ]L$CKUXH ;>^-]:\+Z#X@O/$FEH7T^98[&:$[8[_
M ,PD( "25(/WO;I3-0\7>)?"M]I-QXEM;%M)U!UAE>T#;K.9N@8MPR]L\=#6
M=J7@_P 7^._"NICQ!/!I5_<"(6.GQ-YD-N8V+;I&!.6<G&5SM&.O(JS)I/BG
MQ=8:-HOB/1ELH+69+C4+PW$<HN6B/RB-5)/S]6W 8&: ,R3XB>-;Z]\66^E:
M+IA&@2?O&>9CE%#Y '&YCLR.@&".XK1;XH276@^%KF,6NFS:X'S<7@9H(60[
M2,C'+$<9QQUJEX?T#Q+9:C\0IY?#MS&-<1Y;+?<V^"P67"-MD.TDN.>1UR14
M&B:#XDM?!^A>&]:\&'4=*CAGBO[?S[8R(Y?=')&QE _B(Z@C&?3(!H>+?$FO
M:7\*CK6K:-I5Y?176V:.4!X!&9&1)4!SNR"F.>C9K;U;Q;>MXEL_"N@1VAU2
M2T^USS76XQ0)CY1A>22>W&!7%7G@;Q-#\%;CPO;:7/<WEU?&2&W>[BS:0B0.
M S%@K'"]%/5O;F_J.@>+-+^(.G^,=$T%[TW5DL.HV$UU"C0$ #"OOP3WR,C@
M^M &9X-UNY\*WWQ(\3>([>&*2">%)8K8_*\PWX5?9BZ<GUR:WM*^)&KR>)]*
ML[ZS@ELM4P@^S03*;*0@861G4!LG(X]#6+!X&\6^*--\9V>NZ1;:2=7FCO+2
M4W0DV3(1M4A"V5(&"QP1G(4]MKP]<?%"XATS3M;T=+2&U<27.HBYADEN43D1
MA Y =L8+'COQUH 32/B'XRUO6;RTLO"5I);V5^ME<3"\/R9/+=.0 ,G'J.M4
MKGXKZQI_DZK?6=A!IMU?>1#IDS-'?B'=M$I4_0G! ^I'-;?P_P!'U[39O%+7
M^DS:9)J5Z]W:R2RPS*N1@ A')R#SCICO7G#^%?&TW@26PD\(*=3745EO+^:X
M$EU?L')&WK@+D L6VXY&23@ [2PU#Q#=_'>_MWDL'AMM.0+'\ZA8&=6)'K)@
M]\#\JDT;Q[9:?<>.KV^T.TT^32+B-)WM6!>\<F15W' RQ(&/]XT6>D^,;/XL
M-X@'ARW>SO["&VN&.H(%MB N[G&Y\;<<)R2.0.:R[?X>:SK5QX^L]3L;K3;?
M7+E+JRNO,AD :-V90RJY()W _0'D'&0#H;[Q_KWA_3M%UGQ#H]C;:5J$R13^
M7<,9K3>"5+ K@X R<>E$OCGQ-<^-?$6@Z1H5G<II21OYTUP8P,INP>#DMG
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M:XFNT""6'(&['5<Y!P:\RU35X=1^"N@Z;#:WZW=C<6D<L<EG(I8J"S%./F
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M27B-Y49D8%DC4':.2 3DXR?0&L'4U37O$'B_Q/IUE<0Z;%H<U@)WA=#>SNN
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M:>/"RX+#<AZ$?*?IQZUT&Q1T&/I0% .: '4444 %%%% !1110 4444 %%%%
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M^G0R&2.W9,JC'.2/3J: ,#X=:9X:TR\UQ/#FJ7FH++*DEU(Y3R!(P)Q&(U5
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M86,4TLT<&M.BR2N78@(O4GJ?>M77/AQ8:M?:3>V=Y>Z1<Z7"+>WEL&53Y0&
MAR#P!Q^)JUX1\#6G@^XO9+/4-1G6\;S)8[F4,OF=WX'WC@#/M0!U8Z4M(*6@
M HHHH **** "DS2GI7%>*?$&KZ7XW\*:;:&,:?J,\B7&82S':I; ;H!W]>*
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M_&5[=_$_4?",^GQ116UE]KCN%E+F0;D R,#'WS^5=CN'?K0 ZBF[Q_D4;@:
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M-)N61L$C@YW$'''L:ZGXQZ3:77P\O;]D\N\TW9<VEQ&-KQ.K #!'(')_GU%
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MBW&A:5.R_P!I7=[+&9"@8$I$J,V<XZG&>AP,YW_^%I>!O^AFL/\ OL_X4?\
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M(O\ XJ@#?HK!_P"$X\)?]#1HG_@PB_\ BJ3_ (3CPED?\51HG/\ U$(O_BJ
M-^BL >.?"1''BC1#_P!Q"+_XJC_A.?"0_P"9HT3G_J(1?_%4 ;]%8/\ PG'A
M+_H:-$_\&$7_ ,51_P )QX2_Z&C1?_!A%_\ %4 ;U%8)\;^$QU\4:+_X,(O_
M (JC_A./"7_0T:)_X,(O_BJ -ZBL'_A./"7_ $-&B?\ @PB_^*H_X3?PF3C_
M (2C1<_]?\7_ ,50!O45@_\ ";^$\X_X2?1<_P#7_%_\51_PFWA3&?\ A)]%
MQZ_;XO\ XJ@#>HK!_P"$X\)?]#1HG_@PB_\ BJ/^$W\)_P#0T:)_X,(O_BJ
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MS8%S<<N78XP!G?C '&!0!R6JW^H>+/AYXK\4'6M1@C1YK>SLH9 D4<2D*0P
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M4 %%%% !1110 444F: %Q1BDS1F@!<48HHH ,4444 &*,444 &*0@&EHH 0
M#I2T44 &**** "BBDS0 M&*3-+0 48HHH ,444F: %HQ110 48HHH ,48HI,
MT +1BBDS0 N**3-&: %Q1BBB@ HI,TN: #%&*** #%&*** #%%%% !1BBB@
MHQ110 48HHS0 8HQ29I: #%&*** #%&*** #%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !63XC.K?V%=#0O+&ILH6W:3&U26
M +'/!P"3^'?I6M2$#KW% 'C>M7GC;1_'WA[PRWCMF35$=GN7TRW785!X4;>2
M2,#W(J[KMYXX\.VJ)>ZZ+F ZO9Q0WBVT4;SQ2-AXRJCY<$=>^:K^/N?CCX"(
M_P!K_P!"-;GQ@M8[[PE86DNX13ZO:1/M.#AGP<?G0!VMGK>EZA<3V]EJ5I=3
MP'$L4$RR-'SCY@#D<@CFF?\ "0Z+_:G]F?VO8?V@&V_9/M">;G&<;,YSCGI7
MDVHZ9'X?^-$L7AZVM[%5\+RR,D,>"S#>%*@=6RL?;D*>]<GH6D:3J_P_T[6+
M_P 9&VN;&=I6AM;6,W:S-(>C9$CLV0>_Z4 ?2NX8)["LRU\2Z%?7ILK36=.N
M+L$CR(;E'DR.OR@YXJCXLO\ 3].\":I<:K+.+(V;1RNB_O"'&S@?WB6'T)KQ
M6 Q6_B#X:W$TFF65MN#V]I&%\V*# VO-)QEFQGH!G/7F@#WN7Q#HMO\ :?/U
M:PB^R[?M&^X0>3N.%W\_+GMGK22>(]$B:U$FL:>ANU#VP:Y0&93T*<_,.1TK
MQ[1?"F@ZQXX^):7NF6TJ0!!"-N!$760EE X#94'=UZ^ISR6BZ!I$WP%N]:FL
MX?[2BU%0ET3AP R84$]OF;@>OK0!]+WVI66F6C76H7<%I;J0&EN)!&@)X )/
M%$&HV=S:+=V]W!+;,-RS1R!D(]0PXKRXSQZK\<8-(UQ(9[&+10^GVUS&&1I3
ML+,H.06P'Y] :QM2TQ=(UKXD:1ID6S0FT<74MJ@_=0W3*IPH_A)&6P/;L!0!
M[<;J!2@:5 7^X"P^;Z>M5+KQ!HUD]PEWJUC UMM\\2W**8MWW=V3\N>V>M>%
M^)+JVN-,^$;N\$L@GA+B+Y6V[H@.O(&0?R-:]KX0T'4OBW\0$N]-BF6"WCFB
M5P2%DEB#.X![EB3[9XH ](\5^-]*\+:'%J4T\4_VAT6VBCF4-."R@E#T( ;=
MGI[C-=#%-'+&'CD61#G#*P(...HKY[\)0P7WP>T1]16.=+3Q';I&9P&"(9D#
M+S_"03D=*]_LK2TL;2.VL;>"WMDR$B@0(B\DG ' YS0!%/K>EVM]'8W&I6<5
MW(NY+>2=5D8>H4G)K#\>^)'\.^'A+:WEI:WES<0VL$MU@I'O<*S[<@G:NYN_
M3TS7":5I.B^(_A]XQO=9BM)[W[9>A[V<!I(MF?+^;JH7 P!Q^=5(%^T?!?P?
M?:Q9+>ZE_:%O%$;B)6FEB-T2L:EQT:-5XZ$#GB@#T/PM8>)-,O\ 4#K'B.WU
MG2F >VF9%26-_P",,% 4+Z<G'M5SPWXPTSQ2^H/IT\4D%K>-:12+)GS]L:.S
M*,#@%R.,@[<YYK5M]+T^UL6L;>PMH;,Y4V\<2K&0>HV@8YKP_0M-AT+X9_$&
MYM8H1JMAJ=[;07L<0$T:!8U.QA\RC!)X/% 'MT.M:7<7\EA!J-I+>Q#,ELDZ
MM(GU4'(K+L_&.DW_ (NO_#UM<PO<6,2/,PE'WV8CRP.Y7"YQT+ =<BO+_%.D
M:)9?"'1/$/AR"&VU&T^SR6EW;H!*\C8#*Q'+$MG(.>:W-&@TA/BIXPO-2M+/
M?:VEE>AI($+1L(RSR+D9!R>2.<X]J /24UC3);]["/4+1[R,9>W693(H]2N<
MUR.CZ]K<_P 8-;T*\G!TRVL(Y[6-80F=S+\Q/))&67KCCIFO)GL8[L>#[_2H
M+&QTVXUL_99Y& O9QO)9Y7' !Q@+VXKU+3V1OCWJX5E)&AP@@'I^\SS^!% '
MH$DB1(7D=44=68X K"\3^+])\,>&[K6;JZA:.$8CC609FE()6-<9Y./3@9)X
M!-9OQ*T:Y\0>%O[/L)+-;TW,4L$=YCRYF1MVP@\'..E>1ZQ/IMS\+_'-N^@1
MZ3KEG<VCWMO$ 84D\U4#Q8^[D!P0/4^M 'ONG:M!>Z/:Z@SQ1+-$DA!D!"%@
M#MW>V:NI-'*@>-PZ'HRG(/XBO&/LMA/X^\%:!>6%HNB-I7VM;8QA89KDIRQ7
M[KMP.H/6L7Q/>:CX-?Q_IWAJ\:VTR".UD6&)MOV1YG <Q_W1U7 Y&\$=* />
MVNDFAF%G+%-,BG:JN#\W8'GUKD/AIXAU/6/!YU+Q#>0FY-W-%G8L00*Y 7C@
MXP>?Y]:S=(TSP38:SX4UW0V>TEOK7[-:6]H !=1[,YF4=2F/F8]P,\@5Y]X2
MOK9M1TS2_%\$(\-2WUW)IQDP8I+L2D?O?H&( /'/.<\ 'T2LJ-&)%=60C(8'
M((]<UYUK/Q%.H^#O$FI>%)X%N-'D>-Y+N,LL@4?,T8!!SR,%AC(Z$5W\5I;0
MV:6D5O%';*GEK"B!45<8VA1P!CC%?/WAS2["W^'7Q*N8;*!;B">ZMHI @WI%
M@?(#UV\#CVH ]UT'4/MNA:;+/<))=RVD4LN, DL@).T=.3Z5F:3)XF/C76O[
M3EM/[#6.,6$4)!<'N6_BR??CICO7EEWH-AX<\1?"V_TU9XKW4'47=PT[,\X*
M1<,2>F&(QTQQ736-FJ>//B0EO<"P>:QB/VLL1Y3-&W[S.> .OX4 >G)>6TLG
MEQSQ._\ =5P36;XH\1V7A7P]<ZS?E_(@7.U!EG)X"CW)KR7P/9?V#X\T+0]?
M\.P:7K-O;2QV5]8(/)OHPC;_ ##W88!W=<YR!N%;GQ_M[B7X>PR11O)##>1O
M.%[+@@$^@R>OO0!>TW5OB1X@T^WUVQM="L+.>/S8=.NFDDED0CY=T@P 3U&
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MPK/9CRUE;[S+N964_*P(/4$'!R* .-TR2ZFT"#0M7O-2U&33->:VL[:UR_\
M:FT?ZMF8X5%ZDDD*">*O:4^I:=;?%/1+Q7LC!8_;8+6VNF>.T+1N^U&X[,F<
M  [<=*](F^&&@OH=CI=N]_9"QF:XANK6Z*7 D889B_.2W?CZ8J*T^%/A^SO]
M1NTDU1VU&U:VNDDOG990RE69N[,02?F) )R ,# !C?"3PA%!HVE>*)=5U*YO
M;BT*-'-/F((3PH7VQQSW-'Q7@N]!U#1/'FG*[-I5P(KZ)6P)8'.WGJ/XBN<$
M_O,]J[KPUX<M_"^DIIEE<W<MK&S&-;F0.8P?X5.!\H[9JUK.DVNN:->:7>IO
MMKN%H9,8R 1C(R#@CJ#V(% 'F=Y>:?K'AKQEXJEUR6SL+O\ T*SO(T9RD"!0
M2B!ADNY8=CP*P?"YN-&^,>@6$-I=:387VELPM)KDN]QM23;)*H)5)#Y>XJ"<
M8&3N)KU2Y\$:-=>"5\)O PTU(EB7;C>N#G<"1C<3DDXZDUEVOPMT:TUK2M8%
M]K$NHZ;\L=Q->EVD0<!&R/N@$C"XR"<YS0!R\UC>6GA7XFQVSO\ ;(]2EN(G
M@<JRDHD@(/&" W/X]:I:O?ZG_9?PDNDU*Y5;F[MH[D"1@9][1'YCW'!Z_P!Z
MO0-/\ VMC_:P;5]7NTU4/]K2YG1@[,NW<,("I P!CC  QQ67!\'] @;37:^U
MJ>33)DEM#->[A$$P0BKC:%R >!GWH XK3]!UGXA+XAOIM4L[&^M-6EA%RZ2^
M?;+&1M"XD544#/!7D@DY->S:,7_L2Q\R_CU!Q$H:[CQMF./O#!(YKE-0^%&A
MWVNWVK1W>JV$U^0;N*PN_)CF]=P R<]3SU)/>NTM;.&QLH;2UB6*&% D:+T5
M0, 4 >(Z=:RZ]\&I/&9U6\3Q1%]HNGOX9B'#*[#RB!P$VA<)C SD#FK-Y!:^
M+M6^&&J:E"[3ZDDQN-LK#)2'((P1M^89XQ7:_P#"KM%CBOK.UNM1M-)OKC[1
M<:7;S*EN[<9 &W<JG RH8#MT  LZYX L]9O--NX[^]L9-*YT^.V\M8H&XYV[
M<D<#()Z<<4 =#':6ECI,=FJJEE!"(MKMD"-5QR3VP.IKP>[L]0^%OBNYU#0!
M'KF@-8K<RVLK#]U:O(<!&Y! ;G('0@D'J/?6MO,L3:RNT@:/RW<X!;(P3QP#
M^%>:2?""2?4HK6Y\1:C-H$5JEO\ 9F9%DD19"PA9U4$IS]?R& "#P-J5GJ'Q
MC\3745FRIJ6EV%Y:22*%80F&/*@>^Y<X. 4J?X-0FWD\71I)YEJNL2"%@"%[
MYP#T["NGU?P+:WUY97^F7<VBZA9P_98[FR5<FWQCRBK @@=N,@]*8/ %E:>$
M9= TF_U#3C+)YSWT$Y%R\F<EF?C<3T- &)=7B6W[15E$R@FZ\.&)22!@B=WR
M!W.$(_&O//%=HPUCXKE9AM,%M(Q49'WU.T\]?\XKV37/!4&L_P!DW*ZC>6>J
MZ5_QZZA P,@RH5@P8$.&QSG^1(,NB^#;#1],U"S>6XOWU-F>^GNWW/<%EVG.
M ,#'  Z4 >;?%WR+SX+^&Y[-%MX!/:20PMA2%,#A5 Z9&X<>@-:'Q7MI_LO@
M26Z8_:(=4MUE!Y+.=N>?J#6_8?#&*"XT^/4-:O-2TG2FWZ;ILZJ$A;^$NPYD
M*CA<XP/J<ZOC#P:/%Z:>KZC+9_8;@7,9BC#$R#H3GL/2@#J<UX]K-EJ>K?&B
M]\/IXFUBSL+K35N2EO,!Y9SC:F0=JG&>.>3S7KT0=8D61P[@ ,P&,GUQVKQG
M5GEO_P!HG[/IFNII]U'IJQLXB67<P)8QX;N00>* ,!_$_BKPWX6U?0;S67>X
M@U^#3OM\LS*\<+HS$B3!*C$8YP2 S<9Q7::-X?\ %^D>*1-+<BRT*XA>%K)]
M:DNG5RIP\9D0'<,#C/KSVK8?X5:'<>%M0T:[::ZFU"X-W<:A*09FGR<2#C Q
MDC '0GU--T#X<7.D,LU_XEO=7N;:(QZ>UVF4LR5VEPF[YFQQDGIGUH XOX2Z
M?K_BB6+7+[Q;J36^DWTL'V)CN$PVYRS9YR7YR#P,#'&.]^)HU]?#]M<:%%>3
MB"[22\M[*0I-- ,[E4CGTX'-3?#_ ,#MX$TZ]LAJAOHKF?[1EH!&5<@!NC'(
M.!]*T?$WAZZUS[!+9:Q<Z9<V4QFCDA4.&)4C#*>&'/2@#R#6=6T[7?@YXO\
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M-=+?>%O%VD>*H?%/AS[!-=WEI';:II]Q.WDY0* T;84GA< D9&2<'<0 #JO
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MP<)*@8!AT.#WJQ@4M% "8%&!2T4 )@48%+10 F :,"EHH :5SVHV^PIU% "
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MFQC<29.3E6)'7GI0!9^)9LK?X9>)X-.D1;]K>TFO-G#E&9$!;/<I&PQZ"D^
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M.,5=OO'7C'4?&$>B^';73MMYI45_;FZ# Q!QD[SGD]1@>U9]Q\,?&4W@^_\
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MYV)@LQ8\#(!VMR*S7^,6MP>$=6OYM"M/MVG3+"9O,E2WG#,562-63)&0/E+
MX.<]J /::3%>5ZG\2/$^@:+-J>O>&;33H;B[M[73S+>!U'F(Y>24Q[CM78#@
M*#AL<D9KK_#6J:]>ZGJ-OJMG8K:P+&;:\LW9H[D-G)&>.",$9R#[$&@#IL45
MA^+_ !+#X0\*W^NW$#SQVJ@^4A +LS!5&3T&YAD]ADX/2N4N_'^N>&XM&O\
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M)IT<2V+M%(22%D$V/+V#.22PZ$CC!H Z;Q!\6;31]:72K+1-0U6XDM%NX7M
M&26-@2&!SG&!UQ3[WQXNK6=Q8V?A>^U0_8$GU&U+*GDQRJ?W39/+E<_*.V:Q
MM&TU] ^)NA6KVE[)'9Z#'ITEXEG*T+3 @@>8%QC'?H,\X-1KK&M> O'?BCS_
M  MJFJ6&J.+VTN=.@:7Y]NW8V.!W'J,9P0P( ,WX3^);?PO\*;25[2>[GO-5
M:VM[>W W2R-MP.< <#]*[-OBE91:9XAN;C2-0CN-!=$N[90CM\QP"&!P1U)/
M8"O-O#=KX@TOX6:;I\FDZY! VM.FH?9K)Q<K 5!W1@C<!GC<!V(JUIB&PC^(
M=K:>$]>L+74]-9;%6L)&#GRV09P"0S-(#C!Q\Q8C!H [S3?BQI^H:GHEK)I&
MI6D&LJ/L=U<1A8W? )4<YX)"YQ@]1QS5C5?B5::=)JTD.E7M[8:1(D=]>0;=
MD;,1D $Y8KD$XZ5QM\+F71OA;C3-3SILL O =/FS!Y<:*VX;<CGH>AZC(IOA
MS5-9^'][XDT2_P#"NM:K#/>27-G-9VYFBEWCA6;& #QD\XR<CCD [S4OB%I]
MK>06>GVTNIW$MH+XK"ZH(X",JS%R,%N,+UYZ5H>$/&&F>--&&HZ:SA0QCEAD
M&'B<?PL*\7\317'A[X@6_B#QIX634]-O]-MX[LPP^8D$X10VW^$,&0@#/*G@
MUZM\.8Q_8<UW!H<&BV-W.TMI:I!Y<GE< -( <;CC/TQUZT 6O&OC-/!6F1ZC
M<:9=7EJTGER/;E?W1.-N[)'!)QG_ !JK%X^#^,K+PT^BWD<]Y!]HCGWHT?E[
M<[N#GKQ_]:M+QKX>A\4^$-1TB5<F>(^4<D8D'*'CW KQI/#WBR7P7I7C6:"2
M3Q!I,\(M+1$D+O;1_(495^;).20,<9S0!V/CCQ5H6L>$/$5OKNDZI_9FGWZV
M32VSJ3+,IW94@G:!A<EN,N!UJ/4_&][H6O>%M!T31+^6P:R$XBC*,]Q%Y?RH
MNX\;>YR*J>-M.GT;]G>2RO!(=0N%ADN P+,UQ).LL@)'?<6_*L[5]<AT_P 1
M_#SQ(MG?WE@NF- @M+8O))+MV[ IQSG_ .M0 6>M67A3XS^-;M=*U"\O)+>!
MHK:V#2/AHTDER2< #@\^F%]*]9\*>)[+Q?H%OK&GAU@FR"DG#(P."IK@/"VJ
MV?\ PNSQP[.ZM+;0-&AB;<WE1J) ..2IP,#KVR*O_!/4;:]\'7,<&\/'?S2-
M&\90HKL67VZ>A- &W\4;K5;/X<:O/HK3)?!$"O "9%4NH<KCD':6Y'(ZBO+_
M  UI7@_Q9I=A=>%VN+#Q+:SP3WEM)>.7N=K#S"VYL.#\S9 'T[5['XNU"_TG
MPU<7^FVT]U=0/$P@@B,KR+YJAU51U)4L/;KVKQCQUI7A37KJRO\ P098_%<U
MR/\ 1+.-D9"&^=IDQF(J<Y)Q^(YH ]8UGQ]8:7K;Z-;6=YJ>H01B:Z@LT#&"
M+^\V2,GD':,GFFK\1_#\OA^PUBWEFN(K^7R+:"&(M-))GE=GJ.I]N:\DUR/2
M?"7Q+URY\;:'?ZA9ZF$ELKR#)VM@;D7E01\V.N1M7@ALU9U&XG\.6OA3Q7IW
MA5[+P_:7MS*;2.-C*(G"JLL@_A9E!ZG'W>>: /0-2^*6G0Z)KES::?>RZCHX
M'GV$T?ENN>C-Z)ZD9_45RNJ:YI?B3X+:?=>-FU:)7:/?<VT6WSI,G# #Y2I
M[C&3Q@XJ?5?%/_"?>"_%$^@Z%=1V!TTAKF>VVRW,V[A4*DA@JJ2>IY'3'/+Z
MKJEOJG[--M:V@G>2SD@BE)@=5+;VX5B,/CO@G'&>M 'L-QXPTC1FTS2X([J\
MN[BW$D%I:Q^9*(@H.YAV&/7J:KK\3?#[>&;S7=UT(+*7R;J'R#YT#YQATZCZ
MGBN-T[4/^$7^)D6L:H\5OH.KZ/;Q1:@X_="5$7"M)C"$[6XSSP:P]9MS+:?$
M[Q#;0-#H^HQ10V<K@J+J3Y0SQ\896;)##KNXSS0!Z7I'Q0\/ZUKEGI-LM\D]
MXI:V>>U:-)0%W':QZ\ _E7:9KQV35;1O$?PJE\R+[.MO*#<Y^7<T(C"$]CNP
M/J<5[%0!YKXD^'-WXIN=5OM<\27<$2AO[.AMI=D%J@7[T@(^8YY/3@=?2AX,
M3Q-XW^$NEPW6L7-A(\[1RWJG,\]JNX#![,3A=W4A23DFJ_C[XE:!<Z[+X0N]
M3FL=-0$:G=0Q,[2XQ_HZ8&1N!.YL8P,=ZTKCXJ:!HWP^;6=,TZY2PBG:PTN)
MXC$ESL7AE](^HR>?E(QGB@#,\+Z;J'@_XL3^&M,U>[OM*?3FN_LMW(7$$G 7
M<V.,GN .#T.*S_&OA+4O!_AJ3QDGBC5)?%$<\3S2"7$,S,X!18\?= ( !XPN
M,#H+G@/QUX5CO"RWDVI^)-7<SZC<):M&L2JA<@9_@0+C R2>><U!+\4/!7B'
M6?[2US4S'8:5.7T[3A!(QN)%'%P^%QGG"*2,<D\G@ ]CTV6>;3;::Z01W$D*
M/*F,;6*@D8[<UGZ_XIT[PZ;2.Z,LMU>/Y=M:6Z&2:9O]E1V'<]!5O1M2.KZ-
M::@;2:T^TQ"40SXWH#TS@D9Q@_C7GOC34U\+_%CPYX@U*+9HTUI)I\EV02L,
MC$L,^G;GTW>AH ZS2/'&DZY;WK6:W1N;)MMQ9/"5N$.?^>?4_A7E7@S1;3XD
MP7NIZA/K-IK_ /:,T\&IP.P\F-=JB%6Z#AN@P>/08KI?#_DZA\7=;\6:;=H=
M BL5@N+S $,LJ_>VOG#!0,EAQ[]*C^ VI64GA*\L$O+9KP7\TQ@64&01G8 V
MWKMR<9Z4 >@^(M9_X1OP[=ZF;2XO3;Q[O*A&6? [^@]3VKR/Q5KY\6_"*QU:
M_%Y;W$-Q;//@-%;3!Y,$$?=D V@\]" >_/KGBL%O".LA0238S8P,D_(:\(O?
M%NG3_ G0M.@+.T-_:VMR\L;(B$%I#M)&'P%7('0.,]10![1H?C[0O$&K7FFV
M4LR7-JOF,+B%H@\?]]=W5?>H/^%E>&Q>V5O)<S11WSF.UNI8&6"8CCY9",$9
MXS7(:WJ>FW'Q?N8+>]M9+B\\./!"(Y%)DD;<R*#TR5((!/((]17!^'SX&O?#
M^FV(T2]O_%\<JVXTF2XG\II0P!=N=BQ\9([<@C'- 'TSFO+;[5M6\<_$>Z\-
M:9J-QIFC:,N=1FMGVRW#L<",,.4'#<@]C[5Z@.]>-FY;X:_%W5+_ %1)!H'B
M+:WV_P LE+>;)PKMT R6_ J?6@#HM3\'/I>KZ->Z9XFU9#;WD;W5K>ZM(Z30
M9^;AV[?KR*WM<\>Z'X>NVMKR6X>1(Q-+]GMWF$2'H7*@A1@$\]AFO-/BUJ.A
M^(]9\(QZ7>6&J7!OMDB6<RS/Y9*\$(2=IK,NKCPSI7Q*\5Z?XV;4+*"\D\VV
MN(9[A(Y(BN/+98S\PQP.".",],@'J]Y\3/"=E)IZRZJICU")IK>9(V:-U4D?
M> ZY!&.N:M^'O'.A>)K6\N-.NB$LCBY$Z&)HN,Y8-T'!Y]J\DN6T2WUGX7.U
MG)HNDK+=RP07;G<H\U3&SDYP7^5CV&[KCFJE_&^K7OQ<ATEUGFE$#(+=MQ=5
M?+@;>3P&!'X&@#U[3_B+X>U'5+73DGG@GNXS+:FYMWB6X7U0L,-GJ/6J4?Q;
M\'S7<%K#J323377V5 ('_P!83@9XX!)ZUYMX?O\ X?ZG_P (U-86FI:AXBBE
MA_T2:[G9;(+@R2%F.SRU"YXX/R\#G'1_#B\T>0^-+NT^SZC<Q:G+>1P18=F5
M5.QDP#G/(!&>30!U:?%'PI)?1VHOWV2R^1'=&!Q \F,[1)C:3V^H-9UC]IA^
M.6H0/?W<]N^E+,D$LF4A)?!"#H!Q]?>O%]0U33;_ ,)>&;\ZQ'#.FJD?V';@
M);6$(D<[B ,[CD'<QRP8XSM)'L5IJ%C-\=[CRKVUDWZ+&$"3*2QW%L 9Y.T@
M_3F@#T@GY37E>AZAK?Q)\1:M/!K5[H_AW3YOLL4-H%6:=QG+%RIP/;Z5ZFZ[
MT9<X!&,BO&/AKKMOX#U'5?!/B1UTYX;F2ZM+N\D6-+B-B!G<3@D@ C'N.HH
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MW3/;&>O'6@#H?QI<>]>1:?XOC\/?&+Q99^(?$;1Z<D<36J7<NU$9U1RJ@#'
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MD"B8[\%4&22%/'&<?2M_3O%_A[5[YK+3=<TZ\N0,^5!<H[$8SD 'Y@!UQTH
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M^U8"CS5WDD*<8&<=,UU5S8VEX%6ZMX9PO*B6,-CZ9%31QI%&L<:JB*,*JC
M]A0!X3\3/$,$NK^--*;4+726ALH$*;2TVIG;N5<M\JJOF$84;CZXZ5[/6+"V
M@^$E[-?0QVEI%<+/,SX2,B-=P)['M7NL^EZ?=3&6XL;6:0CEY(58_F10^D:<
M\*0O8VK0H25C,*E5SUP,8&: )6$5Y9D??AF3J.ZD?X&O (/#6LZA;:S\+H8P
M+?3IYK];DJ &1DW6\>>VYVR3_=4X[U]"XP.M1K;PI-)*B(LDN-[ #+8Z9/?B
M@#QCP=?77B;PKK'B75X'A?3M&&CP//*6+,B$SR'=C#,2@/?Y2,U1MFTVW^$G
MP\FS:1-'KMH\CC:"I\QBY)]< $_AFO;Y=+LIK.6SEMHGMIMWF0L@VON)9LCO
MDDD^YJ@WA#PZ]DMFVB6!ME<R"(P+M#'@G&.IX_*@#S#6"C?M(VIMBAE;1W_U
M>"2WE2XSCOC;^&.U4?#/B?PO<?">QT[4[);O5]-N1Y6E>88IIKH.=C8&#R6.
M<YZ'->QQ^&]&AU(:C%IEJEZ,8N!&-XPNT<]?NC'TIT7AW1X-3.I1:9:1WS9)
MN%A4/D]3GU- 'FVA)9/\<?'E]-/;+-!8VZ*'<9 ,*;R/8% ">V16C\"T9?AO
M%N8$&[F9 &!PN[CZ=#Q7:CPQH:W%S<#2K,372NEQ)Y0W2ASEPQ[@GK5C3=&T
MW1HWCTVR@M(W.YEA0*">F<"@#S3Q=96.H_'CPC!??9988[*>0P3X8.V'V@ ]
M3NPPS_=K'TNPT5[_ .*9FM-.8PAO)W11_(/*;&WCCD#IW [UZ[/X>T>YU-=2
MN--M9+Y&5EN'C!=2O*X/7BHT\+: JW2KI%D!=#$X$(_>C.?F]>>: /#]2DAT
MSP[\*9_MEQ9:,BG[3=6K*?(GD53N)8,H()<\C@!L4WQ9I&D6VC^+)O"^J:GK
M>HW%O$^I79>.5 AE!93L4<D#)]A7N4OA;0IM&;1Y-*M#IK-O^R^6 F[.[./7
M/-3:7H6EZ)9&RTNQ@M+8DDQ0H I)ZY]: /*-,L_"6MZOX3UG_A)=6U?55DB^
MR6A> M" -S>8JQ@A%P23V[<FKOPRU/3HXO%^G7MU;B>35[V1K:5@6:,9W$J>
MHQG->A:3X2T#0;F:XTK2;2SGF&))(8P&89SC/IFEA\*:#!J%W?QZ3:+>7@9;
MB81C=(&^\"??O0!\]^)?)?\ 9T\/O'L.W69 I7^$$7''MVX^E>G3Z7I.D?&G
MPS'IMG:6BMI=PI6! FX+C;D#KP374_\ "O?"7]G#3_[!LOL8E,X@V?+YA 7=
MC/7  JS_ ,(?H$<UE<1Z3:BXL0!:2E,F'&<8.<X&30!X?=7:W.G^.O#F;29K
M_6&>"]O+N.-8B"-SL'.X8"\$9)SBO=O#-E'IOAG2["*YCNDM+.*W$\>-LFQ
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M_P"&#>';:S6%]10&XA"EY@'B(+L.6.<]>F3C%>F:)\.?#NB>';K1([5KBVO
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M'[L$]Q]:M>!+RY\:'0]!U*U:W7PP2^H0F,!7G0[(1QQP,L?<4 >TLX52Q(
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M"=I.!V!K,\/^'M&UKP#HFNW'B6QTV2QFWR7"0*+I9B[95W#%F+'D9&2".,4
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MQI\.9;][AIM5L%^URI,R,Y$0.01]TY)SC%>ZP0I;01PQYV1J%7<<G X&3WH
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MD>XDD,AR3D[B>>>W;BN=O/@WX.OO%*Z]+9RB3?YLEHKC[/*^2=S(1GDD$@$
MXZ<G,<_Q0DM;FWMKCPW>0W#:I%ILZ2RJ/),F-KY .Y2"2,=<=:]!#9[B@ 5
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M:>&+9C! R6_GO*#) A;J >I.<9[9H ]!GU&QM;J"UGNX([BX;;#$\@#2'!.
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M\QFGVO)YJA&"KCJJC()/)/8#G!\8^#?$GC""\T^_TC2)6%TQTW5A<F.6VA+
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M<_.WF%3C]!F_\*=!U;39M075TE"Z63I=B6CVAX Y??TY.6 R/3%>H8% &.E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %&*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "DV@>M+10 F/K05SW-+10 W:/>EVCU/YTM% ";12;
M1G-.HH ;L'O1M'J:=10 FT8QS2;![TZB@!H4 YYIU%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1&-L]L]#^!P: .3;XJ:<O@M/%HT?6&TEIFB9PD6Y,';O(\S[I;Y?J#VP3?\
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M!KQW-I>J!KOPUJ*,LJM'YB30G(#;3P77.&'.1D=Q79^-N/V:M-]?L&G?RBH
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M@;LG:,$XZ BJ=I\8="U&REO++2_$%S:0Y\VXATUWC3 R<L"0, YYK#\ JO\
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MUE9/FX (.0<GD8((S6G=:_KNO>.=1\.>'[^TTZ+2H$>XN9K;[0TDC\A -RX
M!'/)H Z;PYXDT_Q3827^EO*]LDSP;I8C&2RGG@\X^H!K9KS;X)22S>"+F6=E
M:9]3N&=E& 6+ D@5Z-(VQ"W. "3B@!V:6O)[7Q5XWUWPY=>*M"%K/%%?-'%H
MWV;YWA1BK9DW9WGKP,<=\UOZKK>M:IXYE\,:#J5KIXL[1;J[N9K7SV+,V%15
MW #CDYYY&* .XS17D4_Q&\20^#/%8DBL$\0>'IA#-*$;RG1C@2*O][V)QQGI
MQ5#4?'7Q)T[PLOB6:UT5+"_%L;./YF=1(H/&".N>=W3/% 'MN:*\KL?&7B[0
M?&]GI7C/^S/L6HVDUU'+9(P6V,:%V#$GD!5;/7J,&H[7QAXRUSP?=^-M*:PB
ML87D:WTJ2W+O-#&V&9I0XVOPV %QP.N: /6*3->37_Q/\076K>%HO#VEV,MO
MKUNTD4=VSB1& (.XKP%4@GH20.W6B]\2?$#3[#3(-6?3='=;.6XOM2FC656E
M$CB.%$#8R5"$XR?FZ#&" >K2S1PIOED5$&,LQP.>.M8NJ^+M(TCQ!I>AW=PZ
M7^IDBW01DCC/)/09(Q]?;FO']:\8>(/%_P .?#^JR7%M9+<:O':7-M' 669E
MD#*Q);(4$#*=R/O#I77Z_P")M9T?XB>%-!NHM*N1?-F6[6V97(RP(52QV#E2
M,,>1Z<4 >GT5YS+XI\6:Y;:YJ7A6/339:=(T%M%=V[M)=R(?WA!$BA5';().
M.U8U]\6-:N+#P?J&B:59/%K=PUK-;W4K!Q,'"%58<*N?XB&SGH,<@'K]%<+X
M0\2^)+SQ3K'A[Q);Z:MS90Q3I+IY?85?/RD,2<C'7CZ5W5 &-I7BO1M:U2_T
MW3[LS7FGMLN8C"Z>6<XZLH!Z=B:V:\<U"_\ $MC\3?&$WANTL)YH[&WEEDO9
M&"JJJ3M"C!)//< 8K7M/'^MZI\/-#URSMK&WN;V=HKRYN@1:V:(7\R1@&SCY
M,*-W4XST% 'IE%>2V7Q6U ^%/%>HSVUG=3Z)<"&">W#)%<AB0DA4DE1C!X8Y
MSQZUTG@SQ!KVMW]R]W<:5?:.8$DM+[3XF0.Y/S(X9VVL/3W% ';445YI-XQ\
M8:E_;&H>'-,T^YT_2[P6@M)%<W-X58"0J00J<'C(;H?I0!Z717GOB?Q?XALI
MHS8VUAI5FNFB^FNM:5L!R2!;@(P&\=^3U_/.M/BI?7GAWPEJD>G0*=8U)=/N
M49S^[8N%+)[=3S[4 >IT5R"^*;^/X@:GX?N+6W-I;:8-0AEB9C(PW!=K C&<
MANG;'O6!X6^(.N>();/4/(TB71YVD^U+:O(T^GJJ,P\T'@DX X Y..: /3JB
MN+F&TMY;FYFCA@B4O)+(P544#)))X 'K7C,WQEUE[:TUNPT^QN=+N)VC_LY4
MF-W'&"5$CR >6,E<X .,@9/)'8WOBO6]3\276C>%(=.DDTZ&.:\DOV?#,_2%
M=GW6P.6.<9'!H Z3P_XETCQ392WFBWBW=O%,T#R*C* X )'S 9X8'(XYK6KR
MGX!EV\(:T9(UCD.M3;T7HI\N+(_.O2]1:]6PN#IZPF[$9\D39V;NV[')'L/T
MZT 5M=\1:5X9TW^T-8O%M;7>$WLK'+$$@  $D\&M"*9)H4FC.4=0RG&,@\BO
MG^TDUJ^_9_UNXU-+&6T<S3+*2S7#7!N<LS C:.2W()/2NRL?'?B/3M9\.Z;K
M/AR&STW5=L-O,+G?*N$!!8 8R>..V?:@#O;7Q)I%[K=WHUM?1R:C:+NGMP#N
M0<<GC'<?G6K7 ^&K^WF\?>,DD\/6-C?:=Y.^[A(>6Y1PS LV!@%40[?7KFH_
M!?CG6O%CZ9>_V?8C2[U9O--O,TDEHZ?=63( ^;M0!Z%103@9KB-3\7:Q<^*+
M[0O"]A:74^FVXEO)+UW1 S#*1H5!RQ'/.!0!V]%>=:I\3I-+\.Z/<7FE/I^L
M:K(T*6M\Q2. H0'D=@"2@R",#+9%9VE_%J^O+3Q$)-(MY+O2+<W,4EO.WV>Z
MC!P2&9<@C(X[\],4 >JYK,U;Q'I&AR6D>IWT=L]W)Y< <']XWH,"O)?$GC_Q
MGJWP_OM2MM!ATK2Y]-63[=).7=@["-A&%Z-\Q(S@XYZXJ[X@\177]@>#;_7O
M"VEWSZA=1&&9KAF^S;U5D.&4,7(W9[90<G/ !Z?K&O:9H%H+K5+R.VA9Q&I;
M)+,>P R2< G JEH?C7PYXENY+71M6@O)XT\QTCSD+D#/(]2*X7QC)XB/QB\-
M)IUG82O%:W#V@N;IPG(VN[ #@@''&[(/Y6_#]UH.C?%+Q#HVG^'K#2UL+ 7$
MUY ,,X;8Y&T#"J-W0?W1]* /3J*\V3XA>(9X-/UNU\,BX\.WUR((VCF)NE1F
M"K*R8P%)[9],D4GBWXC:IHDNKS:?IMF]EI!1)VOIS#)<.W)$(Q\P4$<]R> <
M<@'I.X9QWI:\BUGQ1XAO/B7X3ATP6XLKNR:\@@:[>-9BR'(E*J>G88(SS5KQ
M'\6+G3YM4_LBRL+J/2KC[-.D]R4FFD7&\1(%Y"Y R3SS@<4 >ITA.*SM!UF#
MQ!H5GJULDD<-U&'5)5PR]B"/4'-<Y\4]4UG1OA_J5[HSQQS( LDK.5>.-OE+
M1X_C!(QDC')Z@ @': YZ4M>?V_BG6=/TW0=!>S@NO%%Y; K&UV6B$:* TTLA
M4')Y. "<^O6M#PEXQN-8U74= UJTAL-?TXAI;:*7S$DB(4B5#@<98 CMD>M
M'7DXJAIVN:7J\MU'IU]!=-:R>5/Y+A@CXSMR.,__ *JOD9KQ6QU_6_#NL^/'
MT#PX^I>5JGG3-O5(DC$8W <Y9_8#IS[$ ]KHKSE_BM9W&@:%=V<<$-[K*LT,
M=_.(8H0C;7+R8/ ;@8&6]!6EX!\='Q@-3M;BVCM[_2YO)N!!)YD+Y) 9&[@[
M30!VE%%% !1110 4444 (>G%>9^(/ASKVM^-[/Q3%K]G;7-BP%M$+-F4(">&
M._))R0>GMBO3:* .+U;PYXFU'Q1I.L0ZSIT":>C*(/L;MYF\)YN27[[?EQR
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M#P?XYN_#0TFWDT"TFDLDL+F^C\PRRPKG"CC &&/YGUKU:B@#SCQ?\,/[5O\
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MG2]LP0V1(Q?"@_>QDC(SR.E>B>!9-7O?M^HZAHD6B6DYC%GI_E*LJ +\S.5
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MS2U#;3+/;12JKJ'16VR(589'0@\@^U34 %%%% !1110 4444 %%%% !1110
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M[=)(E-NP_<F, L 2I4GCC 'KQ0OO NNZOXV\=L]DT%CK-F(+6Z>1-I=?+(R
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M% !BC%%% !BD*@]12USOBKQ.WAM=.V:=+>O>W:VP1)5CQGT+<%CP "0#W(H
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M*XU*"T1+RY.9I1G+G&.?P K0HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&/U(Y-:6Q1G@<]:=@"B@!"BGJ/>@J#U&:6B@ P!1110 4444 %%%% !1110
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MSLC')/J3W_&M'IT'7WHR!U 'XT ."*.B@<YX%!12<E1GZ4W/H!^=-:0*I9B
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MQ/*IW/V)#9.!Q@]*TO%C1ZE=:;X?#*6NI1+,O_3->>?8X_2NJCP#@#'' ]J
M.87P%X:5B?[.E!(VY%W/G'IG?TJMJ'PW\*:A:BSFTY]N"L;M<2LT9_V=S'%=
MIBDP/2@#A],^&N@66G6UG)'=SFW4*K&_G4X!R.%< 8]A5\>!- VA3;7I49P#
MJ5T0,\G&9.,DY/K74X Z"B@#E6\!>'V&/LMYCT&HW0'_ *'3!\/_  X./L=Y
MV(QJ-SVZ?\M.G-=;6%XPU=M$\-7=Y%S<[?*MD[R3/\J*/<L1^5 &7!X,\,7N
M_P A;F3R3Y3^5J=R,,.H.)/_ *]2CX>Z O2+4 3Z:Q>?_'*\]^'&IS^%=?\
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M72QOL=HM=O& ;KCB6JE[XTN=0U Z7X<TC^UIUM([R4W,@A1(Y!E%YZD@UD?
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M);XHY7;_ ,A!?_B/UIW_  @3'_F;O%'_ (,%_P#B*[' HP/2@#CO^$&<<?\
M"7^*.?E_X_E_^-U8TKPNVG:F+L^(=>O"HV^3=WBM&?\ @(45U.!Z4N* &J,*
M 3FG444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\N86@@BC'S88M@DYVG !Z>N*]$T[7M'U@M_9>J6%]L^]]EN4EV_7:3ZBM'%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(I(;R-QO9'W$?+_$JE?UZB@#;\*76MV3:_!XFU2&[^P3+Y=WY*P)Y/E*^XX
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M#[,23]D')/N:Y7Q-X/TSXBZ[JS6,LNC>)M#N$A^THV3(I0/&[!>1U(!Z\?@
M#IO!&L:]<SZ]8>(Y+22XTR[$2SV\1C5T*A@QR?0_AR.:W;3Q1H=_;W5Q::O8
MW$-HF^X>*=6$2X)RQ!X& ?RKPS5O%'BB[^&WB32/$5PC7.FZC;V=U<0 ;FB8
MG=G'7H/3K75:/X7T"T\5:!K$7B-=2.J12VD5M#;1)%<PB&0MO1, JO .0>0
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MK:=X5^&FFSV5S8P:.LEDS- [7>XJQQR26.X\#&[.,<8KKWT?29#E]*LF/^U
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M!Q_X4 6O[5TP_P#,1L__  )'^-/34M/8';?6K8_Z;!OZU3_X13P\>OA_2?\
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M_P!_!2B]M1_R\P_]_!6"? 7A!^3X9TL?]NRC^E!^'_@\KC_A&M+_ / 9?\*
M-_[;:G_EYA_[[%+]KMO^?B+_ +[%<V/AUX/[>&M-_"$"F/\ #GP=GGPU8_\
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MOFQ_WU_.N4'PX\*$?\@HCV^T2_\ Q5+_ ,*X\)_] L_^!,O_ ,50!U/FQ_\
M/1?SH\V/_GHOYURO_"M?"9Y_LL_^!,O_ ,51_P *T\)_] L_^!,O_P 50!U7
MFQ_\]%_,4>;'_P ]%_.N4_X5IX2_Z!9_\")?_BJ4?#3PG_T"S_X$R_\ Q5 '
M5>:G]]?SH\V/^^OYURO_  K;PD/^86W_ (%3?_%T?\*T\)G_ )A9_P# F7_X
MJ@#J_,0C[Z_G2[@>A%<I_P *Z\*KP-+?'M<R_P#Q5'_"O?#/:PG ]!?3 ?\
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MD+N3@KC@8-2>(="UZW^(^D^*M%A2[A2QDL;ZU:58V:/<77:2/[Q!_P" #UH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 &*3%+10 8HQ
M110 8HQ110 8HQ110 5!=VD-]97%G<)O@N(VBD4$C<K#!&1R.#4]% '.^%/!
M&A^"["6UT:V:,3,'FED<N\A' R?0 \ 8 R>Y-/NO".G7OBZQ\3327)O[)&CA
M42XC"D,#\N.^XG\JWZ* #%&*** "BBB@ HHHH **** "BBB@ HHHH **** "
JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>page2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 page2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M? %GK5C*$N+2[\00020 D##!NDF3]SN,'/- 'J-%4K365O[-)X1&\<J"1,2
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M"J=N[+ 8!ZT 3454L-5^W3&/RVC81+)AB,C<3P?IC]:MT %%!.!1F@ HHHH
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MWZYJ/P7\9/"_Q"U"^AT'Q)X;UVYL6BBN%TN_AO'MF>1O*\Q(7<QKGS!EL9_
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M((<;,-][=O;](/!E[!XT\+6.L6]PTEMJD<=W;RJ 1/"?FC;#+E0ZL#M/*[L
MC%&@Z;H/BC0&^RPZ7J&GSKY+&-DN(9D"@!2>0R@8X/3 ]JT5D324CMX_W:*P
MAA5B2#\N>O7 '\J /SF_X)]_$/0]>_X+C_M[:?I^L:>\\B^"(K:+SA*0VG:;
M/;7 PQ4[XY&"]2,YSFOCG_@H'X>^#/QOU;_@H]X^OO$ND2>)O!6J^%X?#&I+
MJY@DTS5[73$A#PA9E4;KEI+8D Y=&.1C _<?0[70M5NY[[3X=)GN9"R7%W:+
M&QD?/S([+\V0<\$YZTEW\$_!^H+,L_A?P_(MTQDN4-A%LNF.23*NW$G))^?/
M)SUYH _%O]J#Q;\'_'W[67QDT#XU_&#6_!FI7/A_P?<>#&L=#LY]3U.R32UD
M#^'[XQ7,C327C,&QARS?*5Y(^X/^"M?Q&\/?##_@D5J=[XF7Q5<:.;?0M/\
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M^#O@7X9T'0?%WB33_&_A;QO<?$>W\9OI]I]NN=8G>03M=PPB-)HIH)YX/+X
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MD7X@?$JT^(NGZSXATG49M>\FQEMI;+29)49XX[.W*[55$))9B, G'6?M!?\
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ML3Z3X3UCP;X7\(W>GZ)/'<^&O"<4@TZP#JY$$08[F?!P2#RQ/M0!\[_L\?\
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M5VCPI*OQC%?0WP5^-/A?]H7X8V/B[P5KVE>+/#.I(6L-0TP[X9]A(<(?]X$
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MXE/\0/!>L:;X"CM1KEOHFI13O;WDR@1VQPQRTCLPC&/F\M^3M;'Y5_&[Q/\
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MH:#:R?!'Q+HMSK,>E^<+W;'I;VNFW+A&#1AFU-H4;K(R@??Y /V"U?\ :+\
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MGQF^&7_!23PG\ 8/VK_C?/X?\2?#G6?&^I7+PZ$NJ&YANYEACMI6TV3R8!@
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MO"/P%U[6-7\)Z!K/@:"X%M#JL;PWML]Q'=1NP>.64A@%"RS.X7&U%M?M1_\
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MH?LWZMJEMX<CN= EMO#E]X>OO*2:PNUB8W$LL@@$C2%L*9F11NC2X.+\2_\
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M?7/B]X@T75? MMK/B&&.SOH[24VMPEUY;AX6>VEDFCY(W(%;!X/Z1@8HV^U
M%717FDTZ-K@;9F4%TW;@C8&0#W .>>]6J ,44 %%%% !1110 444'I0 45\&
M?LH_\%$]2_:_^.7QD^+9^(6G^!?V7?@!JM_X-:VGM+5)/%>HVMO%+>ZK?7,R
M,]M9PB9/L\5NT;REM\K +Y)[W0O^"C7@?]ORQ\1> OV=_BQ_PCOQ>T?2;#Q9
M9P^(O!>HV:S6#30R1O+:ZA;V\D]A<JR1/+;,'2.Z1XY%8QL0#ZVHKY[_ ."9
M?[<?_#P+]EC3/'5UHJ>%O$5O>7>@^)-!%Y%=-HFK64S074!=&/R[@LB;L,8Y
M4)Z@G\]?%G_!87]J:QU;]M:ZT[Q!\!;;3/V0=3M(X[?5_".H1MXKM[BXO(Q%
MYZZGB"XVV@6-1&XFEF1,QYS0!^QU%?!?[-/_  <0_LV_$SX9> O^$W^)7AGP
M?\1_%&C:5>ZCX<C2[NETZ\OHPRVJSK#L9@V<KNW("N_&X$^_>&_^"FOP'\7_
M !JM?AYIOQ*\/W/B[4;RZT[3[3,D<.JW5LRK<V]I<NHM[F:)F"O'#([JV5(R
M"  >[45\[^$/^"M'[-_COXAZYX6TOXQ>#9M8\.V6H:C?+)=&WMEMK#)O9H[B
M15@F2!5=W:)V"I'(WW48C'MO^"U7[)E[XEO=)@_:$^%<]UI^G/JL\D>NQ/:I
M OWL7 /DM)S_ *I7,A[*: /J"BOG&/\ X*\?LRGX9>#?&4OQN^']GX8^(%]/
MIN@W]YJ2VL=]<0,JSH1)M:/RC)'YC2!502QEB ZD^>_M&_\ !=KX!_"+]D;2
M?BYX3\9:!\1M*\0>);3POI=MIM\T1FO))XA<),WE.;4P6TC7+"=$!41@$&:,
MD ^T**^.-&_;ZT5?VW?&FJ3_ +0WP7O/@-X2^'UEJ6JZ4EY&M]X=U&[NX%M+
MZXO IA%O/"T@\MIE=2\!\LK(&'T#X=_:^^%?B]/ [:7\1/!>H?\ "S/M1\(B
MWUFWD/B<6H+7)L@'S<")1ES'D(",XR* /1J*\L^"G[</P;_:3\7WOA_X>_%+
MX?\ CC7-.@:ZNK#0M?M=0N((5D$32E(G8^6)"%+C*AB!G)%4_CC_ ,% _@7^
MS-XM'A_XB?&'X:^"==,0G_L[6_$=I978C(!5C%)(' (.02.>U 'K]%?+G[,'
M[8'B/Q3\4?V@M0^(7CS]GN;X6> =8MK?PYJ/A7Q&)KG2+4K*9EUR223RK><?
MN,*-F&,PY4(QY3_@HC_P56L?@Q^PQ\0/B;^S]XA^$OQ=\3> +2WU:_TJ'Q$F
MI)!IS3I'+<F.R=G8('W?,T:!0S%_EVL ?9U%?/ND?\%)/A(/V:/%GQ"O/B/X
M%OK?X<Z1%?\ C"/2-:M;MM!N'@W_ &:11+\DKR!HHXY"&>0!!ELBM3X%?\%
M?AA\9/V<_AS\1KCQEX1\.Z=\2[6S;3H-1U^S1EOKB-';3 _F;)+N)V,3Q(2P
M=", T >W45%8WT.IV4-S;RQSV]P@DBDC8,LBD9# C@@CD$=:^(O^"DG_  6!
MOO\ @EW\>OAQI_Q#^'=E<?"?XD:J=+@\9:=XK4WFD,L<32R7>G2VB*J(TA(,
M=U)F*-W.UML3 'W%17S=\?/VVO%7P^_:^^"OPS\%_#S3_'6C_%NQO]7NO$J^
M*H[&#P_IUA)9?:KKROL\OVD>7?0&-4=?,=U7*+ND7WFS\<:/<:@U@NK:;)J,
M98/:K<QF=2O)!0'(([CM0!L453U?7[+0-,:\OKJWLK-,;IKB18HTR<#+,0!D
MD#ZFO-?&W[:WPY\ ?&SP#\/K[Q%8MXF^)"7LNCP03Q2*8[6%I9))2&^1"%95
M8@AG&T<T >K4527Q%8OK*Z<MU;G4##]H-MYB^<L6<;RF=VW.!G&,D5#?>*M/
MM]:BTHZA91:I<#=%:M<(L[K@DLJ$[B  3P.Q]* -.BOE/_@FW_P4DN/V^_B%
M\?M&F\(KX7B^"OC^\\$PRKJ1O3JZV[O']I8>5'Y19HW.SYL!E&25+-)^PS_P
M46UG]K3]K/\ :)^%6N_#N3P+>_ 2^TBS:9];CU)]7%_%=2K(5BC"1 );HP =
MR1, VQE9: /JBBHA=JR[@LC+C.0M?-/QO_;R\2?";_@HQ\&/@7#\-[B\T/XO
M6.KWZ>,)-=MXXK-=.LVFGBCM K2R2*[VH8L47;<*4,FV01@'TW17S?\ M=?M
M[2?LN?&_X(^#H?#,7B6/XN^,4\'WE]%KMO:R>&99+=IX9'MBKS3>8L<I 541
M1'\TBEXP_P!!IXALVU(V/VB'[<L7G-;!P9A'G;OV [MN>,XQ0!=HJK_;%O\
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MA: )J*POB3\3-!^#_P /M8\6>*-6LM"\-^'[.34-2U&\D$=O901J6>1V/0
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MCI/B5KKXH>#=,36=8T1M,NXC96CF(+(9WB$#9\^$A4D9B) V,<UZM0 4444
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MWI%',(BS?/N_HECLM-\336.L0?8;QE@;[%>QJDI6.4*6,<G.%<*A.TX8*O7
MJCI'PI\-Z#XUN_$EGH.BVOB+4(C#>:I#811WMXAV_+),%\QE^1."V/D7T& #
MX2_X. T\-^+?A;\%_#.I>./A/X3\3#QVOB#P]I_Q1TW[9X*\7/8V%RD^G:G(
MP:*WBDBNB5DDR2ZHJ%9&61/S+_8W^(/PJ^,G[1?[#?B?6/AOX%\#>&[[PGXS
MT;1K+QX]M>:/J&HP7UT^GXG>"/?$M_=,D*K&7B?<J;F^=OZ)O'GPR\-_%+2X
M;'Q-X?T3Q%9V\WVB*#4["*\BCDVE=X616 ;:S#(&<,1W-4Y?@MX3E&@>9X;\
M/-_PB?\ R!2VF0$Z/]W/V;Y/W.=B?ZO;]Q>F!0!_.;\/-3\/_$'_ ()F:'XS
M\-7$^F?\%(-'^.4IN-XCM?&^LZU/>E9K62%\7!T]+&X DB<1P)+;3(P \P/[
M9!\1_P!F_P"*'[0'[0UK\:+WQU?_ +3'A7]IJ>^\(0^&-*MX_'>K6$5S'9:/
MI.F7$H'FZ?\ 9X&\R-I(D0.KL1F)Y/W$L_@IX1M/'[>+(_#7AM?%#,2VL+I<
M"Z@VY!&<S[?,Y3Y?O?=XZ5>?X:Z"WC9_$JZ-I">(I+?[(=5%C%]N\G@^7YVW
M?LR =N<<4 ?S>?#?XC^!_"_[=OQ _P"%^>']!\2?LK7'[47C!=3NK>XCV67B
M>;*:=<ZS&<F?24MOM1@CRB%I-0=S*L9A?H?VK_A'^S]\=O'W_!4#X@WD_@O5
M%\ Z3X4C^&^JZ9KBQV5C-)IS1B.R^SRB&0M):VT(4!L!6C7 =U/[^6?[)_PS
ML-*N+&'X>^ X;&\:%[BVC\.V:PSM$'$3.@CPQ3S9-I/W?,?&-QS"?V.OA+@?
M\6O^'>Y00I_X1JRX_P#(5 'XX_%[0OAG^T[^TI^V;8_M,:QI/]IZ7\%M!OO@
M_J/B&Y,C:=I3:-<75WJ.E OB:9;]8G>12\SMYL>XH\J'/\!_M,_%$ZK_ ,$]
M[[4IO$6N?'SP[\'?B5XHTZS\4RDW'BN\N-/=-(M)Q(ZSS>=]B0\E&D7RV60G
M<5_9GQ1^QA\)/'%WX;GUKX7_  WU>;P7*9O#DE[X8LKA_#[&192;,O&?LY,B
MH^8]IW*&Z@$=)JOP4\):]XVM?$M_X9\.WWB*R">1JMQI<$E]#LSLVS,I==N6
M(P1@L<4 ?S^?L]:K^RS;>'?^"?/Q6TOQQX=NOV@=<^)45S\1M6U37%?6[V2Y
M^UO?SZIO8MA;X6Z0RRE=R2@C<&)%S]ACPA\./V@OCS\/_B5XB^-UK;?M#0_&
M^\L=4\,>&/#5P?'OB1;C6&AN(-3N)+]1+HZ:9AI)+:VB@MK9;A")9(F0_N1H
MG["7P6\,^(=4U?3?A'\+=-U;7+D7FH7MKX1T^&YOIPS.)99%BW22!G=MS$G+
MD]2:UM!_90^&GA7XQZA\1-+^'_@73?B!JZLE]XGM/#]I#K-XC;0RR7BQB=PP
M10=SG(5?04 ?D3_P:/\ [$WPQ\9_ 32OVBI/[4O/B]HVJZWX:NKF/6IFA\B9
M+-E%Q;!RN]4WE=P ;[4SLKL(7CD_X*":3\-?VG?^"IW[7_AO]H;Q1'I>F_"K
MX3:?>?"IM3UN71X= FFM89[B_L3O2.2Y^WO;J7.XN0D)$BJ4'['?#_X.^%_A
M/;RP^%_#N@^&[>X8/-#I6G0V4<Q PI98U4$@< GH*Y?XS?L7?"']HKQ?8^(/
M'_PL^&WCC7--@6UL]1\0^%['5+NTB5VD6..6>)G10[LP4$ ,Q/4F@#\</V:_
MA"/VG?BC_P $R]8_:-T^77/'OC;PEXZ6^N=:N;B#4M7MK*.%]#:1MZ2-,+60
M2+)]^4N9&9V.^OI/_@Y6^&/@+4[7]C74/&4-A;Z'8?'/0]#U*^OM0>TM[31+
MI6.H"67S%$:&.UB9IF(:-8B0Z98G[U^)'[$OP9^,7Q%A\8>,/A5\,?%GBZR\
MKR=<UGPM87VI6XB;=%MN)8FD78>5PPVGD8KH?C;^SSX!_:9\,6^A_$+P7X.\
M?:+9W*WT-AXCT6VU:UAG"LBS+'.CJL@1Y%# 9P[#."<@'X%_MC>!_"^H?$+_
M (*7?%7P_P"+?%GA>]^$=IX _P"$'U7P9K]U:PDW%K%##*_V>95N_,6.)!/*
MTFQ9I)5RV#76?ML_%7QO^U5^VW\<M#\0_M >%?@+<?!WPUX4O?".J^(_%6MZ
M3<6R"S34+[4--L[6>*VNYYYB%E\VWN'*&V6(!DW-^M%S_P $>OV8+S_A*/,^
M!?PT9O&D@EUMAHL:F_87'VGDC[@\[#[4P,JO90!-\1_^"1W[-_Q?\3^ =8\3
M_"'PCK5]\,+&#2_#;7,#F.QLH!B"U>,-LN+>+),<5P)$0DE54F@#YL_X.'KS
MQ)\2_P#@@!XPU;P[+KFH37NEZ%J>HRV\$EC<3V+7-J]Q)-!M5HX]C%Y(W0!%
M#[U4(V/H+Q%^T%^SKXM_X)M6OB;Q9X@\"W7P%U#PM#:WIN[B.ZL+BU^S+BQ"
M1KNEN-H"+!''YQD"JD8?"U]*ZCI,.KZ9):72QW$$R&.5)8U=95((8,I&"""0
M01@@D5\R_"C_ ((J_LL? [XW2?$7PI\$/ ND^+OM:ZA;7(M7FM],N5<.DUG:
MN[6]I(C %6MXXRI VXP* /S4^,WB/4?VP? O_!0[XL>+/BQ\0O"/Q,_9O\1S
M6OP^TW3]>O-(@\%V&G;[C3Y5MH)A#-)J<L4D+FXB<@Q J5/W5^!WP&\2?\%0
M/^"KVD_\+&^)WQO\"W&M_ +PK\3KFQ\(>,Y]*CT[695LX7%LH#);P$EY?+10
MPE=FWCD5^H_QC_X)/?LY_M"?'>U^)WC;X0^#/$GCJWDCF?5;NS.Z^>-42-KJ
M-6$5UL6.-5\]'VA% QBNIC_8R^&_@GXZ^(/C-H'P]\*R_&'6+*2";Q!<*T-W
M?_N8XTBDN LC1H5AAC+)&Q5%X5OND _!_P",/@SXH?!K]CSP9^U%X!_:6^._
MCWQO)\>K[P9X.T?6/%E]JELVEQZA?6MK:SVLSM))<S_8U>2-L))#<A#".7/I
M'QL_:=^)GQ!_82_:2_:@LOCM\5/!_P ;OA+\;?[,L?!ECXHO(M!TJTM[RSLK
M;1)-':06UPLD<K3.Y@W3202*P.)U;[7_ ."/_P#P0F\,_L9[O'/Q4\#> -1^
M.EGK6HWUIXHT37]2U6V6"ZD9T,=O=06\5O-&CM"'2)W*@L)5\PHOT9X@_P""
M27[.GBK]J#_A<FH?#71KCXB'5;?7'OC>7:VEQJ-NCI;WLMBLPLY;F,2.5F>%
MI S%PV\[J /SRA\._%3Q+^T+^UE\3->_:\^,GPK\$_LZZO+XAM_#D<G]JV]C
M/>>'H;[9)!/*BW%I#<F-(=/D78PB>-666=YJ^9_#7QB^*U^WQB\$^)OB5\7+
M?PSXN_9#U7X@6%AKOQ+NM<U.\N;<>?:ZE,#/+'IUQ?0P/+)I]O)(J6=R(V=B
MSA/VT^''_!+CX$_"CQS\4/$6B^"8QJ'QL2YC\<Q7VLZAJ5CXG%Q+)-+]HL[F
MXDMR2TLN"(P465T4JK,I\Y^$/_! ']D'X&:_J&H>&/@YI=G?:EH]_H-R\^MZ
MI>[K.]MGM+I L]TX1I+>66(R*!($E=0P#-D ^(_@IXA\6_LV>&/^"85MX0^*
MGQ5DT[XC:D(?%6B:OXG?4[4I<:/:RC3Y(RH58+=96$$)'[E70CYDC=>,^$'[
M3GQD\:?LB_ ']MU?C]X\;Q=\1/B];>&O$OPVFU]/^$3N]+N-;N+'^R=/TT1,
ML5PMK%$XE</-L,LVXN%8_I#\,?\ @AE^S#\'[7X;KH/PYDLYOA-J[>(?#4R^
M(M55K?4WEAFDOIE6Y"7,[M;P*SS*^8H8X<"%%C%WX?\ _!%S]G/X6?M&R?%#
M2? \D/B(Z]-XKM[*?5[R;1;'6)0%DU&#3GE-M'<_W9%CS&=I3853: ?F7HMO
M^T1\,?@]K?QKD_:I^,6N-\+_ -H^7X>Z3X?U"_6?3]7TG^W(=*G.H(%1;B60
M%64,&BA"OY2(\NZ/]%_^"UNM?&K1/V2M,C^!-UK'_"777BRP2^L-'UJTTK7-
M9TJ*.>YN[/39KI'47;QP @1QRR[$E(CD ,;=)XJ_X(S_ +//C7PGXIT'4/!^
MN2:'XT\5_P#";ZSI\/C37K>VN=9WSR?;$CCO56%R]P[D1!$++$Q7,,)C] _:
M?_83\!_M?_"[PWX1\:_\)+-IOA#6+'Q!I%U8:_>6.IV5_9JZVUPM['*+@R)O
M+>89"Y?#EBPS0!^,?AW7-<_X*>S?L::!X?\ CI\3)O$5K\8/&=F?%7B'2([/
MQ1X2CM-,@U0V$N 8IKV*S*Q^>%,8DE(V;(]E>E?!C_@HM\=M._9=@\%WGQD\
M4:]\1_#?[3>L_"?3VT?1M+G\6_$+2[*T1A;Q?;HWLK=A<W43RW<X1((%!+.R
MB.;[^\%?\$1/@#\.?&7P\\0:)I/B[3]9^&6NW7B?2;R+Q7J/G76IW<RRW=Y>
MN9B;R:X")#*\Y8R01I"V8U"C&;_@@7^SJW@G3]&_L_Q\L^E^,KWQ];ZRGC;5
M$UI=:O(;>&YNS>K,)C)(+6%B2V=ZE@06;(!\06W[6GQ,_;*_X(,:+XJ^+&K+
MKGC33?CIH>B7%]]EMK>:6.W\368195MDC@+Q[C'NCC16"*<$DLWTO^PD<_\
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M (U:K\ _B=X$T.7PRNHV7AR'6K6^TPR/+';/;22Q1E4>64A9/,C.Y3L5D5@
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MG_QBO@SQMK \2/%XANKB"6"/49],L/LQBEAM?M"-NGGA\U?F^0!BGTC^W_\
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M+;_$%M+O_A2^EQ-<0>'?M:6$>=1&+A-4:3]]A@T6VZBDV!$,4GUYX;_X(/\
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M^(GBCXK>,O%FM2^)/$_BS7S_ *3J^H/;VMJ&2/<WDPQV]G;Q)#O?8D8 ;H
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M^IZI9:)=_P!C7G]E:[X<U",&:RO%,AD%PLLMX%ECP-EP,C?&K#ZS_P"":_\
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M!8EL1GK_ /@D/^R+J_[)/[#6@Z9XO>2Z^)_C*>7QAX\O925EO-<O@DDP< [
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M;QY\-YOAIX7\0Z9:6NGSZY9>%D(F6XN98X]L5JLA$+--)RSR%2^%15[35_\
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M\=G(EQ=0Q//?M=O;^5;P894$LS21B-!* ?17@7]NKX+_ !.^*VN^!?#OQ4\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!TIU% #3$I;=M7=QSCTZ4-&K')52?4BG44 -6)5'"J/H*!$J]%7@Y''>G44
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MWM+2!8((%_NHB@*H]@*NT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825390544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 15, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Actinium Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,693,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,136,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825797584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,673,308<span></span>
</td>
<td class="nump">$ 17,399,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash - current</a></td>
<td class="nump">40,075<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">616,222<span></span>
</td>
<td class="nump">439,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">14,329,605<span></span>
</td>
<td class="nump">17,838,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $266,381 and $215,660</a></td>
<td class="nump">118,799<span></span>
</td>
<td class="nump">57,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">49,859<span></span>
</td>
<td class="nump">49,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">391,131<span></span>
</td>
<td class="nump">390,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">14,889,394<span></span>
</td>
<td class="nump">18,337,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">5,814,004<span></span>
</td>
<td class="nump">4,650,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">249,239<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">6,063,243<span></span>
</td>
<td class="nump">4,666,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Long-term capital lease obligation</a></td>
<td class="nump">13,354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">6,076,597<span></span>
</td>
<td class="nump">4,666,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 600,000,000 and 400,000,000 shares authorized; 115,703,044 and 80,072,334 shares issued and outstanding</a></td>
<td class="nump">115,703<span></span>
</td>
<td class="nump">80,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">195,554,332<span></span>
</td>
<td class="nump">176,744,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(186,857,238)<span></span>
</td>
<td class="num">(163,153,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">8,812,797<span></span>
</td>
<td class="nump">13,671,103<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 14,889,394<span></span>
</td>
<td class="nump">$ 18,337,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811652256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">$ 266,381<span></span>
</td>
<td class="nump">$ 215,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">115,703,044<span></span>
</td>
<td class="nump">80,072,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">115,703,044<span></span>
</td>
<td class="nump">80,072,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826831408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">17,094,778<span></span>
</td>
<td class="nump">17,719,855<span></span>
</td>
<td class="nump">17,828,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,732,544<span></span>
</td>
<td class="nump">9,190,933<span></span>
</td>
<td class="nump">9,019,194<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,827,322<span></span>
</td>
<td class="nump">26,910,788<span></span>
</td>
<td class="nump">26,847,481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(23,827,322)<span></span>
</td>
<td class="num">(26,910,788)<span></span>
</td>
<td class="num">(26,847,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense)</a></td>
<td class="nump">173,359<span></span>
</td>
<td class="nump">5,430<span></span>
</td>
<td class="num">(5,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on change in fair value of derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">304,123<span></span>
</td>
<td class="nump">2,530,764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">173,359<span></span>
</td>
<td class="nump">309,553<span></span>
</td>
<td class="nump">2,525,757<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,653,963)<span></span>
</td>
<td class="num">$ (26,601,235)<span></span>
</td>
<td class="num">$ (24,321,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">106,041,809<span></span>
</td>
<td class="nump">66,746,389<span></span>
</td>
<td class="nump">48,463,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825697888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 44,067<span></span>
</td>
<td class="nump">$ 134,160,059<span></span>
</td>
<td class="num">$ (112,230,078)<span></span>
</td>
<td class="nump">$ 21,974,048<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2015</a></td>
<td class="nump">44,066,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">4,297,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,297,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">81,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock and warrants, net of offering costs</a></td>
<td class="nump">$ 11,504<span></span>
</td>
<td class="nump">16,011,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,022,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock and warrants, net of offering costs, shares</a></td>
<td class="nump">11,504,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of options</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">18,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of options, shares</a></td>
<td class="nump">23,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from exercise of warrants, shares</a></td>
<td class="nump">125,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification', window );">Transfer of warrant derivatives from liability to equity classification</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24,321,724)<span></span>
</td>
<td class="num">(24,321,724)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 55,802<span></span>
</td>
<td class="nump">154,504,329<span></span>
</td>
<td class="num">(136,551,802)<span></span>
</td>
<td class="nump">18,008,329<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="nump">55,801,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">3,474,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,474,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">93,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock and warrants, net of offering costs</a></td>
<td class="nump">$ 24,173<span></span>
</td>
<td class="nump">18,765,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,789,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock and warrants, net of offering costs, shares</a></td>
<td class="nump">24,172,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from exercise of warrants, shares</a></td>
<td class="nump">4,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,601,235)<span></span>
</td>
<td class="num">(26,601,235)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 80,072<span></span>
</td>
<td class="nump">176,744,068<span></span>
</td>
<td class="num">(163,153,037)<span></span>
</td>
<td class="nump">13,671,103<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="nump">80,072,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability', window );">Modified retroactive adjustment for derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66,154<span></span>
</td>
<td class="num">(50,238)<span></span>
</td>
<td class="nump">15,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">1,798,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,798,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">156,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock and warrants, net of offering costs</a></td>
<td class="nump">$ 34,614<span></span>
</td>
<td class="nump">16,941,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,976,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock and warrants, net of offering costs, shares</a></td>
<td class="nump">34,614,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of commitment shares to Lincoln Park</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="num">(853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of commitment shares to Lincoln Park, shares</a></td>
<td class="nump">852,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">4,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from exercise of warrants, shares</a></td>
<td class="nump">7,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,653,963)<span></span>
</td>
<td class="num">(23,653,963)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 115,703<span></span>
</td>
<td class="nump">$ 195,554,332<span></span>
</td>
<td class="num">$ (186,857,238)<span></span>
</td>
<td class="nump">$ 8,812,797<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">115,703,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of modified retroactive adjustment for derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ModifiedRetroactiveAdjustmentForDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of warrant derivatives from liability to equity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_TransferOfWarrantDerivativesFromLiabilityToEquityClassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813336912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,653,963)<span></span>
</td>
<td class="num">$ (26,601,235)<span></span>
</td>
<td class="num">$ (24,321,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,798,655<span></span>
</td>
<td class="nump">3,493,731<span></span>
</td>
<td class="nump">4,297,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">50,721<span></span>
</td>
<td class="nump">55,938<span></span>
</td>
<td class="nump">77,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GainOnChangeInFairValueOfDerivatives', window );">Gain on change in fair value of derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(304,123)<span></span>
</td>
<td class="num">(2,530,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">100,032<span></span>
</td>
<td class="nump">1,397,129<span></span>
</td>
<td class="num">(1,032,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,133,499<span></span>
</td>
<td class="nump">405,214<span></span>
</td>
<td class="nump">2,720,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(20,571,056)<span></span>
</td>
<td class="num">(21,553,346)<span></span>
</td>
<td class="num">(20,789,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payment of security deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(49,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(96,092)<span></span>
</td>
<td class="num">(24,739)<span></span>
</td>
<td class="num">(59,960)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(96,092)<span></span>
</td>
<td class="num">(24,739)<span></span>
</td>
<td class="num">(109,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(265,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of shares of common stock and warrants, net of offering costs</a></td>
<td class="nump">16,976,237<span></span>
</td>
<td class="nump">18,814,634<span></span>
</td>
<td class="nump">16,022,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">4,849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">16,981,086<span></span>
</td>
<td class="nump">18,814,634<span></span>
</td>
<td class="nump">15,775,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(3,686,062)<span></span>
</td>
<td class="num">(2,763,451)<span></span>
</td>
<td class="num">(5,123,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">17,790,576<span></span>
</td>
<td class="nump">20,554,027<span></span>
</td>
<td class="nump">25,678,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">14,104,514<span></span>
</td>
<td class="nump">17,790,576<span></span>
</td>
<td class="nump">20,554,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Stock issuance costs included in accounts payable and accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable', window );">Prepaid expenses financed by accounts payable and notes payable</a></td>
<td class="nump">276,932<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Capital lease of office equipment</a></td>
<td class="nump">16,078<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification', window );">Transfer from derivative liability classification to equity classification</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GainOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain on change in fair value of the derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GainOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid expenses financed by accounts payable and notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PrepaidExpensesFinancedByAccountsPayableAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock issuance costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer from derivative liability classification to equity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_TransferFromDerivativeLiabilityClassificationToEquityClassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816308864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and
Summary of Significant Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business
-</b> Actinium Pharmaceuticals, Inc. (the "Company", "Actinium", or "We") is a clinical-stage,
biopharmaceutical company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell
therapies such as a BMT or Bone Marrow Transplant or CAR-T, <font style="background-color: white">a type of cellular therapy that
genetically alters a patient's own T cells to target and kill their cancer cells,</font> and for other adoptive cell therapies.
In addition, the Company is also developing potential therapies for targeting and killing of cancer cells either as single agents
or in combination with other drugs. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Going concern</b>
- <font style="font: 10pt Times New Roman, Times, Serif">The Company has never generated revenue. Currently
it does not have a recurring source of revenue to cover its operating costs. The Company has incurred net losses and negative
operating cash flows since inception. As of December 31, 2018 and 2017, the Company's accumulated deficit was $186.9 million
and $163.2 million, respectively. The Company's net loss was $23.7 million, $26.6 million, and $24.3 million for the years
ended December 31, 2018, 2017 and 2016, respectively. These conditions raise substantial doubt as to our ability to continue as
a going concern. As of December 31, 2018, in the Company had a balance of its cash and cash equivalents of $13.7 million. The
Company's consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States
of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to
continue as a going concern. As of the date of filing this report, the Company expects that its existing resources will be sufficient
to fund its planned operations into the fourth quarter of 2019; however, additional capital resources will be needed to fund operations
longer-term. If the Company is unsuccessful in accomplishing its plans, it may have to delay or terminate existing and/or planned
clinical trials and other related activity, which could have a material adverse impact on its business. The Company plans to continue
as a going concern include obtaining capital from the sale of its equity securities, potential exercise of outstanding warrants,
fees from licensing one or more of our product candidates, additional collaborations with our Iomab-ACT program and AWE technology
platform, and short-term borrowings from banks, stockholders or other related parties, if needed. However, the Company cannot
provide any assurance that we will be successful in accomplishing any of our plans.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company's ability
to continue as a going concern is dependent upon its ability to successfully accomplish the plans described above and eventually
to secure other sources of financing and attain profitable operations.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The consolidated financial statements include the Company's accounts and those of the Company's wholly owned
subsidiaries. All significant intercompany accounts and transactions have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates
in Financial Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash and Cash Equivalents
-</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Property and Equipment
-</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three
to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related
gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets
are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated
useful life of the related property or term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value of Financial
Instruments</b> <b>- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives
the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable
inputs. As required by ASC 820 "<i>Fair Value Measurements and Disclosures</i>", financial assets and liabilities
are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's
assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation
of fair value assets and liabilities and their placement within the fair value hierarchy levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1 Inputs - Unadjusted quoted
prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2 Inputs - Inputs other
than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might
include quoted prices for similar assets or liabilities&#160;in&#160;active markets, quoted prices for identical or similar assets
or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such
as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated
by market data by correlation or other means.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3 Inputs - Unobservable
inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions
that market participants would use in pricing the assets or liabilities.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><b>Income Taxes -</b> The Company provides
for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based
on the differences between the financial statement carrying amounts of existing assets and liabilities at each year-end and their
respective tax bases, and are measured using enacted tax rates in effect for the year in which the differences are expected to
affect taxable income. Significant judgment is required by management to determine the Company's provision for income taxes,
deferred tax assets and liabilities, and the valuation allowance to record against net deferred tax assets, which are based on
complex and evolving tax regulations throughout the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax assets
and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. There were
no tax positions for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly
increase or decrease within the next year. The Company recognizes interest related to unrecognized tax benefits in interest expense
and penalties in operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Tax Cuts and Jobs Act,
or the Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the
Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. As of December
31, 2018, upon completing its analysis of the Act, the Company believes that its disclosures in its financial statements as of
December 31, 2017 remain accurate.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition
</b>- The Company adopted new accounting guidance for revenue recognition, effective January 1, 2018, which did not have a significant
impact on the Company's financial statements. Beginning January 1, 2018, revenues are recognized when control of the promised
goods or services is transferred to customers in an amount that reflects the consideration expected to be entitled to in exchange
for those goods or services<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. Research and development reimbursements are recorded by the
Company as a reduction of research and development costs.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments
-</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common
Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average
number of common shares outstanding during the reporting period. For the years ended December 31, 2018, 2017 and 2016, the Company's
potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation
of diluted net loss per share as the result would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,236,101</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,174,592</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,906,886</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,820,876</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,662,340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,964,752</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">63,056,977</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">30,836,932</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,871,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Subsequent Events
</b>- The Company's management reviewed all material events through the date the consolidated financial statements were issued
for subsequent event disclosure consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Reclassifications
- </b>Certain reclassifications have been made to the prior-year financial statements to conform to the current-year presentation,
including the addition of restricted cash to cash and cash equivalents on the consolidated statements of cash flows as a result
of the adoption of new accounting guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Accounting Standards
Recently Adopted </b>- In November 2016, the Financial Accounting Standards Board ("FASB") issued an Accounting Standards
Update ("ASU") amending the presentation of restricted cash within the consolidated statements of cash flows. The new
guidance requires that restricted cash be added to cash and cash equivalents on the consolidated statements of cash flows. The
Company adopted this ASU on January 1, 2018 on a retrospective basis with the impact to its consolidated statements of cash flows
for the year ended December 31, 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Previously Reported</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Adjustment</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As Revised</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in investing activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(380,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">356,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(24,739</td><td style="width: 1%; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was
no impact to the cash flows from operating, investing and financing activities for the year ended December 31, 2016 as the
amount of restricted cash did not change during 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary
of cash and cash equivalents and restricted cash at December 31, 2018, 2017 and 2016, respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,673,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,399,636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,519,294</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,733</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">390,940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Cash and cash equivalent and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,104,514</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,790,576</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,554,027</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB
issued ASU No. 2014-09, <i>Revenue from Contracts with Customers</i>. Under the new standard, revenue is recognized at the time
a good or service is transferred to a customer for the amount of consideration for which the entity expects to be entitled for
that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of
adoption. The Company adopted this ASU on January 1, 2018 and the adoption did not have a significant impact to the Company's
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2017, the FASB
issued ASU No. 2017-11, <i>Earnings Per Share</i> (Topic 260); <i>Distinguishing Liabilities from Equity</i> (Topic 480); <i>Derivatives
and Hedging</i> (Topic 815): (Part I) <i>Accounting for Certain Financial Instruments with Down Round Features.</i> These amendments
simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard
the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability
or equity classification. The guidance was adopted as of April 1, 2018. See Note 2 for further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Recent Accounting Standards &#8211;
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016,
FASB issued ASU No. 2016-02 <i>Leases</i> (Topic 842), which creates new accounting and reporting guidelines for leasing
arrangements. The standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A
lessee should recognize on its balance sheet a liability to make lease payments (the lease liability) and a right-of-use
asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a
lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and
lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the
earliest period presented using a modified retrospective approach. The guidance in ASU 2016-02 is effective for annual and
interim reporting periods beginning after December 15, 2018. The Company's initial evaluation of its current leases
does not indicate that the adoption of this standard will have a material impact on its consolidated statements of
operations. However, the Company does expect that the adoption of the standard will have an impact on its
consolidated balance sheets for the recognition of certain operating leases as right-of-use assets and lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2018, the FASB
issued ASU 2018-07 to expand the scope of ASC Topic 718, <i>Compensation - Stock Compensation</i>, to include share-based payment
transactions for acquiring goods and services from nonemployees. The standard is effective for fiscal years, and for interim periods
within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating
the impact of the new standard on its financial statements and related disclosures, but does not expect this ASU to have a material
impact on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the
FASB issued ASU 2018-13, <i>Fair Value Measurement - Disclosure Framework (Topic 820).</i> The updated guidance improves the disclosure
requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay
of adoption of the additional disclosures until their effective date. The Company is in the process of evaluating the provisions
of the ASU but does not expect it to have a material effect on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, the
FASB issued ASU 2018-18, C<i>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,</i>
which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be
accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impact
the standard will have on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the
SEC adopted the final rule under SEC Release No. 33-10532, <i>Disclosure Update and Simplification</i>, amending certain disclosure
requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure
requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis
of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate
statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which
a statement of comprehensive income is required to be filed. The Company anticipates its first presentation of changes in stockholders'
equity will be included in its Form 10-Q for the three months ended March 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629660432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><b>Note 2  -
Derivative Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, the Company
accounted for certain instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with
FASB ASC 815-40,&#160;<i>Derivative and Hedging &#8211; Contracts in Entity&#8217;s Own Equity</i>. This was due to an anti-dilution
provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity-linked instruments
in the future at an effective price per share less than the exercise price then in effect for the warrant (&#8220;down round provision&#8221;).
As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value
were recorded as non-cash adjustments within other income (expense), net, in the Company&#8217;s accompanying Consolidated Statements
of Operations. The Company recorded a gain on the change in the estimated fair value of warrants of $0.3 million and $2.5 million
for the years ended December 31, 2017 and 2016, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 1, 2018,
the Company early adopted ASU 2017-11, which revised the guidance for instruments with down-round provisions. As such, the Company
treats outstanding warrants as free-standing equity-linked instruments that are recorded to equity in the Consolidated Balance
Sheet as of January 1, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
the guidance presented in the ASU 2017-11, the fair value of the derivative liability balance for 57,212 warrants as of December
31, 2017 of $16 thousand was reclassified by means of a cumulative-effect adjustment to equity as of January 1, 2018. These warrants
had an original exercise price of $2.34. The exercise price is adjusted based on a formula whenever the Company issues, or is deemed
to have issued, any common shares for no consideration or a consideration per share less than the exercise price of warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Company&#8217;s
adoption of ASU 2017-11, the exercise price of the warrants was reset to $1.25 as a result of various offerings. The difference
of $5 thousand between the fair value of the warrants with the exercise price prior to the price reset and the fair value of the
warrants with the exercise price after the price reset was accounted for as a deemed dividend. The impact of the adoption was as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Derivative liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(15,916</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,154</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(50,238</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,916</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the
derivative warrants was calculated using a binomial valuation model with the following assumptions at December 31, 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Market value of common stock on measurement date (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.66</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Adjusted exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.09</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant lives in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.1 years</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability of stock offering in any period over 5 years (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Offering price estimated as of December 31, 2017 (6)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(1)</td><td style="text-align: justify">The market value of common stock at the above measurement
dates was based on the Company&#8217;s closing price quoted on the NYSE American.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(2)</td><td style="text-align: justify">The risk-free interest rate was determined by the Company
using the Treasury Bill rate as of the respective measurement date.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(3)</td><td style="text-align: justify">The volatility was estimated using the historical volatility
of the Company&#8217;s common stock.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(4)</td><td style="text-align: justify">Management does not expect to pay dividends for the foreseeable
future.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(5)</td><td style="text-align: justify">Management determines the probability of future stock offering
at each evaluation date.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(6)</td><td style="text-align: justify">Represents the estimated offering price in future offerings
as determined by management.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt">As a result of an agreement with Lincoln
Park Capital Fund, LLC (See Note 7) the exercise price was further reset to $1.23 per share, with an immaterial change in the fair
value of the warrants before and after the price reset.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816396944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Prepaid Expenses and Other
Current Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and
other current assets consisted of the following at December 31, 2018 and 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">339,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,371</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,997</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,758</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,954</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">439,322</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company issued a note payable of $249,239 for its insurance premiums; payments are scheduled during 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629660432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 - Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment
consisted of the following at December 31, 2018 and 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid"><b>Lives</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">176,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116,070</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment &#38; furniture</td><td>&#160;</td>
    <td style="text-align: center">3 - 7 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,940</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(266,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(215,660</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,799</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">57,350</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company entered into a five-year capital lease agreement for office equipment and services for $906 per month. At December
31, 2018, the capitalized value associated with the lease agreement was $16,078.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense
consisted of the following for the years ended December 31, 2018, 2017 and 2016, respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2016</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research &#38; development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,170</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,632</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,586</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,891</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50,721</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55,938</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">77,523</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6631245040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License and Research Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered
into agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services under
which the Company may incur obligations to make payments including upfront payments as well as milestone and royalty payments.
Notable inclusions in this category are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">a.</td><td style="text-align: justify">Oak Ridge National Laboratory (&#8220;ORNL&#8221;) &#8211; The Company is contracted to purchase
radioactive material to be used for research and development, with a renewal option at the contract end. During the years ended
December 31, 2018, 2017 and 2016, the Company purchased material from ORNL of approximately $0.3 million, $0.6 million and $1.0
million, respectively. On December 19, 2018, the Company signed a contract with ORNL to purchase $0.2 million of radioactive material
during calendar year 2019.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">b.</td><td style="text-align: justify">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred
Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon previous and ongoing clinical trials, with BC8 (licensed
antibody). FHCRC has currently completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive
rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC
upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of
2% of net sales will be due to FHCRC. </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">c.</td><td style="text-align: justify">On February 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology
Inc. (&#8220;Goodwin&#8221;). Goodwin oversees the current Good Manufacturing Practices (&#8220;cGMP&#8221;) production of a monoclonal
antibody used in the Phase 3 clinical trial of Iomab-B. As of December 31, 2018, the remaining cost of the service agreement is
$1.0 million. During the years ended December 31, 2018, 2017 and 2016, the Company paid Goodwin $1.2 million, $1.4 million and
$0.7 million, respectively.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">d.</td><td style="text-align: justify">On February 16, 2016, the Company entered into an agreement with Medpace, Inc. (&#8220;Medpace&#8221;),
a Contract Research Organization, (&#8220;CRO&#8221;). Medpace provides project management services for the Iomab-B study. The
total project is currently estimated to cost approximately $10.2 million. As of December 31, 2018, the remaining cost of the agreement
is approximately $3.3 million. Medpace bills the Company when services are rendered and the Company records the related expense
to research and development costs. During the years ended December 31, 2018, 2017 and 2016, the Company paid Medpace $3.1 million,
$2.8 million and $2.6 million, respectively.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">e.</td><td style="text-align: justify">On August 4, 2016, the Company entered into a CRO agreement with George Clinical Services, (&#8220;George&#8221;).
George provides project management services for the study of Actimab-A used for a Phase 2 clinical trial. The total project is
estimated to cost approximately $4.6 million. As of December 31, 2018, the remaining cost of the agreement is approximately $0.5
million. George bills the Company when services are rendered and the Company records the related expense to research and development
costs. During the years ended December 31, 2018, 2017 and 2016, the Company paid George $1.9 million, $0.7 million and $0.1 million,
respectively.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Lease Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not
own any real property. It currently leases office space located at 275 Madison Avenue, New York, NY. The lease is for 5,790 square
feet and has a term of seven years and three months, with an expiration date of September 6, 2022, with a current annual rate of
$312,660 until June 8, 2019 and $341,610 for the remaining life of the lease. The Company is also responsible for certain other
costs, such as insurance, taxes, utilities, and maintenance. The Company issued a letter of credit of $390,825 in connection with
the lease and maintained a $391,131 certified deposit as collateral for the letter of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2017, the Company
also entered into a license agreement for furniture and fixtures located at its office space. Pursuant to the terms of the agreement,
the Company leases the furniture and fixtures and tenant improvements located in the office space for the same term as the office
space for $7,529 per month. At any time during the term of this amended agreement, the Company has the right to purchase the furniture,
and fixtures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company entered into a five-year lease agreement for office equipment and services for $906 per month and the capitalized value
associated with the lease agreement was $16,078.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future minimum obligations
on all of the Company&#8217;s operating leases with a term over one year are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">For the year ending December 31:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,896</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431,958</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431,958</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">287,972</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 10pt; text-align: left">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,571,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629660432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 - Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 18, 2018,
the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement and a registration
rights agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock
having an aggregate value of up to $32,500,000, subject to certain limitations and conditions set forth in the agreement. As consideration
for entering into the purchase agreement, the Company issued to Lincoln Park 852,537 shares of common stock, determined to be offering
costs as part of the financing. These shares had a fair value of $0.6 million based on the market price on the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the purchase
agreement, Lincoln Park initially purchased 3,376,554 shares of common stock, at a price of $0.74 per share, for a total gross
purchase price of $2,500,000. As often as every business day from and after one business day following the date of the initial
purchase and over the 30-month term of the agreement, and up to an aggregate amount of an additional $30,000,000 (subject to certain
limitations) of shares of common stock, the Company has the right, from time to time, at its sole discretion and subject to certain
conditions, to direct Lincoln Park to purchase up to 400,000 shares of common stock, with such amount increasing as the closing
sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed
$1,500,000, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a
&#8220;Regular Purchase&#8221;). If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it
then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations
in the agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount
of common stock that may not exceed the lesser of (i) 300% the number of shares purchased pursuant to the corresponding Regular
Purchase or (ii) 30% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the
applicable purchase date as set forth in the agreement. Under certain circumstances and in accordance with the agreement, the Company
may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company controls
the timing and amount of any sales of its common stock to Lincoln Park. There is no upper limit on the price per share that Lincoln
Park must pay for its common stock under the agreement, but in no event will shares be sold to Lincoln Park on a day the closing
price is less than the floor price specified in the agreement. In all instances, the Company may not sell shares of its common
stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its
common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement does
not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject
to certain exceptions) the Company may not enter into any variable rate transaction (as defined in the agreement, including the
issuance of any floating conversion rate or variable priced equity-like securities) during the 30 months after the date of the
Purchase Agreement. The Company has the right to terminate the agreement at any time, at no cost to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through December 31,
2018, the Company elected to sell to Lincoln Park an additional 1.0 million shares and received $0.7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, the
Company sold an aggregate of 30,237,894 units consisting of an aggregate of 30,237,894 shares of common stock, 7,559,445 series
A warrants and 22,678,393 series B warrants, with each series A warrant exercisable for one share of common stock at an exercise
price of $0.60 per share and each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per
share, resulting in gross proceeds to Actinium of approximately $15.1 million (each unit was sold at $0.50 per unit), and net proceeds
of approximately $13.8 million after deducting expenses relating to dealer-manager fees and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company issued 2,672,973 shares of common stock for gross proceeds of approximately $4.0 million as part
of its At-The-Market sales agreement with an investment bank. The Company paid expenses of approximately $0.2 million resulting
in net proceeds of $3.8 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2017,
the Company completed an underwritten public offering of 21,500,000 shares of its common stock and warrants to purchase 18,275,000
shares of the Company&#8217;s common stock at an offering price to the public of $0.75 per share and related warrant. The warrants
have an exercise price of $1.05 per share and have a term of five years. The gross proceeds from this offering were approximately
$16.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company
resulting in net proceeds of approximately $15.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company issued 67,385 common shares for consulting services. The shares have a total value of $99 thousand
based on the Company&#8217;s stock price on the grant date at $1.47 per share. During the year ended December 31, 2017, the Company
also issued 4,234 common shares for the cashless exercise of warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 4, 2016,
the Company sold 8,000,000 shares of its common stock at a price of $1.25 per share to the public through an underwritten public
offering, for net proceeds of $9.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2016, the Company
also issued 3,500,000 shares of common stock for net proceeds of $6.8 million as part of an at-the-market (ATM) sales agreement
with an investment bank.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company issued 125,862 common shares for the cashless exercise of warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2013 Amended and Restated Stock Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013,
the Board of Directors of the Company approved the Company&#8217;s 2013 Stock Plan. The expiration date of the plan is September
9, 2023 and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors
and consultants of the Company under the plan was 2,750,000 shares. In December 2015, shareholders of the Company approved the
second amendment to the plan and increased the number of shares authorized under the plan to 9,250,000 shares. In December 2016,
shareholders of the Company approved the fifth amendment to the plan and increased the number of shares authorized under the plan
to 12,750,000 shares. In December 2017, shareholders of the Company approved the sixth amendment to the plan and increased the
number of shares authorized under the plan to 17,750,000 shares. In December 2018, shareholders of the Company approved the seventh
amendment to the plan and increased the number of shares authorized under the plan to 22,750,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2013 Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013,
the Board approved the Company&#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September 9, 2023 and the
total number of shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company
under the plan was 450,000 shares. In December 2013, the shareholders of the Company approved the plan and increased the number
of shares authorized under the plan to 1,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restricted Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;During
2018, the Company granted 107,911 restricted common shares for consulting services, which all vested during 2018. The shares
had a total value of $72,825.&#160;During the year ended December 31, 2018, the Company issued 156,393 common shares for
restricted shares that became fully vested, of which 81,393 shares were granted prior to 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2018, the Company has yet to issue 254,819 common shares for restricted shares that have vested. As of December 31, 2018, all
restricted shares granted were vested with no unamortized compensation expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company issued 26,000 common shares for restricted shares that became fully vested. The Company also granted
59,393 common shares for consulting services. The shares have a total value of $65,813 based on the services provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company granted 250,700 shares of restricted common stock to consultants with a fair value of $0.4 million
based on the stock price on the grant dates.&#160;The Company issued common shares totaling 21,000 for restricted shares granted
in 2015 and prior years and 60,700 for restricted shares granted in 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the years ended December 31, 2018, 2017 and 2016, the Company recorded stock-based compensation expense of $0.1 million, $0.2 million
and $0.6 million, respectively, for the restricted shares granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary
of option activities for the years ended December 31, 2018, 2017 and 2016:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number of Options</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted <br /> Average <br /> Exercise <br /> Price</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted <br /> Average <br /> Remaining <br />
    Contractual <br /> Term <br /> (in years)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Aggregate <br /> Intrinsic <br /> Value</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2016</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,971,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,964,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,225,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(266,485</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,212</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,906,886</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,704</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,597,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,329,794</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,174,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,648</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,577,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,515,650</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.96</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,236,101</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.74</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,021,818</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.88</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.55</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2018, the Company granted its employees and members of the Board of Directors 3,577,159 options to purchase Company
common stock with an exercise price ranging from $0.344 to $0.7829 per share, a term of 10 years, and a vesting period from 4 to
4.2 years.&#160;The options have an aggregated fair value of $1.7 million that was calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 2.34% to 2.99% (2) expected
life of 6 years, (3) expected volatility range from 78.8% to 80.4%, and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2017, the Company granted its employees and members of the Board of Directors 2,597,500 options to purchase Company
common stock with an exercise price ranging from $0.57 to $1.58 per share, a term of 10 years, and a vesting period from 4 to 4.2
years.&#160;The options have an aggregated fair value of $2.4 million that was calculated using the Black-Scholes option-pricing
model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 1.84% to 2.28% (2) expected
life of 6 years, (3) expected volatility range from 80.83% to 82.37%, and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2017, a
director, resigned from the Company and the Company entered into an agreement with the director. Pursuant to the agreement, all
the outstanding vested options, (which originally were to expire 90 days from termination date), as well as 68,200 unvested options
granted prior to December 31, 2016, shall be exercisable until the end of the term of each option grant agreement. As a result
of the modification, the Company recorded an additional expense of approximately $174,000 for the incremental fair value of the
options, calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include:
(1) discount rate range from 0.97% to 1.39% (2) expected life of 3 months to 8.9 years, (3) expected volatility range from 45.72%
to 79.81%, and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company granted employees, consultants, and its board members 2,225,000 options to purchase the Company&#8217;s
common stock with exercise prices ranging from $0.95 to $2.25 with a 10-year term vesting over a 4-year period.&#160;&#160;The
options have an aggregated fair value of $3.1 million that was calculated using the Black-Scholes option-pricing model. Variables
used in the Black-Scholes option-pricing model include: (1) discount rate of 1.28% - 1.97% (2) expected life of 6 years, (3) expected
volatility of 81.45% - 87.95%, and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended
December 31, 2018, 2017 and 2016, options to purchase 1,515,650, 3,329,794 and 266,485 common shares were cancelled, respectively,
upon the termination of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no exercises
of options during the years ended December 31, 2018 and 2017. During the year ended December 31, 2016, the Company received gross
proceeds of $18,105 for the exercise of stock options for 23,212 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of
all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense
at December 31, 2018 was approximately $2.6 million. During each of the years ended December 31, 2018, 2017 and 2016, the Company
recorded total option expense of approximately $1.7 million, $3.1 million and $3.6 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary
of warrant activities for the years ended December 31, 2018, 2017 and 2016, respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2016</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,018,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.93</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,199,230</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(183,718</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,964,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,445,786</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,496,575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,364</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,789,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,662,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">995,373</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,360,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,332</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(194,598</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">55,820,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.20</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.04</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">569,038</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">55,613,377</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.03</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">566,676</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2018,
the Company amended certain warrants, originally dated December 17, 2012, that had been issued to three entities affiliated with
the family of the Mr. Sandesh Seth, Chairman and CEO, Amrosan LLC, Carnegie Hill Partners, and Bioche Asset Management, LCC, in
the amount of 375,556, 353,023 and 721,068 shares, respectively and extended their date of expiration from December 17, 2019 to
February 21, 2022. The warrants had originally been issued in 2012 as part of investment banking and advisory services provided
by Mr. Seth. The incremental fair value for the warrants due to the amendment was immaterial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, the
Company sold an aggregate of 30,237,894 units consisting of an aggregate of 30,237,894 shares of common stock, 7,559,445 series
A warrants and 22,678,393 series B warrants, with each series A warrant exercisable for one share of common stock at an exercise
price of $0.60 per share and each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2018, the Company granted 122,628 warrants to consultants. The warrants are exercisable for periods ranging from 4
to 5 years at exercise prices ranging from $0.36 to $0.80 per share. The fair value of the warrants was approximately $27 thousand
at the grant date and was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing
model include (1) discount rate range of 2.34% to 2.99%, (2) expected term of 4-5 years, (3) expected volatility range of 77.01%
to 79.00%, and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2017,
the Company completed an underwritten offering of 21,500,000 shares of its common stock and warrants to purchase an aggregate of
18,275,000 shares of its common stock at a price of $0.75 per share and related warrant. The warrants are exercisable for a period
of 5 years at an exercise price of $1.05 per share. The transaction date relative fair value of the warrants of $4.9 million was
determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing model include (1)
discount rate of 1.83%, (2) expected term of 5 years, (3) expected volatility of 82%, and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain warrants were
issued to the Company&#8217;s Executive Chairman (now Chairman and CEO) as part of investment banking and advisory services either
prior to and outside of his role as a Board Member and subsequently Chairman and CEO. On March 14, 2017, the Company canceled a
warrant to purchase 57,212 shares of common stock of the Company, dated December 19, 2012 and issued a new warrant to its Chairman
and CEO to purchase 57,212 common shares with the term of the warrant expiring on February 11, 2022. The new warrant has the same
exercise price in effect as the exercise price as the old warrant, but the expiration date was modified from December 19, 2017
to February 11, 2022. The Company also amended the warrant to purchase common stock of the Company, dated January 31, 2012, issued
to its Chairman and CEO and an entity affiliated with its Chairman and CEO to purchase 64,746 and 99,617 common shares, respectively.
Pursuant to the terms of the warrant amendments, the term of the warrants was extended to February 11, 2022 from January 31, 2019.
As a result of the replacement and modification, the Company recorded an additional non-cash expense of $64 thousand for the incremental
fair value of the new warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company granted 130,000 warrants to consultants. The warrants are exercisable for periods ranging from 5
to 10 years at exercise prices ranging from $0.98 to $1.77 per share. The fair value of the warrants was approximately $116,000
at the grant date and was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing
model include (1) discount rate range of 1.13% to 1.20%, (2) expected term of 5-10 years, (3) expected volatility range of 79.79%
to 84.84%, and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended
December 31, 2018, 2017 and 2016, the Company recorded stock-based compensation expense related to warrants of $33 thousand, $0.1
million and $0.1 million respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629804784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Note 8  - Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Tax Cuts and
Jobs Act, or the "Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to
21%. As of December 31, 2017, the Company remeasured its existing deferred tax balance by recording a provisional charge of
$17.9 million, which was fully offset by a change in the valuation allowance. As of December 31, 2018, upon completing its
analysis of the Act, the Company believes that the disclosures in its financial statements as of December 31, 2017 are still
accurate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income taxes
reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities
at December 31, 2018 and 2017 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34,531,577</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,826,534</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,950,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,731,413</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,896,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,324,998</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,369</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,394,528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,894,314</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has recorded
a valuation allowance of $46.4 million and $40.9 million against its deferred tax assets at December 31, 2018 and 2017, respectively,
because management determined that it is not more-likely-than not that those assets will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For federal income
tax purposes, the Company has approximately $144.5 million of unused net operating losses ("NOLs") at December 31,
2018 available for carry forward to future years. Prior NOLs have begun to expire as they are unused.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For state income tax
purposes, the Company has approximately $66.8 million of unused NOLs available for carry forward to future years. These NOLs will
begin to expire in 2035 if unused.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has federal
research and development tax credits of approximately $1.4 million at December 31, 2018 which will begin to expire in 2033 if unused
and orphan drug credits of $7.5 million which will begin to expire in 2037 if unused.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Internal
Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and development tax credits could
be limited by any greater than 50% ownership change during any three-year testing period. As a result of any such ownership change,
portions of the Company's net operating loss carryforwards and research and development tax credits are subject to annual
limitations. Accordingly, the Company's ability to utilize these carryforwards may be limited as a result of an ownership
change which may have already happened or may happen in the future. Such an ownership change could result in a limitation in the
use of the net operating losses in future years and possibly a reduction of the net operating losses available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to
pre-tax losses for the year ended December 31, 2018, 2017 and 2016 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -10pt; padding-left: 10pt">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,967,332</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(9,044,420</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(34.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,269,386</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(34.0</td><td style="width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,413,678</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,940,945</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">973,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in federal statutory rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,939,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,090,816</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,511,380</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43.3</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and Development/Orphan Drug Tax Credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,986,609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,029,074</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,769</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Unrealized derivative gain/loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(120,870</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(956,840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.9</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,500,214</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,908,066</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,892,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6808546288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9  - Subsequent Event</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2019, the
Company sold 924,500 common shares through its at-the-market program and realized net proceeds of $0.4 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since December 31,
2018, holders of the Company&#8217;s March 2018 Series A warrants exercised approximately 2.5 million shares, resulting in proceeds
to the Company of $1.5 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since December 31,
2018, the Company granted stock options to its employees to purchase a total of 530,000 common shares at a price range from
$0.43 to $0.58 per share related to new hires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 6, 2019, the Company
executed an amendment to the Company&#8217;s 2013 Amended and Restated Stock Plan, as amended (the &#8220;<u>Plan Amendment</u>&#8221;).
The Plan Amendment increased the number of shares of common stock that the Company is authorized to issue under the plan to 22,750,000
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 6, 2019, the
Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State
of Delaware to increase the number of authorized shares of Actinium&#8217;s common stock from 400,000,000 to 600,000,000 shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SubsequentEventAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SubsequentEventAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825097312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="margin: 0pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nature of Business</b> - Actinium
Pharmaceuticals, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, or &#8220;We&#8221;) is a clinical-stage, biopharmaceutical
company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell therapies such
as a BMT or Bone Marrow Transplant or CAR-T, <font style="background-color: white">a type of cellular therapy that genetically
alters a patient&#8217;s own T cells to target and kill their cancer cells,</font> and for other adoptive cell therapies. In addition,
the Company is also developing potential therapies for targeting and killing of cancer cells either as single agents or in combination
with other drugs.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GoingConcernPolicyTextBlock', window );">Going concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Going concern</b>
- <font style="font: 10pt Times New Roman, Times, Serif">The Company has never generated revenue. Currently
it does not have a recurring source of revenue to cover its operating costs. The Company has incurred net losses and negative
operating cash flows since inception. As of December 31, 2018 and 2017, the Company's accumulated deficit was $186.9 million
and $163.2 million, respectively. The Company's net loss was $23.7 million, $26.6 million, and $24.3 million for the years
ended December 31, 2018, 2017 and 2016, respectively. These conditions raise substantial doubt as to our ability to continue as
a going concern. As of December 31, 2018, in the Company had a balance of its cash and cash equivalents of $13.7 million. The
Company's consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States
of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to
continue as a going concern. As of the date of filing this report, the Company expects that its existing resources will be sufficient
to fund its planned operations into the fourth quarter of 2019; however, additional capital resources will be needed to fund operations
longer-term. If the Company is unsuccessful in accomplishing its plans, it may have to delay or terminate existing and/or planned
clinical trials and other related activity, which could have a material adverse impact on its business. The Company plans to continue
as a going concern include obtaining capital from the sale of its equity securities, potential exercise of outstanding warrants,
fees from licensing one or more of our product candidates, additional collaborations with our Iomab-ACT program and AWE technology
platform, and short-term borrowings from banks, stockholders or other related parties, if needed. However, the Company cannot
provide any assurance that we will be successful in accomplishing any of our plans.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company's ability
to continue as a going concern is dependent upon its ability to successfully accomplish the plans described above and eventually
to secure other sources of financing and attain profitable operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned
subsidiaries. All significant intercompany accounts and transactions have been eliminated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates
in Financial Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash and Cash Equivalents
-</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Property and Equipment
-</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three
to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any
related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease
assets are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated
useful life of the related property or term of the lease.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value of Financial
Instruments</b> <b>- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives
the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable
inputs. As required by ASC 820 &#8220;<i>Fair Value Measurements and Disclosures</i>&#8221;, financial assets and liabilities
are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s
assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation
of fair value assets and liabilities and their placement within the fair value hierarchy levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1 Inputs - Unadjusted quoted
prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2 Inputs - Inputs other
than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might
include quoted prices for similar assets or liabilities&#160;in&#160;active markets, quoted prices for identical or similar assets
or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such
as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated
by market data by correlation or other means.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3 Inputs - Unobservable
inputs for determining the fair values of assets or liabilities that reflect an entity&#8217;s own assumptions about the assumptions
that market participants would use in pricing the assets or liabilities.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><b>Income Taxes -</b> The Company provides
for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based
on the differences between the financial statement carrying amounts of existing assets and liabilities at each year-end and their
respective tax bases, and are measured using enacted tax rates in effect for the year in which the differences are expected to
affect taxable income. Significant judgment is required by management to determine the Company&#8217;s provision for income taxes,
deferred tax assets and liabilities, and the valuation allowance to record against net deferred tax assets, which are based on
complex and evolving tax regulations throughout the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax assets
and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. There were
no tax positions for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly
increase or decrease within the next year. The Company recognizes interest related to unrecognized tax benefits in interest expense
and penalties in operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Tax Cuts and Jobs Act,
or the Act, was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the
Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. As of December
31, 2018, upon completing its analysis of the Act, the Company believes that its disclosures in its financial statements as of
December 31, 2017 remain accurate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition
</b>- The Company adopted new accounting guidance for revenue recognition, effective January 1, 2018, which did not have a significant
impact on the Company&#8217;s financial statements. Beginning January 1, 2018, revenues are recognized when control of the promised
goods or services is transferred to customers in an amount that reflects the consideration expected to be entitled to in exchange
for those goods or services<b>.</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. Research and development reimbursements are recorded by the
Company as a reduction of research and development costs.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments
-</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common
Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average
number of common shares outstanding during the reporting period. For the years ended December 31, 2018, 2017 and 2016, the Company&#8217;s
potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation
of diluted net loss per share as the result would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,236,101</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,174,592</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,906,886</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,820,876</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,662,340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,964,752</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">63,056,977</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">30,836,932</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,871,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Subsequent Events
</b>- The Company's management reviewed all material events through the date the consolidated financial statements were issued
for subsequent event disclosure consideration.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Reclassifications
- </b>Certain reclassifications have been made to the prior-year financial statements to conform to the current-year presentation,
including the addition of restricted cash to cash and cash equivalents on the consolidated statements of cash flows as a result
of the adoption of new accounting guidance.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AccountingPronouncementsRecentlyAdopted', window );">Accounting Standards Recently Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Accounting Standards
Recently Adopted </b>- In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an Accounting Standards
Update (&#8220;ASU&#8221;) amending the presentation of restricted cash within the consolidated statements of cash flows. The new
guidance requires that restricted cash be added to cash and cash equivalents on the consolidated statements of cash flows. The
Company adopted this ASU on January 1, 2018 on a retrospective basis with the impact to its consolidated statements of cash flows
for the year ended December 31, 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Previously Reported</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Adjustment</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As Revised</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in investing activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(380,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">356,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(24,739</td><td style="width: 1%; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was
no impact to the cash flows from operating, investing and financing activities for the year ended December 31, 2016 as the
amount of restricted cash did not change during 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary
of cash and cash equivalents and restricted cash at December 31, 2018, 2017 and 2016, respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,673,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,399,636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,519,294</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,733</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">390,940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Cash and cash equivalent and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,104,514</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,790,576</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,554,027</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB
issued ASU No. 2014-09, <i>Revenue from Contracts with Customers</i>. Under the new standard, revenue is recognized at the time
a good or service is transferred to a customer for the amount of consideration for which the entity expects to be entitled for
that specific good or service. Entities may use a full retrospective approach or report the cumulative effect as of the date of
adoption. The Company adopted this ASU on January 1, 2018 and the adoption did not have a significant impact to the Company&#8217;s
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2017, the FASB
issued ASU No. 2017-11, <i>Earnings Per Share</i> (Topic 260); <i>Distinguishing Liabilities from Equity</i> (Topic 480); <i>Derivatives
and Hedging</i> (Topic 815): (Part I) <i>Accounting for Certain Financial Instruments with Down Round Features.</i> These amendments
simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard
the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability
or equity classification. The guidance was adopted as of April 1, 2018. See Note 2 for further discussion.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>Recent Accounting Standards &#8211;
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016,
FASB issued ASU No. 2016-02 <i>Leases</i> (Topic 842), which creates new accounting and reporting guidelines for leasing
arrangements. The standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A
lessee should recognize on its balance sheet a liability to make lease payments (the lease liability) and a right-of-use
asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a
lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and
lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the
earliest period presented using a modified retrospective approach. The guidance in ASU 2016-02 is effective for annual and
interim reporting periods beginning after December 15, 2018. The Company&#8217;s initial evaluation of its current leases
does not indicate that the adoption of this standard will have a material impact on its consolidated statements of
operations. However, the Company does expect that the adoption of the standard will have an impact on its
consolidated balance sheets for the recognition of certain operating leases as right-of-use assets and lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2018, the FASB
issued ASU 2018-07 to expand the scope of ASC Topic 718, <i>Compensation - Stock Compensation</i>, to include share-based payment
transactions for acquiring goods and services from nonemployees. The standard is effective for fiscal years, and for interim periods
within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating
the impact of the new standard on its financial statements and related disclosures, but does not expect this ASU to have a material
impact on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the
FASB issued ASU 2018-13, <i>Fair Value Measurement - Disclosure Framework (Topic 820).</i> The updated guidance improves the disclosure
requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay
of adoption of the additional disclosures until their effective date. The Company is in the process of evaluating the provisions
of the ASU but does not expect it to have a material effect on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, the
FASB issued ASU 2018-18, C<i>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,</i>
which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be
accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impact
the standard will have on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the
SEC adopted the final rule under SEC Release No. 33-10532, <i>Disclosure Update and Simplification</i>, amending certain disclosure
requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure
requirements on the analysis of stockholders&#8217; equity for interim financial statements. Under the amendments, an analysis
of changes in each caption of stockholders&#8217; equity presented in the balance sheet must be provided in a note or separate
statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which
a statement of comprehensive income is required to be filed. The Company anticipates its first presentation of changes in stockholders&#8217;
equity will be included in its Form 10-Q for the three months ended March 31, 2019.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AccountingPronouncementsRecentlyAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounting pronouncements recently adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AccountingPronouncementsRecentlyAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6611088672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,236,101</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,174,592</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,906,886</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,820,876</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,662,340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,964,752</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">63,056,977</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">30,836,932</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,871,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of impacts to consolidated statements of cash flows</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Previously Reported</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Adjustment</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As Revised</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in investing activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(380,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">356,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(24,739</td><td style="width: 1%; text-align: left">)</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of cash and cash equivalent and restricted cash</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,673,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,399,636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,519,294</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,733</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">391,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">390,940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Cash and cash equivalent and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,104,514</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,790,576</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,554,027</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816354976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative warrant instruments activity</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Derivative liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(15,916</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,154</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(50,238</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,916</td><td style="text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock', window );">Schedule of fair values of derivative warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left">Market value of common stock on measurement date (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.66</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Adjusted exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.09</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant lives in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.1 years</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability of stock offering in any period over 5 years (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Offering price estimated as of December 31, 2017 (6)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(1)</td><td style="text-align: justify">The market value of common stock at the above measurement
dates was based on the Company's closing price quoted on the NYSE American.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(2)</td><td style="text-align: justify">The risk-free interest rate was determined by the Company
using the Treasury Bill rate as of the respective measurement date.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(3)</td><td style="text-align: justify">The volatility was estimated using the historical volatility
of the Company's common stock.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(4)</td><td style="text-align: justify">Management does not expect to pay dividends for the foreseeable
future.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(5)</td><td style="text-align: justify">Management determines the probability of future stock offering
at each evaluation date.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.38in; text-align: left">(6)</td><td style="text-align: justify">Represents the estimated offering price in future offerings
as determined by management.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative warrants on basis of valuation model.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6807644896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">339,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,371</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,997</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,758</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,954</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">439,322</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6632308736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid"><b>Lives</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">176,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116,070</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment &#38; furniture</td><td>&#160;</td>
    <td style="text-align: center">3 - 7 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,940</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(266,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(215,660</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,799</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">57,350</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfDepreciationExpenseTableTextBlock', window );">Schedule of depreciation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December&#160;31,</b></td><td><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2016</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research &#38; development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,170</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,632</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,586</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,891</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50,721</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55,938</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">77,523</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6631160160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum obligations on the lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left">For the year ending December 31:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,896</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431,958</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431,958</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">287,972</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 10pt; text-align: left">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,571,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783141936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option and warrant activities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number of Options</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted <br /> Average <br /> Exercise <br /> Price</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted <br /> Average <br /> Remaining <br />
    Contractual <br /> Term <br /> (in years)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Aggregate <br /> Intrinsic <br /> Value</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2016</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,971,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,964,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,225,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(266,485</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,212</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,906,886</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,704</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,597,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,329,794</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,174,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,648</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,577,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,515,650</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.96</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,236,101</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.74</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,021,818</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.88</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.55</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option and warrant activities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2016</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,018,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.93</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,199,230</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(183,718</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,964,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,445,786</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,496,575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,364</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,789,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,662,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">995,373</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,360,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,332</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(194,598</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">55,820,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.20</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.04</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">569,038</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">55,613,377</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.03</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">566,676</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816473920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td><b></b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2018</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2017</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34,531,577</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,826,534</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,950,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,731,413</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,896,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,324,998</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,369</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,394,528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,894,314</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of difference between income tax provision and U.S federal statutory rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br /> 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -10pt; padding-left: 10pt">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,967,332</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(9,044,420</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(34.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,269,386</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(34.0</td><td style="width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,413,678</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,940,945</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">973,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in federal statutory rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,939,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,090,816</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,511,380</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43.3</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and Development/Orphan Drug Tax Credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,986,609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,029,074</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,769</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Unrealized derivative gain/loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(120,870</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(956,840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.9</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,500,214</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,908,066</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,892,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825279936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">63,056,977<span></span>
</td>
<td class="nump">30,836,932<span></span>
</td>
<td class="nump">14,871,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember', window );">Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,236,101<span></span>
</td>
<td class="nump">5,174,592<span></span>
</td>
<td class="nump">5,906,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">55,820,876<span></span>
</td>
<td class="nump">25,662,340<span></span>
</td>
<td class="nump">8,964,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6808894800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">$ (96,092)<span></span>
</td>
<td class="num">$ (24,739)<span></span>
</td>
<td class="num">$ (109,819)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(380,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6653800160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,673,308<span></span>
</td>
<td class="nump">$ 17,399,636<span></span>
</td>
<td class="nump">$ 20,519,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">40,075<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">391,131<span></span>
</td>
<td class="nump">390,940<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalent and restricted cash</a></td>
<td class="nump">$ 14,104,514<span></span>
</td>
<td class="nump">$ 17,790,576<span></span>
</td>
<td class="nump">$ 20,554,027<span></span>
</td>
<td class="nump">$ 25,678,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825387712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,653,963)<span></span>
</td>
<td class="num">$ (26,601,235)<span></span>
</td>
<td class="num">$ (24,321,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operations</a></td>
<td class="num">(20,571,056)<span></span>
</td>
<td class="num">(21,553,346)<span></span>
</td>
<td class="num">(20,789,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">13,673,308<span></span>
</td>
<td class="nump">17,399,636<span></span>
</td>
<td class="nump">$ 20,519,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (186,857,238)<span></span>
</td>
<td class="num">$ (163,153,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives, description</a></td>
<td class="text">Seven years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property and equipment depreciation method</a></td>
<td class="text">Straight-line basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives, description</a></td>
<td class="text">Three to five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property and equipment depreciation method</a></td>
<td class="text">Straight-line basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825802048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="num">$ (15,916)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">66,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="num">(50,238)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=atnm_TotalstockholdersequityMember', window );">Total stockholders' equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 15,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=atnm_TotalstockholdersequityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=atnm_TotalstockholdersequityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6654038608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Details 1) - Derivative [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MarketValueOfCommonStockOnMeasurementDate', window );">Market value of common stock on measurement date</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Warrant lives in years</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear', window );">Probability of stock offering in any period over 5 years</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionOfferingPrice', window );">Offering price estimated as of December 31, 2017</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The market value of common stock at the above measurement dates was based on the Company's closing price quoted on the NYSE AMERICAN.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by the Company using the Treasury Bill rate as of the respective measurement date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The volatility was estimated using the historical volatility of the Company's common stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Management does not expect to pay dividends for the foreseeable future.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Management determines the probability of future stock offering at each evaluation date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Represents the estimated offering price in future offerings as determined by management.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumption offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_FairValueAssumptionOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MarketValueOfCommonStockOnMeasurementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market value of common stock on measurement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MarketValueOfCommonStockOnMeasurementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent probability of stock offering in any period over five years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ProbabilityOfStockOfferingInAnyPeriodOverYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825692384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeLiabilitiesTextualAbstract', window );"><strong>Derivative Liabilities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeLiabilitiesTextualAbstract', window );"><strong>Derivative Liabilities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Original exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member', window );">Adoption of ASU 2017-11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeLiabilitiesTextualAbstract', window );"><strong>Derivative Liabilities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Original exercise price</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeLiabilitiesTextualAbstract', window );"><strong>Derivative Liabilities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Original exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeLiabilitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DerivativeLiabilitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630248176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 339,336<span></span>
</td>
<td class="nump">$ 72,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PrepaidClinicalTrialExpenses', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">171,128<span></span>
</td>
<td class="nump">226,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">105,758<span></span>
</td>
<td class="nump">139,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 616,222<span></span>
</td>
<td class="nump">$ 439,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PrepaidClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PrepaidClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6632308736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract', window );"><strong>Prepaid Expenses and Other Current Assets (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Prepaid insurance financed by issuance of note payable</a></td>
<td class="nump">$ 249,239<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PrepaidExpensesAndOtherCurrentAssetsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813851280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (266,381)<span></span>
</td>
<td class="num">$ (215,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 118,799<span></span>
</td>
<td class="nump">57,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atnm_LabEquipmentMember', window );">Lab equipment Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 176,500<span></span>
</td>
<td class="nump">116,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment &amp; furniture Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 208,680<span></span>
</td>
<td class="nump">$ 156,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment &amp; furniture Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment &amp; furniture Member | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atnm_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=atnm_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6758254784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 50,721<span></span>
</td>
<td class="nump">$ 55,938<span></span>
</td>
<td class="nump">$ 77,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research &amp; development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">20,170<span></span>
</td>
<td class="nump">20,352<span></span>
</td>
<td class="nump">41,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 30,551<span></span>
</td>
<td class="nump">$ 35,586<span></span>
</td>
<td class="nump">$ 35,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630448416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PropertyAndEquipmentDetailsTextualAbstract', window );"><strong>Property And Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CapitalLeaseAgreement', window );">Capital lease agreement</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OfficeEquipmentServices', window );">Office equipment and services</a></td>
<td class="nump">$ 906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CapitalleaseOfOfficeEquipment', window );">Capitalized value of lease agreement</a></td>
<td class="nump">$ 16,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CapitalLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CapitalLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CapitalleaseOfOfficeEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitallease of office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CapitalleaseOfOfficeEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OfficeEquipmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office equipment and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OfficeEquipmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PropertyAndEquipmentDetailsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PropertyAndEquipmentDetailsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816318512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>For the year ending December 31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 419,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">431,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">431,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">287,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,571,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826198160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 19, 2018</div></th>
<th class="th"><div>Aug. 04, 2016</div></th>
<th class="th"><div>Jun. 15, 2012</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 16, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCosts', window );">Cost of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease agreements, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease is for 5,790 square feet and has a term of seven years and three months, with an expiration date of September 6, 2022, with a current annual rate of $312,660 until June 8, 2019 and $341,610 for the remaining life of the lease.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Deposits', window );">Certified deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent for office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CapitalleaseOfOfficeEquipment', window );">Capital lease of office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CapitalLeaseAgreement', window );">Capital lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OfficeEquipmentServices', window );">Office equipment services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember', window );">Oak Ridge National Laboratory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PurchaseOfMaterials', window );">Purchase of materials</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_MedpaceIncMember', window );">Medpace Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentInProcess', window );">Total project estimated to cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProjectRemainingCost', window );">Project remaining cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_GeorgeClinicalMember', window );">George Clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProjectEstimatedCost', window );">Project estimated cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProjectRemainingCost', window );">Project remaining cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember', window );">License and Sponsored Research Agreement [Member] | Fred Hutchinson Cancer Research Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_GoodwinMember', window );">Goodwin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProjectRemainingCost', window );">Project remaining cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CapitalLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CapitalLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CapitalleaseOfOfficeEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitallease of office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CapitalleaseOfOfficeEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of royalty payment to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfRoyaltyPaymentToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongTermPurchaseCommitmentMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term purchase commitment milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongTermPurchaseCommitmentMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OfficeEquipmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office equipment and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OfficeEquipmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProjectEstimatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project estimated cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ProjectEstimatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProjectRemainingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project remaining cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ProjectRemainingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PurchaseOfMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of materials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PurchaseOfMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of expenditures for a real estate project that has not yet been completed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_MedpaceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_MedpaceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_GeorgeClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_GeorgeClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_FredHutchinsonCancerResearchCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_FredHutchinsonCancerResearchCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_GoodwinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_GoodwinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825839616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning</a></td>
<td class="nump">5,174,592<span></span>
</td>
<td class="nump">5,906,886<span></span>
</td>
<td class="nump">3,971,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,577,159<span></span>
</td>
<td class="nump">2,597,500<span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="num">(1,515,650)<span></span>
</td>
<td class="num">(3,329,794)<span></span>
</td>
<td class="num">(266,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending</a></td>
<td class="nump">7,236,101<span></span>
</td>
<td class="nump">5,174,592<span></span>
</td>
<td class="nump">5,906,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">3,021,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning</a></td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="nump">$ 4.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.69<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">2.96<span></span>
</td>
<td class="nump">2.85<span></span>
</td>
<td class="nump">2.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending</a></td>
<td class="nump">1.74<span></span>
</td>
<td class="nump">2.83<span></span>
</td>
<td class="nump">3.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning</a></td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">7 years 10 months 25 days<span></span>
</td>
<td class="text">8 years 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Ending</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">7 years 10 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Beginning</a></td>
<td class="nump">$ 2,648<span></span>
</td>
<td class="nump">$ 51,704<span></span>
</td>
<td class="nump">$ 2,964,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Ending</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">51,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825975072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 1) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning</a></td>
<td class="nump">25,662,340<span></span>
</td>
<td class="nump">8,964,752<span></span>
</td>
<td class="nump">9,018,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">30,360,466<span></span>
</td>
<td class="nump">18,496,575<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(7,332)<span></span>
</td>
<td class="num">(9,364)<span></span>
</td>
<td class="num">(183,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="num">(194,598)<span></span>
</td>
<td class="num">(1,789,623)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending</a></td>
<td class="nump">55,820,876<span></span>
</td>
<td class="nump">25,662,340<span></span>
</td>
<td class="nump">8,964,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">55,613,377<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.67<span></span>
</td>
<td class="nump">1.05<span></span>
</td>
<td class="nump">0.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.66<span></span>
</td>
<td class="nump">0.78<span></span>
</td>
<td class="nump">0.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">9.00<span></span>
</td>
<td class="nump">2.22<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">1.89<span></span>
</td>
<td class="nump">3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning</a></td>
<td class="text">3 years 7 months 13 days<span></span>
</td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Ending</a></td>
<td class="text">2 years 15 days<span></span>
</td>
<td class="text">3 years 7 months 13 days<span></span>
</td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">2 years 11 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Beginning</a></td>
<td class="nump">$ 995,373<span></span>
</td>
<td class="nump">$ 1,445,786<span></span>
</td>
<td class="nump">$ 10,199,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Ending</a></td>
<td class="nump">569,038<span></span>
</td>
<td class="nump">995,373<span></span>
</td>
<td class="nump">1,445,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable</a></td>
<td class="nump">$ 566,676<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6945092768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2017</div></th>
<th class="th"><div>Oct. 04, 2016</div></th>
<th class="th"><div>Dec. 19, 2012</div></th>
<th class="th"><div>Oct. 18, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Aug. 02, 2017</div></th>
<th class="th"><div>Jun. 06, 2017</div></th>
<th class="th"><div>Mar. 14, 2017</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Jan. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Nov. 08, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds on exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EmployeeOptionToPurchaseShare', window );">Employees options to purchase granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AdditionalNoncashExpenseIncrementalFairValue', window );">Additional non-cash expense incremental fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares of restricted stock, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option/restricted shares canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,329,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RestrictedCommonSharesGranted', window );">Restricted common shares granted vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RestrictedCommonSharesGrantedValue', window );">Restricted common shares granted, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RestrictedCommonSharesGrantedFullyVested', window );">Restricted common shares granted fully vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RestrictedCommonSharesGrantedFullyVestedValue', window );">Restricted common shares granted fully vested, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued', window );">Restricted stock granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Total option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option/restricted shares canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,515,650<span></span>
</td>
<td class="nump">3,329,794<span></span>
</td>
<td class="nump">266,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option/warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,159<span></span>
</td>
<td class="nump">2,597,500<span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Total option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Director left - option extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the agreement, all the outstanding vested options, (which originally were to expire 90 days from termination date), as well as 68,200 unvested options granted prior to December 31, 2016, shall be exercisable until the end of the term of each option grant agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember', window );">Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atnm_TwoThousandThirteenStockPlanMember', window );">2013 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,750,000<span></span>
</td>
<td class="nump">17,750,000<span></span>
</td>
<td class="nump">12,750,000<span></span>
</td>
<td class="nump">9,250,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atnm_TwoThousandThirteenStockPlanMember', window );">2013 Stock Plan [Member] | Employees, directors and consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option/warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Plan expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  09,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atnm_TwoThousandThirteenEquityIncentivePlanMember', window );">Employees, directors and consultants [Member] | Employees, directors and consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option/warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Plan expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  09,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockRepurchasedDuringPeriodSharesAdditional', window );">Additional shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockRepurchasedDuringPeriodValueAdditional', window );">Additional shares of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfMarketPrice', window );">Fair value of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.28%<span></span>
</td>
<td class="nump">2.28%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.40%<span></span>
</td>
<td class="nump">82.37%<span></span>
</td>
<td class="nump">81.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7829<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionsExpectedDiscountRate', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0299<span></span>
</td>
<td class="nump">0.0228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">1.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.80%<span></span>
</td>
<td class="nump">80.83%<span></span>
</td>
<td class="nump">87.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.344<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionsExpectedDiscountRate', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0234<span></span>
</td>
<td class="nump">0.0184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="nump">18,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds of public offering</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from common stock issued</a></td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Warrants, vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Underwrittenoffering', window );">Underwritten offering common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="nump">18,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberofWarrentIssued', window );">Number of warrant granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsToPurchaseOfCommonStock', window );">Number of warrants issued to consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option/restricted shares canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,598<span></span>
</td>
<td class="nump">1,789,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option/warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,360,466<span></span>
</td>
<td class="nump">18,496,575<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,332<span></span>
</td>
<td class="nump">9,364<span></span>
</td>
<td class="nump">183,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberofWarrentIssued', window );">Number of warrant granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,565,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Options to purchase common shares, cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Total option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option/restricted shares canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,515,650<span></span>
</td>
<td class="nump">3,329,794<span></span>
</td>
<td class="nump">266,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option/warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,159<span></span>
</td>
<td class="nump">2,597,500<span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_LincolnParkCapitalFundLlcMember', window );">Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockRepurchasedDuringPeriodSharesAdditional', window );">Additional shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockRepurchasedDuringPeriodValueAdditional', window );">Additional shares of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchased shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,376,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchased value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase of shares (will not exceed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AcceleratedPurchaseDescription', window );">Accelerated purchase, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the total number of shares of the Company's common stock traded during a specified period on the applicable purchase date as set forth in the agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Maximum beneficially owning, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Received amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sales of aggregate of commonstock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares for consulting services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common shares for consulting services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_ConsultantsMember', window );">Consultants [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares for consulting services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common shares for consulting services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,393<span></span>
</td>
<td class="nump">250,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock granted value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option/restricted shares canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesAWarrantsMember', window );">Series A warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsExercisablePeriod', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Description of warrant exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each series A warrant exercisable for one share of common stock at an exercise price of $0.60 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate series warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,559,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesBWarrantsMember', window );">Series B warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsExercisablePeriod', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Description of warrant exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each series B warrant exercisable for one share of common stock at an exercise price of $0.70 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GrossProceedsFromWarrantExercises', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate series warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,678,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Underwrittenoffering', window );">Underwritten offering common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Gross proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Mr. Sandesh Seth [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
<td class="nump">1.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsToExercisableTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Fair value assumptions, expected discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember', window );">Warrants [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option/warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,628<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sales of aggregate of commonstock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,237,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,237,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672,973<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockForIssuedCashlessExerciseOfWarrants', window );">Common shares issued for cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,234<span></span>
</td>
<td class="nump">125,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AcceleratedPurchaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description accelerated purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AcceleratedPurchaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AdditionalNoncashExpenseIncrementalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional non cash expense incremental fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AdditionalNoncashExpenseIncrementalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockForIssuedCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued for cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CommonStockForIssuedCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EmployeeOptionToPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent employees options to purchase granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EmployeeOptionToPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity textual abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionsExpectedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_FairValueAssumptionsExpectedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of market price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_FairValueOfMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrossProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrossProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberofWarrentIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberofWarrentIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RestrictedCommonSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted common shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RestrictedCommonSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RestrictedCommonSharesGrantedFullyVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted common shares granted fully vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RestrictedCommonSharesGrantedFullyVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RestrictedCommonSharesGrantedFullyVestedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted common shares granted fully vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RestrictedCommonSharesGrantedFullyVestedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RestrictedCommonSharesGrantedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted common shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RestrictedCommonSharesGrantedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockIssuedDuringPeriodRestrictedStockAwardNotIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockRepurchasedDuringPeriodSharesAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock repurchased during period shares additional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockRepurchasedDuringPeriodSharesAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockRepurchasedDuringPeriodValueAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock repurchased during period value additional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockRepurchasedDuringPeriodValueAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_Underwrittenoffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwritten offering common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_Underwrittenoffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantsExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsToExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantsToExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued to purchase of common stock to consultants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantsToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased on the open market during the period for issuance to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atnm_TwoThousandThirteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atnm_TwoThousandThirteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=atnm_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=atnm_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atnm_TwoThousandThirteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atnm_TwoThousandThirteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atnm_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atnm_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=atnm_MrSandeshSethMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=atnm_MrSandeshSethMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816373504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses carry forward</a></td>
<td class="nump">$ 34,531,577<span></span>
</td>
<td class="nump">$ 30,826,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,950,963<span></span>
</td>
<td class="nump">3,731,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IncomeTaxReconciliationResearchAndDevelopment', window );">Research and development/orphan drug credits</a></td>
<td class="nump">8,896,703<span></span>
</td>
<td class="nump">6,324,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">15,285<span></span>
</td>
<td class="nump">11,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(46,394,528)<span></span>
</td>
<td class="num">(40,894,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncomeTaxReconciliationResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncomeTaxReconciliationResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815094592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income taxes</a></td>
<td class="num">$ (4,967,332)<span></span>
</td>
<td class="num">$ (9,044,420)<span></span>
</td>
<td class="num">$ (8,269,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income taxes, percentage</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">$ 1,413,678<span></span>
</td>
<td class="num">$ (1,940,945)<span></span>
</td>
<td class="num">$ (973,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Change in Federal statutory rate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,939,714<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Change in Federal statutory rate, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">67.40%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IncomeTaxReconciliationDeferredTrueUp', window );">Deferred true-up</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,090,816<span></span>
</td>
<td class="num">$ (10,511,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps', window );">Deferred true-up, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
<td class="num">(43.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and Development/Orphan Drug Tax Credit</a></td>
<td class="num">$ (1,986,609)<span></span>
</td>
<td class="num">$ (3,029,074)<span></span>
</td>
<td class="num">$ (141,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and Development/Orphan Drug Tax Credit, percentage</a></td>
<td class="num">(8.40%)<span></span>
</td>
<td class="num">(11.40%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Unrealized derivative gain/loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (120,870)<span></span>
</td>
<td class="num">$ (956,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Unrealized derivative gain/loss, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">$ 40,049<span></span>
</td>
<td class="nump">$ 12,845<span></span>
</td>
<td class="nump">$ 13,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other, percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 5,500,214<span></span>
</td>
<td class="num">$ (6,908,066)<span></span>
</td>
<td class="nump">$ 18,892,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, percentage</a></td>
<td class="nump">23.20%<span></span>
</td>
<td class="num">(26.00%)<span></span>
</td>
<td class="nump">77.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income tax, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncomeTaxReconciliationDeferredTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncomeTaxReconciliationDeferredTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6825821184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss expiration date</a></td>
<td class="text">Dec. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 46,394,528<span></span>
</td>
<td class="nump">$ 40,894,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease related to tax cuts and jobs act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal', window );">State income tax purposes, net operating losses</a></td>
<td class="nump">144,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesForeign', window );">Federal income tax purposes, net operating losses</a></td>
<td class="nump">66,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss expiration date</a></td>
<td class="text">Dec. 31,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=atnm_OrphanDrugCreditsMember', window );">Orphan Drug Credits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss expiration date</a></td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in foreign income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=atnm_OrphanDrugCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=atnm_OrphanDrugCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815212624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Realized net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,976,237<span></span>
</td>
<td class="nump">$ 18,789,634<span></span>
</td>
<td class="nump">$ 16,022,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ExercisedSeriesWarrantsIssuedForThePeriod', window );">Series A warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds series A warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EmployeeOptionToPurchaseShares', window );">Employees options to purchase granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Common shares price range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Common shares price range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Realized net proceeds, shares</a></td>
<td class="nump">924,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Realized net proceeds</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Plan Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member] | Delaware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum [Member] | Delaware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EmployeeOptionToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EmployeeOptionToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ExercisedSeriesWarrantsIssuedForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ExercisedSeriesWarrantsIssuedForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_ThePlanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_ThePlanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_DelawareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_DelawareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " !$B&].+KT$L^X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/2L0P$(=?17)O)]FRBJ';B^))07!!\1:2V=U@\X=DI-VW-ZV[
M740?P&-F?OGF&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E<EX0OS5U(
M3E%YICU$I3_4'F'%^34X)&44*9B 55R(K&N-ECJAHI!.>*,7?/Q,_0PS&K!'
MAYXRB%H ZZ:)\3CV+5P $XPPN?Q=0+,0Y^J?V+D#[)0<LUU2PS#40S/GR@X"
MWIX>7^9U*^LS*:^Q_,I6TC'BAITGOS9W]]L'UJVXN*UX4XGU5MQ(+B1?OT^N
M/_PNPBX8N[/_V/@LV+7PZRZZ+U!+ P04    " !$B&].F5R<(Q &  "<)P
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M*Q*98T]KKK^]_9D+V@Q1)$J#W_MKU>KKM;^3H,'F-H2#(1P-07S7$ V&R#"
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ML_^M>"L.4=Y&$GT\E8>Z^SMY>JV;\MBW$D,YYM\NG_M3]_E^^8_'WDPVP-X
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MDD]UW87(4GR)_':AV)YORO#4]9<N7C>GP]W335<?QX/KY'QZOOX?4$L#!!0
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MN5Q;G9)(O5;5)FW2J=.VSUSB)*B ,R"7[M\/2)IE6[0O@(W?\[,Q^8CFU78
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MP[,=QVPTO.FF'\3F;US\ E!+ P04    " !$B&].7&329;,!  #2 P  &0
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M*D4CH-6-;)&",L4/F\-Q[_ >\-; H!=[Y#HY2_GA@N]%BB-7$'#(C5-@=KG
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M>VOW:GK+DV%D/X\I6?X5^5]02P,$%     @ 1(AO3@T,8)NU 0  T@,  !D
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M-G%[/8WC9%C5SR\-69Z[XB]02P,$%     @ 1(AO3LT:)2C! 0  -P0  !D
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M[_DS[Y:XT(^",)E;9\$E'H[C-PJ/K7G'2^?@&\<NL0HDGW=.=4_K!?4^]F[
MW!4;QM"+HQER:T'"$&-UY[V9?Q9DG. @"N$L?3!I-37E9]/&A9.S2R/UC9U$
MQZ?B$>I6-8MO]!-B6MBK3/_^_"#\7#;".3"I&J%I5R?&)%5Y>@_J=!?JR1L7
M%3U)/8W4G/=]OU](U@YO&A@?UNP_4$L#!!0    ( $2(;TX>H$A3'@(  /8%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(U4T8Z;,!#\%<1[SV (
MA(@@71)5K=1*IZO:/CMD$]#9F-I.N/Y];4,X$MQK7V+O,C,[Z]B;=UR\R I
M>:^,-G+M5TJU*X1D60$C\H&WT.@O1RX843H4)R1; >1@28PB' 0)8J1N_"*W
MN2=1Y/RL:-W D_#DF3$B?F^ \F[MA_XU\5R?*F42J,A;<H)OH+ZW3T)':%0Y
MU P:6?/&$W!<^X_A:I<:O 7\J*&3D[UG.MES_F*"SX>U'QA#0*%41H'HY0);
MH-0(:1N_!DU_+&F(T_U5_:/M7?>R)Q*VG/ZL#ZI:^TO?.\"1G*EZYMTG&/I9
M^-[0_!>X -5PXT37*#F5]M<KSU)Q-JAH*XR\]FO=V+4;]*\T-P$/!#P2PN1=
M0C00HC="_"XA'@CQ'0'UK=BSV1%%BESPSA/]O]L2<XG"5:Q/OS1)>]CVFSX>
MJ;.7 D=ICBY&:,!L>@R>8,(1@;3Z6 *[2FSPC(YO"VSGB"B[A>SFD#1UFXB<
M?4:6']_TN;SKL\<L+*:QF ]9$F3W;ATP'*<SQPY8&&3+,'/;CIVV8X?MOP@L
MG *+?_>][3')U&FT#+(X<1=*G(62>:$X< ND3H'T/YRFLS.-%@D.[F\"FMQ^
M!N)D)XOT2GYNE+E$D^PXO!ZQ>3UW^8T>:OT,>I/I)^)7(DYU([T]5_IMVA=T
MY%R!=AD\:(.5'L)C0.&HS#;5>]&/HCY0O!VF+!I'??$'4$L#!!0    ( $2(
M;TZ4IB*62@(  /$&   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(U5
MT9*;(!3]%<</6%% XXYQILENIYUI9S+;:?M,$A*=1;% XO;O"VBL0=K9E\#%
M<\X]]T*@Z+EXE16E*GAK6"O78:54]QA%\E#1AL@'WM%6?SEQT1"E0W&.9"<H
M.5I2PZ($@#1J2-V&96'7=J(L^$6QNJ4[$<A+TQ#Q>T,9[]=A'-X67NISI<Q"
M5!8=.=-O5'WO=D)'T:1RK!O:RIJW@:"G=?@A?GQ.#=X"?M2TE[-Y8"K9<_YJ
M@L_'=0B,(<KH01D%HH<KW5+&C)"V\6O4#*>4ACB?W]0_VMIU+7LBZ9:SG_51
M5>MP%09'>B(7IEYX_XF.]> P&(O_0J^4:;AQHG,<.)/V-SA<I.+-J**M-.1M
M&.O6COVH?Z/Y"<E(2"9"C/Y+@",!OI> 1@)Z+P&/!.P0HJ%VV\PGHDA9"-X'
M8C@.'3&G+G[$>KL.9M'NCOVF^RGUZK5,4%Q$5R,T8C8#)IEC[A';)0+F]Y"G
M)23+[B'/GCSH;Z9(US$5DWB+2:P G G$*/,+0*\ M )H)K!HQ@#!%M(..6":
M00A63D\\P SF>0I3IS-+8 )PG"<Y\EM'7NMH:=W9I<T 26>)$  9=GQ[A*#C
M>"D$D6Z!WR[VVL6++(F;9H.7:?(XALZ.;'TPD"/@F%YF1/]PG'H=IQ['R'&<
M+O<<Q0#AV %N/< LRP'.W,.Q!.K#@1%(W#^/!XC3;*4?#*?(:'8UF,?@*Q'G
MNI7!GBM]R]B[X,2YHEH4/&B]2K\_4\#H29EIIN=BN(6'0/%N?&"BZ94K_P!0
M2P,$%     @ 1(AO3O[ARZ@- P  +PP  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&ULE5=1;YLP$/XKB/<5;&,;JB12DVC:I$VJ.G5[=A,G007,L)-T
M_W[&4):8HVM? C;????=X3LNL[-JGO5!2A.\E$6EY^'!F/HVBO3F($NA;U0M
M*_MDIYI2&+ML]I&N&RFVSJ@L(AS'+"I%7H6+F=N[;Q8S=31%7LG[)M#'LA3-
MGZ4LU'D>HO!UXR'?'TR[$2UFM=C+'](\UO>-744#RS8O9:5S506-W,W#.W2[
MQK@U<(B?N3SKB_N@#>5)J>=V\74[#^-6D2SDQK04PEY.<B6+HF6R.G[WI.'@
MLS6\O']E_^R"M\$\"2U7JOB5;\UA'J9AL)4[<2S,@SI_D7U - SZZ+_)DRPL
MO%5B?6Q4H=UOL#EJH\J>Q4HIQ4MWS2MW/??\KV:P >X-\&" WS8@O0$9#%#R
MID'2&R2>0=2%XG*S%D8L9HTZ!TWW>FO1GB)TF]CL;]I-EVSWS*9'V]W3 B=T
M%IU:HAZS[##X H,&1&39!Q<8<K'$(W-\[6 U1I#L&K(>0SB'11 P3N+LR56<
M#"9(0(+$$217!-Q+%(1)O5@AC!_LVY@KL1042T<$J>=CV4&H@U0.\@D31DG&
MB*<80C(6(TR\@[*&D G!B.,$5L] ]6P</HT]^1V&7;F**4<Q99Y\"(DH)23Q
MD&N0DZ<9)A-'C8/R^4A^@CSU?.0)$<8)B?W3 @ YR>P[\K7S4>IM.E"&LXG,
MIZ#T="2=>;6Z3,?O&*4LI1P37SP$9011$D\E- -59<!YF.A *(:[7/S^\D<3
MC1+]OP&L(!#%$W[ ;GF',$!!)BC@7H<^T.P0W.W0.]K="@2E$W[@1H7&G0K3
MB2.+X&Z!V >BA2L6C4L6T]%7$ )-^8'+"XWK"U/_(P*"IK(*%PR"*F;B X+A
MBL$?J!@,5PR&BL'/*@1B\80?N&(P5#%^5D&0G]7H8FHJ9;-W$ZD.-NI8F7;X
MN-@=IMX[-_1Z^TL[#7>SZS^:;I3^+II]7NG@21D[T[G):Z>4D59C?&.+X6"G
M]V%1R)UI;[F];[H1MEL85??C>33\1UC\!5!+ P04    " !$B&].OOG*PMT!
M   1!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R%5-&.G" 4_17#
M^RZ*(V,GCDEGFZ9-VF2R3=MG1J^C61 +S+C]^P*ZQG9HYD6XEW//.1>$8I3J
M1;< )GH5O-=[U!HS[##650N"Z4<Y0&]7&JD$,S949ZP'!:SV18)C$L<4"];U
MJ"Q\[JC*0EX,[WHXJDA?A&#J]P&X'/<H06^)Y^[<&I? 93&P,WP#\WTX*AOA
MA:7N!/2ZDWVDH-FC]\GND#N\!_SH8-2K>>0Z.4GYXH+/]1[%SA!PJ(QC8':X
MPA-P[HBLC5\S)UHD7>%Z_L;^T?=N>SDQ#4^2_^QJT^Y1CJ(:&G;AYEF.GV#N
M)T/1W/P7N *W<.?$:E22:_^-JHLV4LPLUHI@K]/8]7X<IY64SF7A C(7D*6
M3+U,0M[Y!V9862@Y1FK:^X&Y(TYVQ.Y-Y9)^*_R:-:]M]EH2FA3XZHAFS&'"
MD+\P9,%@R[^(D* (\02;%4&6_J,Q03(/Z3WD(<G>)30LDP9ETAL90M,PP29(
ML+GO<X+0E4]*DVP35LF"*EG YG\(:)" WK=);VP^9#%)\[#,-BBS#?C,P@1Y
MD""_[S._.?;0J>/5W^P>BZ],G;M>1R=I[,7POV\CI0'+&#]:LM:^3TO H3%N
MNK5S-=W2*3!RF!\@O+R"Y1]02P,$%     @ 1(AO3@5P*;31 @  '@L  !D
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MD"7QLB!,ZI6+,!D64D(A)2#(/2$(4^ D%":A@*#TDB ,]:I%F H+J:"0ZIZ
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M/X9[.>=P#H9BT.;-=@ .?4BA;(D[Y_H-(;;N0#)[IWM0?J751C+G2W,@MC?
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M(3XL* (%18"@2:)-=),(H21.TXF>#D9&L"@.HADU!%1# #48)HA!@OC^#Y2
M! F@()CX 6%".$D*)DD!@FB2)+TU/2:1/_E9MNF-Z0@1/YYQ'?EP;_J (#)#
M,=/>Z'[G$=B^:X3OL*4'C7W!?D*2J2\ 3O=&&LX9 _<["@!)\0P%W/$H_( Q
M<(\BJ$FG/R4(2F;RP-V'H/:;DPKW'_I  R*X ]$]+0B!\/3;>J.SJ6;B9(]Q
MZ>3\W-@[Q&AWN"JLL3W;WN#=/>,'%:>RD<Z>*WU"VG/LR+EB6HO_H)TO]-5F
M6%3LJ,PTUG/1G>_=0O&VO[MXPP5J]0]02P,$%     @ 1(AO3DY$ V0V @
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M\8B0K#I@1-[Q$0:]TG#!B-*A:)$<!9#:%C&*<!1EB)%^",O<YLZBS/FD:#_
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M_3MV?]'(K?[_P#O^B;'X!U!+ P04    " !$B&].9?E"W] #   B$0  &0
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M CXHA.(KQA=$H[W[F= 'NH>%DDF@<!7%R>P/IN#:D!5S4L"H9&&)$+SS$_9
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M?(>)QTH81S-2*2B5 E+6![!*)U)QG,XH9:!2!BB%L /DP]W !UQ@NQWXTT>
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M\ES!=29*8RWRIOUWUH=&BJ)G4:D4Z7MWS<KV>NJ>,-J'X0'0!\ 00"X'!'U
M\!G +@:$?4#X&1!>#*!] /UJ .L#F!'@=8/5COY]*M/EO!8GI^XF4)7J>4IF
M3+W?M>YL7V?[3+V 1O4>ES2.Y]Y1$_68NPX#(TPRQJQL#!D0GLI@2 .P-.[
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MU'W=G1:ZAA15?Q+RAN/8\C]02P,$%     @ 1(AO3I\P/\TV30  YS ! !0
M  !X;"]S:&%R9613=')I;F=S+GAM;.U]:7/;2);@Y\&OR*B5IZ4(B(6#),BJ
MGHJ09;G*/;["LJ>CHV,_0"0D88HDV !H61W[X_<=>0&9("G;/3&SVQ^J3)%
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M_)PW]T3:%OBA^-NN_)ROX'D':A\*(&+E M=%CYZ+!8_<>Q 9Q4_-%@C9O_T
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M' PDAB.(TW":I6$:S?"/+$SG<\"G*?P!2#F)YV$R'P?] .-__5^S)(Y_UN'
M8XQPG,"=2O$\T\'G46DGS5JD\SB,TQC^1;R(Q/G@(KVP.D'4CR.X5/&8UYW!
M0)-,K7LR#J,D0W??&U#G 71CIDHO+ZZ?!S+Z\N+ZDWA;C>C7\V@>:CI"6 9:
M"1G#I2YZ"<@/G!_T11CS3[O5HV4\'1@T.X_A(*[R>D,**)(3HB.H,B#.[J3V
M9T=:TM0R",A$_K)0\5NQO&-WFK[#B-R7H-CD'17)5EYH\2]02OI0H07E94&V
M]P;IXZ+HVN<U15#G!6H0O'!3[]"N3_@7X%Z%N]?I>92 ")BCD9H M"DD_OH
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M *I\**04P0,:2%1=Q,.TF9T,C9)D/W".:ZT7VC$9D@0 R'Y7%[P+(A,R3#O
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MY'HPSYSE+WA@4SQ0ACC'_;/.H684I%2_X-/I77W'R>I>??N<U+*79JV<2 <
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MBX$7I-:6/>)OB0/()&T9YH;%!^SW.0-XP?),]4 &",JIIOW-1_/Y,[F.H!-
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M$)>J-A[&\OUV2_S:5(9BP-I5T$;4<)I$G%Y/WC]T*JRP!D$1+4W16PT6/[$
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MS+/@4HOLMUY8@_1Q#B,!TY^G\S #>66: 4U^QM];HDN]*\YW6_EX&D98YAC
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M<G%G(\X>\VC9*7DD:WHK.ZZ*>L"SHV()Y)GZVPY$G)6R[&$5-ZO^WT=# ?_
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M+>9K'7]NZ:N.X\^][-_D U05I/8-^W1WH!AR![JRV5=[!L53/(.'2/LQ8M9
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MG0A_IUVF@T.C9.80Z]CWY<%Y.ATTW9EFT6CL\H59,DHS]]MX-)XXWZHHA>2
M$N*0V:,A?Y#LSH[5%^-1ZL9G9//1+';#K'KNA"=C0(R]2=TOYRY<L]EHYCF#
M"%N'.]]B<LHQBST(M%3"RA44/$L<3T99XGS[?G>S A58N[0'"6FO/\FV^Y['
MI&BYR#W6,4NCZ81G<"F5(<0[)$E\P@(G#W79 K,V>]JKR6@&H3*W!H0AY\%&
MF.;L%C4=TJZL<SWDA?*]<L S]LZC4O4:62^&[%,#5K3#ZTQ&<_=Z#(]V8 M
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M?>W2?2F)<@_DYGZ%.3;'V.2[><!/")RTLG1]FL+^I%TO&_)DZGIXRM%)NHZ
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MY=B7W:H;S=KO8:&/W8?&R]]02P,$%     @ 1(AO3CZQ;16U 0  EAH  !H
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MG3_O?O.>I_Y&N(O74*\_4$L#!!0    ( $2(;T[,+=9/L@$  ,D:   3
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M     %]R96QS+RYR96QS4$L! A0#%     @ 1(AO3B?HAPZ"    L0   !
M             ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !$
MB&].+KT$L^X    K @  $0              @ &9 0  9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !$B&].F5R<(Q &  "<)P  $P
M@ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $2(;T[\D&/L
MTP(  )D+   8              "  ?<(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !$B&].YOU(+:(#  "H#P  &
M@ $ #   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 1(AO
M3N5^A;I> @  2 @  !@              ( !V \  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( $2(;T[8))(@1 ,  *4,   8
M      "  6P2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" !$B&]. ?8C:R,%  !O&0  &               @ 'F%0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 1(AO3MU9J,3=!   21<  !@
M             ( !/QL  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( $2(;T[7D6<7L0$  -(#   8              "  5(@  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !$B&].;_DR"+4!  #2
M P  &               @ $Y(@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ 1(AO3IMQ0,FT 0  T@,  !@              ( !)"0
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $2(;TX=HE/]
MM $  -(#   9              "  0XF  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ 1(AO3EHB_\:V 0  T@,  !D
M ( !^2<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !$
MB&].7&329;,!  #2 P  &0              @ 'F*0  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $2(;TY_LF3<M $  -(#   9
M          "  = K  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ 1(AO3LCCYI&T 0  T@,  !D              ( !NRT  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !$B&].(YDI;8,"  #<
M"0  &0              @ &F+P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( $2(;TX<7YN\S@$  )P$   9              "  6 R
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 1(AO3JC&
M"$[& 0  -P0  !D              ( !930  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    " !$B&].#0Q@F[4!  #2 P  &0
M    @ %B-@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M $2(;TY3W')QQ0$  #<$   9              "  4XX  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ 1(AO3NN:E#*W 0  T@,  !D
M             ( !2CH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " !$B&].3:;V^=P!  #Z!   &0              @ $X/   >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $2(;T[-&B4HP0$
M #<$   9              "  4L^  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ 1(AO3C<9]:AG @  9 <  !D              ( !
M0T   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !$B&].
M'J!(4QX"  #V!0  &0              @ 'A0@  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( $2(;TZ4IB*62@(  /$&   9
M      "  39%  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ 1(AO3O[ARZ@- P  +PP  !D              ( !MT<  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !$B&].OOG*PMT!   1!0
M&0              @ '[2@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( $2(;TX%<"FTT0(  !X+   9              "  0]-  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 1(AO3H[( H2
M @  O0@  !D              ( !%U   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " !$B&].=UQ:K08"  ""!0  &0
M@ '.4@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $2(
M;T[=XBFMLP$  -(#   9              "  0M5  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ 1(AO3@D.< R1 @  3 D  !D
M         ( !]58  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " !$B&].3D0#9#8"  "'!@  &0              @ &]60  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( $2(;TYV#(Q7W@$  * $
M   9              "  2I<  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ 1(AO3K:*&W#H 0  _00  !D              ( !/UX
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !$B&].0I1D
M(( #  #0$   &0              @ %>8   >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( $2(;TYE^4+?T ,  "(1   9
M  "  15D  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M1(AO3@L+SE/S P  0!(  !D              ( !'&@  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " !$B&]./$TV&^P.  #A:   &0
M            @ %&;   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( $2(;TYHE?G$. (  *4&   9              "  6E[  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 1(AO3FL42[6X P
MVQ   !D              ( !V'T  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " !$B&].0>-958P"  #]"   &0              @ ''
M@0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $2(;T[C
M'$&#,0,  )H-   9              "  8J$  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ 1(AO3I\P/\TV30  YS ! !0
M     ( !\H<  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ 1(AO
M3EI+'1M: @  : P   T              ( !6M4  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !$B&]._:*\JI(#  #L'   #P              @ '?UP
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 1(AO3CZQ;16U 0  EAH  !H
M             ( !GML  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 1(AO3LPMUD^R 0  R1H  !,              ( !B]T  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     #0 -  >#@  ;M\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>184</ContextCount>
  <ElementCount>270</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DerivativeLiabilities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PropertyAndEquipment</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Equity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails</Role>
      <ShortName>Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Derivative Liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetails1</Role>
      <ShortName>Derivative Liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Derivative Liabilities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesDetailsTextual</Role>
      <ShortName>Derivative Liabilities (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Prepaid Expenses and Other Current Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsTextual</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Property and Equipment (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetails1</Role>
      <ShortName>Property and Equipment (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails1</Role>
      <ShortName>Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="atnm-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/SubsequentEvent</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnm-20181231.xml</File>
    <File>atnm-20181231.xsd</File>
    <File>atnm-20181231_cal.xml</File>
    <File>atnm-20181231_def.xml</File>
    <File>atnm-20181231_lab.xml</File>
    <File>atnm-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001213900-19-004269-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-19-004269-xbrl.zip
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M)>&Y<O1@21562S!P[/2_" #)A^>]]![+\78ID(P@%+XK#YB83#?P&Z]%<-*
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M2LC/ MTBQ+H%?HY!?P2N";POZ19,9Y^OH0/&>/@WY@OS3GYEP _@ZJ:GO5B
MF3LN ZU;!D<TD.&FXV-NQD/ ,9K/:'9X/6!6+K0-T45_8\]EEEFAXCUTWWE,
MB0JH]46-BS)J7+1+#6EG:A"[DOH?=_-O4'6Z)N2WWK7TU@Y1I4HY925O8E,+
MV^TB?B=8I0Y@+9$N.\&:=E=; G:7-F&E4KTBK(D(APZ X2&PZ)Z]IINLA_R8
MF3)34]&60EAVAGO7#)@?GOG)-JU?SWPW &?,Q\8 54^#V/9*<LP(U]= @6P
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M\7X.<C:$1 $T+0#=FC^S:<I6!#JA-GL[*\M8!%D0=@&QO9!IVBS8!N.]"^8
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MOER@+DFW=N[,M7XIOAM4G>RLRB#MAL.N.ZLVF%&B76[KK#[4JJI(XM:Y'SN
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MMAU33H$7*H>%Z_5R93EK (Z'=<NPA=)V25U2@B4G"RK'B3RW#W1W5 *)N..
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MVW'AEBJ&(+4*%[H.+.!".62$5UX!3W?-U0:PN]/]\P?S9P9NC)\8?P$8F[3
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MYJW%.3U0JOCK%1*K$ Z2"(0>B!PB8.#!=%=0KWM0.,%U#UQL*5XZ[LIQ0]\
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MDB+:8&'6;IP'F:@V(I+B"M5(/2#CC[D!&FY >YYX'RE2Q/F+<5=@#[*G!5>
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M=$B>L@_N,,_:UG-A[R#^PX0:U24[/3T%=-,)"DW%Q#%^--O<B?-7YB8Z2_>
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M;'6\CM  :4O$SFA_^!.*G>O\U+7.@ 88(<F"E)Q<HD')K6#=+=@:>I2O1E*
M\"H30%J=O%:Y&:XK2(#WT=[3D^D[MIS06>$/1(G\X\1F!<%:G^2<M!#L@!MR
M\Y<YTPRC!ALI\,45\09T -'M)W-PL<E)QMT%'U6X$))((F&#4/3LT5E'[Q]G
M5.E^UKF1&TG1:+7R&<\#G%3T*S7H]:^:U 8[H=L<3KPK:HVLCF5,DB2I,,W<
M$3VRAE!;T1UWA^OTGK13D2/O_3DJ9V*";L:DTZR/G!7[JTFUC2])#Z(=7$@S
M#*K&TVPC"XR1!_B3:R\FFZC\[!@S J2:YA ->M*@!JBD,MCQ*JZTT4?.EJ!J
MJ?Z"%F@>0&2+\/]I3,I!);HS#'2(CMQY5Y2NO!OTES,(E_-KMOCVE?>G$1S[
M*N</:@U4,OCE^D\PU6N@#_^_\B'T3J.0Y26.;L#>W^@GNT0"[#$5#@190F\C
M7P3=(M!-%Q%F=V+QLAF+>KN0\6SFP(&UMT .83:2?D_6WES]+FF^]A?I)1+=
M^^F5M>\$.FFTIDGH#V91FD8K^DQOVS16+[L".4%Q4'.%KS_)Z<='%R6Z2EY'
MNM"#;C[IJD>];NW#=0KWH_>G]=E?7 CK-X]SX]9[;X9F%U?_F0KMW-ZKCY]_
M>Z]_=5X]MW38YQ33 .Q5I[$,9"-KG8&J4LFBV%OX\A#;PO0-[0]X"#SZ#&,T
MW'RQ4F^<J[L2043I%YMW*SH=X"# ]Z(U!X>IS+'Q6V&_+[H65T/I@!FUP$+J
M@+)9GDCCC*_#X[VB(Z#(7^3TDBN$#$'OP5N#)OA&N2@('9[VNGW<?0$09N-O
M(_4;#?_4Z?:(!OU(GAX(;KK61\-5<Z:*.I,<C"S0J\JG2TPA:@QFXZM=_6H@
MLXKQ')$SH^9XT+CP8DXOP'NG96EZD<;YC[C76I70>)4PNX-*"*U_9F XG"&)
MGUL4/VE++;:C$*_G7DD";G82<2BM-K ^;"8A?:NL\/]D*9X?0+QMG6-6)\Y=
MFG-Z0T'UO/V?\\_G!=V#"B/S QG[KV-QY4<9.XA1>!&1/!=,<")UQ^OSB?5,
M$KV0\7#JSZ+%S?.N1>\ACT&"H08W*FS 9%A$NN<3[2Z'WL4_NV5SK]Y4C.1Q
MW!GF'B_P>!0&%-_([EY)Q:B]#60WTJDH*YP;K+P$V8,B;,V\\$^E'SE;1S.
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M$4?<26MH3G+^)2F_H)\'3/FL9_!!4E@@.BG2$^9#I)!/;M1QH7EF@FWPS"H
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M/;.N)>@Q%T6[]F@\L?O3OGS(>JT?D&$MH?S)/^IO@P(DH&-/55IB>H(=DG+
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M/(XM;8U;+[^-C$Z&9P^=I5(M9+<&4+N?U=Y?1]J[*N+;6]..@9$CV]E237J
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M#ZFW-P&,IA$#;0MKVL,^YZJ+G&QHK-"WL;,GPLX& ?Y_!+$KJ(\L++Z$Z-A
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MPB:/[_+^90PG#:^]A*@(M9OLQ56"+)^A# =EM8,PRMA*C]J.D>:(J;%P$=3
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M?!/QW$<P<&\-[/X&ZB(5 2QO=ZBX+1?0AK5)LH"P[OU0KPW1DD;FVVFYG'R
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M 4X] ]Q#,<"M88#;! :X]0QP#L6 ?@T#^DU@0+^> <-#,6!0PX!!$Q@PJ&?
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M#*8 \R9@(=K-Q4F9P6J^N[_&I/ANK-=^$/!7/9UH@^%P7_@5^K&&,:5/,<"
MO_S]!4[9?XG_A5__?U!+ P04    " !$B&].;E"#,GL0   DL   $0   &%T
M;FTM,C Q.#$R,S$N>'-D[1UK<]LV\O/=S/T'GF=NKC<=69:=I(V;M",_ZSD[
M\MA*T_9+!R8A"0T%* !I2_WUMP )BD^0E.F2O6$^9&1@=[$O+!8+"'KWPWKI
M6H^8"\+H^[W1_L&>A:G-'$+G[_<^W@_&]Z=75WO6#]__X^\6_'OWS\' NB#8
M=8ZM,V8/KNB,?6=]0$M\;%UBBCGR&/_.^@FYOFQA/Y_<7<.? ?UCZ]7^X1MD
M#085J/V$J</XQ[NKB-K"\U;'P^'3T],^98_HB?'/8M]FU<C=,Y_;.**%/+K\
MU^'9X<'HV]'AT6A_/0.NSY '7=#V%KH.CN"_T>OIZ.WQP>AX].;7BN-XR/-%
M-,[!^B#\5PW]A@@[0O[ZR^I7\<WZCOP\Q_1;?XQ^7-]\0I,/E_;$6;_^]8]/
MO[@GCY]6?\RFR__2S<'B"[Z?/)*C7^Z_?OPT=\0D&/*=L!=XB2PP-!7O]V):
M?#K:9WP^/#PX& U_OKF^5W![ >#QVB7T<Q[XZ.W;MT/5JT$SD.L'[FK21T/9
M_8 $CBA#+S' $RH\1.T$O.-%"''@U\.@,P%*<D'?!*!$@SHX!2>PO3]GCT/H
M&$J_&!R,!D<C#>Z+P1RA580R0^)!D0X[\E$X<['(Q5$].4B44>HO\[7C>'SH
M;59X"$ #@,*<V!%>.5(2 7B0S?G<J9X<[N2TB1"0[1%*_.5J@?@2V=CWB(U<
M.2670SVQ()JX>(FI=\'X\@S/D.^");_XR"4S@IT]RT-\CCWI_&(%-.H1UQ,*
M4<I@WD&("5MDVVI%8&)!P]_>20\\EAJ?@ER6_ !QI=)0$G8(D]27,HRI<TX]
MXFWDC 50.>">19SW>T8(R0(PI)AP\ S&4IR&<6%D#2R-'O^(J&,%M*P8L7?#
M-)D8<5]@9T*_5Y]7' L@HY"NH2%$#$$*D$!LVW?KX6Q9R44)&[3RFS#'"7)E
M>+A?8.R)0/_))K/"#T'+,DKC4..GC KF$@=:'"LD9 64>FVGM'V+.(BYP HH
M1_7)?K,=CJK;P?HJ0?@_O5WP,%*=F,PF*YEXP>#A="CH,]OCE<D>6XH6FUE;
MFKTE8I:8S$X7B,ZQN*+W'K,_+YCK0.9[_L6'*)ZRC!G6;*G7E2PE#16.81%J
MQ4?YMQ6,TULO.8].D5A<N.PI9QIMN\RV>5-]%DF2EJ+9VP&2+"QL3E9RR,GL
MQ!>$8B$@G[KWETO$-Y/9/9E32!IM!&F6;3,?<B,ZOP7=V@2'!GLF#;-EOY'9
M&6S/7"9\CN4?V]&D.?5X*G,+1Y3ML3&M[:"6'K6WO;0])X_ Y".^)NB!N##X
MUJ1Y769+?9NUE"9BQ:CTFL?#6XY7B#CGZQ6F LNY,H$LBY_Z7.9;8R&B%+L2
MI-DN;]-V"6E:FJB:.HJL%=*U L*]J:2I&*1=WD;N,6'U7LEU1)LFI\=HBM%!
MUA0!C6#?J:GT>L?#4[9<$D^MVJ!@6,]E^,9TN^J8 ,Q6&*6M$".E#)$@UAL#
M#^.Y=)5<>7285G&?^6I=7E'XB*=HK1TYWF#6ZE%:JP&JI7![W<*NPG\0^(L/
MTIT_1G$ZW6C6\:NTCK?HEL+O]?S<74.3NX=JNXC1ZY?915A?Z4]]<>S9;C%%
M#VXS3A%2,KO$FY=RB6#TWB&*=IA).Q<#F,V74Q?(VVWVYJBY[8Q;IP:\V5B9
MTD#E+6AOOY*]:-)>A?UF^^24"/+VI;TQJFU0XS8I!S.:YC!3,C!N5GL+97:M
M<6,D6LQZSQ0) MQ>P?E;V;B6L\UF56>*!?%M;:_PQA+L,^PAXC:286M29L-F
MZA5-I=CA\+U/-.43HP:=8E3B%9D*2\->88UZOVC*+PX;](O#$K]XL1J-]HO#
MWB^:\HLI7GN^OHO6*$6SC[Q8T4;[2,A&[RE%U9M4$F& ,%NR<OVF7^NK6614
M;I*RE;GB#8Y^I:UNE52@+ <T6RA3J"FS4!_/ZI4_$^&M#H+1;D<Y%S\J%T#[
M +B3"1,S;P<\LT$SY:'Z!NWG9DEI.S47BP',ILJ4EXJ*V_U$JV2/4:E!2O*,
MHTQ=J,0B?9Y19I-4L"N%,]LG4Z$ILT\?R2J="R4"6@4XLY4R]9*2DZ$^O-4Q
M4F)&50<WFRQ3OJAFLGY^94[U$E,IV60V0:;NH,_U^NE1H.-1CI++5OA,)2&E
MY7Y%S^HY$7%R>\PZS]0&TCKOHTCNT74BE.2T&[7^*K.S3QY>]U'%I/-1D=)+
MXLNKS/8[5^M]E"G0>R+4%'>;;5!R;:./.J7?3TA$GH(^LPTR.^GTMQ7^'R.0
M_$^^;'2'9Y9Z$>E8/ISS?D^0Y<J5[Q>IM@7'L_=[\NF<@7ZYYC<0;7^]=#6(
M)&UX$4F9+*V-<&!- G$[0R7S8A,04?MGR.F'FGE-P".>1+^-#6/)<< KADV(
M[**'NB(#"G9?4-9K2;]1(<'[Z@J9<M@7$O5T.TJC L/4J2MP<K:]D+QGT2!Q
M<<.WH8;;QZ'"O],/2+T#P1GW+)IYF,KT7EGPTMHULQ4I XK\:Z#Q!K)I,#H<
MR'?HA+/EM X36S748T+C[<!$_D-L%8?7"'+<U[5&+'JG+6]@480D/PRVV%49
M,+[Z5B"Y&C\7<8A=3^B69W*3?;%M=W84K1WXJ?!8717OB&-^"!"EE[R5WCEZ
M\TQF=F-D9RX2SJ=N^_"-5/8W5:R4AZ?_&&R)[,:+.@JT=V FCAC]]5QV\-I>
MU)_-$9;ZM(/')J@1^HB%)^D=U5%(#"W\/-B2V(D1BH@M:AMFBQ5\?*Y)!+$E
MM5$='C2._##8(N\VOK?B]5TBPE*?GA-4!??JQU.-%,12^*N8@_!A3+7EDCG5
M;]>,SJ>8+V]];B]@2=Z6Y&^("V[%*!:W:!.\^R$9AP2V%@IQ7?D-AO=['O=E
MOB3?83V&/(HP9ZK2/<?GX:.60=]#\ H?=. ' A2"I##H6P)M#_'-E8>7$AL4
M!#L^R+Y\2>&2,W^E00F F 1/7-N\8QOD>IN0ZRF[PZY\.^L6<?GN0R!V'80:
M0L?%$QXG=-Z <+><_8YM[QRPEY*O4R8B\Q7T==5.VLLFLQO@EA,D*P:A)+E=
M717D$^(<44^<KS&WB9 \WBJNM#@F@!T=2K<VYU)W$(Y@CT/G.2Z5[BME.MB,
M>'^R(6X0_XP]]=SU9":#%PM>0YS0&XQD(4G=& "/TN+50:@N<R =9'FR^WZ!
M.&Y M@M$N&)T+(2_#(/5#,NP<@O)9"12!;B6)0&?>@AN=,HK]$K=(8-7=$PW
MP<R8/&+^"T8\YHBUD&I/JU!(&UAM0,9+F"X3&KR7>44CFTQFVWNM4;"K"+M[
M]+,Y=EYPUBF_D)M^6'"6\I*@XF(L0]Y<@9YLMB#ANCI^0MR9*.\4$]^3[B9_
M(^ 3)O,%K%QC,"2:XUC8@4T*LF6]7>8GD>K:&;K]D*TFP!U>A<ND<^:K^:U8
M"":_XZAJE3P+"555"Z6K2ZU)"F5I44_R')Q=,SQ%J0$1Q[8-;5PEG2'+L015
M"U4*U7:BJG.>*=LF<[$5-IT:%8.U;8\/_O(!<S:3G,K% 995'&5V19UM,QW>
MVCYU(8;9$+ED"JUO<&^75"-,1W.\2C?>HY-#>4A[XL;\;7?T^AF%^NV-8T_3
M:"+\V0OL^*[*#58<VT0-& JCWA/("%P/I0M"GJ(5\9#K8A4,(,V#K#7V1&D@
M5AE0M[.ED_*4Y:0@9;F4X1([%=.51*+T9X[:?HX42Z2#;5[^-BG=V]&P]Y$Z
MF#]QXGF8LG#GHV4IZ&M[#0J7]FH)0'?7_YVGCOKO)RR\*-M\]FS,)=G^5(L9
M[(+Q( F2/T?@8J%K7F!6G>I%(;PN5MN><(=E=FRKRJIB71$.0Z.6J@RHTT*H
MB%A)$@W9V776R/V%[[H;.8\JVBT)WVD3QEBM;LT<I,X:-O;2!F<4/MK!;Z#<
M85F[<S=CAZUB=JT.WH7<-[?ZIT/@A,*"0,1D)B$4)S?,P6Y^WM\(I2ZH1"T0
MP>H0K]QL_5D!J)7Q TMMSW?$;7N"Y]3PA=RQ28[EYE0Z]%WL&*,&_(ZBK?Q&
M2O_1E6R8?8S:Q UVHV /C"#[@]WX&7[$+DML]>HB=32#+Q#C#$/"#A%S"LQ^
M7)7(G 'N:IWV'+8AMHPXE02)4L+Z:"V?\^@\U;F'(;'0\36())#53A>IH^ Z
M"&V'H6UM-G9P':\JF #:WY5$P5\ZO#RX%N!5KN]@YXJ&68&\S2*YA!@"+<"H
MDRZ2/I=(9].H5"'T@E YK'.RR4H%2R/6?Q;446N@=U8C4_!E ?'E@K-E]D6C
MS:F+A%!OK4G*X/+J6XC)5JV=9DAU5E,%:56PI4A==BE-QHJQVHY_!0RK3*NN
ME(5(G36R]N&H!!.[CB#].O+F:E-A=S*=U1#LF=3/CM]ACS.D\I:Q\[LOO/ 7
MRG-F?G3Q:"?4SFHB/(VYEJ<QXSG'..>H)M/9?H:0.C:"E.P1_H[6_N+NKJ;=
M "S$+6<VQHZ:7>&<TP%G>^>H F!7A=S>UO@ 6P,D%F$2 HE9<&$/N=&&.*H"
MU</IJNCGRY7+-A@'IW+;,Q.UAD9;C!*@MI=5(W^BDA1=. VX9,'!IXTY5>_M
M;C(U.#-(%XIK%[ N_.A[]H)0P>BI]&&N"RNG (GY#98W7*)*4W7X7<5SF#Q4
M;D"V:PC6,,7E@\TK^;/97"ZW8<U(+T-)Z6IAM"[?)69\CO7UG:0D!7VM\WR#
M'?GU& B[27YSVEOG]9(QYXG0E&)3C:US&=213O36(LEM46='N!Z;N,YVML[U
M!'V^(\X<?T!!+G&-'AB,R/@F*4 %N-9EF3+(>83<K"Z8ZV N7]> 7492D#*@
MUJ4 S4;Y>2J6Y_6TSJ_.8@H6H.+NUCF_)M1F+KU%_'.XH;OPJ7/MVNDEM RL
M=4D@(1.^ZV7C3EY'Z]Q.G]ATP7R!J#-=$.YA'%R9N84-1VJR5H%L71Z=UXLS
MPK$-,3%\>3+?))6A6Y<K1_M!/0MR&@ DC[B2Q4PXK<N8OUQW;YV^X?>@4BP6
M]]A;I!+-W*[6.9[PU0+1,^[/3U6E+J7BXN[6.3_#+GJ"+762X4QKZWS*@U68
M3&-H=;(+;V%OZWR?,=M7]S^I<PXA0<:&&>/+X,8HT)37KB.M5X)%X2<M4^M?
M%5('A%,6G"$2Y-Y[R LN::4%K +9.?%2#^"E92KL[IP@S_SQ\N"]Q(S/-DNT
M<TJ+Y-CE0E[65QHAUCDEY?]<>I'#5('MG(BF+[ GKPA5@FS_\"SXZF/V6G].
M>]T'!QJNU%?YSE_:R^KA=-#;*OS"??[\V@FU@PHH_*V0K, 50/]* HYJ2#CZ
M:XI8Z+O5,3HG;OF/<:3%K8/1.7&C&N=X3:+%(]7X)S/M>,<.@=%%N$)68O],
M[?0R NCFYXO0?/VST&L*IE4=C,[YV07API,2R)LML&5$Z=>Y3 #MIUGZUM$%
MCEU*3K9U];:*NO$5OR\>;VA?L^'Y!/D#.XJQJ*J0=XFYX'KX,VGL_%65E_Z.
MW1S"V!QY^(K*:2B('7R]*!472L$Z%PR"\GH8M#+K:5%OY\20<P@\+2B:1&<D
M43&SJ'='M@GU\!SS!@\0H@O0)YNPZ<?@?#E]IF ";/L"6/*&6NP%(Q2\CI%X
M;Z(J\*[?9VKJ<;[HBU<%J8"AO^U)D2JD%B7-I6"=F^UIC@M,4PK6HF#OAL%[
MQ_#Q?U!+ P04    " !$B&].<#?D 8 +   #E   %0   &%T;FTM,C Q.#$R
M,S%?8V%L+GAM;.U=6V_;.!9^7V#_@]:#Q<P^.(Z=MCO)-#M(<QD8R-9!TLX.
M]J5@)#HA*I,>4LKEWR\I2[&H"WF41"(#;!_:1N$Y/-_YR,/#B\2/OSZLXN .
M<T$8/1Q-=W9' :8ABPB].1Q]O1H?71W/YZ- )(A&*&84'XXH&_WZK[_^)9!_
M/OYM/ [."(ZC@^"$A>,Y7;)?@L]HA0^"WS#%'"6,_Q+\CN)4/6%_?+H\ES]N
MJCL(WNW,/J!@/ 9H^QW3B/&OE_,G;;=)LCZ83.[O[W<HNT/WC'\7.R&#J;MB
M*0_QDRZ4T-7?9R>SW>G/T]G>=.=A*:T^08G\E7RV+W^UNR?_FK[_,MT_V)T>
M3#_\%UA/@I)4/-6S^[";_]F(?XP)_7Z@_KI& @>2"RH.'@0Y')70W>_M,'XS
MF>WN3B=__/O\*KS%*S0F5'$2XE$AI;0TR4WW]_<GV6^+HK62#]<\+NK8FQ3F
M/&F6OR6&\B5+!#D0F7GG+$1)UJ2LU02M)=1/XZ+86#T:3V=C18^(1H7S,P]R
M%N-+O S4O[*-/-6*PH10DJ[6MXBO4(C3A(0H5LUD-5%E)Y*O=(5I<D2C4YJ0
MY%&1)XLJVR6>3/DMQ\O#D6HBXVT#$=$/$-GD<2U[C""K=2S],WD=HS^A6/G[
MZA;C1-BL;"S<OUD7B$O7W.*L4"<;&R5[,5AU3JP8%(OE8JV"E63.ZE"S5+^&
M+I;'MXC>8#&G5PD+O]^R.)+!]/3/5#8_L.$@+;U[_!B)V[.8W7=R>$VH%S-/
ML @Y62MB%\M/J2 4"R&[^56Z6B'^N%A>D1M*EE)*]OXP9*GL_O3F@L4D)-B*
MYW6T]P2<DSO9H._P.4'7)"8)"(]!J!<S+SA>(Q*=/JPQ%5CY;B$#!C].N0H=
M1T( XF(7'3V!8#)Z)(]J^) ];ZU:N-WH=IE>C#QFJQ5)LLXGZSQF65.4"2*@
M60!$>S$9%@P'"'9SF4>O\!?T8/=50]%^XF]Z+?"?J>3D] [0W%J*>QASAXF]
M \7@EYCX!5W'?;M!KV.X@0B*S2KJ;%""(>BN:; !"@K )CGT8 6S&ZR@QX$+
M9FE3V;X',9AEK0(>!LL3G" 2]QPM*Y7XZX;I('Z8^N^(V2".F/GOB"_X(4GM
MRS=]U#5<5@$. G;9P8T&=%F \.!F@]L56(6SC [8>IZARC4D($G/USA8T@KF
MR"HZM,G6_@V1'=IH<,.!:AAZL@!L+W -C@  B>BLJ,?9#]#UC87[-\O:'9M+
M]V\8D&F33-^S1R"S[1(#&6CEV" RD(E MJV"0RPQ VDW2YD,E;6':9QMPI[+
MGS4)"1?3"$>%'F7@ZYX-D(^5ROQ0QS08!X54^;^(1L%&1:#I& I)\QD S?29
MM/=IHU7^7PX#0D[0(ODD"G+Y(%>06UW8';-0LS569S\8URG/3<T.>"R1N,Y.
M>:1B?(/0>J*:P@3'B2B>9(UCO#O-#WO\D#_^MDDG\]RRJ"!&USC.JOV6EZL4
MF[@S6.U7JT%5_J."[QV*LV$V.4:</\IA-CL7U X$*%X%6&I)1SP,&(\P/QP]
MA2G$0ZW]U$_>Y"4F0LW@E9HQD2VCD%]RMC+Y._<M>PZ4,B_2BE%PC\G-;9)9
M[Y#'2RP23D+9&9IQM%-HEX2Q-W/*'A2_=\3IT]-B=@J,(R!A&'U[3NGKX 7O
M&-2/8K0%>U^"8 L!;\/5Q93\(D:;M*>8EW_&QEYBDO(CNK7V"SM@[UBZPF'*
MLWG<F@EB(*96T(]0U<)%"RSOW*\/A="!'^K\=VZ<WPS*.]^7]@&L@W=369?#
MV&;C2UR@1[4M+H.-?,)3''7!U$F)ZP&Q'5AU<.SN&N]:YF>6X * E<;&PJX'
M2C!=!JC>T=*XA6CEQRSE>A0%$P4![QUC#6?(C;'=JSC70L0;<O\Q6I,$Q><8
M";RXCLG-YO66SXR&MEX#$/4HQK4N4P'Q>\=<^ZL\#3.#AK)N%VF66'HWRNRR
MK(DV%G8= PSO4=568MJ@>M>BU,8PHQ!.ZB5=]W0P(6T@O6/C*(J(PHWB"T2B
M.<TCE6&RT";@.H$!<V.![!U%EVK;DN+H%'%*Z(V0TYATI3R+HQ.\)*%IL08B
MZWH) 4P<W!'><5A*$=01U@Z#JEW2]2@%Q=:>OGI+&^!MP^9AJU7(]0CV3++
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M(<!@YJW+J=*/F,T95II1M3G/JG1\*\L3V6IJ*,]*Z07BG&!ODF[GW)B?'<G
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M%[KE.UC-Y&[ES-\4FTYG_X<7_##'"7%"[V'N1S%"688((TFX$,@[3HX-!6@
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M'!<EL>]2-G]Q\6(_E1 E'"_0@_.*R#F*'3]8Q>C$?LP&.DC_>W\PVALQ RW
M)(D0_2/K.$I[COZ2]_UKB:>NZ3[D$WZH1/CHT"3IN?;Q&3A28R ?XZ_O3)I)
MU')G+P$5&+JB'X6QQ-MMC5IX.3D/;*%4(#MOIW6V<@*F O17+_[JXC"FB%X$
MZ=.^O2-HQCYLSV$">0)F&H]3_A6B!2U4]9#W[5T<)1R6.T2)JOQ9A.@,?$87
MR.441VD0RJLOT#-!%ZW8S2GOD9L\HCWZ+5T12M4H8*RJ$&!5PD'([ /GN[-
MY^DB7!.B<D>])D$!SYY7H6L+)3D "H!M\V_=/2MMX3;A74*L"SHT=9(@;CQ;
M:L8V916"5TNIR^;PWB&"*#GSFXH-O(UFM=V$5\R@35.\YDN$9;1#:.BN#S".
MJ)T7GD?)+*.;@')FS8'6DZX=GV;2EG&@_1!+SQNPLK?S((%X*389H/9VVPMB
M+CFKCF68R%8;N(<9\T B;QDXEAL%^O"QV0S0@J'-BS^ED$7GNV?L7"U:RFP
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M@3=QJ$RKLF%TFU%C:T@_R\;$!09WUJI*CGXZV7V,$@;VQ'6J]8+6]P[!;F<
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MAA([L& )C]W,R17=,#SRR.G[0TM3M=>*["BB>\F+N@O(]S.D9FH6^; Z4CC
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M9G?TZ,GI><9>GL(I?7:JF@5UBY<QW.X@-=JD%E_6K$# -E9? 7FM +9^Z8F
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M<Y,_90D1D\3EX998MC@RY9\%.B4Y,GHT&)\;.5\<'"_BYSC":>04C-V/_I-
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M-SY'BW#W2-<TX]KGNL;QPP#=-*5-\#N9A?"G+(UPM"<M\)#@*@1HE20PHUP
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MQR\R"NY 3PX !F.T%#I8RR;IG>Z?KLF_D3_7?R+_0[<=Y"__#U!+ P04
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MB))W'!#=41G2,;!<YW.J0T&4.]7*,<NFB93,ME]#+?Q.7I=:"C@ ^T1"REO
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MG]6Z=>AP'V(G3)RBIO3IIOX7>8R@3A\'@:\.PSAB\^KC4D7C\=KB@$U?627
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M-]M>5Q#K-L0N>D1).6B])Y1^L%U/#BX$&RA<9D&P*3;R?;!HD$,1L?V>HJY
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MI)+&L.6;UQ]0B<:/73*Z8(LEA]JPY)=,<^^?6?'BFO[AO=L!V-N#!V!-X>!
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MSJ?\"_O/(U4S^IO_ 5!+ 0(4 Q0    ( $2(;T[1?CNMOL0  -8O"0 1
M          "  0    !A=&YM+3(P,3@Q,C,Q+GAM;%!+ 0(4 Q0    ( $2(
M;TYN4(,R>Q   "2P   1              "  >W$  !A=&YM+3(P,3@Q,C,Q
M+GAS9%!+ 0(4 Q0    ( $2(;TYP-^0!@ L   .4   5              "
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8;6Q02P4&      8 !@"* 0  ^*D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
